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Background: Epilepsy is a serious chronic neurological disorder that has a higher 
incidence in children and young people (CYP) than in adults. Epilepsy negatively 
impacts physical and psychosocial quality of life of CYP. Good outcomes of 
epilepsy are associated with optimal choice of drug treatment and adequate 
adherence to the prescribed medicines. Research on the patterns of medication use 
and adherence to prescribed medicines in CYP remains limited. The long-term 
clinical outcomes and costs of treating epilepsy have not been extensively studied 
in CYP in the UK.  
Aim of the study: This thesis aimed to investigate the pattern of antiepileptic drug 
(AED) prescribing and the dynamic of medication adherence in CYP with 
epilepsy. The long-term clinical outcomes and direct costs of treating epilepsy in 
CYP were estimated at population level.   
Methods: This study is an observational cohort study of CYP, age 0-17 years, 
identified from The Health Improvement Network (THIN) primary care database 
from the UK between January 1988 and December 2004. Four different analyses 
were carried out on this cohort. First, a cross-sectional design repeated annually 
was employed to estimate the incidence and prevalence of epilepsy and the pattern 
of AED prescribing in this population. Secondly, the long-term adherence to 
prescribed AEDs was calculated using the medication possession ratio (MPR) 
method. Applying panel data analysis and the Generalised Estimating Equation 
(GEE) multivariate regression, factors that may have been associated with 
adherence to the prescribed AEDs were examined. Thirdly, seizure outcomes in 
terms of seizure frequency and remission of seizures and potential associated 
factors were assessed using the method of multiple failure survival analysis. 
Finally, the direct costs of treating epilepsy in CYP in primary care were estimated 
and stratified by the number of years after the first recording of epilepsy in THIN 





Results: Of total 528,760 CYP born on or after 1st  January 1988 and registered in 
general practices contributed to THIN until 31st December 2004, 2020 CYP were 
identified who had a diagnosis of epilepsy, from under 1 up to 16.3 years of age 
(mean=5.6; SD=4.1). The annual incidence of epilepsy in CYP stratified by 
calendar years ranged from 44.4 (95% CI=31.9-61.8) to 61.2 (95% CI=50.6 -74.1) 
per 100,000 person-years. Incidence of epilepsy was significantly higher in 
children with greater socioeconomic deprivation than those with lower 
deprivation. Around 60% of CYP with epilepsy were prescribed monotherapy 
each year. Old AEDs such as carbamazepine and sodium valproate were the most 
frequently prescribed drugs and often prescribed as monotherapy to control 
epilepsy throughout 1990-2003. Prescribing of lamotrigine, a new AED, increased 
from 0.07 per person-years in 1992 to 2 per person-years in 2003. The calculated 
annual adherence to AEDs showed that around 50% of CYP adhered to at least 
80% of the prescribed medications each year. Demographic characteristics of CYP 
were of little significance to affect adherence levels.  
The incidence of seizures was 0.73 (95% CI=0.71-0.75) per person-years. 
Incidence of seizures was higher in younger children up to 2 years and decreased 
with increasing age. A proportion of 94% (95% CI=93%, 96%) of CYP achieved 
1 year remission of seizures, 80% (95% CI= 78%, 83%) achieved 2 years and 47% 
(95% CI=43%, 50%) achieved 5 years remission of seizures.  
The mean total direct cost associated with treating epilepsy in CYP, according to 
information in the general practice records that also indicated specialist and 
hospital care, was estimated at £ 1,153 (SD=1,808) per child in the first year 
following epilepsy diagnosis and at £459 (SD=1,633) per child for subsequent 
years. The costs of hospital care and AEDs represented the highest contribution to 
the total direct costs of epilepsy. The annual direct cost was significantly higher in 
younger children up to 2 years old. No significant difference in the annual costs 
was observed between CYP who adhered to at least 80% of medications and those 





Conclusions: The incidence of epilepsy was highest in young children and CYP 
of higher socioeconomic deprivation. Old AEDs were most often prescribed as 
first-line drugs and as monotherapy to control epilepsy. Of newer AEDs, there was 
an increasing trend of prescribing lamotrigine and topiramate as add-on therapy. 
Long-term adherence to prescribed AEDs was suboptimal in one-half of CYP and 
positively associated with higher seizure frequency. Inpatient hospital care and 
drugs were the major contributors to the direct costs of treating epilepsy in CYP. 
Non-adherence to prescribed medicines was associated with higher hospital care 
costs but not with total direct costs as the medicines themselves made large 
contribution to the direct costs 
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1 Chapter one: Background and rationale for the thesis 
1.1 Introduction 
Throughout the thesis, the term `CYP` is used to refer to children and young 
people less than 18 years old. The National Institute for Health and Clinical 
Excellence (NICE) guideline for diagnosis and management of epilepsy in children 
and adults defines children as ranging from 28 days to 11 years and young people 
from 12 years to less than 18 years 1 . 
Epilepsy is a prevalent neurological disease affecting children in the UK and 
worldwide.  Anticonvulsant drugs, commonly known as antiepileptic drugs 
(AEDs), are the first choice treatment strategy for managing epilepsy in CYP. 
However, until recently, there has not been conclusive evidence in regard to the 
first-line drug to use when starting monotherapy or specific guidelines in place for 
combining AEDs if monotherapy fails to control seizures. The first guideline for 
the diagnosis and management of epilepsy in children and adults was produced by 
NICE in 2004 1. There is little information about the use of AEDs in CYP in 
primary care in the UK and adherence to the prescribed AEDs. No study has 
focused on estimating the costs associated with treating epilepsy in this age group 
in the UK. 
This thesis has investigated the trend of incidence and prevalence of epilepsy in 
CYP and the pattern of AED prescribing using data from primary care practices in 
the UK. The long-term adherence to the prescribed AEDs and the long-term 
recorded seizure outcomes were calculated. The direct costs of treating epilepsy in 
CYP were estimated at a population level. All these analyses are addressed in 
detail in different sections of the thesis and are presented as follows: 
Chapter 1 provides an introductory background about epilepsy regarding its 
definition, aetiology, classification, and the burden in the UK and globally. Chapter 
1 presents a review of the literature, which describes what is currently known 
about the use of AEDs in primary care and CYP adherence rates to prescribed 




AEDs.  The review also provides an overview of the common methods of 
measuring medication adherence and the factors associated with non-adherence. 
Chapter 1 also describes of the nature of The Health Improvement Network 
(THIN) database, the data source for all analyses in this thesis, and the strengths 
and limitations of using THIN in conducting medical research. This is followed by 
a justification of the thesis and objectives of the thesis. 
Chapter 2 describes the methodology of extracting a sample of CYP younger than 
18 years who were diagnosed with epilepsy and registered in general practices 
contributing to THIN and describes their basic demographic characteristics and co-
existing morbidities. Chapter 2 also presents the first analysis on the study group 
that was the calculation of incidence and prevalence of epilepsy stratified by the 
&<3¶VDJHVH[DQGFDOHQGDU\HDURIGLDJQRVLV 
Chapter 3 investigates the AEDs used by CYP in primary care, as well as the 
proportions of CYP who were prescribed monotherapy and polytherapy.  The 
chapter also explores trends in prescribing old and new AEDs and trends in the use 
of AEDs in regard to CYP age over calendar time between 1990 and 2004. Chapter 
SUHVHQWVDFDOFXODWLRQRI&<3¶VORQJ-term adherence to the prescribed AEDs and 
a regression analysis of factors that may have been associated with adherence. 
Chapter 4 presents a quantification of the recorded clinical outcomes of epilepsy in 
THIN in terms of seizure frequency and remission of seizures and examines factors 
that may have been associated with the incidence of seizures. 
Chapter 5 presents an estimate of the health resource utilisation (HRU) by CYP in 
primary care and the associated direct costs for treating epilepsy in this age group 
and assesses whether there were any variations in FRVWVE\&<3¶VDJHVH[
socioeconomic status and adherence to AEDs. 
  




1.2 Definition of epilepsy 
Epilepsy is a serious neurological disease characterised by spontaneous recurrence 
of unprovoked seizures. According to the International League Against Epilepsy 
(ILAE) definition, `Epilepsy is a disorder of the brain characterised by an enduring 
predisposition to generate epileptic seizures and by the neurobiological, cognitive, 
psychological, and social consequences of this condition'  2. Seizures are the main 
symptom of epilepsy and are defined as time-limited paroxysmal episodes that 
result from a transient disturbance in the electrical activity of the brain with a 
sudden overload of neuronal discharges. This disturbance produces temporary 
changes in a person's movement, behaviour or consciousness that can occur at 
inconvenient, embarrassing, or hazardous times 3. The ILAE defines an `epileptic 
seizure' as a transient occurrence of signs and/or symptoms due to abnormal 
excessive or synchronous neuronal activity in the brain 2. Seizures are usually 
short, lasting less than 5 minutes, and are sometimes anticipated by a prodromal 
phase (vague pre-attack symptoms such as depression, irritability, giddiness, and 
myoclonic jerking)  and are followed by a long postictal phase (post-attack 
symptoms, such as unconsciousness and/or headache, vomiting and pain in the 
muscles) 3. 
The diagnosis of epilepsy requires the occurrence of at least one epileptic seizure. 
Although epilepsy is characterised by recurrent seizures, not all seizure attacks   
refer to epilepsy and misdiagnosis of epilepsy is common 4, 5. 
1.3 Causes of epilepsy 
Epilepsy is caused by any condition that alters the structure or disturbs the function 
of cerebral neurons 3. There are three broad categories for the causes of epilepsy: 1. 
symptomatic epilepsy, which has a definite cause that may be congenital (such as 
heterotopias and cortical dysplasia), infectious (such as meningitis, encephalitis, 
and abscess), head trauma, tumour and vascular (such as vascular malformation, 
stroke and subarachnoid haemorrhage) 6. 




2. Idiopathic epilepsy has no apparent cause, but could be due to a genetic 
tendency. Most population-based studies have reported that the aetiology of 
epilepsy was unknown in 60-70% of participants 7. 3. Cryptogenic epilepsy is 
similar to idiopathic epilepsy in that no apparent cause can be defined. However, 
there is strong evidence that this type of epilepsy may be the result of a condition 
that causes brain damage. There are some factors that may trigger seizures in 
children with epilepsy, including sleep deprivation 8, flashing lights (photosensitive 
epilepsy) and emotional stress 9. 
In addition, there are other conditions that provoke seizure attacks but may not 
develop into epilepsy. These conditions include metabolic abnormalities (such as 
hypoglycaemia, hyperglycaemia, hyponatraemia  and hypocalcaemia), prescribed 
medications that lower individual level of resistance to seizures (e.g., theophylline 
and tricyclic antidepressants), systemic infection and high fever in children 10. 
1.4 Classification of epilepsy and epilepsy syndromes 
Epilepsy is a heterogeneous set of neurological disorders. The current familiar 
international classification of epilepsy and epilepsy syndromes was introduced by 
the 1989 ILAE classification of epilepsy syndromes (Appendix 1)11. Epilepsy 
syndrome refers to a complex set of clinical signs and symptoms that are 
characteristic of an identifiable disorder or disease 12. 
The 1989 ILAE classification scheme depends on two main factors: seizure type 
(localised or generalised) and the cause (e.g., idiopathic, symptomatic, or 
cryptogenic). Sub-classification of epilepsy syndromes is based on anatomic 
localisation (e.g., frontal, rolandic, occipital, or temporal lobe epilepsies). The 
disorder may also be classified according to predisposing factors. A clear glossary 
of standard terminology for epilepsy, epileptic syndromes and epileptic seizures 
was developed by the ILAE in 1980 and revised in 200113. 
Since seizure type is the main domain of classifying epilepsy syndromes, the ILAE 
previously introduced the 1981 classification of seizure types (Appendix 2) 14. The 




classification scheme depends on the part or parts of the brain the seizure activity 
starts in.  Figure 1-1 illustrates the classification of seizure types. Simply, seizures 
are either focal (partial) or generalised. 
 
Figure 1-1: Classification of seizure types 
1) Focal seizures (localised) involve seizures that arise in specific loci in the brain 
cortex. Focal seizures are divided into simple focal and complex focal. 
a) In a simple focal seizure the patients are fully conscious and aware of their 
surroundings, despite seizure activity 
b) In a complex focal seizure the consciousness is impaired and the patients may 
not remember the seizure afterwards, or they have unclear memory of it. 
2) Generalised seizures involve a large volume of the brain and are usually 
bilateral and associated with early impairment of consciousness during the seizure 
attack. 
Sometimes, the epileptic seizures start as a focal seizure and then spread to both 
sides of the brain. This type is known as secondarily generalised seizures. 
Although the 1981 and 1989 classifications have received many criticisms of being 
dated and unsatisfactory for epidemiological research, they remain in use 15. In 
1997, the ILAE established a Task Force of experts in order to evaluate the current 




system of classification and terminology. Although the Task Force has proposed 
some modifications 6, they have argued that it is difficult to replace the current 
international classification system with an updated version that would be widely 
accepted and universally employed. The Task Force has postponed the replacement 
of the current system until a better method of classification is developed 15. 
1.5 Epilepsies typical of children 
Children and young people can manifest specific epilepsy types that differ in 
prognosis from adult epilepsy 16. There is a set of epilepsy syndromes that have the 
age of onset only in children and do not occur in adults; however, some of these 
syndromes can persist into adulthood 17. This section summarises the most 
common epilepsy types occurring in CYP.  
1.5.1 Epilepsy in neonates 
Neonates, are also called newborns, include young infants from the date of birth to 
the 28th  day of life 1. The incidence of epilepsy is greatest in neonates and during 
the first year of life. The highest incidence occurs in neonates of younger 
gestational age or lower birth weight (4.4-5.75/1000 population) 18. The most 
common types of neonatal epilepsy are benign neonatal convulsions and early 
myoclonic encephalopathy. 
  




1.5.2 Epilepsy in infancy and childhood 
Different types of epilepsy are manifested in childhood that could be classified 
according to age of incidence, intensity, and characteristic seizures type. In a recent 
report (2010), the ILAE proposed a classification of clinically defined epilepsy 
syndromes according to the age at onset, which is presented in Table 1-112. A 
summary description of each syndrome is shown in Appendix 3  
Table 1-1: Classification of childhood epilepsy syndromes according to age of 
onset 
Age of onset Epilepsy syndromes 
Neonates Benign familial neonatal epilepsy 
Early myoclonic encephalopathy 
Ohtahara syndrome 
Infancy Epilepsy of infancy with migrating focal seizures 
West syndrome 
Myoclonic epilepsy in infancy 
Benign infantile epilepsy 
Benign familial infantile epilepsy 
Dravet syndrome (Severe myoclonic epilepsy in 
infancy) 
Myoclonic encephalopathy in non-progressive disorders 
Childhood Febrile seizures plus (FS+) (can start in infancy) 
Panayiotopoulos syndrome 
Epilepsy with myoclonic atonic (previously astatic) 
seizures 
Benign epilepsy with centrotemporal spikes 
Autosomal-dominant nocturnal frontal lobe epilepsy 
Late onset childhood occipital epilepsy (Gastaut type) 
Epilepsy with myoclonic absences 
Lennox-Gastaut syndrome (onset at 1-7 years) 
Epileptic encephalopathy with continuous spike-and-
wave during sleep 
Landau-Kleffner syndrome 
Childhood absence epilepsy 
Adolescence  Juvenile absence epilepsy 
Juvenile myoclonic epilepsy 
Epilepsy with generalised tonic±clonic seizures alone 
Progressive myoclonus epilepsies 
Autosomal dominant epilepsy with auditory features 
Adopted from Berg et al. (2010) 12 




1.6 The burden of epilepsy 
The burden of disease can be evaluated from different aspects including incidence 
and prevalence of disease in the general population, mortality rates and morbidity 
associated with disease and the financial costs of disease to individuals and their 
societies. In 1993, the World Health Organization (WHO) developed the Disability 
Adjusted Life Years (DALYs) measure to quantify the global burden of diseases 19. 
This measure combines the burden due to death (years of life lost due to premature 
mortality) and morbidity (years of life lost due to time lived in a health state less 
than ideal health) into one index. This section briefly discusses the relevant aspects 
of measuring the burden of epilepsy in CYP. 
1.6.1 Age-specific incidence of epilepsy in children 
The incidence of epilepsy has been reported to be higher in CYP than in adults 
with at least 50% of cases beginning in childhood or adolescence 20. The peak 
incidence is in the neonatal and infancy periods. Despite differences in the sources 
of data, the definition of epilepsy and age ranges of participants, the incidences 
rates in childhood can be categorised into common ranges. For example, the 
incidence of childhood epilepsy in Europe and North America decreases from 
around 150/100,000 population during the first year of life to 60/100,000 
population at age 5-9 years and 45-50 /100,000 population in older children 18. The 
incidence in South America, Africa and Asia shows higher rates (median= 
68.7/100,000) 18, 21. 
Previous incidence studies of childhood epilepsy in the UK have reported similar 
incidence rates to that in Europe. A population-based study used a national primary 
care database, the General Practice Research Database (GPRD), and estimated 
incidence of 63/100,000 population at age ranges between 5-9 years and 
54/100,000 population at age ranges between 10-14 years in 1995 22. However, a 
more recent study by Heaney et al. (2002) estimated an incidence of 190/100,000 
person-years at age 0-4 years and 75/100,000 person-years at age 5-14 23.  




1.6.2 Age-specific prevalence of epilepsy 
Epilepsy is one of the most prevalent neurological conditions affecting populations 
of all ages worldwide. Globally, the WHO reported that there are over 50 million 
suffer from epilepsy in the world in 2004 with an estimated 2.4 million new cases 
of epilepsy occurring each year 20. Around 85% of people with epilepsy live in 
developing countries. However, a recent study by Ngugi et al. (2010) estimated a 
higher figure of the global prevalence of life-time epilepsy (LTE) and active 
epilepsy (AE; a patient with at least one epileptic seizure in the previous 5 years 
regardless of AED treatment). In developed countries, the prevalence of LTE and 
AE were estimated at 6.8 million and 5.7 million, respectively 24. In developing 
countries, these were 45 million LTE and 17 million AE in rural areas and 17 
million LTE and 10 million AE in urban areas. 
Studies on children and adolescents in Europe have reported prevalence rate ranges 
from 4.5 to 5/1000 population 25. The prevalence rate of epilepsy rises with 
increasing age of children. It has been estimated to be 3.5/1000 population at ages 
of 0-5 years; 4.5/1000 population at ages of 5-10 years; and 5/1000 population at 
ages of 11-16 years 18. 
In the UK, there are no direct estimates of the prevalence of epilepsy 26. Wallace et 
al. (1998) used the GPRD database and estimated prevalence rates of 3.2/1000 
population at age 5-9, 4.1/1000 population at age 10-14 and 5.2/1000 population at 
age 15-19 years in 1995 22. In England and Wales, the Office for National Statistics 
(ONS), reported that the prevalence of epilepsy in CYP under 16 years old was 
4.4/1000 for males and 4.1/1000 for females in 1998 27. Large population databases 
suggest the prevalence of epilepsy to be between 0.4% and 0.5% for CYP 22. Based 
on a population of 11.6 million CYP under 16 years in the UK in 2010 28, this 
would suggest there are between 46,400 and 58,000 CYP with epilepsy in the UK. 
 




1.6.3 Mortality and morbidity associated with epilepsy 
Population-based studies have reported that CYP with epilepsy have standardised 
mortality ratio (SMR) of 7-13, which is higher than the reported SMR of 2-3 for all 
age groups with epilepsy 29, 30. A recent population-based study by Acker et al. 
(2011) used the GPRD in the UK and reported an SMR of 22.4 (95% CI=18.9, 
26.2) in 6190 CYP diagnosed with epilepsy 31. In newly diagnosed epilepsy, death 
is mainly attributed to the severe underlying disease (for example, vascular disease, 
and brain tumour). In chronic epilepsy, however, higher mortality is commonly 
caused by seizure-related death, idiosyncratic drug reactions and rarely due to 
sudden unexpected death in epilepsy (SUDEP) 30, 32. SUDEP accounted for 6% of 
the deaths in the UK paediatric study 31. 
The World Bank in collaboration with the WHO and the Harvard School of Public 
Health evaluated the Global Burden of Diseases (GBD) via assessing mortality and 
disability from diseases 19. The WHO 2001 report assessed the GBD for 2000 and 
estimated that mental and neurologic conditions accounted for 12.5% of the 
DALYs of all diseases and injuries 33. They estimated that epilepsy represents 
0.5% of the total burden of diseases in the world 33. 
A wide range of morbidities and disorders are associated with epilepsy in CYP, 
including cognitive and learning difficulties, behavioural, social and psychological 
impairments that may persist into adult life. These disorders are reinforced by the 
adverse effects of antiepileptic treatments, and the negative social attitude toward 
epilepsy 34, 35. Common relevant morbidities associated with epilepsy in CYP are 
briefly discussed in the next sections.     
1.6.3.1 Cognitive impacts of epilepsy  
Epilepsy has been demonstrated to impair the cognitive functions and mental 
development of children 34, 36. Attention, intelligence scores (IQ), visual-motor 
skills and language skills are important indicators for the cognitive outcomes of 
epilepsy. These domains can be evaluated though standard scale-measures and 




tests 37. Cognitive functions were commonly addressed by interviewing children 
with epilepsy and their caregivers where children were administered standard tests 
to measure their mental skills. Examples of studies that have addressed the impact 
of epilepsy on cognitive function are discussed in this section. 
Schoenfeld et al. (1999) examined a cohort of 57 CYP, aged 7-16 years, with 
chronic complex partial seizures and 27 healthy siblings, control group, of the 
same age in the USA 38. All children and control were administered a set of 
neuropsychological tests of intelligence, receptive and expressive language, 
academic achievement, visual-motor skills, verbal and non-verbal memory and 
problem solving. Their findings showed significantly poor performance of CYP 
with epilepsy than the sibling control in all domains of cognitive function; verbal 
memory (p<0.005), non-verbal memory (p<0.01) language and academic 
achievement (p<0.01) and motor skill and mental efficiency (p<0.05). Similar 
findings were reported by Cormack et al. (2007) who interviewed 79 CYP, 
younger than 18 years, with temporal lobe epilepsy in London- UK 39. The authors 
reported subnormal intellectual function (IQ <79) in 57% of participants Age at 
onset of epilepsy was the only significant predictor of cognitive impairment where 
the highest cognitive dysfunction occurred in those who had onset of epilepsy in 
the first years of life (p<0.001).   
In another study by Berg et al. (2008), 613 children with newly diagnosed 
epilepsy, aged 1 month to 16 years, were prospectively enrolled in an observational 
study in the USA 40. Children and their families were interviewed at the start of the 
study and at about 8±9 years after enrolment. At 8-9 years after the start of the 
study, children were administered age-appropriate neuropsychological tests such as 
Wechsler Intelligence Scale for Children, WISC-III. The level of cognitive 
function of children was described as normal for 451 (,4, borderline for 31 
(IQ, 70-79), mildly retarded for 21 (IQ, 60±69), moderately or severely retarded 
for 45 (IQ, <60), and neurologically impaired-not testable for 36 (5.6%) children. 
Subnormal cognitive functions were suggested for 26.4% of the participants. 




Because of the heterogeneity of epilepsy in aetiology, age of onset, seizure 
manifestation and sensitivity to pharmacological treatment, cognitive outcomes in 
CYP vary by diagnostic epilepsy subtypes 34.  Difficult-to-treat epilepsy 
syndromes, such as West syndrome, Dravet syndrome and the Lennox-Gastaut 
syndrome, have the poorest cognitive prognosis. The case may be worsened by the 
fact that treating CYP with AEDs, particularly phenobarbital and topiramate, is 
usually associated with cognitive side effects 41, 42. However, some studies have 
shown that the effect of AED treatment on cognition is dose-related or due to 
polypharmcy 37, 43. 
The above discussion indicates that the cognitive and educational impairments 
associated with epilepsy syndromes in CYP are of major importance and 
necessitate an appropriate choice of AED treatment and dose adjustment for better 
prognosis. 
1.6.3.2 Psychosocial impacts of epilepsy  
Psychosocial problems and psychiatric comorbidities are common in CYP with 
epilepsy 35, 44-46. These problems include learning difficulties, poor social 
maturation and functioning, unemployment and mental health problems. 
Educational and employment status were often assessed in randomised controlled 
trials (RCTs) by interviewing adults with childhood-onset epilepsy and/or 
prospectively observing CYP with epilepsy. For example, a population-based 
cohort of childhood-onset epilepsy,  245 CYP with epilepsy younger than 16 years,  
were prospectively observed for a mean follow-up of 35 years 47.  In 1992, the 100 
surviving patients of the cohort and an additional 100 randomly selected employee 
controls without epilepsy of the same birth were interviewed. The authors found 
learning disabilities, lower education levels [Odds Ratio (OR) 2.4; 95% CI, 1.4-
4.1], and lower employability [OR, 3.7; 95% CI, 1.9-7.3)] among patients with 
epilepsy compared to control cases. Questions about self-assessed health, life 
satisfaction, and life management were also included in the interviews 47. The 
authors found significantly lower levels of life satisfaction [OR, 6.7; 95% CI, 1.9-




24.1] and poor perception of general health [OR, 5.1; 95% CI, 1.2-21.3] among 
people with epilepsy compared to controls from the general population.  
In a review article by Pavlou and Gkampeta (2011), the authors concluded that 
learning disabilities and low academic performance are more frequent among 
children with epilepsy to the extent that some epilepsy syndromes may cause 
permanent learning disabilities 48. 
Aspects of interpersonal relationships and social behaviour associated with 
childhood epilepsy were explored by Kokkonen et al. (1997) in Finland. The 
authors interviewed 81patients with childhood-onset epilepsy and 211 healthy 
controls and investigated independence from original family (e.g. living with 
parents, spouse, or outside home), and social development and functioning inside 
and outside homes. The authors found significantly poorer social maturation in 
30% of patients versus 17% of controls (p< 0.05), dependent life styles in 49% of 
patients versus 21% of controls (p< 0.05), and persistent social adjustment and 
competence problems in patients with epilepsy.  
This illustrates that the behavioural and social progress of children with epilepsy 
are influenced greatly by the disease and that epilepsy is a burden at both 
individual and societal levels. 
1.6.3.3 Impact of epilepsy on quality of life 
Research on the impact of epilepsy on health-related quality of life (HRQOL) of 
children and their families has grown in the last two decades 49. Epilepsy has been 
demonstrated to influence a variety of life functions, such as physical function, 
social function and mental health, particularly in children with recurrent seizures or 
uncontrolled epilepsy 50, 51. Emotional (e.g., irritability, anger, and persistent 
sadness) and behavioural problems (e.g., social isolation and reckless behaviour) 
are more common in children with epilepsy than children of the general population 
52
. Population-based studies have revealed that CYP with epilepsy have higher 
risks of depression and anxiety symptoms 53, 54 and an associated higher risk of 




suicide attempts in adolescents 55. A nationwide epidemiological survey (British 
Child and Adolescent Mental Health Survey) in 1999 examined the rates of 
psychiatric disorders in children aged 5-15 years throughout England, Wales and 
Scotland 56. The survey was conducted by interviewing a main carer and teacher 
for 10, 316 children including 67 children with epilepsy, 47 with diabetes and 
10,202 controls. Rates of psychiatric disorder were 37% in children with epilepsy 
versus 9% in control children. 
A variety of generic instruments [e.g., the Child Health Questionnaire and the 
Paediatric Quality of Life Inventory (PedsQL)] 57 were designed to address 
different aspects of HRQOL in paediatric populations irrespective of their medical 
conditions 58. These generic instruments were found insufficient to detect specific 
problems related to epilepsy 50. Therefore, a number of specific HRQOL scales 
have been designed for children and adolescents with epilepsy 59. Examples of 
these specific instruments include the Epilepsy and Learning Disabilities Quality 
of Life Scale (ELDQOL), the HRQOL in Children with Epilepsy measure, 
Adolescent Sigma Scale, Hague Restrictions in Childhood Epilepsy Scale, Quality 
of Life for Adolescents with Epilepsy (QOLIE-AD-48) and the Quality of Life in 
Childhood Epilepsy Questionnaire (QOLCE)58, 59. 
A study by Ronen et al. (2003) provided an example for the development and 
content description of epilepsy-related quality of life (QOL) measuring 
instruments. The authors developed the HRQOL in Children with Epilepsy 
questionnaire, which can be administered to children of 8 years or older, and a 
parent-scale for proxy response 60. The authors examined 381 children with 
epilepsy, aged 6-15 years, and their parents 61, 62. Using the refined version of the 
questionnaire, the authors concluded that impairments in HRQOL in children with 
epilepsy were associated with severity of seizures and the number of prescribed 
AEDs [30]. 
Many other studies implemented a variety of generic and specific HRQOL 
measures and have emphasised the negative impacts of epilepsy on HRQOL of 
CYP with epilepsy 51, 63, 64.  




It is clear from the published literature that epilepsy has serious negative effects on 
the QOL of CYP. 
1.6.4 Cost of illness as a measure of the burden of epilepsy 
Cost of illness analysis comprises another measure of disease burden in terms of 
resources consumed. An estimate of the total cost of epilepsy in Europe based on 
epidemiological data from published population-based prevalence studies and 
reported data on the cost of epilepsy has shown that epilepsy represents a 
socioeconomic burden at individual, family, health services and societal levels 65. 
The estimated total cost of epilepsy in 25 European countries converted to Euros 
IRUZDV¼ELOOLRQRIZKLFKWKHLQGLUHFWFRVWZDV¼ELOOLRQLH, 
represents 55% of the total cost 65. This indicates that the higher proportion of 
epilepsy burden is imposed on the society in the form of unemployment and 
decreased productivity of patients with epilepsy. A review of the cost-of-illness 
studies in childhood epilepsy reported that the annual cost per child, generated at 
UDWHUDQJHGIURP¼WR¼SHU\HDU66.  
In the UK, no study has focused on the cost of treating epilepsy in CYP. Only 
aggregated data of adults and children with epilepsy were reported by Cockerell et 
al. (1994) who conducted a survey study on 1628 patients (including 14% under 
20) identified from general practices 67. Extrapolating to the whole UK population, 
the authors estimated total costs of £1930 million per year of which the indirect 
costs were £1345 million in the form of unemployment and premature mortality.  
Recently, Beghi et al. (2005) reviewed published studies on the cost of epilepsy in 
childhood and concluded that the knowledge of the economic impact of epilepsy in 
children is limited due to the scarcity, inconsistency and poor comparability of the 
published articles 68.  
Data from the UK and Europe on the cost of epilepsy indicate that epilepsy 
represents an economic burden to individuals and health care services. 




1.7 Management of epilepsy 
The principal goals of managing epilepsy are to achieve a seizure-free state 
(remission of seizures) or at least lower the rate of seizure recurrence 1. The main 
strategies of managing epilepsy include antiepileptic medications, neurosurgery 
and vagus nerve stimulation. The first choice treatment strategy and the standard 
approach to manage epilepsy is the use of AEDs, which is the focus of this study. 
There is strong evidence that 70-80% of CYP respond well and enter long-term 
remission of seizures after starting AED therapy 69-71. This means that 20-30% of 
children have refractory epilepsy syndromes (difficult-to-treat) and may seek other 
treatment options, such as the surgical approach 72. 
The surgical approach to the treatment of refractory epilepsy includes epilepsy 
surgery (neurosurgery) and vagal nerve stimulation 73. Epilepsy surgery involves 
surgical removal of the small part of the brain where seizures start (e.g., temporal 
lobe) or separating the part of the brain that is causing seizures from the rest of the 
brain. (SLOHSV\VXUJHU\LVXVXDOO\FRQVLGHUHGZKHQDFKLOG¶VVHL]XUHVIDLOWo 
respond to two or three AEDs in appropriate combination. 73. Studies have reported 
conflicting conclusions about the short and long-term effects of surgery on seizure 
control as well as the cognitive and psychosocial outcomes after epilepsy surgery 
74
. 
Vagus nerve stimulation has been demonstrated as a relatively safe and effective 
adjunctive therapy for refractory seizures in CYP. Vagus nerve stimulation therapy 
is an operation in which a small generator is implanted under the skin below the 
collar bone with two electrical wires wrapped around the vagus nerve at the side of 
the neck 75. The generator sends electrical impulses, at intervals, to the vagus nerve 
and then to the brain. This helps to lower the seizure frequency and severity of 
seizures. The procedure has been shown to decrease seizure frequency to 50% of 
its baseline 76, 77 
Pharmacological treatment with AEDs is usually convenient, non-invasive and 
always applied as the first choice. For effective treatment, the 2004 NICE 




guideline recommended that AED treatment usually has to be individualised 
according to the seizure type, epilepsy syndrome, concurrent medication and 
coexisting morbidity, and counselling of the individual and their family and/or 
carers about the treatment plan 1. The appropriateness of AEDs also depends on 
absence of contraindications to the drug, potential interactions with other drugs, 
potential adverse effects and the licensed indication of the drug 1. 
AEDs are classified into two main classes 3. Conventional or old AEDs were 
approved before 1990 and include clobazam, clonazepam, carbamazepine, 
phenobarbital, phenytoin, ethosuximide primidone and sodium valproate 78. All 
members of this class have troublesome side effects, such as sedation and 
idiosyncratic hepatitis and blood dyscrasias (Appendix 4). 
The second class comprises new AEDs which were approved after 1990 and 
include felbamate, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, 
pregabalin, tiagabine, topiramate, vigabatrin and zonisamide. The initial licence of 
this class was to act as adjunctive (add-on) treatment to old AEDs in refractory 
seizures although they can be prescribed as a monotherapy 79. New AEDs have 
been proven as effective as the older drugs and better tolerated by patients 70. 
1.7.1 Trends in treatment of epilepsy: monotherapy versus polytherapy 
Monotherapy is considered to be the gold standard for treatment of epilepsy with 
the exceptions of some epilepsy syndromes where polytherapy is advised 80, 81. 
Monotherapy is encouraged to avoid the acute and chronic toxicity associated with 
unnecessary polytherapy 82. Moreover, the fact that old AEDs exhibit a wide range 
of pharmacokinetic and pharmacodynamic variability has led to common 
awareness that effective management can be achieved only with careful 
individualisation of dosage through monitoring serum drug concentrations 82.  In 
the late 1970s and early1980s, a series of studies demonstrated that with 
implementing serum drug monitoring, seizure control of both newly diagnosed 
patients and chronic patients was often improved with single-drug therapy 83-86. 
Since the introduction of sodium valproate in 1973, numerous clinical trials have 




demonstrated that monotherapy with sodium valproate is the most effective first-
line choice for treatment of childhood generalised-onset seizures, such as juvenile 
myoclonic epilepsy 87-89 and absence seizure 90-92. Based on the results of clinical 
trials,  approximately 60-70% of children with epilepsy can be effectively 
controlled by a single AED 93, 94. 
Although monotherapy has been proven effective, arguments have developed 
around the use of low dose polytherapy in the other 20-30% patients who respond 
poorly to monotherapy 80. A multicentre study by Mattson et al. (1985) showed 
higher effectiveness of combined phenytoin and carbamazepine over single 
barbiturate treatment in patients with partial and secondarily generalised tonic-
clonic seizures 95. The introduction of new AEDs in 1990s which act with diverse 
mechanisms 96, as an effective add-on therapy has promoted the value of safe and 
effective combination therapy (rational polytherapy) in refractory epilepsies in 
adults and children 82. However, other multicentre clinical trials showed that 
polytherapy was not advantageous and there was no significant difference between 
groups of patients treated with monotherapy compared to polytherapy 81, 97. 
Another issue was that little evidence was available to support clinicians in 
determining how to use combination of AEDs when monotherapy fails 98. 
The concept of monotherapy is well-established and remains widely favoured over 
polytherapy by neurologists for the treatment of CYP with newly diagnosed 
epilepsy 99-101. However, the choice of an initial effective AED monotherapy for 
CYP with newly diagnosed epilepsy remains uncertain and clinicians most often 
select the initial AED treatment based on the CYP¶VVHL]XUHHSLOHSV\W\SH102. 
There is a consensus in clinical practice that carbamazepine monotherapy is 
considered the first-line choice for treatment of partial-onset seizures 92, 103. In 
childhood generalised epilepsy, sodium valproate monotherapy is considered the 
drug of first choice 78, 104 
In 2006, the ILAE including adult and paediatric epileptologists, clinical 
pharmacologists, clinical trialists and statisticians worked on producing a therapy 
guideline. The aim was to provide evidence-based guidance about which AEDs 




possess long-term effectiveness as an initial monotherapy for patients with newly 
diagnosed or untreated epilepsy 102. They evaluated all available evidence from a 
structured literature review of all related articles up to 2005. Because of the lack of 
comprehensive data on AED adverse effects, they failed to develop an evidence-
based guideline to identify the optimal initial AED monotherapy. They concluded 
that the ultimate choice of an AED for any individual patient with newly diagnosed 
epilepsy should consider many variables. These variables include the strength of 
the efficacy and effectiveness evidence for each AED, the AED safety and 
tolerability profile, pharmacokinetic properties, formulations and expense 102. 
The choice of second-line monotherapy when the first monotherapy fails to control 
seizures remains uncertain.  In 2006, a panel of epilepsy neurologists and clinical 
pharmacologists (SPECTRA; Study by a Panel of Experts: Considerations for 
Therapy Replacement in Antiepileptics) was assembled in the US to develop a 
consensus concerning conversions between AED monotherapies 99. Although the 
panel concluded that conversion from one AED to another monotherapy is 
complex, it developed a consensus on the principles for fully titrating an adjunctive 
AED before tapering the baseline drug. When patients are switched from one AED 
to another, a period of transitional polytherapy should be followed. This process 
may be complicated by drug interactions and complex AED pharmacokinetics. 
In the UK health system, similar work was conducted by NICE. The aim was to 
support UK health care providers in improving the quality of care and to provide 
clinicians with an evidence-based reference for the treatment of patients with 
epilepsy. The first NICE guideline for the diagnosis and management of epilepsies 
in adults and children in primary and secondary care was developed in October 
2004 1. The guidance provided some recommendations for better management of 
CYP with epilepsy. NICE principal recommendations specified that AED therapy 
for CYP should be initialised by specialists of managing epilepsy. The treatment 
plan should be individualised according to the seizure type, epilepsy syndrome, 
concurrent medication and coexisting morbidity 1. Moreover, children should be 
treated with a single AED whenever possible. If the initial treatment fails after the 




maximum tolerated dose has been achieved, then substituting the first drug using 
another drug (monotherapy) is recommended 1. The NICE guideline suggested that 
new AEDs can be prescribed as adjunctive therapy with old AEDs in case of 
refractory partial seizures in children and in case old AEDs are poorly tolerated or 
contraindicated 1. If the drug combination is believed to be successful, some 
individuals may be favoured to remain on the combination. The NICE 
recommendations on the choice of initial monotherapy are described in Appendix 5 
and Appendix 6. 
In 2007, the NHS R&D-Health Technology Assessment Programme sponsored a 
large pragmatic, randomised, unblinded, parallel group clinical trial which was 
conducted in hospital-based outpatient clinics in the UK by Marson et al. 105, 106 
The study was also supported by the pharmaceutical companies with AEDs 
included in the study. The SANAD (Standard and New Antiepileptic Drugs) trial 
comprised two arms; one arm compared the effectiveness of new AEDs to 
carbamazepine and the other compared new AEDs with sodium valproate. The 
effectiveness of valproate monotherapy in generalised epilepsy was confirmed. 
Valproate was proven superior in efficacy to both lamotrigine and topiramate, 
maintaining its place as the drug of choice in treatment of generalised epilepsy. 
Lamotrigine was found to be a more active and cost-effective alternative to 
carbamazepine in partial-onset epilepsy. 
There is no strong evidence of superior efficacy of new AEDs in children although 
they are considered better tolerated by children as compared with old AEDs 70, 107-
109
. Therefore, the old AEDs remain the first-line clinical choice for management 
of newly diagnosed epilepsy in CYP 110. 




1.8 Prescribing of AEDs for CYP in primary care 
1.8.1 The organisation of primary care in the UK 
The National Health Service (NHS) is the publicly funded healthcare system that 
was established to provide comprehensive and free health services for all residents 
of the UK 111. Since 1948, the NHS has been funded and controlled by the UK 
government through the Department of Health (DH). The NHS provides health 
care for people through two main sections: primary care and secondary care. 
Primary care refers to all health services offered at the first point of contact for 
most people within the health system. Health services in primary care are delivered 
by a wide range of independent contractors, including GPs, dentists, pharmacists 
and optometrists 111.  
The primary care services are operated by Primary Care Trusts (PCTs). PCTs are 
local organisations that commission community services and secondary care and 
spend around 80% of the total NHS budget 112. The health care services in the UK 
are centred on general practices; referrals to specialists and secondary care are 
arranged by GPs 113. Patients in the UK can only be registered with a single GP at a 
time. Access to care is cost-free for individuals in the UK 113-116. In chronic 
diseases like epilepsy, the majority of medicines used by children are prescribed in 
primary care 113. Most UK general practices maintain electronic records of all 
prescriptions which have been available for an increasing percentage of practices 
since 1988 [131]. Therefore, the healthcare system in the UK allows for the 
development of many powerful clinical databases, such as THIN database which is 
the source of data for this thesis. The nature and advantage of using THIN to 
conduct health research is discussed later in section 1.10.  
 




1.8.2 Prescribing pattern of AEDs in CYP diagnosed with epilepsy  
Until recently, no separate data were available about the prescribing rates of AEDs 
in CYP diagnosed with epilepsy in the UK. Prescribing data for CYP were usually 
aggregated in adult data.  For example, a previous study was conducted in the 
Northern and Yorkshire regions in the UK between 1992 and 1995 117. The study 
used the records of all registered patients from the Prescription Analysis and Cost 
(PACT) database across 16 health authority areas to examine the primary care 
prescribing rates and trends of AEDs. Children were included as part of the ~6.8 
million study population; however, no separate prescribing data were presented for 
children. Another study was conducted by the Office for National Statistics using 
the GPRD database between 1994 and 1998 in England and Wales, UK 27. The 
study examined the prevalence of epilepsy and prescribing of AEDs and included 
prescribing data from children as part of 1.4 million study population.  
Recently, Ackers et al. (2007) used the UK GPRD database to examine the trend of 
prescribing AEDs in CYP under 18 years old between 1993 and 2005118. The 
prescribing data of a total of 7721 CYP revealed that 75% of subjects had a 
diagnosis of epilepsy and 70% of subjects were prescribed one drug. Old AEDs 
were most frequently prescribed to CYP; however, their prescribing significantly 
decreased by 17% by 2005 (p< 0.001). The authors reported a significant 5-fold 
increase in prescribing of new AEDs between 1993 and 2005 (p< 0.001). The rapid 
uptake of the new AEDs in the UK, particularly lamotrigine, topiramate and 
levetiracetam, drove the authors to recommend further research on the safety of 
these drugs due to the patchy evidence available at the time. 
A similar prescribing pattern of AEDs for CYP was reported by van de Vrie-
Hoekstra et al. (2008) from the Netherlands 119. The authors used a pharmacy 
dispensing data of 1527 CYP, aged 0±19 years, between1997 and 2007. Sodium 
valproate was the most frequently prescribed drug followed by carbamazepine and 
lamotrigine. Prescribing of lamotrigine increased during the study period.  




1.9 Adherence to AEDs in children and young people 
AEDs represent the first-line treatment strategy for managing childhood epilepsy. 
Assuming the drug is appropriately prescribed, adherence to AED regimens is 
HVVHQWLDOWRDFKLHYHVHL]XUHFRQWURODQGLPSURYHSURJQRVLVRIHSLOHSV\DQG&<3¶V
quality of life. Poor adherence to medication can be the major cause of therapy 
failure and seizure recurrence 120, 121. 
1.9.1 Definition of adherence to medicines 
Three related terms are often used in the literature to describe the process of 
medication taking behaviour; these are compliance, adherence, and concordance. 
Compliance 
The term `compliance' generally refers to `WKHH[WHQWWRZKLFKWKHSDWLHQW¶V
behaviour matches tKHSUHVFULEHU¶VUHFRPPHQGDWLRQV' 122. Although the term 
compliance is commonly used in the medical and pharmaceutical literature, it has 
been criticised of carrying negative implications in terms of the clinician-patient 
relationship. It signifies a relationship in which the role of the clinician is to decide 
the appropriate treatment and provide the relevant instructions, while the role of 
the patient is to obey the prescriber¶VRUders 122.  
Adherence 
`Adherence'  is a synonymous term and is often used interchangeably with 
compliance; however, it is used by some to imply a more active and collaborative 
involvement of the patient in the implementation of a medication regimen 123. 
Adherence is usually defined as `the extent to which a patient¶VEHKDYLRXULQWHUPV
of taking medications, following diets, or executing lifestyle changes) matches 
DJUHHGSUHVFULEHU¶VUHFRPPHQGDWLRQV' 124. It has been adopted by many, 
particularly within the psychological and sociological literatures, as an alternative 
to compliance, in a way to emphasise that the patient is free to decide whether to 
follow the prescriber's recommendations and that the patient should not be blamed 




if they fail to do so. Adherence is suggested to carry some reasoned agreement 
from the patient toward the treatment regimens 125.To some, the concept of 
adherence seeks to empower patients by providing them with information which 
enables them to decide how they react toward the health care regimen 126. 
Concordance 
Concordance is a relatively new term that has attracted increasing interest in 
relation to medication-taking, particularly within the UK 127. It is a complex 
concept relating to the patient/professional relationship and interaction. 
Concordance is defined as a patient-centred process in which the health care 
professional and the patient reach an agreement regarding the medicines that takes 
into account the beliefs and preferences of the patient 122. 
The Medicines Partnership Initiative developed in 2002 by the NHS Department of 
Health (DH) explains concordance as a process of successful prescribing and 
medicine taking based on partnership where patients are informed about their 
conditions, the treatment options available and the risks and benefits of different 
options relative to their conditions 128. 2QWKHSURIHVVLRQDOV¶VLGHWKH\VKRXOGEH
prepared for partnership, acquire the necessary skills to convince patients and 
invest time with patients to obtain an informed agreement. 
1.9.2 Choice of terminology for the thesis 
Compliance and adherence describe the same aspect which is patient medication 
behaviour based on a scientific agenda (i.e., what the patients actually do with the 
prescribed medications in relation to the given medical recommendations and 
IDFWRUVWKDWLQIOXHQFHSDWLHQW¶VEHKDYLRXU) 122. Compliance does not address the 
normative agenda (i.e., what is `right'  and  `good'  in relation to medicine-taking 
and prescribing) whereas adherence tries to define the normative aspects by 
implying that the patient is free to decide whether to adhere or not 122. 
The term adherence will be used throughout this thesis as compliance may imply a 
SXUHO\FOLQLFLDQ¶VSHUVSHFWLYH. The adherence term is also preferred by many, 




including WHO, over the term compliance in recent research and policy 
publications. Although concordance attempts to address the normative agenda 129, 
every patient-clinician interaction cannot be assumed to reflect the principles of 
concordance whereby shared decisions were considered in prescribing of 
medicines 130. This is especially important because the study time (defined later in 
Chapter 2) of this thesis pre-dates the implementation of the concordance concept 
in the health care system. Moreover, concordance suggests that the relationship 
between patient and prescriber is to be measured and not the medication-taking 
behaviour 127. This thesis was designed to investigate the use of medicine in terms 
of levels of adherence to prescribed medication. 
1.9.3 Measurement of adherence 
Widely varying approaches have been applied to identify and measure adherence 
to medicines in CYP and therefore, variant adherence rates have been reported. 
This may be attributed to the lack of a `gold standard' to measure adherence. 
Advantages and disadvantages associated with each of these methods are shown in 
Table 1-2 131, 132. 











Can adjust drug dosage 
Objective, highly sensitive to verify 
if medicines have been 
administered. 
Commonly used in monitoring 
epilepsy medicines 
 
Pharmacokinetics may affect 
absorption and excretion rates. 
Short-term, invasive, and 
expensive 
Patients know they are 
monitored and may change 






Provide accurate data on frequency 
and time of dosing. 
Continuous and long-term measure. 
 
Cannot prove that medicines 
were ingested 






Cannot prove that medicines 
were ingested 
Sometimes overestimates 
adherence (e.g., patient may 
discard pills before clinic visit) 
Rates of medication 
refill 
Easy to collect information in 
managed care settings 
Non-intrusive 
Difficult to collect information 
if prescription source is 
unknown. 
Not proof of medication 
consumption 
Patient report Clinically feasible- low cost 
More accurate when patients report 
low adherence rates 
Tendency to overestimate 
adherence 
Subject to reporting bias-`faking 
good' 
  




1.9.4 Drug assays 
This method involves measuring drug levels in blood and sometimes in urine at 
intervals as long as several months and is commonly used with epilepsy 133-135. 
Suboptimal therapeutic levels may be indicative of non-adherence. This method is 
direct, quantitative, often useful for therapeutic drug monitoring and dosage 
adjustments, and does not depend on self or provider estimates of adherence. 
However, standardised assays may not be available for all drugs. Also, assays can 
be expensive and invasive, particularly for children 131. In addition, sub-therapeutic 
drug levels may result from factors other than patient adherence, such as improper 
dosing, non-steady state concentrations, pharmacokinetic variations due to the type 
of drug formulations (e.g. enteric coating), physiological factors such as gastric 
pH, interactions with other medications or the paWLHQW¶VDJH136. 
1.9.5 Electronic monitoring 
Microelectronic monitors or event recorder are employed to monitor the daily 
medication-taking process. These devices are microprocessors fixed in the caps of 
the standard medication bottles that record bottle openings where each time 
represents a dose removal from bottle 137. These devices record information on the 
date and time of dose withdrawal over as long as several months and allow 
downloading the recorded data into a computer for analysis. Electronic monitors 
are considered accurate and can provide a continuous and long-term measure of 
medication adherence and the time of dose withdrawal which is not achieved with 
other indirect methods 138. Monitors can also determine a range of adherence 
problems, including under dosing (the most common dosing error); overdosing; 
delayed dosing (dosing which exceeds recommended dosing intervals, which can 
lead to sub-therapeutic supply); drug holidays (avoiding taking medicines for 
several successive days without prescriber approval); and `white-coat adherence' 
(improved adherence by excessive use of medications or taking medications 
consistently a short time before clinic visits) 131, 139. 




The major disadvantage of electronic monitors is that medication consumption is 
not guaranteed and may, therefore, overestimate actual adherence 137. Monitors 
could also misrepresent  medicine taking behaviour if patients take out several 
doses at once to carry away during a holiday or to load pill reminder boxes  131. 
1.9.6 Pill count 
Pill counts or measuring the volume of remaining medicines (for liquid 
medications) in a SDWLHQW¶VERWWOHhave been widely used in adherence research. It is 
easy to do and can be routinely done during clinic appointments or by phone 132. 
The major disadvantage is that the amount of medicines removed does not 
necessarily indicate consumption and so that pill counts may overestimate 
adherence 140. Also, pill counts do not give specific information about the timing of 
daily doses, as measurements are reported over weeks or months and not on a daily 
basis 131. 
1.9.7 Patient self-reports 
3DWLHQWV¶VHOI-report of medication adherence is the most widely used measure in 
the research setting for patients with epilepsy. Self-report measures of adherence 
are commonly achieved by structured interviews, diaries or questionnaires. 
Researchers have used several general self-report measures for CYP with epilepsy 
134, 135, 141
, although few of these measures have been validated for epilepsy 141. 
When the child is too young to fill in the questionnaire, parents or caregivers are 
usually interviewed or asked to fill in questionnaires that assess whether their 
children follow the treatment recommendations, react negatively to treatments and 
if there are problems with treatments (e.g. medication adverse effects) 132. The 
utility questionnaire as a measure for adherence is however, limited. 
Patients/caregivers tend to report higher levels of adherence relative to more 
objective measures due to the feeling that reporting non-adherence may disappoint 
their clinicians 122. Adherence measures by self-reports also vary greatly because 




of the way they are developed, whether they have been validated, and to whom 
they are posted.  
Studies aimed at evaluating the consistency of self-report methods of medication 
adherence (interview, diary or questionnaire) with non self-report methods (drug 
assay, pill count or electronic monitors) revealed that questionnaires and diaries 
exhibited moderate to high concordance with non self-report methods 142. 
Interviews appeared less likely to provide a consistent estimate of adherence with 
other measures. This could occur because diaries and questionnaires afford a 
greater perception of anonymity compared with interviews 142. 
1.9.8 Frequency of medication refill (measuring adherence using databases) 
Worldwide, administrative databases containing anonymous prescription records 
have been extensively utilised to SURYLGHLQIRUPDWLRQRQSDWLHQWV¶DGKHUHQFHWR
medicines 143. These databases also offer users the ability to follow up DSDWLHQW¶V
prescription history. Administrative databases can be derived from health care 
claims databases (i.e., medical and laboratory claims) and pharmacy claims 
databases 144.  
The use of the databases in investigating drug use and adherence can provide a 
valuable source to conduct large population-based studies in a convenient, non-
invasive, objective, and generally inexpensive way. 
7KHXVHRIWKHGDWDEDVHVLQDVVHVVLQJSDWLHQWV¶DGKHUHQFH is, however, limited by 
the inability to determine if the patient actually ingested the dispensed medication 
143
. Therefore, measuring adherence using databases assumes the consumption of 
prescribed medicines by patients. Hence, it is a proxy indicator of the level of 
adherence. The assumption is made that as long as a patient was prescribed the 
medication, it is likely that the patient will consume part or all of the medication. 
PDWLHQWV¶UHFRUGVin claim databases in the USA/Canada are linked to the pharmacy 
dispensing data, so the prescription filling rate is also available and is a better 
proxy measure of adherence. This is not the case with databases from primary care 




in the UK where pharmacy dispensing records are not linked to GP records and the 
measurement of adherence depends on the pattern of issued prescriptions.  
Medication adherence measured using claim databases has been validated using 
other adherence measures such as patient reports, pill counts, questionnaires, and 
interviews 145-147.  
7KHPDMRULW\RIUHVHDUFKRQHVWLPDWLQJSDWLHQWV¶DGKHUHQFHXVLQJGDWDEDVHVZDV
conducted using pharmacy claims data. The first distinctive methodology for 
estimating medication adherence using databases was provided by Sclar et al. 
(1991) through the introduction of the medication possession ratio (MPR) 148. 
Since this time, MPR has become a widely adopted and validated method to 
measure adherence using databases 143, 149.  The MPR is often defined as `the sum 
RIWKHGD\V¶VXSSO\RIPHGLFDWLRQGLYLGHGE\WKHQXPEHURIGD\VEHWZHHQWKHILUVW
fill and the expiration date of the last refill' 150. 
The MPR as a ratio is usually a value between 0 and 1, where 0 means no 
medication supply or adherence and 1 means highest adherence to prescribed 
medicines. MPR >1 would occur in cases of overuse, early collection `early refill' 
or oversupply of prescriptions. 
7RWKHUHVHDUFKHU¶VNQRZOHGJHQo published study has examined adherence to 
prescribed AEDs using THIN database or any primary care databases from the UK. 
However, databases from the UK were used to measure adherence for other 
disorders. For example,  Brankin et al. (2006) examined three UK general practice-
sourced databases; the GPRD (recently re-named as CPRD), the MEDIPLUS and 
the (DIN-LINK) in order to estimate adherence to bisphosphonates among 
postmenopausal women in the UK 151. The authors concluded that overall levels of 
adherence observed using the UK databases are in line with findings from other 
countries. The study revealed the value of using the prescribing information 
recorded in general practice data to examine prescribing patterns and medicine 
taking behaviours. 
 




1.9.9 Adherence rates among children with epilepsy 
The prevalence of non-adherence to AED regimens in the literature varies 
according to the method of adherence measurement, patient sample size, duration 
of study and the criteria or cut-off score for classifying patients as adherent or non-
adherent. 
It is a convention in the adherence literature that patients are considered to be 
adherent if they take 80% or more of their prescribed medications 152-154 The cut-
off score of `80% adherence' has its origin in early studies on adherence to 
antihypertensive medications, which found that participants who took 80% or more 
of their medications had better blood pressure control than those who took less than 
80% 155. The cut-off score of 80% adherence has not been clinically validated for 
epilepsy but it has been applied in studies of other neurological conditions 156. 
Medication adherence is a complex issue in CYP. It involves not only the patient, 
but also parents and other caregivers who are often responsible for giving the 
medication.  
Systematic searches of three electronic databases were performed, including the 
MEDLINE (1946-2008), EMBASE (1980-2008) and PsycINFO (1806-2008), all 
via OVID, in December 2008, to search for articles relating to adherence to AEDs 
in CYP. Search terms comprised three main categories: 1) terms describing 
medication taking behaviour (e.g. adherence, compliance, drug adherence and 
patient compliance); 2) terms describing the age range of the participants (e.g. 
child$, paediatric, young people$, boy$ and girl$); and 3) terms relating to 
epilepsy (e.g. epilepsy, epilep$, seizure$ and antiepilep$).The search was restricted 
to the English language. Details of the systematic search are described in Appendix 
7. 
Studies were included in this review if 1) age range of participants was less than 18 
years. 2) medication adherence rates were reported and 3) study design and 
methods for calculation of adherence were described (e.g., self-report, drug assay, 
pill count and prescription refill). Studies that described factors DIIHFWLQJFKLOGUHQ¶V




adherence and categorised participants into highly and poorly adherent without 
reporting adherence estimates were excluded from this review. Papers of 
interventions that did not include adherence rates were excluded. A total of 88 
abstracts were identified including the key words of the search. A review of the 
titles and abstracts using the inclusion criteria identified eight reports as having 
relevant data on adherence in CYP (Table 1-3). According to these studies, 
adherence to AED regimens ranges from 44% to 88% depending on the method of 
measurement 134, 137, 1576WXGLHVZKLFKXVHGFKLOGUHQRUSDUHQWV¶UHSRUWVDVD
measure of medication adherence have reported higher adherence rates in 
comparison to other adherence measures. This may indicate that self-reports tend 
to show overestimation of medication adherence. In addition, few of these self-
reported measures were validated for use in epilepsy. A study by Modi et al. 
(2008) used an electronic monitoring device and reported a high overall medication 
adherence of 79% 137. However, this study was done over only one month and was 
aimed primarily at assessing adherence for the first month of therapy for children 
newly diagnosed with epilepsy. It is more likely that parents and children adhere to 
their treatment regimens initially. 
An update of the search was carried out on March 2012 which added one relevant 
study by Modi et al. (2011) 158.   
 




Table 1-3: Paediatric studies on adherence rates to prescribed medications for epilepsy 








Main findings and limitations 
Lisk 1985159 
UK 
The study population 
were children attending 




16 (7:9) 0.8-14 Pill counts and a single 
blood drug analysis of 
AEDs 
The authors counted pills left in a container of 
drug quantity for 1-month. 10 out of 16 children 
(62%) were good adherent (consumed 85% of 
drug). 
Blood drug level may mislead actual adherence 
as some children who adhered in pill count 
showed low therapeutic levels in blood analysis. 
 
Small sample size limited to one clinic and short 




Observational study at 
Paediatric Neurology 




9-16 Blood drug analysis at 






Based on the blood data relevant to therapeutic 
levels, 12% of the children were adherent on 1 
of 3 visits, 29% were adherent on 2 of 3 visits, 
44% were adherent on 3 of 3 visits, and 15% had 
consistent sub-therapeutic levels but were 
seizure-free (full adherence was 44%). 
Adherence reported by parent report was not 
correlated with blood data 
Small sample size limited to one clinic and short 
duration of follow-up 







study for one day at one 
outpatient paediatric 
clinic. 
The study was to assess 
accuracy of data in 
medical records and its 








About 52% of children properly adhered to 
medication regimen. 
The remaining 48% of children did not take 
AEDs as prescribed mainly due to taking 
different AEDs than prescribed or different 
planned doses. 
 
Small sample size limited to one outpatient 
setting and short duration of study. 





study. Study population 
were adolescents with 
epilepsy who were 
registered 






13-17 Self-report via patient 
questionnaire 
Overall adherence was 66%. Only 22% of 
adolescents reported full (100%) adherence to 
their regimens,  44% chose the category 
of satisfactory adherence  and the remaining 
34% reported poor adherence. 





longitudinal study of 
children for at least 6 
months as long as 2.5 
years. Children were 
newly diagnosed 
children with epilepsy 







4-13 Parent-report adherence 
using questionnaire,  
serum drug levels, and 
adherence to  scheduled 
appointments 
The principal aim was to model some 
psychosocial, behavioural, and medical factors 
that can predict adherence.  Outcome measures 
were self-report of adherence, blood level 
adherence and visit adherence. 
Mean adherence by parent report =88% and by 
drug assay=86%  
The study was conducted at one clinic so it 
cannot be generalised to all populations. 
Otero 
2000161, UK 
Prospective study of 
children and their 
mothers attending a 
central hospital in 











Good adherence was reported with 12 children 
(57%) 
Higher levels of expressed emotions were 
observed for children with poorly controlled 
seizures and poor medical adherence as 




two points estimates; 
initial started in 1993 
and then 3 to 4 years 
later. Main aim was to 
investigate whether 
there was an association 
between maternal 





compared with children with well-controlled 
seizures and good medical adherence 
 
Not clear how medication adherence was 
measured. 
No data reported on the follow-up adherence 
rate. 






Cross-sectional study on 








Self or parent-report via 
interviews 
Satisfactory adherence was reported by 72% 
No data was reported on questions asked to score 
adherence and what is Satisfactory adherence. 
Cross-sectional study in one epilepsy clinic with 
the possibility of false-positive bias 






of adherence at one-
point estimate on 
children attending a 
new-onset epilepsy 
clinic 






Adherence rate of 79% was reported and only 8 
children (23%) were completely adherent 
(100%). 
The aim was to measure adherence shortly after 
the clinic visit (the duration of study was one 






observational study of 
daily medication 
adherence up to 6 







Adherence rates were 
set as 0, 50% or 100% 
based on specific 
regimens 
 
About 42% of children showed near-perfect 
(100%) adherence and 58% demonstrated 
different levels of non-adherence (mild-
moderate- severe) based on group modelling of 
children with similar adherence behaviour. 




1.9.10 Impacts of non-adherence  
Non-adherence with pharmacotherapy is considered one of  the greatest 
challenges facing medical care and can have adverse effects on SDWLHQWV¶
quality of life, mortality rates  and economic outcomes 162. 
Limited data are known about the consequences of non-adherence in CYP with 
epilepsy 158. However, the data from adult studies could be extrapolated to 
CYP because epilepsy in CYP manifests the same symptoms and has a similar 
drug treatment strategy to that of adults. In cross-sectional studies on adults 
with epilepsy, the potential consequences of medication non-adherence are 
considered to be serious and include loss of seizure control and therapy failure 
120, 121, 162
. In a national survey of 661 adults with epilepsy by Cramer et al. 
(2002) in the USA, 45% stated that they had a seizure when missing a dose. 
There was a higher risk of having seizures among patients taking AED 
treatment four times daily (p=0.04) and among those taking a greater number 
of pills per day (p=0.02) 120. Poor adherence was associated with frequent 
emergency visits and hospitalisations and reduced quality of life 162. In a local 
university hospital in the UK, 265 (6.5%) of 4093 adult admissions in 2001 
were considered to be medicine-related and 30% of these were due to non-
adherence to medicines for chronic illness 163. In a survey of 408 adults with 
epilepsy in the USA, 29% of patients were grouped as non-adherent (based on 
self-report of missing a dose or stopping an AED within the last month) 162. Of 
the non-adherent group, 54% (versus 37% adherent) had lower scores in 
mental health and 29% (versus 12% adherent) had significant absence from 
school or work due to frequent seizures or termination from employment 
(p<0.001).  
Cross-sectional design can be effective in displaying the short-term 
consequences of non-adherence to AEDs such as experiencing seizures. Cross-
sectional surveys, however, may be of limited power to identify the long-term 
consequences of non-adherence to AEDs, such as mortality and HRQOL due 
to the short time frame of observation and data collection. Therefore, 
longitudinal population-based studies may be of higher value in describing the 
long-term consequences.    




Poor adherence has been reported to be a significant risk factor for higher 
mortality and sudden unexpected death from epilepsy 164-167. A population-
based study conducted in the US using Medicaid claims data of 33,658 adult 
patients with epilepsy was aimed at investigating the relation between non-
adherence to AED and mortality rates 168. The authors concluded that non-
adherence to AEDs is associated with a 3-fold increase in mortality risk among 
epilepsy patients, compared with those who are adherent (hazard ratio = 3.32). 
Non-adherence to medications increases the consumption of healthcare 
resources and may impair the ability of health care systems to achieve health 
goals for populations 169. Consequently, the negative outcomes of non-
adherence increase direct health care costs related to epilepsy 156, 170. A recent 
population-based study conducted in the US by Faught et al. (2009) using a 
retrospective database of 33,568 adult patients with epilepsy estimated the 
potential association between AED non-adherence (defined as dispensing of 
less than 80% of medications) and health care costs 170. The authors estimated 
that non-adherence to AED treatment was associated with higher additional 
cost for inpatient ($4,320 per quarter) and emergency admission ($303 per 
quarter). In another population-based study by Davis et al. (2008) estimated 
the costs of non-adherence to AED therapy in 10,892 adults with epilepsy in 
the USA 156. Non-adherence to AEDs (defined as dispensing of less than 80% 
of medications) was associated with an 11% increased likelihood of hospital 
admissions (p < 0.001) and $1,799 additional inpatient costs (p =0.001) per 
patient per year. Non-adherence was also associated with a 48% increased 
likelihood of emergency room admissions.  
1.9.11 Forms of non-adherence to medication 
Non-adherence to prescribed medications can take different forms, including 
dose omissions 120, failure to fill the prescription 156, incorrect dosage, 
improper dosing intervals 171, premature discontinuation of the drug 172,  drug 
holidays and `white-coat adherence'  173. Studies on paediatric epilepsy have 
suggested that non-adherence to paediatric medication regimens may be 
unintentional due to forgetfulness 174, misunderstood directions, busy parents, 
complex medication schedules, and difficulties in access to care 135. In some 




circumstances, non-adherence was intentional as a result of stigma at school 
174
, lack of caregiver support 175, lack of trust of physicians 134 SDUHQWV¶IHDUVRI
addiction, sedation and cognitive problems from AEDs 135. 
This thesis investigated available factors in THIN as possible causes of non-
adherence to AED treatment, which are presented in Chapter 3. In fact, causes 
of non-adherence to medications are numerous and multidimensional. The next 
section will discuss these causes in more detail. 
1.9.12 Risk factors for non-adherence to medications 
Research has uncovered numerous factors as possible causes of non-adherence. 
Generally, non-adherence to medication regimens in CYP with epilepsy is 
multidimensional with no single factor predicting adherence alone 176. The 




Figure 1-2: Common factors that may contribute to non-adherence in CYP  
 
 




1.9.12.1 Patients/family factors 
3DWLHQWV¶GHPRJUDSKLFV 
Studies in CYP with epilepsy have found no significant difference or 
correlation between sex and adherence 134, 174, 177. 
Adherence to medical regimens has been observed to decrease as a child grows 
older with adolescents being more likely to be non-adherent than younger 
children 174, 178.  Kyngas  (2000) found that only 22% of 232 adolescents with 
epilepsy in Finland, aged 13-17 years, were ranked as showing full adherence 
to their medication regimens 141. The reasons why adolescents are less likely to 
adhere are complex. Increased feelings of embarrassment and stigma among 
peers associated with taking AEDs was a possible cause 178. Forgetting to take 
the medication may simply be the cause when adolescents take over the 
responsibility for their own medicines and parents are less involved in ensuring 
adherence. Anderson et al. (2000) reported that 18 out of 19 adolescents with 
epilepsy forgot to take medication at least once during their treatment courses 
174
. 
At preschool and primary school age, parents and other caregivers supervise 
DQGDUHUHVSRQVLEOHIRUWKHFKLOG¶VPHGication regimen. As the children begin 
to perceive of the effect of disease on their daily lives, they are either adherent 
or poorly adherent according to their awareness of how illness impacts their 
daily lives 179. Adolescents may also refuse to follow medical instructions as a 
means of expressing their independence and autonomy from their family 180-184 
or due to a perceived sense of immortality 185.  
Family size can affect the level of adherence in CYP. Asadi-Pooya (2005) 
reported that the number of people in a family could negatively affect 
adolescent adherence to AEDs in Iran 157. Kyngas (2000), however, reported 
no significant association between the family size and composition and 
adherence to AEDs in Finland 141. The effect of family size might depend on 
cultural differences between countries. 
7KHHIIHFWRIVRFLRHFRQRPLFVWDWXVRQDFKLOG¶VPHGLFDWLRQWDNLQJEHKDYLRXU 
has been studied extensively. While poor adherence in adults with epilepsy was 




associated with low socioeconomic status and financial distress 186, pDUHQWV¶
income was not related to adherence to epilepsy medication in 211 CYP in the 
USA, aged 1-15 years, in a study by Shope (1988) 177. Similar findings were 
also reported by Mitchell et al. (2000) who examined the effect of sociocultural 
factors and family environment on adherence to treatment in 119 children (4-
13 years) with epilepsy in the USA135. They concluded that children who 
belonged to lower income families with high levels of stressful life events were 
more likely to adhere to treatment. The authors suggested that families 
reporting high levels of stress used medical recommendations and contact with 
physicians as a helpful coping mechanism 135. 
3DUHQWV¶HGXFDWLRQDQGFXOWXUHDUHSUHVXPHGWRFRQWULEXWHWRDGKHUHQFH
regimens as they mediate understanding and following of medical instructions 
135
. However, families reporting less parental education showed higher levels 
of adherence to AED regimens 135. Shope (1988) also found WKDWSDUHQWV¶
HGXFDWLRQZDVQRWUHODWHGWRFKLOGUHQ¶VDGKHUHQFHWR$('V177.  
Knowledge about the disease 
Amongst the factors that can contribute to medication adherence is self or 
parent knowledge and received education about the disease 135.  Shope (1988) 
revealed WKDWSDUHQWV¶NQRZOHGJHonly RIWKHLUFKLOG¶VSUHVFULEHGUHJLPHQLQ
epilepsy was significantly associated with adherence (p<0.01) 177.  However, 
there was no difference in chilGUHQ¶VDGKHUHQFHassociated with SDUHQWV¶
knowledge of the cause of seizures and seizure care. 
A study by Galletti et al. (1998) of 41 CYP with epilepsy in Italy, aged 6-18 
year, reported that CYP were less involved with clinicians in communication 
about diagnosis, treatment plan and life-style counselling 187. Often children 
appeared to have little information or were completely unaware of their 
condition and the reason for taking medication 187, 188. The lack of enough 
information can also contribute to poor adherence and, therefore, to a less 
desirable prognosis 161. In a survey study by Aytch et al. (2001), parents of 31 
young children with epilepsy, aged 1-5 years, expressed their need for 
sufficient and easy-to-understand information about diagnosis, treatment, how 








Beliefs about illness/treatment 
Factors such as necessity of medicines and health beliefs (alternative treatment 
SUDFWLFHVPD\LQIOXHQFHSDUHQWV¶DELOLW\DQGtendency to follow prescribed 
medication 135. 
No evidence was found in CYP with epilepsy. In a survey conducted in 2002 
of 661 adult patients with epilepsy in the USA, some patients who had not 
experienced seizures for some time began to gradually reduce their adherence 
to prescribed medication 120. They believed that taking medication was 
unnecessary, particularly if they had omitted doses previously with no seizure 
occurring. Patients may not perceive non-adherence as the main attributing 
factor in seizures occurring. When adult patients were asked if anything 
increased the likelihood of a seizure, 41% mentioned stress/emotion, 19% 
fatigue, and only 13% stated missed medication 190. This could be relevant in 
FKLOGUHQLIWKHLUSDUHQWV¶EHOLHIDERXWHSLOHSV\PHGLFDWLRQFRLQFLGHZLWKZKDWis 
mentioned above.   
Some cross-sectional studies have found that some people particularly in 
Africa, believe that epilepsy is an infectious disease and other people believe 
that traditional treatment is the best choice 191, 192. Therefore, amongst the aims 
of the ILAE/IBE (the International Bureau for Epilepsy)/WHO Global 
Campaign Against Epilepsy Demonstration Projects is to show that with 
educational activities and improved awareness about epilepsy, the social 
attitude towards epileptic patients and their families can be reduced 191, 193. 
 
Patient/physician partnership 
Young people with epilepsy who perceived that their physicians were easy to 
communicate were more likely to adhere to medication 178. Hazzard et al. 
(1990) found that SDUHQWV¶VDWLVIDFWLRQZLWKWKHLUFKLOGUHQ¶VPHGLFDOFDUH




influenced adherence to AEDs, while unclear communication with clinicians 
impaired satisfaction with medical care and adherence 134. Failure to 
appropriately communicate with or trust the physicians was suggested as a 
reason for intentional non-adherence to epilepsy medication 135. Kyngas (2000) 
found that support from physicians positively correlated with adherence of 
adolescents with epilepsy 141. Around 60% of 232 adolescents, aged 13-17 
years, reported that physicians were concerned only with epilepsy as a disease 
and gave them orders and made decisions concerning their care without 
negotiating a treatment plan. 
CYP have demonstrated that their health concerns are not always taken 
seriously by their clinicians; they felt excluded from the discussion with 
parents and clinicians tended to decide about their illness without seeking their 
perspective 194. Recent research has suggested that children over 5 years should 
be involved in their healthcare choices 194. At this age, children gain more 
knowledge, skills, and responsibility for their own conditions and are able to 
take care of their medicines in partnership with healthcare professionals 188.  
Therefore, doctor-patient communication and counselling children and parents 
was suggested highly important to prevent bad prognosis of epilepsy and to 
motivate adherence to medication 187. 
 
Coping with epilepsy  
Coping refers to `a dynamic process of cognitive and behavioural efforts to 
manage demands when a person is faced with a stressor' 195. Successful 
adherence, particularly in epilepsy, requires psychosocial adjustments on the 
part of the children and parents (e.g., improved self-efficacy and lower fear of 
seizures and complications) in order to cope with epilepsy and the medication 
regimen (e.g., its scheduling, side effects, and costs)196.    
Negative attitudes towards epilepsy, low motivation  and disturbance in 
emotional well-being were associated with poor medication adherence in 232 
adolescents with epilepsy in Finland 197.  Whereas, adolescents who had a 
strong sense of normality and felt that epilepsy was not affecting their social 




well-being showed an 8.4-fold higher tendency to adhere to medication 
regimens (p<0.01) 197. 
Young people may feel that taking an AED is stigmatising and distinguishes 
them from their peers 198. Although, many studies have reported the feeling of 
stigma among CYP with epilepsy and their families 198-200, the effect of feeling 
stigma on adherence to AEDs in CYP has not been well-documented. In a 
survey study of 696 young people and adults with epilepsy in the UK, young 
people (defined as 16-20 years) who had difficulty in social coping due to the 
stigma associated with epilepsy have reported lower adherence 178. 
3DUHQWV¶ZHOO-being also can influence their ability to adhere to WKHLUFKLOG¶V
prescribed therapy. Parents of children with epilepsy who were highly anxious 
and worried about WKHLUFKLOG¶VKHDOWKKDYHSODFHGPRUHUHVWULFWions on their 
FKLOG¶VEHKDYLRXUZKLFKKDVQHJDWLYHO\DIIHFWHGWKHFKLOGUHQ¶VDGKHUHQce to 
antiepileptic regimens 134, 161. 
 
Social and family support  
Generally, social support from friends and family members has been associated 
with higher medication adherence, while poor family support has been linked 
to poor adherence 135, 141 
Assistance and support from friends and family can contribute to FKLOGUHQ¶V 
adherence by encouraging optimism and self-esteem, reducing depression, and 
giving practical assistance 201. Practical support from family is important for 
adherence (for instance, from the first diagnosis of epilepsy, family are advised 
to help by monitoring seizures and medication dosages, maintaining medical 
appointments and are involved in the initial explanation of the dosing regimen) 
202
. 
Support from parents and friends was associated with a statistically significant 
increase (p<0.001) in adherence to medication regimens in 50% of 232 
adolescents with epilepsy in Finland 141, 197. In a survey of 47 school CYP with 
epilepsy in the USA, about half felt embarrassed by their seizure disorder, one-




third had difficulty in making friends and felt excluded by their peers and less 
than 20% felt that they were mocked because of their epilepsy. Children with 
epilepsy described the attitude of their classmates as having a more negative 
effect than experiencing seizures 174. 
In a study of 21 CYP in London, UK, mean age=12 (SD=2.9), good 
medication adherence in 12 out of 21 children was found to be associated with 
less critical comments and hostility from mothers (p=0.049). Children and 
mothers in the good adherence group had less depressive and stress-related 
symptoms 161.  
1.9.12.2 Disease factors 
Duration of treatment 
Studies in children and young people have demonstrated that adherence to 
medical regimens is inversely related to, and tends to deteriorate with longer 
duration of a disease condition 203. The length of time a an adolescent has been 
taking medications has a negative impact on their adherence level to AEDs 141. 
Adolescents who had epilepsy for 1-3 years demonstrated a significantly higher 
adherence (p< 0.001) than those who had the disease more than 3 years 141.  
 
Seizure type and frequency 
It can be assumed that patients with more frequent and severe symptoms are 
more likely to adhere to their regimen. Shope (1988) examined predictors to 
adherence by assessing serum levels of AEDs in two paediatric populations 
with epilepsy (n=90, n=211) 177. The author concluded that adherence was 
higher in the group that experienced a higher frequency of seizures (p<0.025). 
However, Hazzard et al. (1990) found that children with more parent-reported 
seizures during the previous year were associated with lower adherence to 
medications 134. However, this study was conducted over a short period (3 
months) and it is possible that lower adherence may have produced increased 
disease activity. 




No evidence was found from paediatric studies in epilepsy on the association 
between seizure type and adherence. Specht et al. (2003) assessed AED levels 
of 52 adult patients in Germany and found that out of the non-adherent group 
those with generalised tonic clonic (GTC) seizures were less likely to adhere 
compared to other seizure types 204. However, the authors suggested that this 
finding should be interpreted carefully as patients having GTC seizures were 
more likely to see a clinician soon after having a seizure compared to patients 
with other types of seizures. 
1.9.12.3 Regimen factors 
Complexity 
The general findings throughout the research literature indicate that the simpler 
the schedule, the greater probability of medication adherence. For example, 
adherence with oral medicines was better with twice daily regimen versus four 
times a day 205. Asadi-poya (2005) found that adolescents with epilepsy who 
were on once daily regimen showed a higher adherence than those on 2-3 times 
daily regimens 157. Cramer et al. (2002) calculated that the odds of missing a 
dose increased by 27% each additional time an AED was expected to be taken 
daily 120. Logistic regression models indicated that the likelihood of a seizure 
following a missed dose of medication was positively associated with the 
number of medication pills taken daily 120. 
The possibility of taking AEDs once a day was a significant preference for 
children with epilepsy, aged 5-14 years, who chose once daily monotherapy  
with sustained-release formulation of sodium valproate over conventional 
twice daily valproate 206. Adult patients with epilepsy also preferred to be 
switched from immediate-release to the sustained-release formulation of 
sodium valproate. Patients stated that they could easily fit this into their 









Forms and palatability 
It has been observed that parents prefer oral liquid to solid forms but adherence 
was measured in only few studies 205. No evidence was found for children with 
epilepsy. However, poor adherence to prescribed medications has been 
associated with the bad taste of some drugs (such as HIV, immunosuppressive 





Adverse effects from medications were associated with lower adherence. 
Studies of CYP have suggested that these groups are less aware or worried 
about possible long term harmful effects of medicines compared with adults, 
but CYP are concerned about side effects, and dislike feeling dependent on 
medicines 135. 
Most AEDs have some neurological side-effects which impair an LQGLYLGXDO¶V
psychosocial functioning particularly in children and adolescents 178. In a survey of 
47 school children and adolescents, half of the children were dissatisfied with taking 
AEDs and all reported that sleepiness was the major adverse effect of AEDs 174. 
Children and adolescents have reported that side effects are a cause of non-
adherence to AEDs 134, 157, 178. 
 
Cost 
Treatment costs may represent a burden to some families particularly in 
chronic illnesses. A recent review of current published research has focused on 
the relation between out-of-pocket medication costs and adherence 212. The 
review also examined how patients cope with medication costs in chronic 
illnesses. The authors have concluded that based on cross-sectional and 
longitudinal data, higher out-of-pocket medication costs and lower patient 
incomes are each associated with the underuse of prescribed drugs with 
considerable evidence of cost-related poor adherence. This issue may be 




unimportant for children and many young people with epilepsy in the UK as 
children up to 16 years are entitled to free prescriptions and standardised 
access to diagnostic facilities and epilepsy services. 
1.10 The data source for the thesis  
All analyses throughout the thesis have been conducted using THIN database. 
The structure, advantages and limitations of using THIN are discussed below. 
1.10.1 Introduction to THIN data 
The Health Improvement Network (THIN) is a longitudinal computerised 
primary care database that contains electronic medical records from general 
practices around the UK. THIN database contains data from 514 general 
practices with a total of more than 10 million patients which, in 2010, covered 
5.8% of the UK population. Of these, about 3.6 million patients are actively 
registered with practices and can be prospectively followed 213. The remaining 
patients have either left the practice or died but their historical data are still 
stored. THIN comprises over 57 million person-years of data.   
The data included in THIN is the information that GPs and general practice 
surgeries record on their patients using the Vision general practice computer 
system (In Practice Systems, London, UK) as part of everyday clinical care 214, 
215
. Patient records (stripped of identifying details) are extracted on a regular 
basis and electronically downloaded via a secure internet connection by EPIC, 
UK, the company responsible for incorporating the raw data into the final 
THIN database. In fact, many of general practices contributing to THIN are 
previously and/or currently contributing data to the GPRD; one of the UK 
largest and validated database for pharmacoepidemiological research. Other 
THIN practices have never contributed data to GPRD 214.  
The data collection in THIN started prospectively from general practices in 
September 2002; however, for many practices, electronic records have been 
available since 1987 and these records were assimilated into THIN 215. 




THIN provides anonymous data on demographic information, lifestyle 
characteristics, medical diagnoses (including those resulting from referrals to 
specialists), prescriptions issued by GPs, laboratory results, measurements 
taken during medical practice and free text comments 215, 216. 
A number of different versions of THIN, from diffeUHQWVWDJHVRIWKHSURMHFWµV
development, are available. Major versions are named according to the number 
of practices contributing at the time of data incorporation. For example, THIN-
255 contains data from 255 general practices. Within each major version, there 
may be a number of sub-versions resulting from periodic updates to the 
collected data. For example, THIN-255 (November 2004) provides data from 
255 practices, where the last date of data collection was 30 November 2004. 
1.10.2 Strengths of using THIN in health research 
Size and representation  
The main advantage of using the THIN database in health research is that it 
contains an anonymous and nearly comprehensive history of patients in the 
NHS system. Patient histories include clinical, morbidity diagnosis, treatment, 
disease monitoring, outcomes and health care utilisation data collected 
throughout the daily routine work of the GPs 217. Thus THIN is a large 
population-based database that was derived from a representative subset of the 
UK population. THIN provides longitudinal data which make it attractive for 
studying trends of prescribing, long-term medication use and clinical 
outcomes, particularly for chronic diseases such as epilepsy 217. THIN can 
reflect the real-OLIHVLWXDWLRQRIFRPPXQLFDWLRQZLWKSDWLHQWVWKURXJK*3¶V










Convenience and applicability 
Using THIN database is relatively less expensive and less time-consuming for 
conducting research than other study designs, such as RCTs, which are often 
carried out for shorter durations than would be desirable. Since its 
establishment in 2002, general practices contributing to THIN are increasing 
which has provided prospectively recorded and computerised data 217. This 
makes THIN of potential use for conducting observational primary research for 
chronic conditions such as epilepsy. In terms of medicine use and adherence, 
THIN is not intrusive, since patients and GPs are not contacted for data 
collection purposes. Therefore, frequency of drug use and other study 
outcomes are not affected by research activities. 
 
Validity and reliability 
The validity of THIN data has been examined for clinical diagnosis of major 
diseases. Studies have demonstrated that the THIN database has a high level of 
completeness and reliability in recording of hepatitis C 215, gastrointestinal 
ulcer 216, death 218, lymphoma 219, and skin cancer 220.  All previous studies 
have suggested the usefulness of THIN database in conducting medical and 
pharmaco-epidemiological research. Another study was able to reproduce well-
established associations between diseases and drugs utilising a case-control 
design 214 . THIN has showed a high level of completeness in recording rates 
of prescribing of smoking cessation medication compared to the reported rates 
of dispensing of prescriptions from the NHS Prescription Services data 221.  
A recent study by Meropol and Metlay (2012), concluded that THIN has good 
quality in recording hospitalisation codes of acute pneumonia hospital 
admissions 222. Recording admission dates was of accurate timing for short 
stay, however, not for longer stay.  
 




1.10.3 Limitations of using THIN  
The use of THIN has many advantages, but there are also limitations and 
weaknesses for clinical and medication research. These limitations include 
incomplete recording of certain information that may be desirable for research 
purposes, such as diagnostic subtypes of epilepsy, frequency of occurring 
seizures and some dosage instructions. This is because the data collection is 
based on what the GP considers to be important for the long-term care of 
individual patients 223, 224.  
Drugs prescribed by hospital doctors or other specialists during inpatient stays 
are not recorded in THIN database. However, drugs prescribed on discharge, to 
be continued, are included on the discharge summary, since the GP will be 
responsible for subsequent prescribing of these drugs. 
Measurement of adherence to AEDs relies on the pattern of issued 
SUHVFULSWLRQVE\*37KHUHLVQROLQNEHWZHHQ&<3¶VUHFRUGVLQ7+,1DQG
dispensing data, so measuring adherence assumes that CYP dispensed their 
prescriptions and consumed their medications.    
Although THIN provides longitudinal data, the length of follow-up of many 
individual patients is short as patients are free to move and change general 
practice as they like. 




1.11 Rationale for the thesis 
Epilepsy is a widespread and heterogeneous set of chronic neurological 
disorders that requires continuous treatment for good clinical and psychosocial 
outcomes 27, 135.  Epilepsy has been demonstrated to carry social stigma and to 
have adverse educational, psychosocial and vocational consequences in CYP 
35, 40, 44, 225
.  
Appropriate evidence-based prescribing accompanied by patient adherence to 
medical advice and AEDs is a key factor for achieving better clinical outcomes 
and improvement of LQGLYLGXDOV¶TXDOLW\RIOLIH. Limited data are available 
about the pattern of AED prescribing in CYP in primary care. Research into 
measuring medication adherence in CYP remains sparse with many studies 
using non-validated and non-objective measures. Moreover, the majority of 
research that has examined the problem of non-adherence to AEDs in 
paediatric epilepsy has been carried out using cross-sectional designs and small 
populations. This may influence the statistical power and generalisability of 
the results and therefore, may not necessarily give a precise picture of the 
general SRSXODWLRQ¶VGUXJ-taking behaviour. Since adherence to medication is 
described as a dynamic process 169, the change of adherence levels over time 
cannot be reflected in cross-sectional surveys. This may depict the strength of a 
longitudinal study in characterising the long-term changes in adherence.   
Only three studies have been conducted on the adherence of CYP with 
epilepsy in the UK, which are out of date and non-generalisable 159-161. The 
aims of two studies were to examine the accuracy of data in medical records of 
CYP 160 RUWRPHDVXUHWKHDVVRFLDWLRQEHWZHHQPRWKHU¶VH[SUHVVHGHPRWLRQV
and the well-being of the child and possible effects on medication adherence 
161
. No study has addressed the long-term adherence and its dynamics.  
Very little is known about the consequences of non-adherence in CYP with 
epilepsy in terms of seizure control and prognosis of the disease. Research on 
adults with epilepsy has demonstrated that poor adherence lead to poor 
prognosis and increased mortality rates. The optimal or minimal level of 




adherence in paediatric epilepsy that is necessary to achieve good clinical 
outcomes remains uncertain 137. 
In addition, very limited data are known about the costs associated with 
treating epilepsy in children in the UK. Aggregated data of small cohorts of 
CYP with adult data were only reported in predated studies in the UK prior to 
1999. A population-based study will provide a more robust estimate of the cost 
of illness and, therefore, will aid in assessing the burden of epilepsy in children 
in the UK. 
In chronic diseases like epilepsy, GPs are responsible for prescribing the 
majority of AEDs for CYP and, therefore, play a key role in management of 
disease in the UK. THIN database will most likely provide access to large 
representative samples of CYP with epilepsy in the UK. Using the prescribing 
information recorded in THIN, the pattern of AED use can be illustrated and 
adherence rates of CYP diagnosed with epilepsy can be measured. 
This thesis represents a population-based study of paediatric epilepsy in order 
to quantitatively assess medication use in CYP, examine the longitudinal 
dynamic adherence rates to medicines over time and reveal possible clinical 
outcomes associated with it. Furthermore, the thesis will provide an estimate of 
the direct costs associated with treating epilepsy in CYP in the UK primary 
care. 
1.12 Aims and objectives of the thesis 
1.12.1 Aims 
The aim of this research study is to examine the prevalence of epilepsy in CYP 
in UK primary care and to quantify adherence to AEDs using THIN data. The 
long- term clinical outcomes and the direct costs associated with treating 
childhood epilepsy will be estimated at the population level. 
 




1.12.2 Objectives and thesis outline 
The objectives of the study are to: 
Chapter 2 
1. Determine the incidence and prevalence of epilepsy in a population of 
children under 18 years old who were registered at THIN participating 
general practices between 1988 and 2004. 
 Chapter 3 
2. Examine the prescribing pattern of various AEDs that have been prescribed 
for each child initially and over time. 
3. Measure the adherence of the CYP to AEDs, initially and over time, and 
determine how this varies by key clinical and sociodemographic variables 
(e.g., age, sex, socioeconomic status, type of epilepsy and the number of 
AEDs). 
Chapter 4 
4. Investigate the association between adherence and clinical outcomes, such 
as seizure counts (frequency) and duration and proportion of patients that 
are seizure-free (remission period). 
Chapter 5 
5. Quantify primary health-care resource utilisation by CYP over time, from 
the point of diagnosis and estimate the direct costs of treating epilepsy in 
primary care. 
 
Ethical approval  
Ethical approval for the research project was granted from the THIN internal 
Scientific Review Committee (SRC). 
 
 




2 Chapter 2 Estimating the incidence and prevalence 
of epilepsy in children and young people in the UK  
2.1 Introduction and rationale for this analysis 
Over the last four decades, findings from published literature have reported 
that the incidence of epilepsy varies substantially with age with its highest 
peak in childhood 21. Estimates in Europe have reported incidence of epilepsy 
in CYP to be 50-70 per 100 000 population and is slightly higher in males 21, 25. 
A number of studies have examined the incidence and prevalence of epilepsy 
in the UK (Table 2-1 and Table 2-2) 22, 23, 27, 226-231. Some of these studies have 
provided period estimates of the incidence and prevalence because of the 
cross-sectional design 22, 228, 230. Other studies were conducted in specific 
locations in the UK 23, 229, 231. Some studies included children as a part of a 
wider age-range study cohort 228-230. Other studies were designed to examine 
incidence of specific seizure pattern (such as prevalence of acute repetitive 
seizures) 230.  
Table 2-1: Previous incidence studies of epilepsy in CYP in the UK 









Survivors of 1970 
British birth cohort 






Notes and letters of 
GPs in 1993 
6000 0-20 61 
Wallace 199822 
UK 






















2001-2003 77952 0-14 66 
Martinez 2009230 
UK 









* Incidence calculated per 100,000 person-years 




Table 2-2: Previous prevalence of epilepsy in CYP in the UK 







Ross 1980 226 
UK 
Follow up cohort 
born in 1958 
15,496 11 4.1 
Verity 1992227 
England 
Survivors of 1970 
British birth cohort 
followed up 10 years 
14,676 0-10 2.8 
Cockerel 1995228 
UK 
Notes and letters of 
GPs 1993 
6000 0-20 4.3 
Wallace 199822 
UK 
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Not only incidence is higher in children than in adults, but a population-based 
study conducted by the Office for National Statistics using the GPRD database 
has reported 7% increase in age-standardised prevalence of epilepsy between 
1994 and 1998 for all ages 27.  Furthermore, there appear to be variations in 
incidence and prevalence within the population linked to socioeconomic status. 
Some studies have examined association between incidence of epilepsy and 
socioeconomic status in the UK. A study conducted by Heaney et al. (2002) 
identified 119 patients with epilepsy (including 65 CYP aged 0-14 years) from 
20 general practices in London and south east England 23. The authors reported 
that the incidence of epilepsy varied by socioeconomic status with a possible 
twofold increase in the odds of epilepsy in CYP living in highly deprived areas 
than those living in least deprived (p=0.001). However, in a more recent study, 




Reading et al. (2006) identified 182 CYP, aged 1 month-14 years, who had a 
confirmed diagnosis of epilepsy in the Norfolk university hospital, UK. The 
authors found no association between incidence of epilepsy and area of 
deprivation (p=0.98) 231. A limitation of both studies was that they were 
conducted in specific geographic areas in the UK and on relatively small 
populations of children.  
The current state of evidence in the UK suggests that the prevalence of 
epilepsy is increasing in the population, with the highest incidence in 
childhood, and a possible association with socioeconomic status, However, this 
evidence is sparse or out-of-date, so a population-based study is needed to 
investigate trends of incidence and prevalence over time, to allow more 
appropriate planning for current and future health care resource allocation. 
This chapter aimed to use THIN database to estimate the incidence and 
prevalence of epilepsy in CYP in the UK between 1990 and 2004.   
2.2  Objectives of the analysis 
The objectives of this chapter were to:  
1. Identify a study cohort of CYP with epilepsy using THIN.  
2. Estimate the incidence rate and prevalence of epilepsy in CYP in the UK 
between 1990 and 2004. 
3. Perform a descriptive analysis of the basic characteristics of the study cohort 
by age, sex, level of socioeconomic deprivation and co-existing morbidities.   
  





2.3.1   Data source and study population 
The estimation of the incidence and prevalence of epilepsy was conducted 
using The Health Improvement Network (THIN) primary care database 
(Chapter 1). 
This study used a preformed THIN dataset (THIN-255) that contained 
DQRQ\PLVHGSDWLHQWV¶UHFRUGVIURPJHQHUDOSUDFWLFHVDFURVV(QJODQG
Northern Ireland, Scotland, and Wales. The study population were CYP 
younger than 18 years old who were born on or after January 1st, 1988 and 
contributed to THIN up to November 30, 2004 232.  
The incorporated data in THIN are supplied in the form of four separate 
standard files and two linked files. The standard files are patient, medical, 
therapy and additional health data (AHD) files. Each file contains a unique 
practice identification code and a unique (per practice) patient identification 
code, which together form a unique identifier for individuals within the 
database. The linked files are postcode variable indicators (PVI) and dosage 
records. The main information recorded in the four basic files is shown in 
Table 2-3. 




Table 2-3: Structure of The Health Improvement Network database 
THIN data File         Available information  
Patient 3DWLHQW¶VGHPRJUDSKLFLQIRUPDWLRQDQGUHJLVWUDWLRQGHWDLOVHJ
registration date, transfer-out date, month and year of birth for 
children up to 15 years and then only year of birth for patients 
older than 15/date of death, sex, and a unique (per practice) 
household identifier for members of the same family or patients 
reside at the same address) 
Medical Records of medical symptoms, disease diagnoses, hospital 
admissions, medical procedures and investigations 
Therapy Details of prescriptions such as date of prescription, name of drug, 
drug formulation,  quantity prescribed, dosage frequency, and 
duration of prescription 
Additional Health 
Data (AHD)     
Additional information such as lifestyle and preventative health 
care (e.g. smoking and alcohol habit, weight, height, blood 
pressure, vision, hearing, physical/mental child development, 
immunisations, biological test results, diagnostic radiography, 
drugs serum levels) 
 
 
Diagnoses of diseases and other medical disorders are recorded using the READ 
codes scheme. The Read codes exist in a hierarchical structure of comprehensive 
clinical terminology system relating to observations (signs and symptoms), 
diagnosis, investigations and surgical procedures. The first version of the Read 
code scheme (4-Byte READ) was developed in the early 1980s by Dr James 
Read, a Loughborough (UK) general medical practitioner 233. The technical 
properties of 4-Byte READ scheme were extended to 5-Bytes new code structure 
prior to January 1991. The Read Thesaurus (Version 3 of the Read Codes) is a 
progressive version of medical terminology that aims to support clinicians from 
the primary, secondary and tertiary settings in recording all processes of care and 
manage data in electronic patient records. It was developed during the Terms 
Projects (1992-95).   




In 1988, the National Health Service (NHS) recommended the Read Codes 
scheme as the standard for general practices233. The Read codes scheme is 
structured into chapter headings contained in a comprehensive dictionary.   
The clinical terms in the Read scheme allows cross-mapping to other coding 
systems such as the UK mandated classifications of the Office of Population, 
Censuses and Surveys Classification of Surgical Operations and Procedures 
(OPCS-4) and the International Statistical Classification of Diseases ICD 9 and 
ICD 10.  
Prescriptions are recorded using the Multilex coding system developed by First 
Databank, UK.  
Data from the four basic files were used to identify the study cohort for this 
analysis and other subsequent analyses throughout the thesis.    
2.3.2 Identification of children and young people diagnosed with epilepsy 
The inclusion criteria for extraction of a relevant cohort involved CYP younger 
than 18 years at their registration date at general practices contributing to THIN. 
Neonates who were OHVVWKDQGD\VZHUHLQFOXGHGEHFDXVHFKLOGUHQ¶VSUHFLVH
date of birth (day, month, year) is not available in THIN records as part of 
ensuring anonymity7KHPRQWKDQG\HDURIELUWKDUHUHFRUGHGXQWLOWKHFKLOG¶V
15th birthday, after which only the year of birth is recorded 234.  
The CYP were required to have at least one diagnostic code of epilepsy or 
epilepsy subtype (Appendix 8) and at least one prescription of an antiepileptic 
drug (AED) shown in Appendix 9. This criterion comprised the study definition 
of epilepsy and it has been commonly applied to identify children and adults with 
epilepsy using databases 22, 156, 230. The researcher consulted a clinical associate 
professor (William Whitehouse) in the Division of Paediatric Neurology- 
4XHHQ¶V0HGLFDO&HQWUH+RVSLWDO± Nottingham, to assist in refining the 
diagnostic codes list of epilepsy clinical terms to avoid misdiagnosis of epilepsy. 
Infants and young children who had only diagnoses of febrile convulsions were 
not included in this study.  




2.3.3 Data management for the extraction of CYP diagnosed with epilepsy  
Extraction of CYP with an epilepsy diagnosis from THIN was carried out using 
multiple data files; medical, therapy and AHD file. The &<3¶V records from each 
file were subsequently linked and compiled into one dataset, which then 
comprised the study cohort. Figure 2-1 illustrates a schematic diagram of 
building up the study cohort.  
 
 
Figure 2-1: Summary of building the study cohort of children and young people 
with epilepsy  
  
To extract CYP who had an epilepsy diagnosis from the medical file, the 
master Read code dictionary (Version October, 2008) was used to create a 
diagnostic Read code list. This diagnostic Read code list comprised all possible 
clinical terms of epilepsy and epilepsy syndromes (Appendix 8). The Read 
codes dictionary was in Microsoft ACCESS format. A Read code list was 
generated by running a simple search query using the keywords of epilepsy 
and epilepsy syndromes. The keywords included `epilepsy', `epileptic' and 




`seizures'. The keywords of epilepsy syndromes were identified according to 
WKH,/$(¶V classification of epilepsy and epilepsy syndrome shown in 
Appendix 10. 
To avoid misdiagnosis of epilepsy, the final Read codes list in Stata format 
was refined according to ICD 10 (Appendix 10) by excluding codes that did 
not relate to a diagnosis of epilepsy. For example, CYP who only had Read 
codes that referred to symptoms such as `seizures', `fits' and `convulsions'  
without a clear code for epilepsy were not included in the extraction of CYP 
with epilepsy because not all seizures are epilepsy. However, these symptom 
codes (Appendix 11) were used later in Chapter 4 and 5 for calculation of 
incidence of seizure events for the defined study population.  
The AHD file of THIN database was also searched for any codes related to 
epilepsy. Some AHD codes used for epilepsy monitoring and follow-up and 
others for epilepsy medication review were extracted. These AHD codes were 
added to the diagnostic code list to define study cohort with epilepsy diagnosis 
(Appendix 8).  
The medical file of THIN data was screened using the refined Stata format list 
and then all CYP who had a diagnosis of epilepsy were identified and 
extracted. 
2.3.4 Extraction of CYP with epilepsy from therapy files using drug codes 
As mentioned in section 2.3.1, THIN database uses the Multilex coding system 
to code the name of prescribed drugs. This Multilex coding system 
corresponds with the codes assigned to drugs in the British National Formulary 
(BNF).  
A list of 20 approved AEDs until 2004 was generated to extract CYP who 
were prescribed AEDs to control epilepsy and status epilepticus from the 
therapy file (Table 2-4). Status epilepticus is an emergency condition which 
defined as a repeated generalised tonic-clonic seizures lasting over a 30-minute 
period without recovery of consciousness between seizures 235. The drug codes 
of status epilepticus were not used in extracting the CYP with epilepsy but 




instead they acted as seizure marker and were used together with seizure codes 
to calculate incidence of seizure events for the defined population in Chapters 
4 and 5.  
THIN Multilex drug codes were searched for drugs listed in Table 2-4. The 
BNF codes and the Multilex codes for the identified AEDs are shown in 
(Appendix 9). This drug codes list shows that each drug type can have multiple 
Multilex codes by different dosage packages, dosage forms and dosage 
strength. This Multilex drug codes was copied into Stata format and 
subsequently the therapy file within THIN database was screened using this 
list to extract CYP who were prescribed any AEDs.  
Table 2-4: List of approved antiepileptic drugs in the UK up to 2004 
Control of epilepsy (year of UK 
licence) a 
Control of status epilepticus 
 
Carbamazepine (1965) Diazepam (1963) 
Clobazam (1979) Midazolam (1975) 
Clonazepam (1979) Paraldehyde (1882) 
Ethosuximide (1955)  
Gabapentin (1993)  
Lamotrigine (1991)  
Levetiracetam (2000)  
Oxcarbazepine (2000)  
Phenobarbital (1912)  
Phenytoin (1938)  
Primidone (1952)  
Sodium valproate (1973)  
Tiagabine (1998)  
Topiramate (1995)  
Valproic acid (1993)  
Vigabatrin (1989)  
a: Source: Epilepsy Action, http://www.epilepsy.org.uk/info/treatment/uk-anti-
epileptic-drugs-list   
Thereafter using the unique child ID, all the extracted records from the medical 
and AHD files containing diagnosis of epilepsy were linked to the extracted 




records from the therapy file containing drug codes.  By this linking, all CYP who 
had both epilepsy diagnosis and at least one prescription of AED treatment where 
identified in one dataset as the main study cohort (group 1 in Figure 2-1). Other 
groups of CYP who had only a diagnosis of epilepsy or prescriptions of AEDs 
without diagnosis were defined separately.  
2.3.5 Classification of the children and by epilepsy subtypes 
Because of the heterogeneous nature of epilepsy, CYP diagnosed with a 
particular epilepsy subtype had multiple Read codes of clinical terms for this 
subtype which may be clinically attributed to a different set of symptoms, 
condition severity and/or age at onset.  
To simplify the classification of the study cohort by epilepsy subtypes, the 
clinical terms that referred to the same epilepsy subtype were combined in one 
diagnostic term (Appendix 12) based on the glossary of descriptive 
terminology of the ILAE 13. Thereafter, CYP were assigned a final epilepsy 
subtype. When a child had more than one diagnostic epilepsy subtype, the 
latest diagnosis was considered.  For instance, focal epilepsy was recorded by 
multiple Read code clinical terms such as `partial epilepsy without impairment 
of consciousness', `idiopathic epilepsy with local onset', `temporal lobe 
epilepsy', and `unilateral epilepsy'. All these clinical terms were combined in 
one epilepsy subtype which is `focal epilepsy'.  
2.3.6 Extraction of Read codes of other conditions treated with AEDs 
Many CYP were issued prescriptions for AEDs without finding any diagnostic 
codes for epilepsy in their records. Some of these CYP may have had epilepsy 
and others may have been treated from other mental and behavioural disorders 
due to the fact that AEDs have proven effective as mood stabilizers 236 and in 
the management of certain kinds of dysfunctional anxiety 237 and other 
diseases 238-242.  
A list of the Read codes of disorders treated with AEDs rather than epilepsy 
was created. This list included childhood migraine, neuropathic pain and some 
mental and behavioural disorders such as bipolar and conduct disorders, 




anxiety and other psychoses (Table 2-5). The Read code dictionary was used to 
search for these conditions.  
According to the WHO ICD-10, mental and behavioural disorders include 243:  
Organic, including symptomatic, mental disorders 
Mental and behavioural disorders due to psychoactive substance use 
Schizophrenia, schizotypal and delusional disorders 
Mood [affective] disorders 
Neurotic, stress-related and somatoform disorders 
Behavioural syndromes associated with physiological disturbances and physical 
factors 
Disorders of adult personality and behaviour 
Mental retardation 
Disorders of psychological development 
Behavioural and emotional disorders with onset in childhood and adolescence 
Unspecified mental disorder 
The list of Read codes (Appendix 13) was generated by running search queries 
using the keywords of each disease or disorder as shown in Table 2-5. Searching 
the medical files by keywords of specific diseases or disorders produced some 
Read codes of other mixed behavioural disorders or disorders of adult patients. 
These Read codes were removed in accordance to ICD-10, 2007 guidance243. For 
instances;  
x The Read codes of single manic and depressive episodes were excluded 
from the codes of bipolar affective disorders.  
x Coding of certain sexual attitudes and hyperkinetic disorders overlapped 
with conduct disorders.  
x Coding of certain adjustment disorders was distinguished from coding of 
depression.   
x Coding of certain organic mental disorders was separated from neurotic 
disorders.  
x Coding of behavioural disorders of childhood onset and adolescent was 
distinguished from neurotic disorders.   
x Coding of nonorganic sleep disorders was distinguished from that of 




neurotic anxiety disorders.  
x Disorders of adult personality and behaviour were distinguished from 
behavioural and emotional disorders of childhood and adolescent onset. 
The refined Read code list of 655 codes was used to extract CYP without epilepsy 
who were treated from any of the above-mentioned conditions (Appendix 13). 
Table 2-5: Conditions treated with AEDs, Read codes and ICD-10 codes 
Condition  Key words Read codes chapter 
headings 
ICD-10 codes 








Anxiety and stress Anxiety, stress  
E200.00,  Eu41.00 
 


































E274.00, Eu51.00 F51 



























2.3.7 Extraction of Read codes of co-morbidity  
This study is concerned with co-morbidity and prescribing of multiple drugs as 
part of descriptive analysis of study cohort. Therefore, a list of common 
chronic co-morbidities was developed to investigate whether CYP with 
epilepsy was treated from other co-morbidities (Appendix 14). This list 
included asthma, cardiovascular diseases, chronic renal diseases, cystic 
fibrosis, diabetes, human immunodeficiency virus infection (HIV), and 
juvenile rheumatoid arthritis.  
Some studies have revealed an increased risk of co-existing psychiatric and 
behavioural disorders among CYP with epilepsy 244, 245. It has been shown that 
CYP with epilepsy have higher incidence of psychiatric disturbances relative 
to CYP with other neurological disorders and CYP of general population 54, 244, 
245
. Therefore, mental behavioural disorders which could be associated with 
epilepsy included Attention Deficit Hyperactivity Syndrome (ADHS) 246, 
anxiety, stress, depression 247, conduct disorder, lethargy, cognitive disorders 
248
, mental retardation and other psychoses 249, 250 were added to the co-
morbidity code list. 
The master Read code dictionary (Version October, 2008) was used to search 
diagnostic Read codes of these co-morbidities using Microsoft ACCESS. A list 
was generated by running search queries in using the keywords of each 
disease. The searches in ACCESS were also carried out using the Read codes 
chapter headings of each co-morbid disease as another query (Table 2-6).  
The two lists generated from the ACCESS queries were compiled and refined 
according to ICD-10-2007 codes and copied into Stata format. Overlapping 
codes of differential diagnostic disorders which did not belong to the co-
morbidity of interest were distinguished and removed as previously discussed 
in section 2.3.6. There were other examples of code refining shown below:   




x Coding of acute and transient psychotic disorders such as oneirophrenia, 
brief schizophreniform and schizotypal disorders overlapped with 
schizophrenia.  
x Coding of specific personality disorders such as paranoid and schizoid 
personality disorders was separated from coding of paranoia and 
schizophrenia.   
x Coding of transient global amnesia of transient cerebral ischaemic attacks 
was separated from cognitive disorders 
x Coding of certain chronic obstructive pulmonary diseases was separated 
from coding of asthma 
x Coding of diabetes mellitus in pregnancy, childbirth and the puerperium 
was separated from diabetes mellitus.  
The final Stata format returned a total of 1476 Read codes which were used to 
extract the co-morbidities from the CYP¶VPHGLFDOILOHRI7+,1GDWDEDVH7KH
obtained extracted co-morbidities data was then screened against the epileptic 
cohort to identify CYP with epilepsy who had other concurrent co-morbid diseases 
during the study period.   
  




Table 2-6: Co-morbidity extraction, key words, Read codes and corresponding 
ICD-10 codes 




1.General common co-morbidities 
Asthma Asthma H33..00, 663..00 J45 









I00, I01, I05, 
I06, I07, I08, 
I09, I20, I21, 
I22, I23, I24, 
I25, I34, I35, 
I37 








































2.Other co-morbidities  
 



















Behavioural disorders of 










Depression Depression E112.00,Eu32.00 F32, F33 
 
Mental retardation Mental retardation E3...00, Eu7..00 F70-F79 






















2.3.8 Quantifying the characteristics of the study cohort 
Group 1 (Figure 2-1) represented the main study cohort that met the inclusion 
criteria of having epilepsy diagnosis and at least one AED prescription. The 
basic characteristics of the CYP of this group including CYP¶VGHPRJUDSKLFV
such as age, sex and socioeconomic status were described and tabulated. Group 
2 of CYP with a prescription for AEDs and a medical code for seizures did not 
have a clear code for epilepsy diagnosis, so they may have had non-epileptic 
seizures. Group 3 of CYP with only a diagnosis of epilepsy and no treatment 
PD\KDYHKDGDKLVWRU\RIHSLOHSV\EXWVHL]XUHVDUHLQUHPLVVLRQIRU\HDUV
251
  The characteristics of two groups were presented separately as discussed 
later in section 2.3.13.  
The age of CYP (group 1) was calculated at the date of first recording of 
epilepsy in THIN. This date was defined as the date of first recording of 
epilepsy diagnosis or the date of first prescription of AEDs, whichever 
occurred earlier. The number of CYP was stratified according to the assigned 
diagnostic codes of epilepsy subtypes.  
THIN database provides anonymous postcode linked area-based 
socioeconomic status measure. The socioeconomic status of CYP was 
measured using the Townsend deprivation quintile (index). The Townsend 
index measures multiple deprivation by area and the overall score is calculated 
by summing the Z-scores of four variables derived from 2001 census:  
x The percentage of unemployment in active people over 16 years 
x  The percentage of  households without access to a car 
x  The percentage of households of non-home ownership 
x The percentage overcrowding of households 





status where the higher the score, the greater the deprivation. The scores are 
then grouped into 5 deprivation quintiles from 1 (least deprived) to 5 (most 
deprived).   
Information on co-existing morbidities was included.       
2.3.9 Estimating the overall and age-specific incidence rates of epilepsy 
The estimation of the incidence of epilepsy was performed on CYP of group 1 
(Figure 2-1) between 1st Jan 1990 and 30 Nov 2004. Data before 1990 were 
excluded because of the small number of practices contributing to THIN 
database at this time.  
A child was considered an incident case if the date of first recording of 
epilepsy diagnosis or drug code for AEDs occurred at least 6 months after the 
registration date with the general practice in order not to miscount a prevalent 
case as an incident case (Figure 2-2). However, in order not to underestimate 
incidence in the first year of birth, CYP who had their registration date within 
the first 6 months from birth and had a diagnosis or treatment for epilepsy 
within this first 6 months of life were included as incident cases. The 
assumption was that those CYP had their first ever diagnosis of epilepsy at that 
time.  





Figure 2-2: Definition of incident and prevalent cases of epilepsy 
 
The overall incidence rate (person-time incidence) of epilepsy for the whole 
study period was calculated by dividing the total number of newly diagnosed 
cases with epilepsy (as defined above) as the numerator by the total person-
years of registered data contributed by CYP younger than 18 years at risk as 
the denominator. The person-years of registered data were calculated from the 
registration date in THIN to the practice finish date. The finish date was the 
date of death, the date where the child transferred out of the general practice, 
or the last date of data collection, whichever occurred first. The person-years 
and 95% confidence interval (CI) were generated using the method of survival 
analysis.   
The overall incidence rate was stratified by age of CYP at diagnosis. Age was 
calculated at the incident date and grouped into four groups (0-4 years, 5-9 
years, 10-DQG\HDUV7KHSHUVRQ-years contributed by each age group 
of the study population were calculated. Incidence was calculated as the total 
number of new cases of each age group per 100,000 person-years of the study 
population at risk of same age group. Mantel-Haenszel test was used to assess 




whether incidence was different across age groups. The rate ratio (RR; ratio of 
two incidence rates) by age and significance tests were calculated using a 
Mantel-Haenszel type method. 
The crude incidence rate was also stratified by different deprivation levels as 
measured by Townsend index to examine whether incidence rate varied with 
socioeconomic status. The Chi-squared test for trend was used to test the 
association between incidence and different deprivation levels.  
2.3.10 Estimation of incidence rates by sex and calendar years  
The annual incidence rate was defined as the number of newly diagnosed cases 
of epilepsy each calendar year divided by person-years of registered data 
contributed by the CYP younger than 18 years in each calendar year. The 
annual incidence rate was estimated then stratified by sex between 1990 and 
2004 to examine the trend of the incidence rate over time.  The 95% 
confidence intervals of incidence rates were calculated each calendar year 
using the survival analysis. The Mantel-Haenszel method was used to assess 
whether the rate ratio (ratio of two incidence rates) was significantly different 
between males and females each calendar year.  
2.3.11 Estimating overall prevalence of epilepsy using the mid-year 
population numbers  
All CYP who had diagnoses of epilepsy were considered prevalent cases from 
their date of first diagnosis onward. The overall prevalence was estimated by 
dividing the number of all epilepsy cases by the mid-year population number 
of CYP of THIN. The mid-year population number was all study population 
younger than 18 years who had registration in THIN on the July 1st, each year. 
The difference in overall prevalence between males and females was tested 
using the Chi-squared test. The 95% confidence interval of overall prevalence 
in sex was calculated.     




2.3.12 Estimation of age and sex-specific prevalence of epilepsy by 
calendar years  
Repeated cross-sectional prevalence measurements were performed annually to 
assess any changes in prevalence during the study period. This was done by 
dividing the total number of epilepsy cases each calendar year between 1990 
and 2004 by the mid-year population numbers of study population in THIN 
each year. 
The annual estimates of prevalence were calculated for males and females and 
across different age groups each calendar year. Age of all populations was 
calculated on July 1st, each year and grouped in three groups (0-4 years, 5-9 
\HDUVDQG\HDUVEHFDXVHWKHUHZDVIHZQXPEHUVRIFKLOGUHQROGHUWKDQ
years. 
2.3.13 Quantifying the characteristics of other study groups 
To compare with the study group, the basic characteristics of other groups; 
CYP with seizure symptoms and AEDs codes (group 2; Figure 2-1) and those 
with only epilepsy diagnostic codes (group 3; Figure 2-1) were described by 
sex, age distribution at first recording of symptoms or epilepsy codes and 
socioeconomic status. Other explored characters included number of 
prescribed medicines and number of epilepsy diagnosis codes per individual.  
  




2.4 Results  
2.4.1 Study population 
The total number of CYP registered in the source population of the received 
THIN dataset 1988-2004 was 528760, of whom 270144 (51%) were males. The 
age of population at their registration dates ranged from one day to 16.4 years 
(mean=2.2 years; SD=3.4) 
By screening the medical file of the source population, 2908 CYP were 
identified to have had diagnosis codes for epilepsy or epilepsy subtypes 
(Figure 2-3). The therapy file contained 4028 CYP who have had prescriptions 
records for one or more AEDs.  
By linking the records of the two files, Figure 2-3 shows that group 1 (the study 
group who met the inclusion criteria) consisted of 2023 CYP who had at least 
one diagnosis code for epilepsy and at least one prescription for an AED. The 
diagram also shows that 2005 CYP had records for at least one prescription of 
an AED without a diagnosis for epilepsy. Of those, 376 CYP were prescribed 
AEDs for other conditions (such as bipolar disorder, conduct disorder, anxiety, 
migraine and neuropathic pain) and 405 CYP (group 2) had codes for epilepsy 
symptoms such as convulsions and fits.  
Figure 2-3 also illustrates that 885 CYP (group 3) had only epilepsy diagnoses 
without having records of prescriptions for any medication.  
 







Figure 2-3: Summary of extracting CYP with epilepsy from THIN database 
2.4.2 Characteristics of CYP diagnosed with epilepsy 
Of the extracted 2023 CYP with epilepsy (group 1), three CYP were excluded 
because they were transferred out of general practices on the same date of their 
registration. Therefore, a total of 2020 CYP represented the study cohort, of 
which 1115 (55.2%) were males (Table 2-7). The age at the date of first 
recording of epilepsy (incident date) ranged from 0.02-16.28 years (mean=5.58 
year; SD=4.03). About one-half of CYP (50.2%) were below the age of 5 years. 
A large number of CYP (27%) had only one diagnosis code for epilepsy or 
epilepsy subtypes during the total follow-up time.  
The socioeconomic status data showed that 40.5% were in a deprivation quintile 
higher than 3 (see Table 2-7). More than one-third of CYP (35.8%) had other co-
morbidities of whom, 387 (19.2%) had co-morbidities before the incidence of 
epilepsy. Asthma represented the most common co-morbid disease (23.2%) and 




mental and behavioural disorders comprised the second common category 
(18.3%) of co-morbidities. 
Table 2-7: Characteristics of the CYP with epilepsy (N=2020) 
Characters No of CYP (%) 
N=2020 
















Townsend deprivation quintile  

























Co-morbidities and other disorders 
Asthma  
Conduct disorders 
Nonorganic sleep disorder 
Behavioural disorders of childhood & adolescent  
Anxiety and stress  
ADHS 
Cognitive disorders  
Diabetes  




Depression   
Cystic fibrosis 
Juvenile rheumatoid arthritis 

























2.4.3 Results of compilation of medical terms of epilepsy and epilepsy 
subtypes 
The classification of CYP with epilepsy according to epilepsy subtype is shown 
in Table 2-8. The table also shows the assigned epilepsy subtype according to 
ILAE classification of epilepsy and epilepsy syndrome and ICD-10, 2007.  
The coding of epilepsy subtypes showed that the majority of CYP (69.3%) were 
not assigned a Read code for specific epilepsy subtype or syndromes and instead 
they only had a general code for epilepsy. The two most common epilepsy 
subtypes were the generalised absence epilepsy (9.8%) and the generalised tonic-
clonic epilepsy (6.2%).  
Table 2-8: Classification of epileptic cohort by epilepsy subtypes  
Read code diagnostic term  Number of CYP with the 
diagnosis (%) 
n=2020 
Epilepsy (unspecified )                                                                 1399 (69.3) 
Focal epilepsy   
Simple focal epilepsy  83 (4.1) 
Benign rolandic epilepsy                                                              27 (1.3)
Complex focal epilepsy                                                              25 (1.2)
Generalised epilepsy    
Absence seizures 198 (9.8) 
Tonic-clonic seizures 125 (6.2) 
Myoclonic seizures 25 (1.2) 
Tonic seizures 21 (1.0) 
Clonic seizures 13 (0.6) 
Atonic seizures 7 (0.4) 
West Syndrome 63 (3.1) 
Juvenile absences epilepsy 25 (1.2) 
Lennox- Gastaut syndrome 7 (0.4) 
Juvenile myoclonic epilepsy  2 (0.1) 




2.4.4 Overall incidence of epilepsy in children and young people  
Of the total 2020 extracted CYP with epilepsy, 1457 incident cases were 
identified giving an overall incidence rate of 51.5/100000 person-years of 
study population (Table 2-9). Of the incident cases, 823 (54.9%) were males. 
The male group had significantly higher (Chi-squared; p<0.001) overall 
incidence (56.8/100000 person-years) than females (45.8/100000 person-
years).  
A higher overall incidence rate was found in the younger children, decreasing 
from (54.4/100000 person-years) below the age of 5 years to (44.4/100000 
person-years) over the age of 15 years. However, the decrease in incidence 
rates was not significant across age categories (Mantel-Haenszel test, RR= 
0.99 [95% CI; 0.97-1.00], p= 0.05). Of the age group 0-4 years, incidence of 
epilepsy was higher during the first year of life (82.9/100000 person-years).  
The incidence rates were found to be higher in CYP who lived in relatively 
higher deprived areas as compared to those who lived in the less deprived 
areas. The incidence of epilepsy was higher in CYP who were in deprivation 
quintiles 4 and 5. The association between incidence and deprivation was 
significant (Mantel-Haenszel test, RR= 1.12 [95% CI; 1.08-1.16], p<0.01).  
Table 2-9 shows the cross-sectional calculated overall incidence rates each 
calendar year between 1990 and 2004. The overall incidence ranged from 41.9 
to 61.2/100,000 person-years over the years of study periods. The incidence 
rate ratio was not significantly different per each unit increase of calendar year 
of diagnosis (Mantel-Haenszel test, RR=0.99 [95% CI; 0.98-1.01], p= 0.41).  
  



























51.5   [48.9 -54.2] 
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54.4   [50.6 -58.6] 
49.5   [45.3 -54.1] 
48.2   [42.4 -54.8] 
44.4   [27.2 -72.4] 
Townsend index 





















41.7  [37.1 -46.9] 
40.6  [35.5 -46.5] 
60.4  [55.1 -68.5] 
65.1  [58.4 -72.5] 
57.5  [50.6 -65.4] 
40.6  [33.2 -49.9] 
Calendar year    
1990 20 38,810 51.5  [33.3  -79.9] 
1991 32 58,390 54.8  [38.8  -77.5] 
1992 35 78,830 44.4  [31.9  -61.8] 
1993 45 100,160 44.9  [33.5  -60.2] 
1994 67 124,500 53.8  [42.4  -68.4] 
1995 74 148,280 49.9  [39.7 ± 62.7] 
1996 105 171,490 61.2  [50.6  -74.1] 
1997 90 195,170 46.1  [37.5  -56.7] 
1998 115 218,800 52.6  [43.8  -63.2] 
1999 141 241,160 58.5  [49.6  -68.9] 
2000 138 262,520 52.6  [44.5  -62.1] 
2001 173 284,520 60.8  [52.4  -70.6] 
2002 153 306,430 49.9  [42.6 -58.5] 
2003 152 320,260 47.5  [40.5  -55.6] 
2004 117 279,330 41.9  [34.9 -50.2] 
 




2.4.5 Sex-specific incidence rate over time  
Sex-specific incidence rates stratified by the calendar years of epilepsy 
diagnosis are shown in Table 2-10. Incidence rates were significantly different 
between males and females with unit increase in calendar year of diagnosis 
(Mantel-Haenszel test; RR=0.81 [95% CI; 0.73- 0.90], p<0.001). The 
incidence was higher in males than in females. The incidence ranged from 42.7 
to 71.4 per 100000 person-years in males along the years of the study period. 
The incidence ranged from 34.4 to 63.5 per 100000 person-years in females 
along the years of the study period.  
Table 2-10: Incidence of childhood epilepsy by sex and year of diagnosis 
Calendar year  Male incidence/100,000 
person-years [95% CI] 
Female incidence/100,000 
person-years [95% CI] 
 
1990 44.9 [23.4- 86.4] 58.5 [32.4 -105.6] 
1991 46.6 [27.6 -78.7]   63.5 [39.9 -100.7] 
1992 54.2 [35.7 -82.4] 33.9 [19.7 -58.5] 
1993 42.7 [28.1 -64.8] 47.3 [31.4 -71.2] 
1994 54.7 [39.3 -76.2] 52.8 [37.3 -74.7] 
1995 56.5 [41.9 -76.3] 42.9 [30.2 -60.9] 
1996 70.6 [55.1 -90.6] 51.4 [38.1 -69.2] 
1997 51.1 [38.8 -67.2] 40.9 [29.9 -55.9] 
1998 52.7 [40.8 -68.1] 52.4 [40.3 -68.1] 
1999 63.2 [50.7 -78.9] 53.5 [41.8 -68.4] 
2000 52.1 [41.2 -65.9] 53.0 [41.8 -67.3] 
2001 71.4 [58.9 -86.6] 49.6 [39.2 -62.8] 
2002 61.9 [50.8 -75.6] 37.4 [28.8 -48.5] 
2003 53.2 [43.1 -65.7] 41.5 [32.5 -52.9] 
2004 49.0 [38.8 -62.0] 34.4 [25.8 -45.8] 
 
  




2.4.6 Overall prevalence of childhood epilepsy   
A total of 2020 prevalent cases gave an overall prevalence of 3.83/1000 study 
population (Table 2-11).  Of the identified cases, 1115 (55.2%) were males and 
had a significantly higher overall prevalence (Chi-squared; p<0.001) compared 
to females. Males were found to be 18% more likely to have epilepsy than 
females (odds ratio=1.18 [95% CI; 1.08-1.29].   







population (95% CI) 
Total 2020 526,560 3.83 (3.67-4.01) 
Sex    
  Male  1115 268984 4.14 (3.90-4.39) 
  Female  905 257576 3.51 (3.02-3.74) 
 
2.4.7 Age-specific prevalence of epilepsy over time 
A cross-sectional annual prevalence of epilepsy was calculated and stratified 
by age of CYP starting in the year 1990. The annual overall prevalence of 
epilepsy in all ages was found to increase from 0.89 per 1000 in 1990 to 4.48 
per 1000 population in 2004 (Table 2-12). The age-specific annual prevalence 
values stratified by calendar years were found to increase with age. The 
prevalence estimates in the age group 0-4 years grew less than twofold 
between 1990 and 2004 where small changes occurred (6%) between 1995 and 
2004. However, 80% rise in prevalence within the age group 5-9 years was 
observed (from 2.26 (95% CI; 1.44-3.09) in 1993 to 4.06 (95% CI; 3.67-4.45) 
per 1000 population in 2004). There was also 47% rise in prevalence within 
WKHDJHJURXS\HDUVIUom 4.44 (95% CI; 3.40-5.50) in 1998 to 6.50 (95% 
CI; 6.12-6.95) per 1000 population in 2004). 




























(95% CI)  
1990 33 36892 0.89 0 0 0 0 0 0 0.89 (0.59-1.21) 
1991 70 56636 1.24 0 0 0 0 0 0 1.24 (0.95-1.53) 
1992 112 77162 1.45 0 0 0 0 0 0 1.45 (1.19-1.73) 
1993 134 85050 1.58 29 12838 2.26 0 0 0 1.67 (1.42-1.93) 
1994 160 92939 1.72 81 30007 2.70 0 0 0 1.96 (1.72-2.22) 
1995 168 95975 1.75 164 50514 3.25 0 0 0 2.27 (2.03-2.52) 
1996 190 96569 1.96 261 73257 3.56 0 0 0 2.66 (2.42-2.91) 
1997 185 97447 1.90 263 96257 2.73 0 0 0 2.83 (2.60-3.08) 
1998 184 97628 1.88 417 104235 4.00 69 15549 4.44 3.08 (2.86-3.32) 
1999 197 97219 2.02 473 108798 4.35 160 33892 4.72 3.46 (3.23-3.70) 
2000 193 96592 2.00 474 109138 4.34 306 55562 5.51 3.72 (3.50-3.96) 
2001 183 96419 1.90 485 107974 4.49 477 79152 6.02 4.04 (3.81-4.28) 
2002 184 95557 1.92 470 107215 4.38 644 102779 6.26 4.25 (4.02-4.48) 
2003 172 92725 1.85 439 103677 4.23 789 122556 6.44 4.39 (4.16-4.62) 
2004 161 91436 1.76 410 100970 4.06 930 142337 6.51 4.48 (4.26-4.71) 




2.4.8 Sex-specific prevalence of epilepsy over time  
The difference in prevalence of epilepsy between males and females stratified 
by age and calendar years is illustrated in Figure 2-4. The graph shows that only 
the prevalence of age group 0-4 started from the origin of the line (1990) 
whereas prevalence of age group 5-9 started from 1993 and from 1998 for age 
JURXS\HDUV7KLVUHIOHFWVWKHVWUXFWXUHRIWKHVWXG\FRKRUWDVWKRVe CYP 
who were born on or after January 1st 1988. Before 1993, no child in the cohort 
had yet reached their 5th birthday and so the graph started at 1993 for the age 
group 5-9 years. Before the year 1998, no child in the cohort had yet reached 
their 10th birthday. 
The prevalence of epilepsy in increased linearly from 1990 to 2004. The 
prevalence in males was higher than females from 1996 onwards. The 
prevalence in males increased 7 fold during the study period (from 0.69 (95% 
CI; 0.31-1.06) in 1990 to 4.91 (95% CI; 4.58-5.24) per 1000 population in 
2004). The prevalence in females increased 3.6 fold during the study period 
(from 1.12 (95% CI; 0.63-1.62) in 1990 to 4.04 (95% CI; 3.73-4.34) per 1000 
population in 2004). 
 




























Calendar years  
Male 0-4 years
Male 5-9 years
DĂůĞA? ? ?ǇĞĂƌƐ 
Female 0-4 years
Female 5-9 years
&ĞŵĂůĞA? ? ?ǇĞĂƌƐ 




2.4.9 Characteristics of CYP with seizure symptoms  
The characteristics of CYP defined by AEDs and symptoms of seizures 
(Figure 2-3, group 2) are presented in Table 2-13. The group showed similar 
demographic characteristics to that of the main study group. The total number of 
this group was 405 where more than one-half, 214 (52.8%) were males. The 
mean years of follow-up from the date of first symptom was 5.4 (SD=4.3). The 
age at first recording of symptom ranged from one day to 16.1 years (mean= 
2.9; SD =3.3). The majority (82.9%) were below the age of 5 years on the date 
of first recorded symptom compared to that of 50.2% in the main study group. 
Higher proportions (38.5%) of CYP of this group were in a deprivation quintile 
of more than 3 compared to only 40.5% of the main study group.  
Most of CYP of this group (74.3%) were assigned medical codes for 
convulsions. The remaining medical codes were for symptoms of fits and status 
epilepticus. The majority of CYP (78.5%) received only one drug during the 
whole follow-up years. The most frequently prescribed drugs to CYP were old 
AEDs; sodium valproate (38.8%, carbamazepine (17.3%), phenobarbital 
(12.1%) and phenytoin (7.4%). 




Table 2-13: Characteristics of CYP of group 2 (without diagnosis codes) 
Characters No of CYP (%) 
N=405 

































Unspecified symptoms of epilepsy   
Convulsions  
Fits  
Convulsion and fits in new born 







































2.4.10 Characteristics of CYP with a diagnosis of epilepsy, but no 
prescription of AEDs 
The characteristics of CYP in the third group (Figure 2-3, group 3) who had 
only diagnosis of epilepsy are shown in Table 2-14. This group had also similar 
demographic characteristics to that of the main study cohort.  Of the identified 
885 CYP, 515 (58.2%) were males. The mean years of follow-up from the date 
of first recoding of epilepsy in THIN was 4.8 (SD=3.8). The age at first 
recoding of epilepsy codes ranged from one day to16.3 years (mean=5.1; 
SD=3.9). More than one-half (54.9%) were below the age of 5 years. The 
socioeconomic status of CYP measured using the Townsend deprivation index 
was also similar to the main study group. The data showed that 43.9% were in a 
deprivation quintile of more than 3. 
The highest percentage of CYP (78.5%) had only one diagnosis code for 
epilepsy or epilepsy subtypes. The percentage of CYP with co-morbidity 
(35.5%) was similar to the main study group. Asthma was the major (26.3%) 
recorded comorbid disease and mental and behavioural disorders comprised the 
second most common comorbid disease (12%). 




Table 2-14: Characteristics of CYP of group 3 (without drug treatment) 
Characters No of CYP (%) 
(n=885) 






484  (54.9) 
272  (30.7) 
116  (13.1) 





515  (58.2) 
370  (41.8) 
Deprivation score 




5 (most deprivation) 
Missing  
 
149  (16.8) 
128  (14.5) 
159   (18) 
202  (22.8) 
187 (21.1) 
60   (6.8) 






695  (78.5) 
117  (13.2) 
49   (5.5) 
24    (2.7) 
Other co-morbidities and disorders 
Asthma  
Conduct disorder  
Stress and anxiety  
Behavioural disorders of childhood & adolescent 
onset 





Cognitive disorders  
Depression 























Table 2-15 shows the classification of CYP by epilepsy subtypes. Similar to the 
main study group, the majority of CYP in this group (573, 64.8%) were not 
assigned a diagnostic epilepsy subtype and they only had a general code for 
epilepsy.  
Table 2-15: Combined diagnosis terms for epilepsy and epilepsy subtypes of 
group 3  
Epilepsy description  Number of CYP  
n=885 
Frequency of records 
(%) 
n=1171 
Epilepsy (unspecified ) 578 664 (55.8) 
Focal epilepsy    
Simple focal epilepsy  23 28 (2.4) 
Benign rolandic epilepsy 22 34 (2.9) 
Generalised epilepsy    
Absences seizures 266 298 (25.0) 
Tonic-clonic seizures 54 59 (4) 
West Syndrome 29 34 (2.9) 
Tonic seizures  13 13 (1.1) 
Clonic seizures  11 11 (0.9) 
Myoclonic seizures  11 11 (0.9) 
Juvenile absence epilepsy  8  8 (0.7) 
Epileptic seizures - atonic 6  6 (0.6) 
 
Note: a child can have multiple diagnostic codes so the total number of CYP is 
higher than the actual number of CYP.  




2.5  Discussion 
2.5.1 Key findings 
In this study, the identified CYP with epilepsy were classified into three groups. 
Group 1 was the main study population upon which incidence and prevalence 
estimates were performed. This group1 included all CYP who had a medical 
diagnosis of epilepsy and at a least one code for a prescription of AEDs. The 
second group (group 2) included all CYP with medical codes of seizures and 
codes of AEDs. The third group (group3) comprised all CYP who had only 
medical codes for epilepsy. The CYP of the second and third groups were not 
included in incidence and prevalence estimates either because they did not have 
a clear code for epilepsy diagnosis (group 2) or they may have a history of 
epilepsy but in long-term remission.  
The three groups, however, showed comparable demographic characteristics in 
terms of age range at first recoding of epilepsy, sex distribution and level of 
deprivation according to Townsend index. The numbers of medical codes of 
epilepsy or type of concurrent co-morbidity were also comparable between 
groups 1 and 3.  
This study estimated an overall incidence rate of epilepsy of 51.5 (95% CI, 48.9 
-54.2) per 100,000 person-years. The annual incidence rates ranged between 
41.9 and 61.2 per 100,000 person-years. Males had a significantly higher 
incidence of epilepsy than females. The age-specific incidence in this study was 
found to be higher in children less than 5 years old and decreased with 
increasing of age. Moreover, the overall incidence rate was higher in children 
during their first year of life 82.9 (95% CI; 72.7-94.6) per 100,000 person-years. 
The incidence of epilepsy was significantly higher in CYP lived in more 
deprived areas than those lived in the least deprived areas. 
The overall calculated prevalence of epilepsy was 3.83 /1000 population and 
males had significantly higher prevalence than females. The annual estimated 
prevalence increased from 0.89/1000 in 1990 to 4.48/1000 population in 2004. 




2.5.2  Incidence of epilepsy compared to previous studies  
The estimated overall incidence rate of epilepsy and the annual incidence rates 
were consistent with previous incidence rates reported in the UK and Europe 252. 
It has been concluded that the overall incidence was around 50 per 100,000  
person-years (range of 50-70 per 100,000) in developed countries 25, 252.   
Previous cross-sectional population-based studies in the UK have reported crude 
incidence rates ranged from 43 to 80 per 100,000 populations 22, 23, 227, 228. These 
crude incidence rates were estimated on cohorts of all ages including CYP 22, 23, 
228
. Of the paediatric studies, Verity et al. (1992) estimated the incidence of 
epilepsy in the survivors of 1970 British birth cohort, aged 0-10 years. The 
authors reported a similar crude incidence of 43 per 100,000 populations 227. 
The annual estimate of overall incidence in the present study were slightly 
lower than that of Reading et al. (2006) who examined the association between 
incidence of epilepsy and deprivation 231. The authors used a cohort of 77952 
CYP, aged 29 days to 14 years, presenting to the Norfolk and Norwich 
University Hospital, UK and reported an annual incidence of epilepsy of 66 per 
100,000 populations throughout 2001-2003. However, their finding was applied 
to Norfolk and Norwich area and not to the whole UK.  
Regarding sex-specific incidence rate of epilepsy, the study finding supported 
that of Reading et al. (2006) who reported a slightly higher incidence of 
epilepsy in male CYP than for females 231. Macleod and Andrews reported that 
adult males with epilepsy had significantly higher rates hospital admissions than 
females in Scotland 253.  A possible cause of higher incidence in males may be 
the higher susceptibility for certain risk factors for epilepsy such head injury, 
stroke, central nervous system infection 21. However, a similar finding was 
reported where only cases with idiopathic or cryptogenic epilepsy were 
examined 21.  
The trend of higher incidence rates of epilepsy in young children its decrease 
with increasing of age was consistent with the epidemiology of epilepsy 
worldwide that is the incidence of epilepsy is high in childhood with the highest 
peak during the first year of life 18, 25. Incidence of epilepsy has been described 
to have a bimodal distribution with 50% of cases of epilepsy start in childhood 




and elderly 25, 254. Possible aetiologies for higher incidence of epilepsy in 
children are congenital, developmental and genetic 7. The age-specific incidence 
rate was similar to that reported by Martinez et al. (2009) using the GPRD 
database in the UK for the age groups 0-4 and 5-9 years 230. However, the 
LQFLGHQFHUDWHIRUDJHJURXS\HDUVZDVVOLJKWO\KLJKHUWKDQWKDWUHSRUWHGE\
Martinez and colleagues. This may be because the case definition was slightly 
different where in this study, epilepsy was defined by one diagnosis code and at 
least one prescription; however, Martinez et al. defined epilepsy by one 
diagnosis code and at least two prescriptions.    
This study suggests that there is a link between the incidence of epilepsy in 
CYP and deprivation areas. This finding supported that of Heaney et al. (2002) 
who reported a significantly higher incidence of epilepsy by twofold in the most 
deprived areas (P=0.001) 23. However this finding is more generalisable to the 
UK population of CYP than that of Heaney et al. (2002) who used data from 
London and the South East of England with bulk of deprived areas in London. 
Macleod and Andrews (2002) reported a significantly higher association 
between deprivation and incidence of hospital admissions from 3,340 adults 
with epilepsy in Scotland 253. The authors concluded that likelihood of hospital 
admissions from epilepsy was 3.3 times higher in adults who lived in most 
deprived areas (P<0.001).  
Few studies have addressed the association between socioeconomic deprivation 
and incidence of epilepsy, so it is poorly explained 23, 231. It could be related to 
any other factors like ethnicity. For example, epilepsy has been reported to be 
less prevalent among people with south Asian origin residing in the UK 229. 
However, evidence from the US has suggested no significant difference in the 
incidence of epilepsy among different races based on a cohort enrolled in the 
health maintenance organizations in Houston 255. Ethnicity has been addressed 
in a previous study by MacDonald et al. (2000) as whether it represents a risk 
factor in the incidence of neurological disorders in London-UK256. However, the 
study sample was not representative to the whole UK population and thus the 
authors recommended conducting a population-based study to address the effect 
of ethnicity.  




There was no recorded data in the received THIN database version to account 
for ethnicity.  
2.5.3 Prevalence of epilepsy compared to previous studies  
The estimated overall prevalence of epilepsy in this study was consistent with 
previous prevalence studies in the UK and Europe. The prevalence of active 
epilepsy in CYP in Europe has been estimated at 4.5±5.0 per 1000 population 25. 
Previous prevalence studies in the UK have reported that prevalence of epilepsy 
in CYP ranged from 2.8 to 5.2/1000 population 22, 226-228.  
A possible explanation for the rise in the annual estimated prevalence between 
1990 and 2004 can be attributed to a cohort effect where prevalence was found 
to increase with increasing age of the children. The study population consisted 
of CYP who were born on or after January 1st, 1988 and were registered at 
general practices over time so contributed over the years. The mean contribution 
of incident cases in the database was 7.5 (SD 4.7) years which reflect the 
general practice registration time. Therefore, as CYP remained registered in the 
database and became of older ages, they contributed as prevalent cases in the 
later calendar years.  
The estimated age-specific prevalence of epilepsy showed that the prevalence of 
epilepsy was almost unchanged in age group 0-4 years over the study time. 
Whereas the prevalence in the other two age groups (5-DQG\HDUV
increased over time between 1990 and 2004. However, the increase in 
prevalence of epilepsy in age group 5-9 years (from 2.26 to 4.06/1000) was 
within the reported estimates of the ONS for 1994 (4.2/1000) and 1998 
(4.4/1000) using the GPRD database 27. The annual age-specific prevalence of 
epilepsy was consistent with period estimates of prevalence using the GPRD 
database by Wallace et al. (1998) for 199522 and the ONS for 1994 and 1998. 
However, it was slightly higher than age-specific estimates by Martinez et al. 
(2009) for 2005 230, particularly for the DJHJURXS\HDUV. The present study 
estimated the prevalence of epilepsy to be 6.5/1000 CYP, aged >10 years, in 
2004, while Martinez and colleagues estimated a prevalence of 4.1/1000 CYP, 
aged 10-19 years, in 2005.  




A recent review by Banerjee et al. (2009) reported that prevalence increased by 
age to be higher in young people than early childhood 257. Increases in the 
survival rates of children with severe neurodisability and metabolic diseases 
which require gastrostomies may be a risk factor for epilepsy 258, 259. In addition, 
the poor prognosis because of the presence of neurodeficit and frequent seizures 
may contribute to higher prevalence in older children 260.  
2.5.4 Strength and weakness of findings 
This study is a population-based longitudinal study that estimated the trend of 
incidence and prevalence in childhood epilepsy in the UK over 14 years. The 
study has been performed using electronic records of large sample of CYP from 
all parts of the UK that may be representative of the whole CYP population.  
The findings of this study were comparable to the published literature in the 
area of incidence and prevalence of childhood epilepsy in the UK and 
worldwide. This study can contribute to previous validation studies which have 
demonstrated the strength of THIN database to examine the epidemiology of 
medical conditions on a population level such as incidence and prevalence of 
diseases in the UK.  
There were a number of limitations to this study which included the nature of 
the study cohort of only children who were born in or after 1988, so it did not 
include all children registered in general practices contributing to THIN. 
However, the study cohort was representative of variable ages (infants, children 
and young people).  
CYP with epilepsy were defined by having at least one diagnostic code for 
epilepsy and one prescription for an AED. However, the diagnosis was not 
ascertained, for example, by examining whether the diagnosis of epilepsy was 
accurate or whether it had been confirmed by a specialist in secondary care. 
This could be done by requesting paper records of a random sample of CYP 
with a diagnosis of epilepsy from GP and then consulting a paediatric specialist 
to examine these records. The reason for not doing this was that paper records 
of patients are available to researchers with extra cost which would have 
increased the cost of this study and made it unfeasible. In additions, some of 




population-based studies on epilepsy using the GPRD database have not 
preformed case ascertainment and have relied only on the validity of database 27, 
230
.    
The study only included diagnosed codes of epilepsy and hence cases that have 
not had a diagnosis code by a GP were not included. However, by not including 
these cases misdiagnosis of epilepsy, which is considered an important problem 
in the management of epilepsy 5, 261, would be avoided.   
2.6 Conclusions 
The analysis supports earlier findings on the epidemiology of epilepsy that is 
incidence of childhood epilepsy is higher in young children with the highest 
value in the first year of life. The study showed a social gradient in the 
incidence of epilepsy in CYP in the UK which suggests that socioeconomic 
status may represent a risk factor for the development of epilepsy. However, 
there was not enough data to explore the association between incidence and 
socioeconomic status, so the association is not understood. The prevalence of 
epilepsy tends to be higher with increasing age of children. 




3 Chapter 3: Prescribing patterns and adherence to 
AEDs in children and young people  
3.1 Rationale for the study 
Antiepileptic drugs (AEDs) are the standard approach in the treatment of 
epilepsy. Because of the chronic nature of epilepsy, long-term (in some 
epilepsy syndromes, life-long) prescribing of AEDs is necessarily for better 
prognosis of epilepsy. Thus appropriate evidence-based prescribing and 
therapeutic monitoring of medicines, combined with patient adherence to these 
prescribed medicines remain a key factor in the control of seizures, reduction 
of disease progress and psychosocial sequelae and optimisation of quality of 
life 176, 262.  
Prescribing of AEDs for newly diagnosed or untreated CYP with epilepsy in 
terms of choosing the initial drug, second-line drug and add-on drugs remained 
for so many years complex and uncertain 99, 102. Before the release of NICE 
first guideline for the diagnosis and management of epilepsy in adults and 
children in 2004 1, No conclusive evidence-based guidelines were available for 
standardised clinical prescribing of AEDs in CYP 263, 264. Clinicians usually 
initialise drug treatment based on their own beliefs and experience with AEDs 
265
. The first US evidence-based guideline for pharmacological management of 
epilepsy was also published in 2004 and focused on new AEDs 70, 266. Both 
NICE and the US guidelines referred to the paucity of data from studies 
including only children.  
There are little available data in the literature on the utilisation of AED in CYP 
in primary care in the UK. Chapter 1 provided a review section about the 
available data regarding the prescribing of AEDs in primary care. Aggregated 
prescribing data for children and adults with epilepsy have been reported in 
two studies from primary care settings 27, 117. One population-based study by 
Ackers et al. (2007) focused on AED prescribing in CYP younger than 18 
years old using the GPRD database 118. The study concluded a straight rise in 
prescribing of new AEDs for which, the authors recommended further research 




on their safety in children. However, this study examined all CYP (including 
those with epilepsy diagnosis) who were prescribed at least one prescription of 
AEDs and the case definition of epilepsy was not included.         
Patient adherence remains an important issue to physicians and health care 
providers 176.  Moreover, factors associated with adherence in CYP are 
complex and multidimensional as they involve parents as well 135, 267. 
Available data to understand reasons behind different adherence behaviours 
among CYP with epilepsy are, however, still scarce. 
The majority of research that has examined adherence to AEDs in paediatric 
populations has been carried out using small cohorts of patients and/or specific 
age-ranges 134, 135, 137, 141, 157, 160, 268, 269. This may reduce the statistical power 
and generalisability of the results and therefore, may not necessarily give a 
precise picture of the general SRSXODWLRQ¶VGUXJ-taking behaviour. No large 
paediatric cohort study has been reported in the UK to address adherence to 
AEDs in CYP. Therefore, this study was conducted to include a large 
representative sample to quantitatively assess the adherence behaviour of CYP 
and capture any potential factors which may precipitate non-adherence to 
AEDs regimens. 
This chapter presents an exploration and description of actual AED prescribing 
in CYP with epilepsy. The different AEDs prescribed to control epilepsies in 
general, and by age of CYP and years from diagnosis, are presented using 
THIN database. The chapter then provides a method of measuring adherence 
behaviour to the prescribed medicines and explores factors which may be 
associated with adherence. 




3.2 Aim and objectives of the study 
The aim of this chapter was to investigate the frequency and pattern of use of 
AEDs in CYP with epilepsy in the UK and to assess their adherence to the 
prescribed medicines using THIN database. 
The objectives were to: 
1. Identify individual AEDs prescribed to children and young people.  
2. Describe the frequency of prescribing of AEDs and proportions of 
monotherapy and polytherapy. 
3. Explore any trends in the use of old and new AEDs with regards to 
CYP¶VDJH and changes over calendar time between 1990 and 2004. 
4. Estimate overall adherence to AEDs and adherence over time to assess 
any changes in adherence levels of CYP during the study period. 
5. Perform bivariate and multivariate analysis to determine potential factors 
that may be associated with adherence to AEDs in CYP. 





3.3.1 Study cohort 
The population for this analysis was the 2020 CYP diagnosed with epilepsy in 
THIN between 1st January 1990 and 30th November 2004.  The study 
population were included if  they had  at least one diagnosis code for epilepsy 
and at least one prescription for an AED, as previously described in Chapter 2. 
To explore the use of AEDs, the CYP¶VWKHUDSHXWLFILOHVZHUHXVHG'DWD
before 1990 were excluded because of the small number of practices that 
contributed to THIN database. Data from the year 2004 were also excluded 
because of lack of a full calendar year of data. So the study time for exploring 
the prescribing patterns of AEDs started on 1st January 1990 until 31st 
December 2003 (Figure 3-1).  The total person-years of registered data 
contributed by the study cohort for this analysis were calculated from the date 
of first recording of epilepsy diagnosis or the first prescription for an AED in 
THIN (whichever occurred first) to the practice finish date. The finish date was 
the date of death, the date where the child transferred out of the general 
practice, or the last date of data collection, whichever occurred first. 
The measurement of medication adherence was then carried out using the 
method of MPR on a subgroup of CYP diagnosed with epilepsy. For adherence 
measurement, additional inclusion criteria were that CYP had at least one year 
of follow-up from the date of first recording of epilepsy-related diagnosis or 
prescription (index date) and at least two prescriptions during their registered 
follow-up time. The study time for adherence calculation started at the index 
GDWHDQGHQGHGDWWKHLQGLYLGXDO¶VILQLVKGDWHThis subgroup was also required 
to have at least one prescription with complete daily dosage instruction to 
calculate the length of AED supply for the prescriptions (described later in 
section 3.3.5).  This subgroup comprised 1067 out of the initial 2020 CYP with 
epilepsy (Figure 3-1). 





Figure 3-1: Study populations for prescribing and medication adherence 
analyses 
 
3.3.2 Overall prescribing of AEDs for the study cohort 
This study used the number of prescriptions for each AED as a measure of 
prescribing volume of AEDs. Antiepileptic drugs were classified into two 
groups, according to their market launch year (old: before 1990, new: 
after1990) 78, 79: 
a. Old AEDs included carbamazepine, clobazam, clonazepam, ethosuximide, 
phenobarbital, phenytoin, primidone and sodium valproate 
b. New AEDs included gabapentin, levetiracetam, lamotrigine, 
oxcarbazepine, tiagabine, topiramate, and vigabatrin. 
All different drug preparation codes of each individual prescribed AED had the 
same generic name for each particular drug except for valproic acid and 
sodium valproate. In this study, drug preparations of sodium valproate and 
YDOSURLFDFLGZHUHFRPELQHGXQGHU³VRGLXPYDOSURDWH´DVDJHQHULFQame. 
This resulted in 15 different AED types which were prescribed to the study 
cohort to control epilepsy. Three other drugs; diazepam, midazolam and 
paraldehyde, were prescribed occasionally to the study cohort to control 
prolonged or life-threatening seizures such as `status epilepticus'. The analyses 




in this chapter focused mainly on prescribing of AEDs for long-term, or 
chronic epilepsy control, rather than for acute management of seizures. 
The overall number of prescriptions for all AEDs was calculated and then 
stratified by sex and age at first diagnosis and presented per person-years. The 
total number of AEDs prescribed per individual child was calculated during 
the study period. CYP were considered to be on monotherapy if they were 
prescribed only one AED type within the same 28 days in continuous or 
intermittent intervals each year. This definition may miscount some CYP who 
were prescribed one AED for fewer than 28 days and then were switched to an 
alternative AED because of side effects or other clinical factors. This is 
considered a limitation in the study definition of monotherapy. However, these 
CYP were considered to be few cases because more than one-half of CYP with 
epilepsy were only ever prescribed one AED, as described later in the results 
section 3.4.3. In addition, monotherapy with old AEDs was prescribed 
sequentially in this cohort of CYP before trying combination therapy. 
The total number of CYP who were prescribed each individual drug was 
calculated based on whether CYP were ever prescribed a particular AED type 
during the study period. The total numbers of prescriptions for each individual 
drug were calculated per person years. 
3.3.3 Frequency of prescribing of AEDs by age, sex and calendar years, 
over the study period 
Firstly, the annual total numbers of prescriptions for all AEDs were calculated 
using per-calendar year cross-sectional analyses for the entire cohort. The total 
number of CYP treated each year was calculated and stratified by sex and age 
groups. Age was calculated at July 1st each year and then grouped into 4 
categories each of 5-years. The trend of AED combination was explored by 
calculating the proportions of CYP who were prescribed one drug or multiple 
drugs each year. Then the proportion of CYP who received old AEDs versus 
new AEDs was calculated each year to assess any trend of prescribing old 
versus new AEDs. 




Secondly, the annual total numbers of prescriptions of each individual AED 
were calculated per person-years to illustrate any general trend or use of AED 
type over the study period. The proportions of the CYP who received each 
individual AED were also calculated. This was done by dividing the number of 
CYP who were prescribed a particular drug each year by the total prevalent 
cases of CYP with epilepsy in that year. 
3.3.4 Identification of initial therapies, second line therapies and time to 
second line treatment 
First, second line and subsequent drugs used to manage epilepsy were explored 
to investigate the frequency of medication changes and/or increasing over time 
to control epilepsy. The addition of, or switching to second line therapies was 
examined using the newly diagnosed CYP with epilepsy (incident cases). The 
GDWHRILQGLYLGXDOV¶first prescription was set as the start date and then time to 
add or switch to the second line drug was calculated from this date. It was not 
possible to distinguish between switching and add-on therapy because the 
study population were prescribed 15 AEDs with possible probabilities for any 
two drugs to be combined in a single a course. Combined AEDs were usually 
recorded on the same date within THIN; however, in some cases AEDs were 
issued five to seven days apart which may appear to the analysis programme as 
switching.  A child may also have been prescribed one drug, switched to a 
second drug and then switched back to the first drug in a short period. This 
caused difficultly to set up an algorism to account for all possible options of 
drug switching and additions. Therefore, time for either addition of or 
switching to second-line therapy was examined conjointly.  
  




3.3.5 Estimation of adherence to AEDs 
Adherence was calculated using the method of medication possession ratio (MPR) 
143, 149
. The calculation of adherence included a sequence of steps which are 
described in the next sections 
3.3.6 Data management for calculating the prescription length of 
prescribed AEDs 
To calculate adherence using the method of MPR, the prescription length of 
AEDs (days of supply of AEDs per prescription) were calculated based on the 
dosage instructions.  The THIN database contains some recorded dosage 
instructions which enable the estimation of prescribed number of units per day 
(daily dosage quantity) of individual AEDs. This in turn allows calculation of 
length of each prescription in days. The available recorded data include 
variables such as the total quantity prescribed or package size and some 
calculated daily quantity/volume of drug dosage derived by EPIC. These data 
were not completely recorded for the entire study cohort particularly for liquid 
formulations. Therefore, it was necessary to design methods to impute the 
missing data for the rest of the study cohort to obtain a full picture of 
LQGLYLGXDOV¶WKHUDSHXWLFFRXUVHV 
For the known recorded dosage instructions, the daily dosage quantities of 
prescribed drugs were calculated by translating the recorded prescription 
instructions (daily dosage regimen) of each individual AED into amount of 
volume of liquid dosage forms per day or number of units of solid dosage 
forms per day. The length of each prescription LQGD\V³5[GD\V´ZDVWKHQ
estimated by dividing the total prescribed quantity or package size of each 
individual AED by the calculated daily dosage quantity. 
Rxdays =    Total quantity prescribed or package size 
                      Daily dosage quantity 
 




3.3.7 Methods for imputation of missing dosage instructions 
When it was not possible to directly calculate the prescription length (Rxdays) 
because the dosage instructions were unrecorded or carried unspecified 
instructions  such as  `use as directed', `as directed by doctor', `as directed by 
the hospital', `as directed by specialist', `as directed every night', `as directed 
when required', `asd', `mds' and `mdu'), alternative methods were performed to 
estimate the daily dosage quantities of prescribed drugs. 
A set of assumptions were derived to impute the missing dosage instructions. 
These assumptions were made in a hierarchical order based on the best 
available recorded data within THIN as follows: 
Assumption 1: The missing or unspecified dose instruction for a specific 
prescription event was assumed to be the same as the previous instruction of 
the closest prescription date (not longer than 6 months) for the same child who 
was prescribed the same drug type, package size and dosage strength. The 
hypothetical example shown below (Figure 3-2) is for a child who was initially 
prescribed sodium valproate syrup (200mg/5ml) and then carbamazepine 
tablets 400mg. The unknown dosage instruction of the prescription (P3) was 
imputed from the known prescription (P2) of sodium valproate and the 
unknown dosage instructions of P5 and P6 were imputed from the known P4 
of carbamazepine. The imputed dosage instructions were then used to calculate 
the missing length of prescriptions (Rxdays). 
 
Figure 3-2: Illustrating example of the imputation of prescription length 
using previous known prescriptions  
 
Assumption 2: for the still missing Rxdays, length of prescriptions was 
imputed using the median length of time between each two successive 




prescriptions for each individual child. This time was calculated as the 
difference between each two successive issued prescriptions if the time 
difference did not exceed 90 days. The cut-off of 90-days was considered 
because from the known recorded data, a prescription often supplied an AED 
for a maximum of 90 days. A hypothetical example is shown below 
(Figure 3-3) for a child who had unspecified dosage instructions for the 
prescriptions (P2-P6) such as `take as directed'.  The length of each 
prescription was imputed by calculating the median value of the five intervals 
between prescriptions. This means that Rxdays of P2, P4 and P5 were imputed 
to be 1 month (30 days) and Rxdays of P3 were imputed to be 2 months (60 
days). 
 
Figure 3-3: Illustrating example of the imputation of prescription length 
using the time between two issued prescriptions  
 
Assumption 3: For the still missing Rxdays (e.g. in case of the time between 
two unknown prescriptions was more than 3 months), length of prescriptions 
was imputed using the median length of all other recorded prescriptions 
calculated individually for each child. 




3.3.8 Dealing with the overlapping prescription dates 
7RDYRLGGRXEOHFRXQWLQJRIWKHQXPEHURIGD\V¶VXpply of AEDs and hence 
overestimating adherence, the overlap between prescription episodes for the 
same or different drug types was eliminated by two ways.  First, when two or 
more prescriptions were issued on the same day, the longest one was 
considered. Second, when a prescription (P2) started before the end date of a 
previous prescription P1, the overlapping days of P1 were discarded (an 
example is shown in Figure 3-4) 
The assumption was that if P1 and P2 were for the same drug, P2 was assumed 
to carry a new dosage instruction. If P1 and P2 were for different drug types 





P1 is a prescription to supply drug X for duration of ab. P2 is an overlapped prescription 
to supply drug Y for a duration cd. ad is composite duration of  P1 and P2. 
Figure 3-4: Dealing with overlapping prescription dates 
These assumptions were suggested in an earlier study by Briesacher et al. 
(2008) 270. The authors assessed the drug adherence levels for 4984 adults with 










3.3.9 Estimation of the Medication Possession Ratio (MPR) 
The overall MPR was calculated first on the aggregated data for the whole 
course of therapy during the study period for the subgroup of 1067 CYP. The 
calculation of overall MPR was to provide an overall picture of the distribution 
of adherence of the CYP in the sample. The calculation of overall MPR was 
additive of all prescribed AEDs. This means that proportions of days supplied 
for the initial AED were added to those days of all consecutive AEDs to 
control epilepsy for individuals after accounting for different types of 
prescription overlapping. For example, if a child received a prescription for 
sodium valproate as the initial drug, then the proportions of days supplied for 
sodium valproate as well as those for any further AEDs were calculated. This 
sort of calculation was previously performed in an earlier study by Briesacher 
et al. (2008) 270. 
7KHLQGLYLGXDO¶VGXUDWLRQRIfollow-up was calculated as the difference 
between the index date (date of first recording of epilepsy in THIN) and the 
finish date of the individual FKLOG¶s data. 
The overall MPR was simply calculated as follow: 
MPR = Total days supplied by AEDs during the follow-up 
            Duration between the index date and finish date of CYP 
The distribution of MPR before and after data imputation of the length of 
prescriptions was assessed. As the distribution was left skewed, the Wilcoxon-
Mann-Whitney test was used to examine whether there were differences 
between MPR distribution before and after imputation of missing data. 
3.3.10 Sensitivity analysis for the calculation and description of MPR 
A sensitivity analysis was performed to examine whether there were any 
artefacts in the method of imputation of missing dosage instructions and/or 
length of prescriptions. 




The MPR values were calculated on the raw data of the subgroup of CYP who 
were included to calculate adherence; however, without executing any 
assumptions to impute the missing dosage instructions. 
This analysis was carried out in two ways; one way was to calculate the MPR 
without imputation of missing data, however, adjusting for the overlapping 
prescriptions. The second way was to calculate MPR without imputation of 
missing data and without accounting for the overlapped prescriptions. 
3.3.11 Factors influencing adherence to AEDs 
Factors that may hinder optimal adherence to the prescribed AEDs in CYP are 
complex and multilayered. These factors were simply classified by Rapoff 
(1999) as described earlier in Chapter 1 152. Among these diverse factors, this 
study was able to investigate specific factors that were available within THIN 
data. The investigated factors that may have been associated with non-
adherence are summarised in Table 3-1. 
Table 3-1: Factors influencing adherence to AEDs  
Factor/variable Justification/ definition 
Age and sex Higher adherence levels were reported in girls. Adolescents 
have been demonstrated to have lower adherence than school 
age children or infants. 
Sex was set as a binary variable (0=female, 1=male). Age of 
children was calculated on the index date of each child and 
then categorised into four groups; < 2, 2-6, 7-12 and > 12 
years old. This classification of age groups was used 
according to the BNF categorisation of age for indication and 
dosage of AEDs as the dosage instructions usually vary at 2, 
6, and 12 years cut-off ages 271.  
Socioeconomic 
status 
Socioeconomic classes have been proved to affect the level 
of social support and care received by CYP from their 
parents or caregivers and consequently affects adherence 
behaviour of CYP. 




The database uses the Townsend deprivation index as a 
marker of socioeconomic status (as described in Chapter 2). 
Socioeconomic status of CYP was defined in quintiles of 
Townsend score where 1=least deprived and 5=most 
deprived. 
Family size CYP with epilepsy belonging to a large family size showed 
low adherence levels. A larger family size with higher 
number of children to the same parents was suggested to 
decrease the quality of care given to a child with epilepsy. 
This in turn may lead to a lower level of adherence. 
As mentioned in Chapter 2, the study was conducted on a 
preformed dataset of THIN database 232. General practices 
assign the same `family number' to individuals who reside at 
the same address, which is anonymised and available for 
research. This means that individuals in institutions such as 
residential homes or in apartment buildings may have the 
same family number. To ensure those were excluded, the 
authors excluded individuals with family number of more 
than 20 people. The family number enabled the examination 
of the effect of a proxy of family size or household size on 
the level of adherence. 
Family size was classified into four groups; family size up to 
5 members; 6-10 members; 11-15 members and family 




Complexity of AED regimen was investigated from two 
aspects; the number of AEDs taken concurrently and the 
frequency of doses per day. The hypothesis was that an 
increasing complexity of regimens by adding more 
prescribed drugs and/or increasing frequency of daily dosage 
may be associated with lower adherence 272. 
The complexity of prescribed drugs for other co-morbid 
conditions, although was expected to affect adherence of 
CYP by increasing the number of medicines of daily 
regimen, was not investigated. It was possible to extract all 




drug codes in THIN for all co-morbid conditions in the time 
frame of the study period. This would have made the study 
more time consuming to conduct and more difficult to 
manage so many drugs altogether. 
A binary variable was set whether CYP were on one drug or 
combined two or more AEDs. The child was considered on 
combined drugs if he/she was prescribed two or more AEDs 
within the same 28 days in continuous or intermittent 
intervals. The frequency of doses was also set as a binary 
variable based on the median doses per day of each 
individual child where 0= once daily and 1= twice or more 
daily. 
Co-morbid diseases Concurrent co-morbidities are another factor that can add to 
complexity of drug regimen. Epilepsy has been shown to be 
associated with coexisting psychiatric and behavioural 
disorders 244, 245. It has been reported that adults suffered 
from cognitive disorders and other mental behavioural 
disorders reported lower medication adherence 273, 274. 
Co-morbidities were addressed as binary variables whereas a 
dummy variable was derived as either having asthma, mental 
health disorders or other co-morbid diseases. Asthma and 
mental health disorders were tested separately from other co-
morbidities as these two diseases represented the most 
common two co-morbid classes in the study cohort as shown 
in Chapter 2. 
 
 
Adherence levels were assumed different to individual AED types because of 
different pharmacokinetics of drugs, tolerability and available drug 
preparations 176. As above-mentioned that the MPR was calculated additively 
for all AED, so estimation of adherence for individual AEDs may be affected 
by switching of medications (i.e., a child may start a particular AED, switch to 
a second-line AED and then switch back to the initial drug in which the period 
of the second drug will be calculated as a gap for the initial drug). Therefore, 
the variation in adherence to different AEDs was examined separately on 




subgroup of CYP who received only one AED type during the total study 
period. A variable was generated to include the AED type that was prescribed 
to each individual child. To examine the difference in adherence between old 
and new class AEDs, a binary variable was also created whether CYP were 
ever prescribed old or new AEDs. 
 
3.3.12 Bivariate analysis of factors influencing adherence to AEDs 
Bivariate analysis was carried out to test the association between CYP¶V
demographics and some regimen-related factors and the overall measured 
adherence to AEDs. 
For bivariate analysis, adherence as a function of calculated MPR was set as a 
continuous outcome variable. As it had a non-normal distribution, the 
Wilcoxon rank sum (Mann-Whitney) test was used to test whether there was a 
difference in adherence distributions by sex, number of prescribed AEDs, 
frequency of doses per day and coexisting co-morbidities. The Kruskal-Wallis 
test was used to test whether each category of CYP¶VDJHDWGLDJQRVLVIDPLO\
size and Townsend index had the same shape of adherence distribution. 
The variation in adherence distribution of different AEDs was examined using 
the Kruskal-Wallis test and difference in adherence distribution of old and new 
AEDs was examined using the Wilcoxon rank sum (Mann-Whitney) test. 
  




3.3.13 Multivariate analysis of factors influencing adherence to AEDs on 
aggregated data 
After performing bivariate analysis, multivariate analysis was performed to 
understand the relationships between the identified independent variables and 
which of these variables are the main independent risk factors and predictors of 
adherence to AEDs. 
The analysis was carried out firstly on aggregated data to draw a general 
picture about factors that may affect adherence behaviour of CYP. 
Overall adherence as a function of the calculated MPR was set as a continuous 
variable. The Ordinary Least Square regression model (OLS) was not 
appropriate because the data were skewed and not normally distributed which 
is a common feature of health data 275. The log-scale residuals from a OLS 
model for the transformed data, ln (MPR), showed also that the random errors 
were significantly heteroscedastic (variance of the modelled errors was not 
constant). In such cases, the OLS model on log transformed data will provide 
biased estimates 275. Another disadvantage of transforming data is that the 
regression does not provide a model for the mean functioQȝ[LQWKHRULJLQDO
scale, which in many cases is difficult to interpret 276. 
A recommended alternative model is to choose one of the generalized linear 
models (GLM) 275. The GLM model specifies the relationship between the 
observed outcome variable and some number of covariates. By restructuring 
the relationship between the linear predictor and the fit, relationships that 
initially seem to be nonlinear can be linearised 277. 
The GLM with exponential gamma distribution was applied to analyse the 
relationship between overall calculated adherence and identified factors. The 
gamma distribution is used for data situations in which the response can take 
only values greater than or equal to 0. The variance function in gamma 
distribution is proportional to the square of the raw-scale mean function 278. It 
is used primarily with data of continuous outcome variable but can also be 
used with count data. An overview on GLM model and gamma family is 
presented in Appendix 15. 




3.3.14 Post estimation statistics of GLM model-family gamma 
Diagnostic tests are important for deciding DPRGHO¶VJRRGQHVVRIILW
especially when the data are not normally distributed. A set of diagnostic 
tests can be applied after the usual estimate with the implemented GLM 
model to check for appropriate variance (relevant error distribution) and link 
functions. Three main tests were applied as GLM-diagnostics included the 
modified Park test to test adequacy of gamma distribution 275, 279, Pregibon 
link test (1980) to examine the adequacy of the (log) link function 280 and 
Pearson residuals statistics to measure of overall fit for GLMs. 
3.3.14.1 Modified Park test 
This test determines whether the gamma distribution was appropriate for the 
outcome variable (i.e. reflect the relationship between mean MPR and 
variance) in order to specify the correct power of the mean and variance for 
the observed raw-scale MPR values279. 
To perform this test, the tentative parameter estimates from a GLM model 
based on the hypothesised variance function (i.e. family gamma, link (log) 
regression) are computed. The linear predictors from the initial fit of the 
GLM regression were used to obtain raw-scale residuals by calculating the 
inverse link function. The second step is to regress the squared raw-scale 
residuals on a constant and the linear predictor from the GLM with a log link. 
The estimated coefficient on the linear predictor can determine which 
variance function (e.g. Poisson, Gamma, and Wald) is most appropriate 275. 
Common data distributions based on the power function include: 
x Gaussian: has a constant variance; ȣ=0 
x Poisson: where variance is proportional to the mean; ȣ=1 
x Gamma: where variance is proportional to the square of the mean; ȣ=2 
x Inverse Gaussian: where variance is proportional to cube of the mean; ȣ=3 
 
So if the estimated co-efficient was equal or close to 2, family gamma 
distribution was appropriate to model adherence data. 





7KH3UHJLERQ¶VWHVWIRUOLQHDULW\ was introduced by Daryl Pregibon in 
1980280. The purpose of this test is to examine the adequacy of the 
hypothesised (log) link function used in fitting the GLM model (goodness of 
link). The link function specifies how the mean on the original MPR scale 
was related to the set of regressors (explanatory variables).  PregiERQ¶VWHVW
considers a two parameters generalization after obtaining the initial estimates 
for a GLM model with the hypothesised log link function. The model was 
refitted with the two new parameters as the only predictors.  The Coefficient 
on square of the predicted parameters should not be significantly different 
from zero. If null hypothesis is rejected, then model should be kept the same. 
3.3.14.3 ǯ-squared residuals 
Residuals are considered highly important in checking adequacy of GLM 
models. Pearson¶VUHVLGXDOVLVDSRSXODUapplied measure for overall fit of 
GLMs 281. It is usually defined as the signed square roots of the contributions 
to the Pearson goodness-of-fit statistic, and given by: 
5L ĳ<i - ûi)/ Vi1/2 
where ûi and Vi are respectively the fitted mean and fitted variance of 
function of Yi in the regression model 281. The purpose is to determine 
systematic bias in the predicted values of outcome variable on raw scale. In 
other words, the test reflects whether the predicted values are an accurate 
representation of the observed values. 
 
3.3.14.4 ȋɂǡɂȌ ? ? 
This assumption means that error term of the independent variables are not 
FRUUHODWHG7KHYLRODWLRQRIWKLVDVVXPSWLRQLVFDOOHG³DXWRFRUUHODWLRQ´DQG
results in inefficient estimation of the coefficients. 
 




3.3.15 Longitudinal calculation of MPR over time 
Adherence behaviour is presumed to be a dynamic process with a changing 
and unstable pattern 267. Measuring overall MPR (adherence) does not reflect 
time-based variation in the long-term CYP¶VDGKHUHQFH7KHUHfore, this study 
was concerned with investigation of CYP¶VORQJ-term adherence to assess 
any changes over time. Repeated longitudinal biannual (6-months interval) 
calculation of MPR was carried out. The biannual calculation of MPR started 
from the date of LQGLYLGXDOV¶ILUVWUHFRGLQJRIHSLOHSV\GLDJQRVLVRU$('
prescription in THIN (index date) whichever recorded first. This was done by 
defining the duration of follow-up for each individual child (from the index 
date to the finish date). Then the individual¶VWRWDOGXUDWLRQRIfollow-up was 
divided longitudinally into a number of 6-months intervals. If the last interval 
of an individual child did not fulfil 6 months, the last interval ended at the 
child¶Vfinish date. The numbers of days supplied with AEDs in each 6-
months interval for each individual child were calculated. Finally, MPRs 
ZHUHFDOFXODWHGDVWKHSURSRUWLRQVRIGD\V¶VXSSO\ZLWK$('VHDFK6 
months-interval. 
Figure 3-5 illustrates an example of the biannual calculation of MPR for a 
hypothetical child with duration of follow-up of 912 days (2.5 years) 
 
 
Figure 3-5: Process of biannual calculation of MPR 
  




3.3.16 Analysis of factors affecting adherence over time (longitudinal 
analysis) 
The long-term effects of potential factors on adherence behaviour over the 
years of contribution in the study period were investigated using longitudinal 
modelling analysis. 
In longitudinal data, a group of subjects sometimes of the same age as in a 
`birth cohort'  is often followed up at subject-specific occasions `events' which 
produces unbalanced or `variable occasion' data 282. Longitudinal data are 
likely to have a mix of time-variant (e.g., age and income) and time-invariant 
variables (e.g., sex). 
Multiple events on subjects cannot be assumed independent within subjects; it 
does mean that events are correlated with events nested in subjects so the 
subjects become the clusters. Therefore, it is not recommended to use ordinary 
regression to analyse longitudinal data because the data are clustered. It is 
expected that unobserved between-subjects heterogeneity leads to within-
subject correlations 282. 
Longitudinal data with repeated observations offers the scope to control for 
individual heterogeneity and the dynamics of individual behaviour. Liang and 
Zeger (1986) introduced the Generalized Estimating Equation (GEE) to 
provide more consistent and unbiased regression estimates in analysing 
longitudinal or repeated measures for cross-sectional designs with non-normal 
response variables 283. The GEE models extend the generalised linear models 
to analyse correlated observations that arise from repeated measures of the 
same individuals over time 276. The GEE models are consistent and can handle 
a variety of correlated data even if the correlation structure is misspecified 284. 
The focus of GEEs is on estimating the marginal or average response over the 
population (`population-averaged' effects) taking into account the dependence 
among units nested in clusters (Appendix 16) 282. It means that, for every one-
unit increase in a covariate across the population, the GEE infers how much 
the average response would change 285 




One of the most important things in longitudinal analysis is set a variable 
referring the time period of the analysis during which the repeated observations 
RILQWHUHVWDUHDQDO\VHG,QWKLVVWXG\WKHDQQLYHUVDU\\HDUVRIWKHLQGLYLGXDOV¶
therapeutic courses was chosen as the time variable. The outcome variable was 
the measured adherence to AEDs as a function of MPR. The MPR for 
longitudinal analysis is the per-6-months calculated MPR values over the 
follow-up years of individual CYP and were set in 30 waves where each wave 
equals 6-months interval (15 years of follow-up). It was set as a continuous 
variable for longitudinal analysis. 
The examined factors were the same under pooled analysis which included 
sex, socioeconomic status, family size, complexity of AED regimen and co-
morbidities. However, age of CYP was calculated at each 6-months interval as 
a time-varying variable and again categorised into four groups. A new variable 
which referred to the duration of treatment of each child was included in the 
longitudinal analysis. 
3.3.17 Model diagnostics 
As with GLM models, the GEE approach also needs diagnostic procedures for 
determining the goodness of fit. Among the diagnostic methods, the most 
common is to investigate the randomness of errors by plotting the residual 
values for each observation 286. In the GEE approach, Pearson residuals are 
commonly used to estimate correlation parameters. However, the distribution 
of Pearson residuals for non-normal distributions is often markedly skewed, 
and may fail to have properties similar to those of normal residuals 287. The 
plot of residual values against the linear predictor after the usual fitting of GEE 
model should show no systematic pattern (random sequence). For example, the 
deviance residuals are likely to fluctuate randomly above and below a 
horizontal line at zero 286. 
However, the conventional residuals plots for model diagnosis in longitudinal 
data could mislead a researcher into trusting the fitted model. The scatter plots 
of subjects' residuals against the follow-up time are sometimes helpful 286. 




In this study, the scatter plot of Pearson residuals after the fitting of GEE 
model on longitudinal data against the follow up time was drawn to determine 
the goodness of fit of the model. 
 





3.4.1 Characteristics of study cohort and overall prescribing of AEDs 
During the study period, 2020 epilepsy cases contributed 9562 person-years of 
follow-up since the date of first recoding of epilepsy diagnosis (Table 3-2). 
Among the cases, 1115 (55.2%) were males and the majority (50.2%) were 
below the age of five years at their first date of recoding epilepsy in THIN. The 
patients were prescribed a total of 82,836 prescriptions of 15 AEDs for 
epilepsy control (shown later in Table 3-3). The CYP were also prescribed 
3642 prescriptions of three drugs for controlling prolonged or life-threatening 
seizures. Of the total prescriptions, there were 54905 (66.3%) and 27931 
(34.7%) prescriptions for old and new AEDs, respectively. A small number of 
CYP (80) were prescribed only one prescription during the whole duration of 
follow-up. 
Overall, the mean number of prescriptions per person-years was 9.1 (95% 
CI=8.9-9.3). The younger age children, 0-4 years, had a mean of 8.8 (95% 
CI=8.5-9) prescriptions per person-years while older age groups; 10-DQG15 
years, had a mean of 10.3 and 10.5 (95% CI=9.1-11.9) prescriptions per person-
years, respectively. Over the study time, one-half of CYP (n=1042; 51.6%) 
were prescribed only one AED type to control epilepsy with a mean of 4.5 
(95% CI =4.3-4.7) prescriptions per person-years. Approximately one quarter of 
patients (n=489; 24.2%) were prescribed two drugs and the remainder received 
three (11%) or more AEDs (13.2%). 
 




Table 3-2: Characteristics of study cohort and overall prescribing of AEDs 

















































































3.4.2 Frequency of prescribing of individual AEDs over the study period 
CYP were most often prescribed old AEDs such as sodium valproate and 
carbamazepine (65.2% and 40.8% received valproate and carbamazepine, 
respectively). Phenobarbital and phenytoin were less common prescribed old 
AEDs. Lamotrigine and topiramate were the most often prescribed drugs 
from the new AEDs for 24.4% and 8.5% of CYP respectively. The same 
order could be applied to the number of CYP who were prescribed one drug 
over the study period `monotherapy' (Table 3-3). Among CYP who were ever 
prescribed one drug, the highest number of CYP (n=606) received sodium 
valproate followed by carbamazepine (n=302) and lamotrigine (n=51). 
Old AEDs were most often tried as first-line drugs compared to new AEDs. 
Out of 2020 CYP, 1667 (82.5%) received old AEDs as first line treatment. 
  




Table 3-3: Overall prescribing of individual AEDs over the study period 








No of CYP 
received drug 
as first line (%) 
n=2020 
No of CYP on 
one drug type 
(%) 
n=1042 
Sodium valproate 1318 (65.2) 29,564 (35.7) 986 (48.8) 606 (30) 
Carbamazepine 824 (40.8) 20,353 (24.6) 532 (26.3) 302 (15) 
Lamotrigine 493 (24.4) 16,488 (19.9) 108 (5.3) 51 (2.5) 
Topiramate 171 (8.5) 3,733 (4.6) 18 (0.9) 4 (0.2) 
Vigabatrin 161 (8.0) 3,540 (4.3) 61 (3.1) 18 (0.9) 
Ethosuximide 109 (5.4) 1,972 (2.4) 35 (1.7) 19 (0.9) 
Phenobarbital 104 (5.1) 1,083 (1.3) 76 (3.8) 28 (1.4) 
Clonazepam 94 (4.7) 2,012 (2.4) 16 (0.8) 4 (0.2) 
Phenytoin 84 (4.2) 1,357 (1.6) 38 (1.9) 9 (0.5) 
Levetiracetam 58  (2.9) 794 (0.9) 0 (0) 0 (0) 
Gabapentin 51 (2.6) 1,064 (1.3) 4 (0.2) 0 (0) 
Oxcarbazepine 15  (0.7) 265 (0.3) 2 (0.1) 1 (0.1) 
Clobazam 14  (0.7) 260 (0.3) 0 (0) 0 (0) 
Tiagabine 9 (0.4) 37 (0.1) 0 (0) 0 (0) 
Primidone 3  (0.2) 316 (0.4) 1 (0.1) 0 (0) 
*Note: A child can be prescribed more than one individual AED, therefore the 
number of CYP does not add to the total 2020 CYP.   
 




3.4.3 Frequency of prescribing of AEDs by age and calendar years, over 
the study period 
The study cohort had a specific feature in that it consisted of CYP who were 
born in or after 1988. Data illustrated in Table 3-4 show an increase in 
number of CYP who were treated with AEDs each year from 31 children in 
1990 to 1060 CYP in 2003. The total numbers of prescriptions of AEDs were 
also increased each year during the study period. The number of treated CYP 
ranged from 58% to 69% each year. Around one-third of CYP did not receive 
any medicines each year and ranged from 43% in 1990 to 31% in 2002-03. 
The proportions of CYP who were on one drug each year ranged from 58% 
to 64% of treated CYP and slightly changed over the study period. Each year, 
between 17% and 27% of CYP were received at least two AEDs each year to 
control epilepsy. Higher proportions of children were on one drug in the age 
category 0-4 years during the first 6 years (1990-95). From the year 1996 and 
as children became older and still contributed to THIN data, the higher 
proportions on one drug were in older age categories, 5-9 and ı 10 years, as 
shown in Table 3-4. 
 










No of CYP* 
n=2020 
Sex (treated) No of CYP on one drug by age groups 
(%/year)* 
n=1042 
No of CYP on more than one drug by 

















1990 239 54 31 (58) 17 14 22 0 0 22 (41) 9 0 0 9 (17) 
1991 575 105 71 (68) 31 40 44 0 0 44 (42) 27 0 0 27 (26) 
1992 880 151 89 (59) 49 40 52 0 0 52 (34) 37 0 0 37 (25) 
1993 1307 220 132 (60) 69 63 65 11 0 76 (35) 43 13 0 56 (26) 
1994 1789 308 190 (62) 95 95 83 32 0 115 (37) 50 25 0 75 (24) 
1995 2846 419 265 (63) 136 129 90 72 0 162 (39) 64 39 0 103 (25) 
1996 3940 536 369 (69) 195 174 102 126 0 228 (43) 70 71 0 141 (26) 
1997 5020 652 431 (66) 224 207 89 166 0 255 (39) 71 105 0 176 (27) 
1998 6273 792 527 (67) 272 255 94 212 35 341 (43) 70 106 10 186 (24) 
1999 7439 945 651 (69) 357 294 105 232 80 417 (44) 70 131 33 234 (25) 
2000 8870 1089 733 (67) 411 322 95 205 146 446 (41) 77 147 63 287 (26) 
2001 10385 1267 865 (68) 491 374 94 220 218 532 (42) 72 155 106 333 (26) 
2002 11819 1410 974 (69) 560 414 94 215 298 607 (43) 84 142 141 367 (26) 
2003 12991 1534 1060 (69) 607 453 88 217 378 683 (45) 81 119 177 377 (25) 
 
* The number of CYP does not add to total as a child can contribute to more than one calendar year 




The proportions of CYP on old and new AEDs are shown in Figure 3-6. Over 
the study period, the proportions of CYP on old AEDs ranged from 57% to 63% 
with slight change over time. The proportions of CYP who were prescribed new 
AEDs increased from 11% in 1990 to 24% in 2003. Non-treated CYP ranged 
from 43% in 1990 to 31% in 2002-03. Some of non-treated CYP were incident 
cases and received their first prescription later and others were prevalent cases 
but were not prescribed any drug in a particular year. 
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3.4.4 Frequency of prescribing of individual AEDs by calendar years over 
the study period 
Cross-sectional per year analysis of the AED prescribing revealed that the 
number of prescriptions increased for many drugs such as sodium valproate, 
carbamazepine, lamotrigine and topiramate. There was also an increase in the 
total numbers of CYP who received individual drugs each year. 
The total numbers of prescriptions per person-years of study cohort increased 
for sodium valproate and carbamazepine from the old AEDs (Figure 3-7). The 
total annual number of prescriptions per person-years decreased for phenytoin 
and phenobarbital. The mean numbers of prescription per person-years were 
2.79 of sodium valproate, 1.83 of carbamazepine, 0.25 of Phenobarbital and 
0.16 of phenytoin. 
The annual numbers of prescriptions of the new AEDs per person years 
increased for lamotrigine (0.07 in 1992 to 2 per person-years in 2003) and 
topiramate (0.01 in 1996 to 0.63 per person-years in 2003) during the study 
period (Figure 3-7). An increase in number of prescriptions of vigabatrin, one of 
the new AEDs, was observed till the year 1998 followed by a decline. The mean 
numbers of prescription per person-years were 1.01 of lamotrigine, 0.44 of 
vigabatrin and 0.17 of topiramate per person-years. 
  















































Carbamazepine Clobazam Clonazepam Ethosuximide
Gabapentin Lamotrigine Levetiracetam Oxcarbazepine
Phenobarbital Phenytoin Valproate  Primidone
Tiagabin Topiramate  Vigabatrin




The proportions of CYP who were prescribed a particular AED type relative to the 
prevalent cases of study cohort each year (the probability of prescribing a particular 
AED type if a child was diagnosed with epilepsy) is shown in Figure 3-8. The overall 
prescribing remained higher for old AEDs during the study period. The proportions 
of CYP who were prescribed old AEDs almost unchanged for sodium valproate and 
carbamazepine after the year 1999. The proportions of CYP who were prescribed 
new AEDs such as lamotrigine and topiramate increased over the study period. 
 



































Carbamazepine Clobazam Clonazepam Ethosuximide
Gabapentin Lamotrigine Levetiracetam Oxcarbazepine
Phenobarbital Phenytoin Valproate  Primidone
Tiagabin Topiramate  Vigabatrin non-treated




3.4.5 Time to addition of or switching to a new drug type 
The above-mentioned data in Table 3-3 of prescribing individual AEDs revealed 
that almost all AEDs were tried as first-line therapies to control epilepsy. 
Although the majority of CYP were only prescribed one AED over the follow-up 
time (1042, 51.6%), 24 % were prescribed two drugs and 23% were prescribed 
three or more drugs. The maximum number of AED combinations taken as a 
single course was four drugs. The median time to add a new drug type to the 
course of therapy or to switch to a new AED is shown in Table 7. The median 
time to add or switch to a second type was 173 days (~0.5 year).    
Table 7: Time to change the regimen (either by adding or switching to a new drug 
type) 
Number of the 
added AED 
Median time to add or switch 
to next AED in days (IQR) 
Range 
(min   max) 
Number of 
CYP 
Second 173 (74-423) 5       1898 573 
Third 203 (86-463) 8        2229 436 
  




3.4.6 Results of calculating the daily dosage of prescribed AEDs 
Table 3-5 shows a summary of available recorded data for the calculation and 
GHVFULSWLRQRILQGLYLGXDOV¶GRVDJHUHJLPHQV2XWRI,020 CYP, 953 (47%) 
either had completely missing `unrecorded' dosage instructions and/or less than 
one year coverage of prescription records. Thus the data shown in Table 3-5 
were for 1,067 CYP who had data for at least one follow-up year and at least 
one known dosage instruction. The daily dosage instructions were explicitly 
recorded for 45,779 (63.6%) out of 71,969 issued prescriptions. This means that 
the daily dosage instructions (and consequently the length of prescriptions) were 
unavailable for more than one-third (36.4%) prescriptions. Of the missing 
dosage instructions, 18,896 (26.3%) dosage instructions were completely 
unrecorded and 7,294 (10.1%) prescriptions carried non-specified instructions 
(e.g. `Take as directed'). The exact length of prescriptions in days was recorded 
for only 6% of the total prescriptions. 
Table 3-5: Available data in THIN for calculation of dosage regimen for the 
study cohort 








quantity/package size (solid 
units or mls of liquid) 
1.0 % 99% 112 (56-300) 1 1800 
Calculated daily 
quantity/volume of dosage  
(solid units or mls liquid) 
36.4% 63.6% 2 (2- 4) 0.5 40 
Length of prescriptions 
(days) 
94% 6% 28 (28-30) 1 84 
mls=millimetres (unit measure of volume)  




The extent of recording prescription instructions was examined during the three 
years before 2002 (the year where data collection in THIN started prospectively 
from contributing general practices) and three years from 2002 to 2004. Out of 
23,229 prescriptions issued throughout 1999-2001, 10,318 (44%) prescription 
instructions were missing and out of 28,484 prescriptions issued throughout 
2002-2004, 8,789 (31%) were missing prescription instructions. This suggests 
that the quality of recording data has improved since data collection started 
prospectively in 2002.  
Similar analysis was carried out to investigate the quality of recording THIN-
coded seizure outcomes before and after 2002 and the results were reported in 
section 4.5.2. 
3.4.7 Results of imputation of missing dosage instructions 
To calculate MPR for the study cohort, the available dosage data was utilised to 
impute missing dosage instructions. The overall MPR was calculated at each 
stage of executed assumption and the results are shown in Table 3-6. The MPR 
values shown in the table were calculated at each stage of assumption before 
executing the following assumption. 




Table 3-6: Calculated MPR after each assumption for imputation of missing 
instructions 










Mean MPR (SD)* 
Median MPR [IQR]* 
No assumptions 
 





1067 8949 54728 0.79 (0.20) 
0.86 [0.70-0.95] 
+Assumption 2 
(using median time 
length between 
prescriptions) 






1067 3592 71969 0.74 (0.21) 
0.81 [0.64-0.90] 
* Overlap of prescription dates was accounted for before the calculation of the MPR 
 
Figure 3-9 illustrates different types of overlapping dates of issued prescriptions  
 
Figure 3-9: Different causes of overlapping of prescription dates 
 




3.4.8 Distribution of the calculated overall MPR 
The distribution of estimated MPR after data imputation but without accounting 
for overlapping of prescription dates is shown in Figure 3-10. The median 
calculated overall MPR was 1.06 (IQR= 0.83-1.53).  There were 613 (57.4%) 
out of 1067 CYP had MPR > 1. The distribution of MPR suggested that more 
than one-half of CYP may have had oversupply of AEDs. 
 
Figure 3-10: Overall calculated MPR without accounting for the overlapping 
prescription dates 
 
The distribution of the calculated overall MPR after accounting for the 
overlapping prescriptions is shown in Figure 3-11. The distribution comprised a 
cohort of 1067 CYP who were issued a total of 71969 prescriptions. The overall 
MPR ranged from 0.05 to 1 (median=0.81, IQR=0.65-0.90). It can be observed 
that accounting for overlapping prescriptions markedly lowered the median 
overall MPR. 
Calculated MPR values >1 were truncated to 1 (100%) adherence. Of the 
calculated MPR values, 555 (52%) CYP KDG035YDOXHVZKLFKPHDQV




that more than one-half of CYP had at least 80% AED coverage during the 
study period. 
The calculated MPR after accounting for the overlapping prescriptions differed 
significantly from that before accounting for the overlapping prescriptions 
(Wilcoxon-rank sum (Mann-Whitney) test; p<0.001). 
 
Figure 3-11: Distribution of calculated MPR after accounting for the overlapping 
prescription dates 
 
Another method of dealing with overlapping days of AED prescriptions was carried 
out. When a prescription of the same AED was issued before the end of the last 
SUHVFULSWLRQHDUO\UHILOOWKHWRWDOGD\V¶VXSSO\E\WKHWZRSUHVFULSWLRQVZHUH
summed based on the assumption that a child would not start taking AED doses of the 
second refill unless all doses of the first prescription finished. In such case, the overall 
MPR ranged from 0.06 to 1 (median=0.84, IQR=0.70-0.95) and 575 (54%) CYP had 
MPR values ı 0.8. This figure was considered similar to the above discussed one 
using the described methodology of dealing with prescription overlapping.     




3.4.9 Description of overall MPR and bivariate analysis of factors 
influencing on adherence to AEDs 
Adherence was measured as a function of measured MPR. Using median levels, 
the results of bivariate analysis are shown in Table 3-7 where adherence level 
was tested as a continuous outcome. Male children did not have a significantly 
higher adherence level compared to females (p=0.05). Adherence level was 
significantly increased with increasing age of CYP at the first diagnosis of 
epilepsy (p<0.001). It was higher among age groups of 7-12 years and more 
than 12 years old. 
The data showed a non-significant difference in overall adherence level among 
CYP who lived with families of different family sizes (p=0.05). 
There was a significant association between overall adherence levels and 
deprivation scores (P=0.03). CYP with higher deprivation scores showed lower 
adherence as compared to those of lower deprivation score. 
More than one-half of CYP (55.3%) were on combined AEDs at time to control 
epilepsy and they showed significantly higher level of adherence (p<0.001). The 
distribution of the frequency of daily doses of AEDs showed that one-tenth of 
CYP (115; 10.7%) was on once daily regimen while the majority of CYP (893, 
83.7%) were on twice daily regimen. Fewer number of CYP (59, 5.5%) were on 
thrice or more daily. Increased the frequency of daily doses to more than once 
daily did not significantly affect adherence level (p=0.87). 
CYP who were treated for other co-morbid diseases such as asthma and mental 
health disorders did not differ from CYP with no co-morbidities with respect to 
overall adherence level (p=0.89 for asthma and p=0.07 for mental health 
disorder). 




Table 3-7: Description of overall MPR, demographics and disease related factors 













0.82  (0.68 -0.91) 























0.81  (0.64 -0.90) 
0.78  (0.59 -0.89) 
0.81  (0.69 -0.90) 




















0.82  (0.67 -0.91) 
0.78  (0.60 -0.88) 
0.81  (0.72 -0.88) 





















0.84 (0.70 -0.91) 
0.83  (0.71- 0.91) 
0.80  (0.65 -0.91) 
0.79  (0.55- 0.89) 
0.80  (0.66 -0.90) 







Number of combined 
AED 
No combination 
Two or more drugs 
 
Frequency of daily 
doses 
Once daily 












0.77  (0.57 -0.88) 
0.84  (0.71 -0.91) 
 
 
0.80  (0.62 -0.90) 




































































3.4.10 Adherence to individual AEDs 
The variation in adherence to different AEDs was examined on the group of 
CYP who were prescribed only one AED over the study period (Table 3-8). The 
CYP also had at least one year follow-up period and at least one known dosage 
instruction. The total number of CYP was 389 who were issued a total of 11854 
prescriptions. The overall calculated MPR ranged from 0.07 to 1 (median=0.82; 
IQR 0.63-90). 
The proportions of CYP who were prescribed monotherapy were higher for 
sodium valproate (60%) and carbamazepine (31%) than for other AEDs. A few 
number of CYP were on new AEDs (n=26; 6.7%) as monotherapy.  The median 
MPR was higher for lamotrigine (0.87), carbamazepine (0.80) and sodium 
valproate (0.80).  Adherence of CYP to new AEDs was higher but not 
significant as compared to old AEDs (P=0.65). The results showed that 
adherence to individual AEDs did not significantly vary among CYP (P=0.75). 
 




Table 3-8: Variation of adherence to differnt AEDs among CYP on monotherapy 














0.80  (0.68 -0.90) 

























0.81  (0.72 -0.90) 
0.75  (0.49 -0.88) 
0.79  (0.65 -0.90) 






















0.80  (0.66 -0.90) 
0.80  (0.65 -0.90) 
0.87  (0.66 -0.93) 
0.63  (0.26 -0.90) 













0.80  (0.62- 0.90) 









*Other individual AEDs were prescribed to less than 1% of CYP on monotherapy so they 
were not shown in this Table. 
 
The results of bivariate analysis revealed that some potential factors, such as age 
of children and level of deprivation, significantly affected the measured 
adherence. All of these factors were tested simultaneously using multivariate 
regression. 
  




3.4.11 Sensitivity analysis for the calculation of MPR before data 
imputation but accounting for overlapping prescription dates 
The total number of CYP is 1067 who were issued 45,779 (63.5%) with clear 
dosage instructions out of a total number of 71,969 prescriptions.  The number 
of prescriptions with clear dosage instructions was used to carry out the 
sensitivity analysis. The calculated MPR ranged from 0.01 and 1 (median=0.70; 
IQR=0.48, 0.86) and no CYP had MPR >1. 
Table 3-9 shows that the median MPR values were often around 0.70 with 
different CYP¶VFKDUDFWHULVWLFV and regimen-related factors. The p values 
obtained from the bivariate analysis of the MPR and different CYP¶V
demographics or regimen-related factors were similar to those obtained after 
imputation of missing data. 




Table 3-9: Description of overall MPR before data imputation (overlapped 
prescriptions were accounted for); demographics and disease related factors 
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0.67  (0.42 -0.85) 
0.68  (0.44 -0.86) 
0.72  (0.54 -0.87) 



















0.70  (0.48 -0.87) 
0.69  (0.46 -0.84) 
0.76  (0.64 -0.83) 





















0.73  (0.52 -0.88) 
0.69  (0.52 -0.86) 
0.73  (0.54 -0.88) 
0.65  (0.44 -0.82) 
0.74 (0.45- 0.86) 







Number of combined 
AED 
No combination 









0.70  (0.47 -0.86) 













Frequency of daily 
doses 
Once daily 








0.73  (0.51 -0.90) 

































































3.4.12 The MPR values without data imputation and without accounting for 
overlapping prescriptions 
As above-mentioned the number of prescriptions which had clear dosage 
instructions was 45,779. These instructions were used to calculate MPR, 
however, without accounting for the overlapping dates of prescriptions. The 
range of calculated MPR is from 0.06 to 6.32 (median=1.09) with 603 (56.5%) 
CYP having MPR values >1. The calculated median MPR had higher values >1. 
The results suggested that the percentage of drug coverage was at least 100% 
for more than one-half of CYP. Similar to the main analysis of MPR, sex, 
family size and co-morbidity did not significantly affect the calculated MPR, 
whereas the calculated MPR significantly varied among age groups at diagnosis 
and by the number of concurrent AEDs.  However, compared to the main 
analysis, the calculated MPR values did not significantly vary by different 
classes of socioeconomic status of CYP. 
This sensitivity analysis showed that the majority of the examined factors 
showed similar bivariate associations with MPR, as those displayed between the 
factors assessed and corrected MPR in the principal analysis. This suggests that 
the assumptions used to correct the MPR did not change the relationship 
between the factors assessed and MPR.     
 




Table 3-10: Description of overall MPR before data imputation without 
accounting for overlapped prescriptions; demographics and disease related factors 













1.13 (0.83 -1.73) 






















1.31  (0.82 -2.03) 
1.04  (0.73 -1.66) 
1.06  (0.82 -1.09) 




















1.11  (0.81 -1.71) 
1.04  (0.79 -1.47) 
1.19  (0.85 -1.45) 





















1.06  (0.82 -1.56) 
1.13  (0.87 -1.60) 
1.07  (0.76 -1.73) 
1.11 (0.71 -1.69) 
1.12  (0.84 -1.64) 







Number of combined 
AED 
No combination 
Two or more drugs 
 
Frequency of daily 
doses 
Once daily 












1.07  (0.79 -1.60) 
1.97 (1.27 -2.50) 
 
 
1.25  (0.80 -1.77) 

































1.08  (0.77 -1.61) 
1.09  (0.81 -1.69) 
 
1.10  (0.81 -1.82) 
1.09  (0.81 -1.69) 
 
1.28  (0.97 -1.95) 






















3.4.13 MPR calculation before data imputation in CYP who were on 
monotherapy 
The total number of CYP was 389 who had a total 8251 prescriptions with clear 
dosage instructions after overlapping prescriptions were removed. The statistical 
results showed that there was no significant difference of the MPR values by 
AED class or individual AED type which was similar to that examined after 
imputation of missing dosage instructions. 
Table 3-11: Variation of adherence to different AEDs among CYP on 
monotherapy 














0.77 (0.51 -0.90) 






















0.74  (0.52 -0.89) 
0.72  (0.55 -0.87) 
0.85  (0.43 -0.90) 
0.63  (0.36 -0.87) 














0.74  (0.54- 0.88) 







*Other individual AEDs were prescribed to less than 1% of CYP on monotherapy so 
they were not shown in this Table. 
 




3.4.14 Multivariate analysis of factors affecting adherence: GLM for overall 
adherence using aggregated data 
The output of multivariate GLM regression shown in Table 3-12 is for factors 
that may affect the overall adherence using the aggregated data. The data 
showed that the overall MPR and hence adherence to AEDs did not 
significantly differ between male and female children (p=0.06). Older age 
children of 7-12 and >12 years showed significantly higher adherence levels 
(p=0.03 and p=0.01, respectively) controlling for other factors. 
Adherence was negatively but insignificantly associated with families with 
larger family members. Compared to adherence levels of CYP who belonged to 
small family up to five members, CYP belonging to larger families showed 
lower adherence levels. 
Adherence was negatively associated with higher deprivation quintiles. As 
compared with CYP with better socioeconomic status (quintile 1), CYP who 
had higher deprivation quintiles (score 4 and 5) were associated with 
significantly lower adherence levels (p=0.01 and p=0.04 respectively). 
Complexity of AED regimens showed significantly higher adherence levels 
(p<0.01) in CYP who were prescribed two or more concurrent AEDs to control 
epilepsy. However, the frequency of daily dosage did not significantly affect 
adherence level (p= 0.49). 
The existence of other co-morbid diseases such as asthma and mental 
behavioural disorders did not significantly affect adherence levels of CYP (p= 
0.87 and 0.08, respectively) 
 




Table 3-12: Potential factors affecting adherence: multivariate analysis using the 







Male sex 0.031 [-0.002,  0.064] 
 
0.06 







-0.041 [-0.088, 0.001] 
0.049 [0.017, 0.082] 












-0.037 [-0.078,  0.004] 
-0.035 [-0.168,  0.098] 










5 (most deprived) 
Missing 
 
0.014 [-0.043,  0.071] 
-0.029 [-0.082,  0.025] 
-0.073 [-0.126,  -0.021] 
-0.057 [-0.107,  -0.008] 








Number of combined AED (one drug) 
Two or more drugs 
 
Frequency of daily doses (once daily) 
Twice or more 
 
0.117 [0.082,  0.152] 
 
 












-0.003 [-0.042,  0.035] 
-0.045 [-0.089,  0.005] 






Constant of regression -0.289 [-0.361, -0.217] 
 
<0.001 




3.4.15 Results of post estimation diagnostic tests of GLM model 
The results of post estimation statistics for GLM with family gamma 
distribution are shown in Table 3-13. The modified Park test showed that the 
gamma distribution family is accepted. The coefficient on the modified Park test 
was 1.75 is close to 2, that of gamma distribution. The Pearson residuals 
statistic indicates that the model was unbiased in predicting values of the 
outcome variable on raw scale. The p-YDOXHRI3UHJLERQ¶VOLQNWHVWLVDQG
suggests that the link function is correct. The assumption of independence of 
error terms was not violated by GLM model as none of estimated coefficients of 
the residuals was significant; it means they are not correlated. 
Table 3-13: GLM diagnostics on the refitted model 
Fitted Model: Family Gamma; Link = Log 






















Pearson residuals test :  0.98 





The distribution of original MPR values was left skewed while that of reverse 
MPR was right skewed.  Since the gamma has a probability density function 
(pdf) that can be either monotonically declining across the frequency axis or bell 
shaped, but skewed to the right 278, the GLM gamma family is assumed to fit 
better on reversed values of MPR. However, testing the significance of each 
coefficient of covariates revealed no difference predicting the values of outcome 
variable using GLM gamma link log on original and reverse values. The 




hypothesised relationship between the mean and variance was specified with the 
Gamma distribution. 
3.4.16 Longitudinal calculation of MPR 
The results of biannual calculation of MPR for individual patients to track 
adherence levels over time starting from WKHLQGLYLGXDOV¶LQGH[GDWH are shown 
in Table 3-14. The MPR value of 0 was observed when CYP had intermittent 
periods of no therapeutic data (gaps) for 6-months or more and then reinitiated 
new episodes of AEDs prescriptions. These gaps in AEDs treatment may 
indicate medicines withdrawal due to remission of seizures (untreated intervals), 
non-adherence or registration gaps (i.e. in some cases, all medical files of CYP 
did have any recorded data during these gaps).  
The table comprised two estimates of adherence levels over time. The first 
estimate showed the trend of the per-6-months calculated adherence of all 
registered CYP with epilepsy considering CYP with MPR=0 as non-adherent. 
This estimate shows that adherence levels started higher in the first two years 
after recording of epilepsy (up to biannual four) and then gradually decreased to 
rise again gradually at last few years of follow-up. The median values of MPR 
ranged from 0.77 to 0.33). The second estimate showed the median adherence 
levels of CYP after excluding CYP with MPR=0 (were considered untreated) at 
each interval of follow-up. The median values of MPR ranged from 0.80 to 0.93 
which indicate little changes of the median MPR over time. There were a few 
numbers of CYP (14) who had therapeutic data up to 15 years.  
Figure 3-12 is a graphical illustration of the trend of the calculated adherence 
over the follow-up time.  
Because CYP had different follow-up durations and the number of CYP 
decreased each 6-month interval, changes in adherence levels would not be 
assessed over the whole period of follow-up for all CYP. A subgroup of CYP 
with reasonably long period of follow-up was chosen to assess their adherence 
levels over time. Figure 3-13 shows the values of MPR each 6-month interval 
for the 400 CYP who contributed to THIN for 14 biannual (7 years). The 
median MPR decreased over time and ranged from 0.65 (IQR=0.26-0.91) in the 




first interval of follow-up to 0.31 (IQR=0.11-0.89) at the end of 7 years follow-
up.  
Table 3-14: Values of biannual calculation of MPR including the untreated CYP 
of each interval 
Biannual after 













1st biannual 1067 0.77 (0.33- 0.96) 956 0.80 (0.49- 0.97) 51 
2nd biannual 1067 0.79 (0.41- 0.95) 889 0.85 (0.65- 0.97) 59 
3rd biannual 1067 0.77 (0.45- 0.93) 914 0.84 (0.61- 0.95) 55 
4th biannual 1026 0.77 (0.36-0.94) 854 0.84 (0.63- 0.97) 57 
5th biannual 961 0.76 (0.27- 0.93) 777 0.84 (0.61- 0.96) 57 
6th biannual 901 0.71 (0.11- 0.92) 679 0.83 (0.61- 0.95) 55 
7th biannual 850 0.66 (0.0- 0.92) 627 0.82 (0.61- 0.96) 53 
8th biannual 781 0.68 (0.0- 0.92) 555 0.84 (0.64- 0.97) 57 
9th biannual 709 0.63 (0.0- 0.92) 494 0.83 (0.60- 0.97) 55 
10th biannual 641 0.61(0.0- 0.91) 420 0.86 (0.62- 0.98) 57 
11th biannual 588 0.58 (0.0- 0.90) 383 0.85 (0.61- 0.97) 56 
12th biannual 518 0.58 (0.0- 0.91) 329 0.84 (0.61- 0.98) 57 
13th biannual 447 0.49 (0.0- 0.90) 274 0.84 (0.61- 0.98) 57 
14th biannual 400 0.31 (0.0- 0.90) 235 0.85 (0.51- 0.98) 58 
15th biannual 370 0.33 (0.0- 0.91) 218 0.88 (0.59- 0.98) 59 
16th biannual 336 0.47 (0.0- 0.91) 203 0.87 (0.63- 0.98) 61 
17th biannual 300 0.49 (0.0- 0.90) 182 0.86 (0.61- 0.97) 58 
18th biannual 267 0.35 (0.0- 0.89) 156 0.84 (0.54- 0.98) 58 
19th biannual 227 0.40 (0.0- 0.87) 134 0.85 (0.56- 0.96) 60 
20th biannual 198 0.43 (0.0- 0.89) 127 0.83 (0.46- 0.98) 52 
21st biannual 164 0.50 (0.0- 0.87) 104 0.81 (0.59- 0.95) 52 
22nd biannual 137 0.56 (0.0- 0.89) 87 0.82 (0.61- 0.95) 54 
23rd biannual 112 0.54 (0.0- 0.91) 75 0.85 (0.54- 0.97) 55 
24th biannual 88 0.62 (0.0- 0.93) 58 0.90 (0.63- 0.99) 66 
25th biannual 74 0.50 (0.0- 0.88) 46 0.84 (0.57- 0.97) 61 
26th biannual 63 0.64 (0.15- 0.99) 48 0.93 (0.47- 1.00) 63 
27th biannual 45 0.73 (0.17- 0.93) 35 0.82 (0.52- 0.96) 51 
28th biannual 33 0.61 (0.0- 0.80) 23 0.75 (0.51- 0.95) 35 
29th biannual 22 0.73 (0.0- 0.92) 16 0.87 (0.62- 0.99) 63 
30th biannual 16 0.87 (0.42- 0.99) 14 0.91 (0.56- 1.00) 71 
a: number of CYP including untreated CYP each interval as non-adherent  
b: number of CYP excluding untreated CYP each interval  
 





Figure 3-12: Median per-6months calculated MPR for individual CYP 
 
Figure 3-13: Median per 6-months calculated MPR for 400 CYP with 7 years of 
complete follow-up data 




3.4.17 Multivariate analysis of factors affecting adherence over time 
(longitudinal data) 
The results of multivariate analysis of factors affecting adherence levels over 
time based on average population response are shown in Table 3-15. In the GEE 
analysis, reporting the marginal effect (i.e., the population mean rate of change 
in adherence levels with respect to each the explanatory variables)  is important 
than focusing on the coefficients of regressions from the GEE model 276.  
The data showed that the predicted mean of the per-6-months calculated 
adherence levels for the study cohort was 60%. There was not a significant 
difference in the mean adherence between males and females. Adherence was 
positively associated with older age groups. Children of 2-6 and 7-12 years had 
7% higher mean adherence levels than infants younger than 2 years and young 
people>12 years old had 8% higher mean adherence level than infants. It means 
that the mean per 6-months adherence levels of older children of 2-12 years 
were about 67% (0.60+0.068) and that of young people >12 years was about 
68% (0.60+0.077) 
Adherence levels were negatively but non-significantly associated with higher 
deprivation quintiles (low socioeconomic status). The size of effect of 
deprivation quintiles on the mean adherence levels was small (0.1-5%) 
Adherence levels were negatively and significantly associated with the longer 
duration of antiepileptic drug treatment. CYP who had longer biannual intervals 
of follow-up time showed significantly lower mean adherence levels than those 
who had shorter follow-up time (p<0.01). 
CYP who were prescribed at least two concurrent AEDs had 7% higher and 
significant adherence level (p<0.001) relatively to CYP who were on 
monotherapy. 




Table 3-15: Marginal effects of explanatory variables on the biannual MPR; GEE 
model 
Mean predicted longitudinal MPR=0.60 
Explanatory variables  
(reference group) 
Average-population 









0.068 [0.003, 0.132] 
0.069 [0.004, 0.135] 






Male sex 0.024  [0.001,  0.054] 
 
0.13 





-0.026 [-0.063,  0.012] 
0.007 [-0.047,  0.169] 










5 (most deprived) 
Missing 
 
-0.001 [-0.049,  0.048] 
-0.021 [-0.069,  0.026] 
-0.033 [-0.078,  0.012] 
-0.004 [-0.043,  0.039] 








Duration of follow-up  -0.005 [-0.007, -0.002] 
 
<0.01 
Number of combined AED (one drug) 
Two or more drugs 
 
Frequency of daily doses (once daily) 
Twice or more 
 
0.113 [0.080,  0.146] 
 
 












0.004 [-0.022,  0.029] 
0.007 [-0.039,  0.042] 










3.4.18 Model diagnostics 
Figure 3-14 shows the scatter plot of predicted residuals after the fitting of GEE 
model on longitudinal data against the follow up time. The residuals were a 
little left-skewed with mean, variance, skewness and kurtosis equal to -0.04, 
0.15, -0.34 and 1.52, respectively. This scatter plot indicates that the current 
GEE model fitted the data satisfactorily.  
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3.5.1 Prescribing pattern of AEDs 
The analysis examined 2020 CYP diagnosed with epilepsy and prescribed at 
least one prescription for AED since their registration date at the general 
practice. During the study time, the results showed an increase in the overall 
number of prescriptions of AEDs between 1990 and 2003. This suggests that 
prescribing increased along with increasing number of prevalent cases of 
epilepsy each year in the study cohort as discussed earlier in Chapter 2. 
More than one-half of CYP (51.6%) were only ever prescribed one AED type 
during the whole follow-up time and 58%-64% of treated CYP were prescribed 
monotherapy each year. This is in agreement with the literature which has 
shown that approximately 60-70% of CYP with epilepsy can be effectively 
controlled by a single AED 93, 94. This is also in concordance with the late 
released NICE guidance recommendation that CYP should be treated with a 
single AED whenever possible 1. 
Old AEDs such as carbamazepine and sodium valproate were most often tried 
as the first line of treatment. The overall number of prescriptions was higher for 
old AEDs during the study period. The findings showed that sodium valproate 
and carbamazepine were the most frequently prescribed old AEDs followed by 
lamotrigine and topiramate from the new AEDs. This finding was expected 
because carbamazepine and sodium valproate are considered the mainstay and 
first line pharmacological management of epilepsy in Europe and USA 288. The 
higher prescribing frequency of carbamazepine and sodium valproate in this 
study is in line with the findings of an earlier study conducted in the Northern 
and Yorkshire region in England  117. The authors examined the records of all 
registered patients from the Prescription Analysis and Cost (PACT) data across 
16 health authority. The authors found an increase in prescribing of 
carbamazepine (up to 24%) and sodium valproate (up to 33%) between 1992 
and 1995. 




The proportions of CYP who were prescribed new AEDs increased by 13% 
between 1990 and 2003. However, the proportions of CYP who were prescribed 
old AEDs remained almost unchanged. This reflects that new AEDs were often 
tried as add-on therapy to control epilepsy and as monotherapy on few 
occasions as shown in the results. The straight rise in prescribing of new AEDs 
over time can be explained based on the approval time of these drugs in the UK 
market. At the beginning of this study period (1990), most of new AEDs were 
not launched in the market and even the approved drugs were still under head-to 
head trials with old AEDs. As more clinical trials were conducted, evidence of 
efficacy and/or tolerability of the new AEDs as add-on therapy or monotherapy 
became available. 
The rise in prescribing of the new AEDs for this study cohort was consistent 
with the findings of an earlier study using primary care database 117. The authors 
found that the number of prescriptions for AEDs increased by 15% between 
1992 and 1995 in Northern and Yorkshire region, and that prescribing of the 
new AEDs, vigabatrin, lamotrigine and gabapentin, accounted for one-third of 
this rise. A study reported by the Office for National Statistics has found the 
number of AED prescription items in England increased by 33% and 42% part 
of this increase was attributed to increased prescribing of new AEDs between 
1991 and 1999 27. The large paediatric study conducted using the UK GPRD 
reported a significant increase, up to fivefold, in the prescribing of new AEDs 
particularly lamotrigine, topiramate, and levetiracetam between 1993 and 2005 
118
. However, this study examined the utilisation of AEDs not only for epilepsy 
but for all other conditions such as mood disorders and pain.  
Similar to this study, a more recent population-based study was conducted by 
Nicholas et al. (2012) on 63,586 patients with epilepsy of all ages identified 
from the UK GPRD data 289. The authors reported that carbamazepine and 
sodium valproate were the most often used medications throughout 1993-2008 
and lamotrigine prescribing was substantially increased between 1993 and 2008. 
The rise in prescribing of new AEDs such as lamotrigine and topiramate may be 
due to the fact that both lamotrigine and topiramate are broad-spectrum new 
AEDs. The two drugs were licenced in the UK (1991 and 1995, respectively) as 




monotherapy and adjunctive treatment in adults and children for different types 
of epilepsy including those which are classified as refractory (difficult-to-treat) 
290-292
. Since this time, many randomised controlled studies have proven 
lamotrigine and/or topiramate to be effective treatment in childhood partial 
seizures 103, 293, absence seizures 294, 295 and generalized seizures associated with 
Lennox-Gastaut syndrome (one of refractory childhood-onset epilepsy 
syndromes) 69, 296. 
This study showed an initial increase in the annual number of prescriptions and 
also number of children who were prescribed vigabatrin followed by a gradual 
decline after 1998. This finding was also reported by the two recent population-
based studies using the UK GPRD data 118, 289.  Vigabatrin was launched in 
1989 and has been proven effective as monotherapy in treatment of infantile 
VSDVPV:HVW¶VV\QGURPH79, 290. It has been reported that long term-treatment 
with vigabatrin was associated with retinal toxicity (damage to the retina of the 
eye causing a visual-field constrictions) in children 297. This side effect has been 
reported in 1 in 3 patients who received vigabatrin and was found to be 
irreversible 290, 297. This adverse effect influenced its routine clinical prescribing 
and necessitates the assessment of risk to benefit ratio prior to use 69, 290. This 
potential problem might also be the reason behind the refusal of the U.S. Food 
and Drug Administration to approve vigabatrin for epilepsy management in the 
United States until August 2009 298. This is likely to have been the reason which 
affected the prescribing trend of vigabatrin in this study. 
The utilisation of AEDs in this study produced similar results to that of earlier 
European studies in Denmark and Italy 299, 300. The study in Demark identified 
15,604 patients of all ages including children from a local database between 
1993 and 2002 299. The Italian study was a population-based study and used an 
Italian primary care database between 2000 and 2005 300. Both studies reported 
an increase in the prevalence of AEDs prescribing over time and that old AEDs 
were the most frequently prescribed particularly carbamazepine and sodium 
valproate. Moreover, the rise in AEDs prescribing was greater for new AEDs in 
epilepsy and other conditions such as mood disorders. 




3.5.2 Adherence to AEDs and factors influencing on adherence level 
The calculated median biannual adherence to AEDs in the study cohort was 
around 70% based on proportions of days supplied by medicines. By applying 
the 80% cut-off threshold for adherence, between 50% and 66% of CYP had at 
least 80% adherence per year. Previous paediatric studies have reported that 
adherence to AEDs ranges from 44% to 80% using different methods of 
measurement such as children/parents questionnaire and electronic monitoring 
devices 134, 135, 137, 141, 157. There is a debate on the standard method of measuring 
adherence. However, the use of databases to measure adherence was found to be 
correlated with other direct and indirect methods 145, 146. 
The calculated adherence to individual AEDs on CYP who were prescribed 
monotherapy revealed insignificant differences between individual drugs. It was 
not a surprising finding because 91% of CYP in this study were prescribed 
either carbamazepine or sodium valproate. These two drugs were recommended 
as the first-line and the mainstay for treatment of epilepsy. Adherence to these 
drugs was expected to be similar provided that CYP did not experience serious 
adverse effects.  
Multivariate analysis using GLM with gamma distribution on the aggregated 
data revealed that CYP¶VGHPRJUDSKLFVVXFKDVDJHDQGVRFLRHFRQRPLFVWDWXV
and number of combined AEDs were likely to be potential factors affecting 
adherence levels. The long-term effects of these factors and other explanatory 
variables on adherence levels were examined using longitudinal regression 
analysis. The results showed that out of the demographic factors, adherence 
significantly varied only by age of CYP with older age groups were more 
adherent than infants up to 2 years. Sex, family size and deprivation levels had 
insignificant effects on the long-term calculated adherence. This finding was 
consistent with an earlier finding by Shope (1988) 177. The author examined 15 
demographic variables as correlates to adherence to AEDs in two paediatric 
populations with epilepsy (n=90, n=211) and concluded that demographic 
factors were of little significance in association with adherence 177. Hazzard et 
al. assessed the AED blood levels of 35 CYP, aged 6-16 years, at three time 




points over one year in the USA 134. None of the demographic variables (age, 
sex, family income) were significantly related to adherence levels. 
In this study, the higher adherence levels in older age groups of children, 7-12 
years and older than 12 years, may reflect the fact that older children are able to 
self-manage their medicines whether supervised by their parents or school 
teachers, as compared to infants who are completely dependent on their 
caregivers to give them the medicines. Older children may also have taken their 
medicines based on self-perception of the impact of epilepsy on their daily lives 
and hence the necessity of medicines to control seizures. However it was not 
possible to qualitatively prove that. This may go against the current evidence for 
other chronic diseases that adherence declines as children take over their own 
care, and especially as they enter adolescence 181, 184. However, this could be 
different in case of epilepsy where young people recognise that non-adherence to 
AEDs may result in an epileptic seizure which stigmatises them among their 
peers.   
The deprivation levels (indicator of socioeconomic status) were not significantly 
associated with adherence. This may be attributed to the fact that all CYP up to 
16 years old (age range of the study cohort) are entitled to free prescriptions in 
the UK health care system 301. Thus inability to afford the cost of medicines 
may not be an issue with CYP in the UK and CYP belonging to either poor or 
rich families can have equal supply of medicines as they are recommended by 
clinicians.  Socioeconomic status may represent an issue in other countries like 
the USA where patients have to pay for medicines or health insurance 
companies. Few studies have addressed the effect of socioeconomic status in 
CYP with epilepsy. No consensus conclusion could be drawn. Shope (1988) 
found that family income was not correlated to adherence, however, the level of 
social support was positively correlated (P<0.05) to adherence to AEDs 177. In a 
another study, Mitchell et al. (2000) found that CYP from poorer families and 
those who reported stressful life events were more likely to adhere to prescribed 
regimens 135. 
This study showed that adherence levels were negatively and significantly 
associated with duration of treatment. However, the size of effect was not high 




(i.e. the estimated coefficient was small). This was a common feature in 
adherence to epilepsy and other chronic diseases such as asthma and diabetes141, 
203
.  
CYP who were prescribed two or more combined AEDs to control epilepsy had 
significantly higher levels of adherence than those who were on monotherapy. 
This may reflect how adherence was measured in this study.  Adherence was 
calculated based on medication possession and hence the more prescribed 
medicines, the higher the ratio of days supplied with AEDs and thus the higher 
level of adherence. Another explanation is based on that the fact that epilepsy is 
most often treated by a single drug whenever seizures are controlled. Combined 
medicines may indicate severe or refractory epilepsy syndromes which may 
have motivated CYP to adhere to their medicines in order to achieve a state of 
controlled seizures. Seizure severity as disease-related factor was positively 
found correlated to adherence to AEDs in adults studies 121, 302. The perceived 
severity of epilepsy by CYP and/or their parents could not be confirmed in this 
study 
3.6 Strengths and limitations of this study 
The present study provides a representative sample of CYP where 
generalisation of the results on the UK population could be achieved. Databases 
such as THIN offer a substantial advantage in providing information on patterns 
of medication prescribing in real-world practice that is not subjected to 
interventions or selection bias of other study designs. The prescribing 
information is linked to sex, age and deprivation levels of CYP which can 
describe the trends of AEDs XVHE\&<3¶VGHPRJUDSKLFV. This is the first 
population-based study in the UK that provided a longitudinal estimate of the 
adherence levels of individual CYP to AEDs up to 14 years of follow-up.  
This study encountered some limitations. The study cohort comprised CYP who 
were born in or after 1988, so the prescribing pattern of AEDs did not include 
all CYP registered in THIN between 1990 and 2003. However, the study cohort 
was representative of all ages (i.e. infants, children and young people) as 




indicated by the calculated prevalence of epilepsy which was comparable to the 
reported rates in epidemiological studies (Chapter 2).   
The use of the number of prescriptions as a measure of prescribing volume of 
AEDs has some limitations such as it does not account for time periods in the 
average quantity prescribed per item. However, it can reflect the frequency and 
trends of prescribing of individual drugs and combined versus single prescribing 
of medicines.  
The use of AEDs in treatment of different subtypes of epilepsy was not assessed 
because as a limitation of the data source, subtypes of epilepsy were not often 
reported in the primary care records.  Therefore, it may be difficult to address 
the appropriateness of prescribing at the individual level. The focus of this 
analysis was therefore at the level of aggregated data for the population at risk. 
The study cohort was most often prescribed liquid dosage forms with variable 
daily regimens according to age, AED type, and severity of illness. Because of 
the limitations of the general practice coding systems in THIN, about 37% of 
dosage instructions were missing which required careful imputation. However, 
assumptions on the length of prescriptions using the two thirds of known data 
were made and tested through sensitivity analysis. 
The inherent limitation of measuring medication adherence using health 
database is that it is an indirect measure of adherence and does not guarantee the 
actual consumption of prescribed medications. However, medication possession 
is necessary for its consumption and adherence measured using databases has 
been validated against other direct and indirect methods (see Chapter 1).  
This study was able to examine the effects of specific factors on adherence, 
whereas the effects of other factors such as parental education and ethnicity 
were not examined as these variables were not provided in this THIN version. 
 





The results suggest that there was a higher frequency in prescribing of old 
AEDs over time particularly sodium valproate and carbamazepine that were 
dominantly prescribed as first-line treatment to the majority of study cohort. 
However, the rise of prescribing of new AEDs particularly for lamotrigine and 
topiramate during study period may suggest potential advantages in terms of 
higher effectiveness and/or tolerability. 
The extent of paediatric adherence to AEDs as measured by the frequency of 
issued prescriptions was high in around one-half of CYP during the study period 
and tended to decrease over time.  
The findingVVXJJHVWWKDW&<3¶VVRFLRGHPRJUDSKLFVDQGFRH[LVWLQJPRUELGLWLHV
were of little significance as correlates to long-term paediatric adherence to the 
prescribed AEDs. CYP who were on combined AEDs to control epilepsy had a 
higher level of adherence compared to those who were prescribed monotherapy. 
 





4 Chapter 4: Estimation of epilepsy outcomes in CYP 
and assessing the relationship between adherence 
and outcomes 
4.1 Introduction 
4.1.1 Epilepsy outcomes in published literature 
The short and long-term outcomes of treating epilepsy in CYP have been received 
much interest in the published literature in epilepsy 71, 74, 303. Since childhood 
epilepsy has been demonstrated to influence a variety of life functions such as 
normal development and physical function, social functions and mental health 50, 
51
, the prognosis of epilepsy is commonly studied from various aspects. For 
example, some studies have concerned with cognitive outcomes, psychosocial 
outcomes and health related quality of life to address the long-term impact of 
epilepsy and its treatment on CYP 47, 50, 74, 304-306. Other studies have focused on 
seizure control because optimal seizure control represents the principle goal of 
treating epilepsy and reduces the risk of other neuropsychological impairments 115, 
307-309
.   
Since epilepsy is clinically defined as the recurrence of unprovoked seizures 3, the 
ability of a drug to prevent seizure recurrences or suppress seizure frequency is 
considered a direct outcome measure of drug efficacy in many RCTs 107, 310. This 
kind of RCTs comprises, for examples, head-to-head trials of different AEDs and 
comparative studies of old versus new AEDs. With regards to seizures, the extent 
of seizure control in various childhood epilepsy syndromes can be categorised into 
three main groups. The first group is full remission of seizures without 
pharmacological intervention, e.g., in certain benign childhood epilepsy where 
seizures spontaneously resolve and drug treatment can be often avoided 16, 303. The 
second group is remission of seizures on drug treatment where seizure control is 
achieved only by drugs and relapse of seizures often occur after drug withdrawal.  
The third group is drug-resistant seizures or refractory (intractable) epilepsy which 





is characterised by poor prognosis. Drug-resistant seizures are usually defined as 
the failure to have a state of seizure remission within some period of follow-up 311.  
The most common reported outcome measures of epilepsy and the methods of 
measurement are summarised in Table 4-1. A more detailed description of how 
these outcomes have been used to address the impact of epilepsy on various life 
functions was provided in Chapter 1. 
By exploring THIN data, there were recorded data only for seizures; however, 
other outcomes such as psychosocial and HRQOL were not available for the study 
cohort. Thus this analysis focused on quantifying THIN-coded seizure outcomes 
as an indicator for the prognosis of epilepsy in the study cohort.  





Table 4-1: Common outcome measures of epilepsy 
Outcomes   Methods of measurement  comment 
Seizure 
outcomes 
Remission from seizures `duration of 




Suppression of seizure counts 
(frequency) from a baseline value 
over a defined period  
 
 
Proportion of patients maintaining 50-
75% reduction in seizure frequency 
This method represents the ultimate 
goal of treating epilepsy and 
assessing treatment efficacy in 
seizure control 312, 313. 
 
It is a widely used outcome measure 
in clinical trials especially for 




In case of extreme variations of 
seizure counts between patients, 
percentage of subjects with 50-75% 
reduction in seizure frequency can 
be compared among groups 107. 
AEDs  Time to discontinuation of allocated 
treatment due to side effects, poor 
seizure control or both 316.  
This outcome can measure both the 
efficacy of treatment in controlling 





Interviewing CYP with epilepsy and 
their caregivers and then CYP are 
administered standard scale-measures 
and tests for intelligence score (IQ) 
and language skills 40, 317 
 
This outcome assesses the mental 




Interviewing adults with childhood-
onset epilepsy and/or prospectively 
observing CYP with epilepsy 47, 74, 304, 
305
.  
This outcome assesses aspects such 
as educational and employment 
status, social maturation, eligibility 
for driving licence, marriage rates 







Specific designed scales for CYP with 
epilepsy such as: 
- Epilepsy and Learning Disabilities 
Quality of Life Scale (ELDQOL) 306 
-The HRQOL in CYP with Epilepsy 
measure 60 
-Quality of Life for Adolescents with 
Epilepsy (QOLIE-AD-48) 318 
-Quality of Life in Childhood 
Epilepsy Questionnaire (QOLCE) 319 
These scales address aspects of 
HRQOL such as seizure-related 
injuries, AED side effects, mood, 
physical functioning, cognitive 
functioning, social functioning, 
parental concern, communication, 
and overall health 58, 59 
 
 





4.2 Aim of the analysis 
The aim of this analysis was to quantify THIN-coded outcomes of epilepsy for the 
study cohort and to examine the relationship between outcomes and adherence to 
antiepileptic drugs (AEDs) 
4.3 Objectives 
The objectives of this analysis were to: 
1. Identify any recorded seizure outcomes in THIN database for the study 
cohort.  
2. Calculate the incidence of medically-attended seizure events. 
3. Examine the relationship between incidence of seizure events and sex, age 
as a time-varying variable, years since first diagnosis or treatment and 
number of AEDs prescribed to control epilepsy.  
4. Examine the extent of seizure control in terms of remission of seizures for 
individual CYP based on incidence of medically-attended seizure events.  
5. Determine the relationship between incidence of seizures and adherence to 
AEDs 






4.4.1 Study cohort and study period 
The incidence of seizure outcomes in THIN database were calculated for the 
subgroup of 1067 CYP with epilepsy defined in Chapter 3. This subgroup had 
to have at least one year of follow-up from the date of their first recoding of 
epilepsy diagnosis or treatment in THIN (index date). This subgroup of CYP 
also had at least one prescription with known dosage instruction and whose 
adherence to prescribed AEDs could be calculated using the method of MPR 
(Chapter 3).  
The study period for exploring seizure outcomes started from the index date to 
the finish date for each child. The finish date was the date of death, the date 
where the child transferred out of the general practice, or the last date of data 
collection, whichever occurred first.  
4.4.2 Definition of seizure outcomes in THIN data 
The presented analyses to calculate the incidence of seizure outcomes were 
divided into two parts. The first part was to describe any recorded codes for 
seizure control by GPs during monitoring of epilepsy. For this part, seizure 
control was recorded by GPs on the basis of achieving seizure free periods 
(remission) or reporting the follow-up frequency (count) of seizures as 
described later in section 4.4.3. 
Upon exploration of THIN database, codes for seizure control (Table 4-2) were 
not extensively recorded for all CYP in this sample, so the second part of this 
analysis was to calculate the incidence of medically-attended seizure events 
over time and use it as an indicator to describe the extent of seizure control. A 
medically-attended seizure was defined by either a Read code for seizure, 
convulsion and fit (Appendix 11) and/or a prescription for any of three drugs 
(diazepam, midazolam and paraldehyde). These three drugs are usually 
indicated for immediate control of prolonged seizures and life-threatening 
seizures (status epilepticus) and are prescribed as injection, rectal tubes or 





buccal solutions 271. These drugs were sometimes prescribed without a seizure 
code; however, their use suggested prolonged or cluster seizures (multiple 
repetitive seizures) 320.  
4.4.3 Calculation of the incidence of THIN-coded seizure control 
The medical file and the additional health data (AHD) file of THIN database 
were explored for any recorded episodes of seizure control by GPs. A number 
of codes which referred to extent of seizure control were identified (Table 4-2).  
The main AHD code `1009200000' provided information on the extent of 
seizure control with an assigned description of `epilepsy check-fit details'.  
Further details on the frequency of seizures were provided by the subsequent 
`AHD value 1' code (Table 4-2). According to AHD value 1 codes, seizure 
control were recorded on the basis of achieving remission of seizures (e.g. 
Seizure free >12 months) or reporting the pattern of seizure occurrence for 
individual CYP from the date of epilepsy diagnosis. For example, CYP may 
have experienced seizure attacks in daily, weekly, monthly, quarterly, or yearly 
intervals. 
Table 4-2: Recoded AHD codes of seizure outcomes in THIN database 
AHD code AHD value 1 
code 
Associated 
Read code  
Code description 

























Fit frequency-Daily seizures  
Fit frequency-Weekly seizures  
Fit frequency-Monthly seizures 
Fit frequency- Quarterly seizures 
Fit frequency- Yearly seizures 
Seizure free >12 months  
Epilepsy control good  
Epilepsy control poor 
 
The proportion of CYP who had any of THIN-coded seizure control was 
calculated and the total number of these codes was quantified for CYP.   





4.4.4 Estimating the incidence of medically-attended seizure events 
After medically-attended seizures were defined as described above, the interval 
between each two successive seizure events for each individual child was 
calculated. When the interval was less than 7 days, the two successive recorded 
seizures were considered one seizure event and only the first event was retained. 
This was done to account for overlapping dates of seizure codes and 
prescriptions of diazepam, midazolam and paraldehyde. On many occasions, a 
seizure event such as `grand mal status' was recorded in the medical file of CYP 
then a prescription for diazepam, midazolam or paraldehyde was prescribed in 
the same day or one or two days apart. In such cases, only the date of first 
seizure event was retained.  
The incidence rates of medically-attended seizure events and 95% confidence 
intervals were calculated per person-years as the number of seizure events 
divided by the total follow-up time contributed by CYP. The method of survival 
analysis of multiple events `failures' was employed to calculate the incidence 
rate of seizure events and 95% confidence intervals.  Survival analysis examines 
and models the time to the occurrence of an event 321. In the multiple failure 
method, seizure events for each child were set as ordered events where the data 
were stratified by dates of occurrence of events.  
The incidence of seizure events was stratified by a set of explanatory factors 
which were hypothesised to have effects on the frequency of seizures. These 
variables of interest are shown in Table 4-3. 
 





Table 4-3: Factors associated with incidence of seizures 
Explanatory variables 
(covariates) 
Justification/ definition  
Level of adherence to 
AEDs 
The hypothesis was that high adherence levels to AEDs can 
lead to lower incidence of seizure events and better seizure 
control. 
7KHLQGLYLGXDOV¶ORQJ-term measured adherence in 6-month 
intervals (biannual) from the Chapter 3 was divided into 5 
levels; MPR=0-0.19, MPR=0.20-0.39, MPR=0.40-0.59, 
MPR=0.60-0.79, and MPR=0.80-1.00. A time variable 
which divided the duration of follow-up (started on the 
index date) of each child into 6-month intervals was 
generated. Then the biannual calculated adherence was 
compared to the seizure events using the generated time 
variable. It means that the incidence of seizures each 6-
month was compared to the level of measured adherence 
during that 6-month interval.  
 
Age and sex Different types of childhood epilepsy syndromes have 
different age at onset. Some of these syndromes at infant age 
of onset are associated with poor prognosis and hence 
exhibit more frequent seizures. 
Sex was set as dummy variable; 0=female and 1=male. Age 
as time-varying variable which was categorised into four 
groups; < 2, 2-6, 7-12 and > 12 years old. This classification 
of age groups was used according to the BNF categorisation 
of age for indication as pointed in Chapter 3 271.  
Socioeconomic status The database uses the Townsend deprivation index as a 
marker of socioeconomic status (as described in Chapter 2). 
Socioeconomic status of CYP was defined in quintiles of 
Townsend score where 1=least deprived and 5=most 
deprived. 
Number of prescribed 
AEDs 
Higher number of tried drugs to control epilepsy was 
assumed related to more frequent or sever seizures. 
Number of drugs ever prescribed to control epilepsy and by 





epilepsy subtypes was set as a dummy variable; 0=one drug 
and 1=two or more drugs. 
Subtypes of epilepsy  Certain childhood epilepsy syndromes are associated more 
frequent seizure attacks.   
Different diagnostics subtypes of epilepsy were categorised 
into 5 groups; group 1 included unspecified epilepsy (no 
assigned epilepsy subtype), group 2 included focal epilepsy 
(all subtypes in which seizures are originated locally in 
brain), group 3 included generalised epilepsy (all subtypes 
in which seizures are originated from whole brain), group 4  
included absence epilepsy (this subtype was withdrawn from 
generalised epilepsy into a separate class because of its 
absence seizure nature) and group 5 included refractory 
epilepsy (subtypes of epilepsy which are known in literature 
as difficult-to treat such as Lennox-Gastaut syndrome) 322, 
323
. This categorisation of epilepsy subtypes was derived 
from the International League Against Epilepsy 
classification of epilepsy syndromes 324. 
 
The incidence of seizure events was finally stratified according to years after the 
LQGLYLGXDOV¶LQGH[GDWHV.   
The Mantel Haenszel method was used to examine the difference in incidence 
rate ratios of seizures between males and females, age groups, epilepsy subtypes 
and by unit increase in years of therapy.  
For each group of CYP within all of the above-mentioned categorical 
covariates, estimates of the survival function (the probability of remission of 
seizures to time t) were illustrated using Kaplan-Meier curves. This was done to 
visually illustrate the difference in having seizure events between CYP of 
different groups. Kaplan-Meier estimate, also known as the product limit 
estimate, provides nonparametric estimates of overall survival function S(t) 321. 
The Kaplan-Meier graph can plot multiple survival curves and enables visual 
comparison of the remission of seizures between various groups.  





4.4.5 Multivariate modelling of factors affecting incidence of seizures 
using Cox proportional hazards regression 
Cox proportional hazards regression model is the most widely used and feasibly 
computed method of survival analysis in medical research 321. Survival 
modelling examines the relationship between survival time of group of subjects 
and one or more predictors, usually known as covariates in the survival analysis 
literature 325. Cox models employ the hazard function or the log hazard and 
assume that covariates multiplicatively alter the baseline hazard (risk) function.  
For this analysis, a Cox proportional hazards model was employed to examine 
whether the above-mentioned factors `covariates' had potential effects on the 
hazard of occurrence of seizures. The outcome measure was the occurrence of 
seizures. The recurrence of seizure events for each child cannot be assumed 
independent. So that the estimated hazard ratios of Cox model were adjusted to 
account for the possible within subject correlation of seizure events by allowing 
for clustering by child using the robust standard error option in STATA.  
4.4.6 Tests of Cox proportional hazard assumptions 
The key assumption of the Cox proportional hazards model is proportionality or 
a proportional hazards that is the covariates are multiplicatively related to the 
hazard 325. The model allows for no assumption on the shape of the hazard over 
time that is it could be constant, decreasing or increasing. There are several 
methods to test whether the examined covariates satisfy the assumption of 
proportionality.  
In this study, two methods were employed to test the assumption of 
proportionality. One method was a graphical plot and depended on the 
calculation of transformation of Kaplan-Meier curves. In this method, the 
examined covariate satisfies the proportional hazards assumption when the 
graphical plot of the ln [-ln(survival function)] versus ln of survival time results 
in a graph with parallel lines 321.  
The second method is the log-rank test of equality across strata. It is a non-
parametric test that compares estimates of the hazard functions of the groups of 





a categorical covariate at each observed event time. The null hypothesis that 
there is no difference between groups in the probability of an event at any time 
point 326. 
4.4.7 Exploring remission of seizures using the incidence of medically-
attended seizure events 
Remission of seizures (i.e., the duration of seizure-free period through which 
CYP did not experience any seizure events) is another way to describe seizure 
outcomes where the focus is to calculate the duration of seizure-free periods for 
individual CYP over time rather than reporting seizure events. Remission of 
seizures is considered the main interest in epilepsy literature to examine seizure 
outcomes 115, 308, 309.  
Remission of seizures was calculated for intervals of 1, 2, 3, 4 or more years 
using the method of multiple failures survival analysis of medically-attended 
seizure events both from the index date and from each seizure event. This 
analysis is similar to calculating the interval between two starting points to 
calculate the seizure-free period. A Life-table estimate of the probability of 
remission of seizures out of the entire CYP at risk (i.e., cumulative probability) 
was computed.  
The life table technique (also known as the actuarial method) is one of the 
oldest methods for analysing survival data 327, 328. This table is considered as an 
`enhanced' frequency distribution table and makes use of the data from all 
subjects. In this method, the distribution of length of data contribution of each 
child (remission times) is divided into yearly intervals. For each interval, the 
number and proportion of CYP that remained without seizures and entered the 
respective interval, the number and proportion of CYP that failed in the 
respective interval (i.e., number of CYP that experienced seizures), and the 
number of CYP that were lost or censored (CYP lost to follow-up or seizures 
occurred outside the range of a measured interval) in the respective interval can 
be calculated. The probability of seizure remission was then calculated by 
dividing the number of CYP who did not experience seizures in that interval by 
the number at risk at the beginning of that interval. Therefore, life table provides 





a good indication of the distribution of remission rates in population at risk over 
time 321.  
The main difference between the life-table method and Kaplan-Meier approach 
is that with the life-table method, the cumulative probability of seizure 
remissions can be calculated at fixed times (depending on the interval), whereas 
with the Kaplan±Meier approach it is calculated only when seizures occur (at 
the exact time of seizures) 329. 
 






4.5.1 Study population 
Of the 1067 CYP with epilepsy, more than one-half were males, 591(55.4%) 
and the age at first recording of epilepsy ranged from one day to 15.2 years 
(mean age was 3.9 years). The sex and age distribution of this subgroup of CYP 
were similar to that of the overall population of 2020 CYP with epilepsy. The 
total contribution of person-years was 6467.1 years and ranged from 1.0 to 16.8 
years per child (mean=6 years). 
4.5.2 Frequency of THIN-coded seizure control for the study cohort 
Of the 1067 CYP, 276 (26%) had recorded data on extent of seizure control 
during the follow-up time which are shown in Table 4-4. The majority of these 
codes (85%) were recorded at least one year after the index date. The degree of 
seizure control showed that 6% had daily seizures, 5% had weekly seizures, 
3.6 % had monthly seizures and 4.5% had quarterly seizures. Nine percent of 
CYP achieved at least one year free of seizures. However, the majority of CYP, 
792 (74%) were not assigned any codes for seizure control in this sample.  
Out of the 380 events of THIN-coded seizures, 39 (10%) were recorded before 
2002 and 341 (90%) were recorded from 2002 onwards.  This may suggest 
better quality of recording clinical outcomes since data collection started 
prospectively in THIN in 2002. 





Table 4-4: Recorded seizure control within THIN database for the study cohort 





Frequency of recorded 
seizure-control (%) 
n=380 
Fit frequency-Daily seizures  
Fit frequency-Weekly seizures  
Fit frequency-Monthly seizures 
Fit frequency- Quarterly seizures 
Fit frequency- Yearly seizures 
Seizure free >12 months  
Epilepsy control good  
Epilepsy control poor 




















4.5.3 Overall incidence of medically-attended seizure events for the study 
cohort 
During the study period, there were 2440 recorded seizure codes and 3027 
prescriptions for prolonged and life-threatening seizures giving a total of 5467 
codes. After accounting for codes of seizures occurred within less than 7 days, 
the total seizure events were 4704 for 1067 CYP over 6467 person-years 
(Figure 4-1).  
 
Figure 4-1: Identification of medically-attended seizure events 





The overall distribution of medically-attended seizure events for CYP is 
illustrated in Figure 4-2. Over 6467person-years, the number of seizure events 
for individual CYP ranged from 0 to 97 (median=2; IQR; 3-25). Out of 1067 
CYP, 307 (29%) did not have any records for seizure events, 183 (17%) had 
only one seizure event, 458 (43%) had 2-10 seizure events and 119 (11%) had 
more than 10 seizures. 
When compared to THIN-recorded codes of seizure control, the distribution of 
medically-attended seizure events did not reflect the extent of the recorded 
seizure control. For example, CYP who had codes of poor seizure control (such 
as daily or weekly seizures) did not necessarily have high frequency of 
medically-attended seizures.    
 









The overall incidence rate of medically-attended seizures was 0.73 [95% CI 
0.71-0.75] per person-year (Table 4-5). Incidence of seizure events was not 
significantly different between males and females (Mantel Haenszel test; 
p=0.68). Incidence of seizure events stratified by age as time-varying variable 
was higher, 1.64 [95% CI 1.64-2.01], in the age group under 2 years compared 
to older age groups. The incidence rate of seizure per person-year was 
significantly lower by each category increase of CYP age group [Mantel 
Haenszel test; p<0.001].  
Incidence of seizures was lower in highest deprived CYP (Townsend 
quintile=5) as compared to least deprived CYP (Townsend quintile=1).   
Incidence of seizures was lower in CYP who were diagnosed with absence 
epilepsy subtype, 0.35 [95% CI; 0.32-0.40] per person-year, compared to other 
subtypes where incidence was higher in generalised subtype, 0.94 [95% CI 
0.87-1.02], and refractory epilepsy, 1.03 [95% CI 0.93-1.15] per person-year. 
 Incidence of seizure events was significantly higher, 0.97 (95% CI 0.94-1.00), 
in CYP who prescribed more than one drug type to control epilepsy [Mantel 
Haenszel test; p<0.001].  The incidence rate of seizures was significantly higher 
in CYP who had higher calculated MPR values (higher drug adherence levels) 
as compared to CYP with lower MPR values [Mantel Haenszel test; p<0.001].  





Table 4-5: Incidence of medically-attended seizure events for the study cohort 
(N=1067) 
Character No of CYP 






years [95% CI] 
Total  1067 4704 6467.1 0.73 [0.71-0.75] 
Sex      
Male  591 2527 3510.8 0.72 [0.70-0.75] 
Female 476 2177 2956.3 0.74 [0.71-0.77] 
Age (time-variant)*     
0-2 218 449 274.5 1.64 [1.49-1.79] 
2-6 566 1596 1600.1 1.00 [0.95-1.05] 
7-12 903 1894 3329.9 0.57 [0.54-0.60] 
>12 59 765 1261.7 0.61 [0.57-0.65] 
Townsend quintiles     
1 200 785 1122.3 0.70 [0.65-0.75] 
2 156 718 938.8 0.76 [0.71-0.82] 
3 208 933 1284.9 0.73 [0.68-0.77] 
4 224 1284 1456.8 0.88 [0.83-0.93] 
5 205 722 1231.2 0.60 [0.55-0.63] 
Missing  74 262 433.0 0.61 [0.54-0.68] 
MPR (adherence levels)     
0 506 168 354.1 0.47 [0.41-0.55] 
>0-0.19 284 205 498.0 0.41 [0.36-0.47] 
0.20-0.39 336 242 890.0 0.27 [0.24-0.31] 
0.40-0.59 502 395 806.6 0.50 [0.45-0.55] 
0.60-0.79 812 858 1070.5 0.80 [0.75-0.86] 
0.80-1.00 1046 2836 2848.0 0.99 [0.95-1.03] 
No of prescribed AEDs      
One drug 476 454 2064.9 0.22 [0.20-0.24] 
Two or more drugs  591 4250 4402.2 0.97 [0.94-1.00]  
Subtypes of epilepsy      
Unspecified 711 3158 4177.8 0.76 [0.74-0.78] 
Absence  137 310 881.0 0.35 [0.32-0.40] 
Focal  70 266 407.1 0.65 [0.58-0.74] 
Generalised 109 642 682.9 0.94 [0.87-1.02]  
Refractory   40 328 318.2 1.03 [0.93-1.15] 
Years after first recording of 
epilepsy 
    
1 1067* 971 1067.0 0.91 [0.85-0.97] 
2 1067 716 1023.7 0.70 [0.65-0.75] 
3 961 614 903.7 0.68 [0.63-0.74] 
4 850 572 780.0 0.73 [0.68-0.80] 
5 709 451 644.8 0.70 [0.63-0.77] 
6 588 350 516.9 0.68 [0.59-0.74] 
7 447 239 404.8 0.60 [0.56-0.72] 
8 370 224 335.9 0.67 [0.60-0.80] 
9 300 161 262.7 0.61 [0.58-0.81] 
10 227 116 194.3 0.60 [0.54-0.80] 
11 164 104 136.0 0.76 [0.63-0.97] 
12 112 71 89.3 0.80 [0.54-0.95] 
13 74 47 60.7 0.77 [0.58-1.03] 
14 45 49 32.3 1.52 [1.14-2.08] 
15 22 18 13.0 1.38 [0.87-2.22] 
* The number of CYP in age groups and each year does not add to the total as over time a child 
may have contributed to more than one age group and more than one year of follow-up. 





4.5.4 The incidence of medically-attended seizure events stratified by 
years after the first recording of epilepsy  
The incidence of recorded seizure events stratified by years after first recording 
of epilepsy-related diagnosis or prescription is shown in Table 4-5. The 
incidence per person-year was 0.91 [95% CI 0.84-0.96] for the first year and 
then showed a lower value in the second year 0.70 [95% CI 0.65-0.75]. The 
incidence of seizures slightly changed over time. Figure 4-3 illustrates the 
incidence of seizure per person-years over time. The data for years 13 to 15 are 
not illustrated due to few numbers of CYP followed-up and lower values of 
person-years. The incidence rate was not significantly changed by unit increase 
in years of follow-up [Mantel Haenszel test; p=0.11].   
 
Figure 4-3: Incidence of medically-attended seizure events per person-years 
 





4.5.5 Kaplan-Meier estimates of the probability of seizure remission 
The Kaplan-Meier graphs (Figure 4-4) showed almost overlapping curves of 
males and females which may indicate that no significant difference in the 
hazard of seizures between males and females. However, Kaplan-Meier 
estimates for different age groups showed parallel curves with younger age 
CYP, <2 years, had a lower hazard of seizure incidence (higher remission of 
seizures). Similar results to that of age groups were found in Kaplan-Meier 
estimates across the calculated MPR quintiles (biannual adherence). Higher 
MPR quintiles were associated with higher remission of seizures.  
CYP who were prescribed at least two drugs to control epilepsy were 
associated with lower remission of seizures than CYP who were prescribed 
only one drug.   






Figure 4-4: Kaplan-Meier curves of remission of seizures 
 





4.5.6 Factors affecting incidence of seizures using Cox regression 
The values of the unadjusted hazard ratios from the univariate Cox proportional 
hazards regression for the effect of explanatory variables on incidence of seizure 
events are shown in Table 4-6. 
The data showed that the hazard of seizures was significantly lower with older 
age groups >2 years. The hazard of seizures was significantly higher in CYP 
who were prescribed more than one drug to control epilepsy and by higher 
levels of adherence (MPR>0.59). However, the hazard of having seizures did 
not significantly differ between males and females, different quintiles of 
deprivations or different epilepsy subtypes.  
The hazard ratios of the fully-adjusted Cox model are shown in Table 4-6. The 
data showed that the hazard of seizure events was associated with higher levels 
of biannual measured adherence. Compared to MPR=0-0.19, the hazard of 
seizures, adjusted to other covariates, was higher but insignificant for 
MPR=0.20-0.39 (HR=1.04, 95% CI 0.78, 1.11) and MPR=0.40-0.59 (HR=1.19, 
95% CI 0.90, 1.56); significant for MPR=0.60-0.79 (HR=1.54, 95% CI 1.16, 
2.04DQGIRU035+5 83, 95% CI 1.40, 2.38). 
The hazard of seizures was not significantly different (p=0.40) between males 
and females (HR=0.92, 95% CI 0.76, 1.12). Older age CYP had a significantly 
lower hazard and hence a longer survival without seizures than younger CYP. 
As compared to the reference age group <2 years, the hazard of seizures 
decreased for age group 2-6 years (HR=0.35, 95% CI 0.27, 0.43); for 7-12 years 
(HR=0.13, 95% CI 0.09, 0.17) and for CYP >12 years old (HR=0.04, 95% 
CI=0.03, 0.06). The p-values were highly significant in all age groups 
(p<0.001).  
Compared to CYP who were only ever prescribed one AED type, the hazard of 
seizures increased more than twofold for CYP who were prescribed at least two 
AEDs to control epilepsy (HR=2.18, 95% CI 1.78, 2.66).  
Epilepsy subtypes had little and insignificant effect on the hazard of seizures 
than other factors. Compared to the unspecified epilepsy subtype, the hazard of 





seizures was lower by 37% for absence seizures subtype (p=0.01); lower by 8% 
for focal subtype (p=0.67); higher by 5% for generalised (p=0.69) and 
unchanged for refractory subtypes of epilepsy (p=0.88).  
 





Table 4-6: Factors affecting incidence of seizures: unadjusted and adjusted hazard ratios from Cox regression 
Potential factor affecting 
incidence of seizures  
Hazard ratio [95% CI] 
Unadjusted model  
p values Hazard ratio [95% CI] 
Adjusted for age, sex, 
Townsend index 
p values Hazard ratio [95% CI] 
Fully adjusted model 
p values 
Adherence levels       
0-0.19 1.00  1.00  1.00  
0.20-0.39 1.08  [0.80,  1.36] 0.53 1.11  [0.93,  1.42] 0.10 1.04  [0.78,  1.11] 0.15 
0.40-0.59 1.17  [0.84,  1.64] 0.38   1.23  [0.95,  1.62] 0.16   1.19  [0.90,  1.56] 0.22   
0.60-0.79 1.89  [1.34,  2.68] <0.01 1.62  [1.21,  2.16] <0.01 1.54  [1.16,  2.04] <0.01 
0.80-1.00 2.37  [1.71,  3.27] <0.01 1.92  [1.47,  2.50] <0.01 1.83  [1.40,  2.38] <0.01 
Sex       
Female 1.00  1.00  1.00  
Male 0.98  [0.78,  1.21] 0.84 0.94 [0.77,  1.13]   0.50 0.92 [0.76,  1.12]   0.40 
Age at follow-up years        
<2 1.00  1.00  1.00  
2-6 0.34  [0.28, 0.42] <0.001   0.33  [0.26, 0.41] <0.001 0.35  [0.27, 0.43] <0.001 
6-12 0.10  [0.07, 0.12] <0.001 0.10  [0.07, 0.13] <0.001 0.13  [0.09, 0.17] <0.001 
>12 0.03  [0.02, 0.04] <0.001 0.03  [0.02, 0.04] <0.001 0.04  [0.03, 0.06] <0.001 
Townsend index        
1 1.00  1.00  1.00  
2 1.09  [0.75,  1.56] 0.64 0.96  [0.68,  1.36] 0.82 0.94  [0.66,  1.33] 0.73 
3 1.04  [0.75,  1.45] 0.81   0.94  [0.70,  1.27] 0.71 0.93  [0.70,  1.25] 0.64 
4 1.26  [0.91,  1.76] 0.17 1.15  [0.85,  1.56] 0.35 1.13  [0.84,  1.53] 0.35 
5 0.84  [0.61,  1.15] 0.28 0.77  [0.57,  1.05] 0.10 0.73  [0.53,  0.99] 0.04 
Missing  0.86  [0.52,  1.41] 0.55 0.81  [0.50,  1.30]  0.38 0.87  [0.50,  1.30]  0.57 
Number of prescribed AED        
One drug 1.00  -- -- 1.00  
Two or more drugs 4.46 [3.72,  5. 35] <0.001 -- -- 2.18 [1.78,  2. 66] <0.001 
Subtype of epilepsy        
Unspecified 1.00  --  1.00   
Absence  0.45  [0.32,  0.65] 0.01 -- -- 0.63  [0.47,  0.83] 0.01 
Focal  0.86  [0.50,  1.47] 0.58 -- -- 0.92  [0.54,  1.49] 0.67 
Generalised 1.25  [0.94,  1.66] 0.12 -- -- 1.05  [0.84,  1.31] 0.69 
Refractory  1.37  [0.99,  1.90] 0.05 -- -- 1.01  [0.89,  1.14] 0.88 




4.5.7 Test of proportionality assumption 
Using the log-rank test, sex showed a non-significant proportional hazard 
(p=0.62) which means that incidence rate of seizures did not differ between 
males and females (Table 4-7). The log-rank test across age groups showed 
significant proportional hazards (p<0.001). Similar to that of age was the log-
rank test across adherence quintiles, number of AEDs to control epilepsy and 
epilepsy subtypes.  
Table 4-7: log-rank test for proportional hazard assumption 
Covariate P-values of log rank 
test 
Sex 0.62 




Adherence (MPR quintiles) <0.001 
Number of AEDs to control epilepsy <0.001 
Epilepsy subtypes  <0.001  
 
The graphical plot of ln [-ln(survival)] versus ln of survival time confirmed the 
results of the log-rank test. Figure 4-5 illustrates almost overlapping curves for 
sex and parallel curves for the rest of the examined covariates.  
  





Figure 4-5: Test of proportional hazard assumption for covariates 
 




4.5.8 Duration of seizure remission 
The probability of seizure remissions out of the total number of CYP at risk, 
with 95% CI using life table estimates is shown in Table 4-8. The table 
describes the remission rates of the study cohort over time. Remission rates 
were reported at the end of the interval.  For example, of the 1067 CYP at the 
beginning of the analysis, 976 CYP achieved at least 1 year remission of 
seizures by the end of the follow-up time. A year after the index date, the 
proportion of CYP with seizure remission was 94% [95% CI= 93%, 96%], 
whereas 59 CYP failed to achieve 1 year remission and 18 CYP were censored.   
The proportions of CYP who achieved 2-year and 3-year remissions by 15 years 
follow-up period were 80% [95% CI 78%, 83%] and 68% [95% CI 65%, 71%]. 
The proportion of CYP who entered long-term remission, for example, 5-year 
and 10-year remissions out of the entire study cohort were 47% [95% CI 43%, 
50%] and 27% [95% CI 22%, 31%], respectively.  Figure 4-6 illustrates the 
proportions of CYP with remission of seizures over time.  


















0-1 1067 59 18 0.94 [0.92-0.95] 
1-2 990 140 70 0.80 [0.78-0.83] 
2-3 780 119 67 0.68 [0.65-0.71] 
3-4 594 67 69 0.60 [0.56-0.63] 
4-5 458 47 56 0.53 [0.50-0.56] 
5-6 355 38 62 0.47   [0.43-0.50] 
6-7 255 25 35 0.42  [0.38-0.46] 
7-8 195 24 34 0.36 [0.33-0.40] 
8-9 137 9 36 0.34 [0.30-0.37] 
9-10 92 7 23 0.31 [0.27-0.35] 
10-11 62 7 16 0.27 [0.22-0.31] 
11-12 39 3 10 0.24 [0.20-0.29] 
12-13 26 2 12 0.22 [0.17-0.27] 
13-14 12 3 5 0.15 [0.09-0.23] 
14-15 4 0 3 0.15 [0.09-0.23] 
 
 





Figure 4-6: Cumulative probability of remission of seizures over time 
 





The main aim of this chapter was to use UK primary care data to quantify long-
term seizure outcomes of epilepsy in CYP and additionally to assess the effect 
of level of adherence on outcomes.  Of 1067 CYP who were included in this 
analysis, 276 (26%) CYP had THIN-coded records for the extent of seizure 
control. The extent of seizure control after initiation of therapy was recorded in 
terms of the follow-up frequency of seizure attacks such as daily, weekly, 
monthly, or yearly seizures. CYP who achieved better seizure control were 
recorded to have `seizure free >12 months' or `epilepsy control good'. This may 
indicate that seizure control was an important measure to monitor the response 
to AED treatment and prognosis of epilepsy. However, the fact that only around 
one-quarter (26%) of the study cohort have had records for seizure control 
suggests that GPs did not regularly record seizure state for all CYP within 
medical files of THIN database.  
4.6.1 Overall incidence of medically-attended seizure events compared to 
previous studies 
Since not all CYP of the study cohort had records of seizure control, the 
incidence of medically-attended seizure events over years of study time was 
employed to explore seizure control. The overall incidence of seizures was 0.73 
[95% CI 0.71-0.75] per person-years. Over 6467 person-years, the number of 
seizure events for individual CYP ranged from zero to 97 (median=2; IQR 3-
25). The incidence of medically-attended seizures was poorly correlated to 
THIN-coded seizure control. This may be because the incidence of seizures was 
calculated using only the events presented on the dates of visiting the GPs. It 
means that a child may have experienced daily seizures; however, it was 
counted as just one medically-attended event on the day the child visited the 
GP.  
The frequency of seizures per person-year is much lower if compared to the 
distribution of seizure frequency from published data on the frequency of 
seizures. This study reported only seizures that were recorded at the time of 




physician visits. However, the design of the published studies was different than 
this study where the data were based on self-reported seizure frequency and not 
only the medically-attended. It was not clear if patients/caregivers kept diary of 
seizure attacks or just recalled information. For example, a previous survey was 
conducted by Moran et al. (2004) to describe the clinical characteristics of 
epilepsy in terms of seizure frequency and severity for patients with epilepsy in 
the UK 330. The authors analysed returned postal questionnaires of 1630 patients 
with epilepsy recruited through 80 primary care practices across different areas 
in the UK. The sample included 127 (7.8%) patients aged up to 17 years. The 
questionnaire requested information on the number of seizures in the last 12 
months of the study. The authors presented data of the seizure frequency within 
the last 12 months by age groups. The seizure frequency of the age group <17 
years were that 28.3% of participants reported zero, 3.1% reported one, 28.3% 
had 2-9 and 40.2% had >10 seizures.  
Another community-based survey was carried out by Hart et al. (1995) to assess 
the severity of epilepsy and to address the issue of medical care in the UK 
community 114. Questionnaires were distributed by 119 participating GPs to 
patients with epilepsy identified from 58 general practices. Out of 1628 
responding patients, 14% were under the age of 20 years. Separate data were not 
presented about CYP. The seizure frequency in the last 12 months before study 
were that 46% had zero, 33% had 1-12, 12% had 13-50 and 8% had >50 
seizures.  
The incidence of seizure events in this study was significantly higher, 1.64 
[1.49-1.79], in CYP who had their first recording of epilepsy at younger age, i.e. 
age group up to 2 years old, compared to other age groups. It can be explained 
on the basis that 36 (14%), out of 259 CYP of this age group had experienced 
³LQIDQWLOHVSDVPV´FRPSDUHGWRQRRQHLQRWKHUDJHJURXSV7KLVVXEW\SHRI
epilepsy is characterised by more frequent manifestation of seizure attacks 
(tonic or myoclonic seizures) and is classified  as difficult-to-treat or refractory 
epilepsy syndrome 322, 323. Another possible explanation is that this age group is 
highly dependent and much more supervised by their parents/caregivers which 
may suggest more reporting of seizure attacks if any. 




Incidence of seizure events in this study varied across different epilepsy 
subtypes. Incidence was lower in absence epilepsy as compared to other 
subtypes which was expected as this subtype is characterised by absence 
manifestation of seizures. Incidence was higher in generalised epilepsy subtypes 
and difficult-to-treat subtypes including Lennox-Gastaut syndrome and infantile 
spasm. Generalised epilepsy subtypes manifest different forms of seizures such 
as tonic, clonic, myoclonic and tonic-clonic with widespread convulsive activity 
7
. Difficult- to-treat epilepsy subtypes are usually resistant to treatment and 
manifest poor seizure control 322, 323.   
4.6.2 The incidence of seizure events stratified by years of follow-up time 
Higher incidence of medically-attended seizure events in the first year of 
diagnosis may be expected because at the first year after starting therapy, GPs 
would be seeking seizure reports from CYP or their caregivers to monitor the 
chosen first-line drug treatment and to reach a steady state treatment for CYP. 
For further follow-up years, some CYP were probably seizure-controlled 
provided that the treatment was monitored for them. The incidence of seizures 
was again higher in the year 14 and 15 after starting therapy where obviously 
the person-years contribution of CYP was very small with some CYP 
experiencing higher seizure frequency. The nature the study cohort was that 
CYP were entered the database sequentially as the study progresses. 
Consequently, CYP have been followed for varying lengths of time where some 
CYP have dropped out of the study and become lost to follow-up, some have 
experienced seizures being evaluated, and the rest have not had seizures by the 
time the study was ended.  
4.6.3 Regression analysis of factors affecting incidence of seizure events 
using Cox model 
The Cox proportional hazard model revealed that the hazard of seizure events 
significantly decreased with older age of CYP compared to infants less than 2 
years old. The hazard was much lower in the age group >12 years. This could be 
explained on the different epilepsy subtypes of onset at young ages as described 
above. This may also suggest that infants and pre-school age children were 




much supervised by their parents or caregivers and hence reporting of seizure 
events was higher than older age children. A previous study by Arts et al. 
(2004) reported that children \HDUVDFKLHYHGVLJQLILFDQWO\EHWWHUVHL]XUH
control compared to <6years old using multivariate analysis [odds ratio (OR) 
0.62, 95% CI 0.39-0.99].  
There was not a significant difference in the risk of seizures between males and 
females.  
The interesting finding was that adherence was positively associated with 
incidence of seizures where the hazard of seizures significantly increased with 
higher adherence levels. It can be explained on the basis of the nature of 
managing epilepsy in primary care and how adherence was calculated. Epilepsy 
is an episodic disease that manifests seizures as the main symptoms. More 
frequent occurrence of seizures is a sign of poor control of epilepsy which 
HQFRXUDJHGPRUH*3¶VYLVLWVDQGKHQFHPRUHSUHVFULEHGPHGLFLQHV$V03R 
was used as a proxy measure of adherence and was calculated as the sum of the 
GD\V¶VXSSO\IRUDOOSUHVFULSWLRQVGXULQJDGHILQHGSHULRGRIWLPHWKHPRUH
issued prescriptions to control seizures, the higher the MPR values. This was 
also revealed by significantly higher hazard of seizures (p<0.001) in CYP who 
were treated with at least two AEDs compared to those on one drug.  
Another reason behind positive association of incidence of seizures and 
DGKHUHQFHFRXOGEHWKHVHYHULW\RILOOQHVVDQGPHGLFLQH¶VQecessity. As more 
severe epilepsy syndromes manifest more frequent seizures which may have 
motivated CYP to adhere to the prescribed medicines. The perceived 
susceptibility for the negative consequences of poor seizure control such as 
injuries and hospitalisation may also have driven CYP and parents to adhere to 
prescribed medicines. However, the causality conclusion is difficult to be drawn 
because the prompt consequence of lower adherence in epilepsy is manifesting 
seizures where the time frame is very short. Thus it could be that lower 
adherence levels led to higher incidence of seizures then CYP immediately 
sought their medicines to reduce the risk of seizures. Perhaps the 
pharmacological expectation was that incidence of seizures may decrease with 
higher adherence levels but the results suggested that the behavioural effect was 




dominant that is adherence was correlated to the frequency of uncontrolled 
seizures. Measurement of adherence was very challenging in this study and it 
was encountered by some limitations such as poor level of recoding of 
prescription instructions. Thus the analysis of factors predicting seizures was to 
estimate an approximate association between seizure outcomes and adherence.    
This relation between adherence and seizures supported earlier finding by Shope 
(1988) who examined predictors to adherence by assessing serum levels of 
AEDs in two paediatric populations with epilepsy (n=90, n=211) 177. The author 
concluded that among factors correlated to adherence, adherence increased in 
the group of CYP who had more frequency of occurrence of seizures (p<0.025). 
Another study was conducted by Jones et al. (2006) in the UK on 54 adult 
patients with epilepsy to examine the associations between self-reported 
adherence and seizure control and perceptions of illness and medication 121. The 
authors reported that patients with poorly controlled epilepsy had a greater 
belief in the necessity of medication than well-controlled patients and were 
prescribed significantly more medications (p< 0.01).  
Epilepsy subtypes apart from absence seizures subtype did not significantly 
affect the hazard of seizure incidence. However, epilepsy subtypes in this study 
were not specified for the majority of CYP (67%). The numbers of CYP with 
focal and refractory epilepsy were relatively small. By referring to previous 
paediatric studies, univariate analysis of predictors of seizure prognosis has 
showed that seizure control was significantly worse for infantile spasms and 
myoclonic/atonic seizure types as compared to generalised tonic-clonic seizure 
type 309. Berg et al. (2001) reported that two-year remission of seizures was 
significantly higher for absence seizures type as compared to focal and 
generalised seizure types 313 which was supported by the current analysis where 
the hazard of seizures was significantly lower for absence seizures.  
 
 




4.6.4 Duration of seizure remission 
The multiple events survival analysis of seizure remission showed comparable 
results to what has been published on long±term prognosis of seizures in CYP 
with epilepsy. The study findings showed that 94% [95% CI 92%, 95%] of CYP 
achieved 1-year remission of seizures, 80% [95% CI 78%, 83%] achieved 2-
year remission and 68% [95% CI 65%, 70%] achieved 3-year remission and 
47% [95% CI 43%, 50%] achieved 5-year remission by 15 years follow-up. The 
findings at 3-year and 5-year remission periods were comparable to a 
population-based study conducted by Cockerell et al. (1997) to examine the 
seizure prognosis in patients with epilepsy in the UK 115. The authors identified 
and prospectively followed 792 patients newly diagnosed with epilepsy 
(including 295 (37%) patients aged up to 19 years) from 275 general practices 
in the UK between 1984 and 1987. Patients were followed up to 9 years from 
the index seizure. The authors calculated cumulative remission of seizures as the 
cumulative proportions of patients with seizures ever attaining a 3 or 5-year 
remission from the index seizure. The results of follow up revealed that in the 
age group <16 years, 85% (CI 77,93) and 57% (CI 48-66) achieved 3 years and 
5 years cumulative remission rates by 9 years follow up. While the 3-year and 
5-year terminal remission rates at 9 years for the age group <16 years were 66% 
(CI 56, 76) and 46% (CI 36, 56), respectively.  
The study findings also showed comparable results at 2-year remission with 
some worldwide studies which examined seizure remission in CYP in Europe 
and the United States. For example, in a Dutch study, a cohort of 453 CYP, 
aged 1 month to 15 years, was prospectively followed up to 5 years to examine 
the prognosis of epilepsy 309. Seizure outcomes were examined based on 2 and 5 
years terminal remission. At the end of 5 years, the results showed that 345 
(76%) attained at least one year remission, 290 (64%) at least 2 years remission 
and 248 (55%) achieved more than 2 years remission.    
Berg et al. (2001) prospectively followed a cohort of 594 CYP newly diagnosed 
with epilepsy in the USA and examined seizure outcomes in terms of seizure 
remission 313. The CYP, aged 1 month and 15 years at the first (index) seizure, 
were observed for a median followed-up of 5 years. About 90% of CYP were 




treated with AEDs. The authors reported that 442 (74%) of CYP achieved 2 
years remission.  
The proportion of CYP who entered long-term remission, for example, more 
than 5-year remission was 42% [95% CI 38%, 46%]. This proportion of CYP 
was lower than previous studies which reported that around 65-75% of both 
CYP and adults with newly diagnosed epilepsy had a chance of entering long-
term remission 46, 115. However, a few numbers of CYP in this study were 
followed-up to 15 years as above-mentioned 
4.7 Strength and limitations of the analysis 
The study is one of the large studies on CYP with epilepsy in the UK to 
quantify clinical outcomes of treating epilepsy in general practices in terms of 
seizure frequency and remission of seizures.   
A potential limitation to this analysis was that the estimated seizures frequency 
and seizures free periods (remission) were based on the incidence of medically-
attended seizure events and not the actual seizure attacks. It is high likely that 
seizure events were underestimated because they were not reported by 
CYP/caregivers or were not comprehensively recorded by the GP for the whole 
study cohort.  Research has found that clinicians cannot monitor patients 
FRQWLQXRXVO\DQGWKH\PRVWO\UHO\RQWKHSDWLHQWV¶DQGRUFDUHJLYHUV¶reports of 
seizure activity 331, 332. Some studies suggested under-reporting of seizures by 
patients or caregivers 333, 334. However, the proportions of CYP who achieved 
seizure remission in this analysis were compared to some cohort studies which 








4.8 Conclusions  
The calculated incidence of medically-attended seizures was higher in infant 
and young children as compared to adolescents. This either suggests different 
severity of epilepsy subtypes in infant and young CYP or lower reporting of 
seizure events for adolescents. Length of calculated seizure-free periods suggest 
that approximately half of CYP can have good prognosis of epilepsy in terms 
remission of seizures for 5 years or more. Regression analysis demonstrated 
positive association between the AED adherence and seizure frequency which 
suggest that CYP were more likely to adhere to prescribed regimens when their 
condition were less controlled.    




5 Chapter 5: Estimating the costs of treating epilepsy 
in CYP in primary care in the UK  
5.1 Introduction 
Epilepsy has been demonstrated to be associated with economic burden at 
individual, family, health services, and societal level in the UK and Europe 65. 
Assessment of health resource utilisation (HRU) and the costs associated with 
treating epilepsy is important to understand its economic impact on individuals 
and health care providers. Estimating the cost of illness is also important when 
assessing the cost-effectiveness of interventions to manage epilepsy such as 
drugs, medical procedures or surgery, and also to assist decision makers to set 
priorities for resource allocation within the health care system.  Examining the 
cost of illness includes three main elements; direct costs, indirect costs and 
intangible costs335. Direct costs are the costs of medical (e.g., drug treatment, 
outpatient appointments and inpatient hospital admissions, diagnostic tests and 
ODERUDWRU\LQYHVWLJDWLRQVDQGJHQHUDODQGVSHFLDOLVWV¶YLVLWVDQGQRQ-medical 
heath care resources (e.g., patient/family out-of-pocket costs for treatment-
related travel and time off work and costs for taking care of dependents). Indirect 
costs usually refer to the associated productivity loss due to illness in terms of 
underemployment, unemployment and increased mortality. Intangible costs are 
difficult to measure and value such as the associated psychological disorders and 
reduction in quality of life due to illness.   
Little is known about the costs of treating epilepsy in CYP in the UK and 
previous studies estimating the costs of treating epilepsy in adults are over 14 
years old 67, 336. Recently, Beghi et al. (2005) reviewed published studies on the 
cost of epilepsy in childhood and concluded that the knowledge of economic 
impact of epilepsy in CYP is limited due to the scarcity, inconsistency and poor 
comparability of the published articles 68. A search was carried for more recent 
studies that may have been published since this review. No study was found 
estimating the total direct costs of treating epilepsy in the UK or Europe.  




In a study by Cockerell et al. (1994), children were included as part of large 
survey study and another longitudinal prospective study 67. The study was 
conducted on two populations; one population of 1628 patients was identified 
from general practices throughout the UK and 14% patients were less than <20 
years. The second population included a longitudinal prospective follow-up of 
602 patients of whom 25% were less than 15 years. However, separate data were 
not provided about the cost of epilepsy in children and only combined data for 
the adults and children were presented. The annual direct costs of epilepsy were 
estimated to be in the first year of diagnosis. Ninety three CYP aged 5-15 years 
were also included as part of another prevalence survey study by Jacoby et al. 
(1998) to investigate the direct and indirect cost of epilepsy in the UK 336. The 
authors estimated the total annual health care cost to be £689 per patient. The 
later study had a limitation in that the bulk of information was based on patient 
and parent questionnaires which might lead to an underestimate or overestimate 
of the medical services utilised by patients (recall bias). Morgan and Kerr (2004) 
investigated only the hospital care-related costs for 3,892 people with epilepsy in 
Cardiff and the Vale of Glamorgan- UK in 1999 337. The study was not 
representative of the whole UK population and no separate cost data were 
presented for children.  
The economic aspects of epilepsy should be studied separately in CYP because 
children and adults are different in terms of incidence and prognosis of epileptic 
syndromes, hospital care, referrals to specialists, and the age licence of 
antiepileptic drugs (AEDs) 68. For example, Morgan and Kerr (2004) reported 
that children younger than 15 years were more frequently admitted to hospitals 
than adults 337. Similar findings were reported by Jette et al. (2008) who analysed 
HRU by patients with epilepsy for the year 2001 using a Canadian database. The 
authors revealed that children less than 18 years were more likely to see 
neurologists, visit emergency departments  and  admitted to hospitals 338.  
Sub-optimal adherence to AEDs has been associated with more frequent 
hospitalisations, emergency room visits and higher associated direct costs of 
epilepsy in adults studies (See Chapter1) 156, 170.  




7RWKHUHVHDUFKHU¶VNQRZOHGJHQRSRSXODWLRQ-based study has focused on 
investigating the cost of treating epilepsy in CYP in the UK.  
Epilepsy is one of the chronic conditions for which drug prescribing and 
monitoring are primarily managed in general practices in the UK in collaboration 
with secondary care settings. Thus the primary aim of this analysis was to use 
THIN database to provide estimates of the costs of drug treatments and 
investigations associated with epilepsy on a large and representative sample of 
CYP in the general population. Applying longitudinal analysis in this chapter 
enables understanding of the HRU by CYP with epilepsy and the associated cost 
of treating epilepsy over the study time.  
5.2 Aim of the study 
The aim of this cost analysis was to describe the health resource utilisation and 
associated direct costs in CYP with epilepsy from the Primary care Trust (PCT) 
perspective and to determine the relationship between resource utilisation and 
adherence to AEDs. 
5.3 Objectives 
The objectives of this cost analysis were to: 
1. Extract primary health resource utilisation data from THIN database 
2. Define the unit cost of the resource using Department of Health (DH) - NHS 
Reference Costs Database, the Personal Social Services Research Unit 
(PSSRU) and the British National Formulary (BNF). 
3. Estimate the total costs of resource use by multiplying the unit costs by 
resource use in THIN. 
4. Determine whether there were any variations in HRU and costs by age, sex, 
socioeconomic status of children and adherence to AEDs.  





5.4.1 Study population and study time 
Assessment of the cost of epilepsy was conducted on a subgroup of CYP with 
epilepsy between January 1st, 1988 and November 30, 2004. This cohort of 
children had at least one year of follow-up data after the date of their first 
recording of epilepsy diagnosis in THIN database. The follow-up time ended at 
the finish date of each child. The finish date was the date of death, the date 
where the child transferred out of the general practice, or the last date of data 
collection, whichever occurred first.  
To estimate the costs of HRU, this cohort was again divided into newly 
diagnosed CYP with epilepsy (incident group) and CYP with established 
epilepsy (prevalent group). The incident group met the criteria discussed in 
Chapter 2 where CYP were either registered from the date of birth, so the date of 
the first diagnosis of epilepsy was known or children had at least 6 months 
registration data before the date of first recording of epilepsy (Figure 5-1).  
 
Figure 5-1: Study population for cost analysis 
 
The date of first recording of epilepsy was the date of first diagnosis code or the 
date of first prescription of AED, whichever occurred first as described in 
Chapter 2. Dividing the study cohort into incident and prevalent groups was 
done to compare the overall costs of epilepsy in newly diagnosed cases to the 




established cases and also to compare the cost during the first year of epilepsy 
diagnosis with subsequent follow-up years.  
The HRU and the associated costs were estimated from the date of first 
diagnosis of epilepsy. However, since there are procedures as part of the 
diagnosis process of epilepsy such as general practitioners (GP) consultations, 
VSHFLDOLVWV¶DSSRLQWPHQWVDQGGLDJQRVWLFLPDJLQJZKLFKRIWHQRFFXUUHGEHIRUH
assigning the diagnosis of epilepsy, the analysis time was extended to 6 months 
before the date of first diagnosis of epilepsy for the subgroup of newly 
diagnosed children. For the study cohort, a suspected child with epilepsy was 
usually assigned a tentative code (on examination code) for symptoms such as 
seizure or convulsion before the diagnosis of epilepsy and/or epilepsy syndrome.  
This was considered normal procedure as it was also recommended by the NICE 
guideline 2004 and its update in January 2012 to verify the diagnosis and 
determine subtypes of epilepsy26. The recommendations stated that CYP with a 
first suspected seizure should be referred as soon as possible to a specialist in the 
management of the epilepsies to provide accurate and early diagnosis and 
initiation of appropriate therapy. Alongside the clinical features and history of 
seizure, an electroencephalography (EEG) should be performed to support a 
diagnosis of epilepsy in CYP. If necessary, an EEG should be performed after 
the second epileptic seizure or as assessed by the specialist, it may be performed 
after a first epileptic seizure.  
5.4.2 Extraction of primary health resource utilisation from THIN 
database 
The main outcome measure was the total cost of HRU recorded in THIN 
database. The categories of resource use included costs of GP consultations, 
outpatient such as referrals to paediatric neurologists or other specialists, 
inpatient and emergency hospital care medications for epilepsy, diagnostic 
imaging, and laboratory investigations. The methods of identifying each element 
of HRU are described in Table 5-1: 
 




Table 5-1: Identification of categories of cost related to epilepsy from THIN 
database 
Category of cost  Definition/identification   
General practitioner  
consultations 
The number of GP visits were extracted from THIN 
medical and AHD files using the dates the CYP were 
assigned diagnosis codes for epilepsy, seizure events 
and codes for epilepsy monitoring and medication 
review 
Outpatient hospital care Codes for outpatient attendances including referrals 
to paediatric neurology (specialists for diagnosis of 
epilepsy) were extracted from the medical files of 
CYP using the code list in Appendix 17. Outpatient 
QHXURORJLVWV¶DSSRLQWPHQWVZHUHUHFRUGHGIRURQO\
(9%) of the study cohort.  
Inpatient hospital care Data for inpatient hospital admissions and other 
accident and emergency (A&E) visits were extracted 
from the medical files of CYP using the code list in 
Appendix 18.  The primary care coding system did 
not provide whether the procedures were elective 
SODQQHGSDWLHQW¶VDGPLVVLRQRUQRQ-elective 
XQSODQQHGSDWLHQW¶VDGPLVVLRQDGPLVVLRQ6RQRQ-
elective admission was defined in this analysis to 
include codes of urgent and emergency admissions. 
Other extracted codes were categorised into elective 
admissions or non-admitted accident and emergency 
visits 339. 
Diagnostic imaging Diagnostic imaging for CYP with epilepsy 
principally included EEG (EEG is a main diagnostic 
tool for epilepsy via recording of electrical brain 
activity along the scalp), computerised tomography 
(CT is used to generate a three-dimensional image of 
the inside of an organ and it markedly increases the 




ability to determine an aetiology for epilepsy) 340and 
magnetic resonance imaging (MRI) which uses radio 
waves and a magnetic field to show the physical 
structure of the brain. Codes for diagnostic imaging 
were recorded in the medical and additional health 
data (AHD) files of THIN (Appendix 19) 
Laboratory investigations  
 
Laboratory investigations included biochemistry tests 
for monitoring of serum level of AEDs. Codes for 
laboratory investigations were listed in Appendix 19 
Medications for epilepsy All AED types prescribed in THIN for the study 
cohort including information on the quantity 
prescribed, formulation and dosage strength of each 
drug. 
 
The categories of HRU were extracted from THIN and the number of events 
was quantified separately for the newly diagnosed CYP with epilepsy (incident 
group) and the prevalent group. For each group of children, the HRU was 
stratified by sex, age as time-varying variable, socioeconomic status 
(Townsend deprivation quintiles) and years of follow-up since the date of first 
diagnosis or the date of first recording of epilepsy in THIN for the prevalent 
group. The overall percentage of CYP who consumed each element of health 
resources was calculated. HRU was also calculated per child per year. 
5.4.3 Define the unit cost of the health care resource 
The mean unit cost of HRU in CYP with epilepsy were obtained using PSSRU- 
Unit Costs of Health and Social Care341, the DH-Reference Costs database339. 
The costs were calculated for the year 2011. The costs of prescribed AEDs were 
obtained from the BNF for children 2011271. Table 5-2 summarises the unit cost 
of each element of health resources and the data source of each cost. 
Within the DH-Reference Costs database, the unit costs of health care resource 
were classified into Health Resource Group (HRG) codes. The HRG codes are 





clinicians as consuming a similar level of resource339. The latest version, HRG-
4, has been used in reference costs database since the year 2006-07. The 
SDWLHQWV¶HYHQWVLQ+5*-4 codes are sometimes grouped by diagnosis, age, body 
areas or body systems, length of stay or a combination of factors. For example, 
EEG and electromyography (EMG) scans had the same HRG-4 code which was 
DA14. Thus the unit cost of a diagnostic EEG scan was defined by searching its 
HRG-4 code within the DH-Reference Costs database. 
The unit cost of a GP consultation was obtained from the PSSRU using the 
average unit cost per surgery consultation lasting 11.7 minutes without 
qualifications and including direct care staff cost. Qualifications are specific 
types of pre-registration and post-graduate medical education and training. The 
assumption was that not all GPs have had these medical qualifications.  
The costs of hospital care events were obtained from the DH-Reference Costs 
database. The cost of epilepsy specialist was obtained using the cost of 
outpatient attendances at paediatric neurology. The medical files of CYP did not 
SURYLGHDQ\GDWDIRURWKHUVSHFLDOLVWV¶YLVLWVH[FHSWYLVLWVWRSV\FKLDWULVWVZKLFK
were excluded from the total cost analysis. The unit cost for other outpatient 
hospital care was attached using the average unit cost of all outpatient episodes 
within DH-Reference Costs database. 
It was not recorded in THIN for the extracted inpatient and emergency hospital 
care data whether they were epilepsy-related. So the unit costs of elective and 
non-elective hospital admissions were attached using the average unit cost of all 
elective or non-elective episodes within the DH-Reference Costs database. For 
emergency admission, the cost was attached as non-elective inpatient short stay. 
The emergency short stay was chosen based on the online Hospital Episodes 
Statistics (HES) Database for the year 2011which reported that the median 
length of hospital stay of 120,271 admitted patients with epilepsy and other 
episodic disorders (including 18,253 CYP less than 15 years) was 1 day342.  




The costs of diagnostic imaging and blood chemistry tests were obtained from 
the DH-Reference Costs database. 
The costs of AEDs for individual children were calculated for each issued 
prescription by multiplying the price guidance obtained from the BNF for 
children 2011271 for each drug formulation by the quantity prescribed for each 
child. For example, if a child was prescribed 600 ml of sodium valproate liquid 
and the unit price in the BNF was £6.13 for 300ml-pack, so the cost of this 
prescription was calculated as 2x £6.13=£12.26.  
Formulations (1% of the total number of prescriptions) for the four AEDs 
clobazam, clonazepam, midazolam and paraldehyde did not have price guidance 
in the BNF because these formulations are extemporaneous preparations and are 
usually provided by special order. The costs of these formulations were obtained 
from the NHS Electronic Drug Tariff 2011343. 
 




Table 5-2: Unit cost of health care resource 
Health care resource  Number  Cost (£)  Source  
GP consultation  1  30 PSSRU 2011 
Hospital care episodes  
Paediatric neurology outpatient attendances 
Other outpatient attendances  
Elective inpatient admissions 
Non-elective admissions (e.g. emergency) 
A&E visits (not admitted) 
 












DH Reference Costs 2011 
DH Reference Costs 2011 
DH Reference Costs 2011 
DH Reference Costs 2011 
DH Reference Costs 2011 













DH Reference Costs 2011 
DH Reference Costs 2011 
DH Reference Costs 2011  
Blood chemistry tests  1 1 DH Reference Costs 2011  
Cost of AEDs 
Old AEDs 
Sodium valproate capsules 150mg  
Sodium valproate crushable tab 100mg 
Sodium valproate EC tablet 200mg  
Sodium valproate EC tablet 500mg 
Sodium valproate MR tablet 200mg 
Sodium valproate MR tablet 300mg 
Sodium valproate MR tablet 500mg 



































Carbamazepine chewable tablet 100mg  
Carbamazepine chewable tablet 200mg 
Carbamazepine MR tablet 200mg    
Carbamazepine MR tablet 400mg                         
Carbamazepine tablets 200mg   























Ethosuximide capsule 250mg 





BNF for children  2011 
 
Phenobarbital elixir 15mg/5ml  
Phenobarbital tablet 30mg  
Phenytoin capsule 50mg 
Phenytoin suspension 30mg/5ml 
















Primidone tablets 250mg  28 tab 12.60 BNF for children  2011 




Diazepam injection 5mg/ml 
Diazepam rectal tube 5mg 
Clobazam tablet 10mg 
Clobazam suspension 5mg/5ml 
Clonazepam oral drops 2.5 mg/ml 
Clonazepam suspension 500µg /5ml 
Clonazepam tablets 500µg 
Midazolam buccal solution 10mg/ml 



















BNF for children  2011 
 
 
NHS Electronic Drug Tariff 
NHS Electronic Drug Tariff 
NHS Electronic Drug Tariff 
BNF for children  2011 
NHS Electronic Drug Tariff 
NHS Electronic Drug Tariff 
 
New AEDs 
Lamotrigine dispersible tablet 25mg 
Lamotrigine dispersible tablet 100mg 
     Lamotrigine tablet 25mg 
Lamotrigine tablet 50mg 
Lamotrigine tablet 100mg 

















BNF for children  2011 
 
Topiramate capsule 15mg 
Topiramate capsule 25mg 
Topiramate capsule 50mg 
Topiramate tablet 25mg 
Topiramate tablet 50mg 
Topiramate tablet 100mg 















BNF for children  2011 
Vigabatrin sachet 500mg 





BNF for children  2011 
 
Levetiracetam tablet 250mg 
Levetiracetam tablet 500mg 







BNF for children  2011 
Gabapentin capsule 100mg 
Gabapentin capsule 300mg 
Gabapentin capsule 400mg 
Gabapentin tablet 600mg 











BNF for children  2011 
Oxcarbazepine tablet 150mg 
Oxcarbazepine tablet 300mg 
Oxcarbazepine tablet 600mg 









BNF for children  2011 
 




5.5 Estimation of the total costs of health resource utilisation  
For individual children, the unit cost of each element of health resources was 
attached. The total costs of the health resources were then estimated by 
multiplying the quantities of each resource per year by the fixed unit cost values. 
The total costs of all observed HRU were aggregated and estimated for 
individual child per year. Finally the mean total costs per child per year were 
estimated and presented. The total costs of actual recorded HRU in THIN were 
presented first. Referrals to outpatient paediatric neurologists were recorded for 
few CYP (9%). The NICE guideline 2004 and its update 2012 26 have 
recommended that the diagnosis of epilepsy should be established by a 
neurologist or a paediatric specialist of expertise in managing epilepsy to avoid 
misdiagnosis of cases. So the recorded data in THIN for outpatient specialist 
attendances were considered an underestimate of what would have been 
performed under the new practice recommendations. Therefore, the costs of 
HRU in first year of diagnosis was re-estimated after assigning one visit to 
paediatric neurology for each child with newly diagnosed epilepsy during the 
first year of epilepsy diagnosis. 
The annual total direct costs per child were estimated and stratified by sex, age, 
Townsend deprivation quintiles and adherence groups as a function of the 
calculated MPR. With regards to adherence, CYP were categorised into two 
groups; adherent (MPRı0.8), non-adherent (MPR<0.8). The threshold of 0.8 
(80%) has been commonly used in the adherence literature including two recent 
previous studies assessing the association between costs and non-adherence in 
adult populations with epilepsy 156, 170. Some CYP may not have constant supply 
of AEDs during the follow-up time as because of remission of seizures or other 
medical reasons. So CYP without any drug prescription for 180 days or more 
were classified as untreated during this period.  
The arithmetic mean of cost data provides information about the total costs 
required to treat all patients and so it is considered the most useful measure for 
health care policy decisions. Common methods of skewed data (common for 




cost data)transformation such as the natural log transformation and square root 
transformation to achieve approximate normal distribution do not enable 
comparison of arithmetic means 344. Nonparametric bootstrapping is an adopted 
method to compare arithmetic means of cost data 344. Therefore, nonparametric 
bootstrapping was performed using Stata software. On the data generated by 
bootstrapping, t-test was used to compare the annual total cost between sex and 
adherence groups. Analysis of variance (ANOVA) was applied to compare the 
total costs between age groups and deprivation quintiles.  
 




5.6 Results  
5.6.1 Study population  
The analysis of the direct medical costs of HRU was conducted on 1067 CYP 
with epilepsy of whom 798 were newly diagnosed CYP (incident group) and 
269 CYP were prevalent cases. Of the incident group, 444 (56%) were male 
and the mean age at first diagnosis of epilepsy was 5.6 years and ranged from 1 
day to 15.2 years (Table 5-3). Age of CYP varied over the follow-up years and 
the proportions of age are shown in Table 5-3. About 18% had the lowest 
deprivation score (Townsend =1) and 17% had the highest deprivation score 
(Townsend=5).  
The prevalent group had similar characteristics to that of the incident group 
where out of 269 children, 147 (55%) were males. The mean age at first 
recording of epilepsy in THIN was 5.2 years and ranged from 1 day to 15 
years. The proportions of age over the follow-up years are shown in Table 5-3. 
One-fifth (20%) had the lowest deprivation score (Townsend quintile=1) and 
26% had the highest deprivation score (Townsend quintile =5).  The total 
person years of registered data of the whole study cohort were 6467 years and 
the mean follow-up years was 6 and ranged from 1.0 to 15.9 years.  
 




Table 5-3: basic characterics of CYP with epilepsy 







Sex   
Male  444 (56) 147 (55) 
Female  354 (44) 122 (45) 
Age time-varying* (years)   
0-2 192 (24) 67 (25) 
2-6 441 (55) 155 (58) 
7-12 663 (83) 227 (84) 
>12  338 (42) 154 (57) 
Townsend quintiles   
1 147 (18) 53 (20) 
2 123 (15) 33 (12) 
3 168 (21) 40 (15) 
4 170 (21) 54 (20) 
5 135 (17) 70 (26) 
Missing  55 (7) 19 (7) 
*A child may contribute to more than one age category over time so the number of CYP does 
not add to total 
5.6.2 Health resource utilisation by the newly diagnosed CYP with 
epilepsy (incident group) 
The overall HRU by the newly diagnosed CYP with epilepsy in the sample is 
shown in Table 5-4. Each child in this sample had at least one GP consultation 
during the follow-up time which varied for each child. The total number of GP 
consultations was 4629 of which 2041(44%) occurred during the first year 
after diagnosis. 
Thirty one percent of CYP (250) were treated at hospital as outpatients 
including 25 (3%) paediatric neurology attendances, 147(18%) of CYP had 
inpatient hospital admissions and 122(15%) had emergency visits.  
Twenty two (3%) of CYP had CT scans, 185(23%) had EEG scans and 116 
(15%) had MRI scans. The blood drug levels of AEDs were monitored for 98 
CYP (12%). All CYP were treated with AEDs (one of the inclusion criteria of 
identifying CYP with epilepsy) and the total number of prescriptions was 
50,506. Thirty eight percent (306) of CYP were on one drug whereas 




492(62%) were prescribed at least two drugs to control epilepsy.  A detailed 
description of the number and the most commonly prescribed drugs was 
discussed in Chapter 3. 
The HRU per year following diagnosis is described in Table 5-5. The data 
showed that in the first year of epilepsy diagnosis, the mean number of GP 
consultations was 2.56, 0.45 outpatient attendances, 0.16 inpatient admissions, 
0.33diagnostic imaging and laboratory tests and 11.41 drug prescriptions per 
child. A wide variation in the HRU was observed between CYP during the 
follow-up years. For example, in the first year of epilepsy diagnosis, 93% of 
CYP were treated with AEDs, 11% admitted to hospital, 4% had accident and 
emergency visits, 15% had EEG, 7% had MRI and 2% had CT scans. This 
figure decreased in the eighth year of follow-up at which point 90% of CYP 
were treated with AEDs, 5% admitted to hospital, 7% had accident and 
emergency visits, 2% had EEG, 2% had MRI and 0% had CT scans. The mean 
number of drug prescriptions remained almost unchanged over time.  
 




Table 5-4: Health resource utilisation by the incident group (n=798); total episodes in THIN data 





Hospital care episodes 
 




Sp visits Outpatient Inpatient A&E CT EEG MRI 
Total 798 4629 30 951 368 253 25 245 154 156 50506 
Sex            
Male  444 (56) 2552 19 617 228 133 18 141 74 86 29065 
Female  354 (44) 2077 11 434 140 120 7 104 80 70 21441 
Age time-varying*            
0-2 192 (24) 754 1 159 69 42 9 32 15 5 3784 
2-6 441 (55) 1409 3 362 167 85 10 70 39 32 15365 
7-12 663 (83) 1860 15 432 118 81 5 118 70 79 24639 
>12  338 (42) 606 11 98 14 45 1 25 30 40 6718 
Townsend index            
1 147 (18) 894 4 85 40 53 6 45 28 25 8241 
2 123 (15) 688 8 204 62 44 5 39 30 30 7909 
3 168 (21) 820 8 229 59 59 4 41 40 40 10491 
4 170 (21) 1161 3 233 100 52 8 54 25 32 12534 
5 135 (17) 800 6 137 64 34 2 41 21 27 8311 
Missing  55 (7) 266 1 163 43 11 0 25 10 2 3020 
 
Spvisits=paediatric neurology attendances, A&E= accident and emergency visits  
*A child may contribute to more than one age category over time so the number does not add to total of CYP. 











 Hospital care 
 




All outpatient Inpatient A&E CT EEG MRI  
1 798 2.56 0.45 0.16 0.13 0.03 0.17 0.08 0.05 11.40 
2 755 0.94 0.25 0.07 0.08 0.00 0.03 0.03 0.05 12.45 
3 647 0.83 0.18 0.08 0.09 0.00 0.04 0.01 0.03 12.03 
4 514 0.77 0.23 0.06 0.05 0.00 0.04 0.04 0.04 12.18 
5 381 0.73 0.21 0.11 0.09 0.01 0.04 0.02 0.02 12.29 
6 288 0.64 0.13 0.05 0.09 0.00 0.02 0.03 0.03 12.06 
7 201 0.65 0.19 0.05 0.15 0.00 0.05 0.04 0.01 12.05 
8 162 0.78 0.15 0.05 0.13 0.00 0.03 0.03 0.03 12.00 
 




5.6.3 Health resource utilisation for the prevalent group of CYP with 
epilepsy  
To compare with the incident group, the HRU by CYP with established epilepsy 
(prevalent group) is shown in Table 5-6. The total number of GP consultations 
was 1571, of which 559 (36%) occurred in the first year of recording epilepsy in 
THIN data. Each child in the group had at least one GP consultation during the 
follow-up time.  
One-fourth of CYP (68) were treated at hospital as outpatients including a few 
of CYP (6) had records of referral to paediatric neurology with a total of 9 visits 
during the whole follow-up time, 41 (15%) CYP had inpatient hospital 
admissions, and37 (14%) had accident and emergency visits.    
Ten CYP (4%) had CT scans, 43(16%) had EEG scans and 25 (9%) had MRI 
scans. The blood drug levels of AEDs were monitored for 23 CYP (8%). All 
CYP were treated with AEDs and the total number of prescriptions was 20790. 
Eighty three (31%) CYP were on one drug whereas 186 (69%) were prescribed 
at least two drugs to control epilepsy.  A detailed description of the number and 
the most common prescribed drugs was discussed in Chapter 3. 
The HRU per child per year during 8 years of follow-up are shown in Table 5-7. 
The mean number of GP consultations per year was approximately 1 except for 
the first year where it was 2.08.  Outpatient attendances ranged from 0.09 to 
0.18, 0.01-0.09 inpatient admissions, 0.04-0.14accident and emergency visits, 
0.05-0.13 diagnostic imaging and laboratory tests and 11.67-15.56 drug 
prescriptions per child. 




Table 5-6: Health resource utilisation by the prevalent group (n=269); total episodes in THIN data  










Sp visits Outpatient Inpatient A&E CT EEG MRI  
Total 269 1571 9 193 75 67 10 50 30 42 20790 
Sex            
Male  147 (55) 815 3 98 39 37 2 24 15 17 11836 
Female  122 (45) 756 6 95 36 30 8 26 15 25 8954 
Age time-varying*            
0-2 67 (25) 228 0 9 12 1 1 7 2 1 953 
2-6 155 (35) 488 2 42 27 12 9 20 7 4 5922 
7-12 227 (36) 591 5 110 29 33 0 14 13 26 10498 
>12  154 (4) 264 2 32 7 21 0 9 8 11 3417 
Townsend index            
1 53 (20) 246 3 28 21 8 2 9 8 3 3770 
2 33 (12) 171 2 11 7 5 2 6 2 3 2278 
3 40 (15) 309 4 22 11 23 1 5 5 7 3680 
4 54 (20) 282 0 46 7 12 2 15 6 17 3650 
5 70 (26) 461 0 79 24 17 2 10 7 8 6018 
Missing  19 (7) 102 0 7 5 2 1 5 2 4 1394 
 
Spvisit=paediatric neurology attendances, A&E= accident and emergency visits 
*A child may contribute to more than one age category over time so the number does not add to total of CYP. 
 




Table 5-7: Health resource utilisation by CYP with established epilepsy (prevalent group); mean per year 
 







 Hospital care 
 




outpatient Inpatient A&E CT EEG MRI  
1 269 2.08 0.16 0.07 0.05 0.01 0.08 0.02 0.02 11.67 
2 222 1.00 0.11 0.09 0.05 0.01 0.01 0.03 0.01 14.46 
3 192 0.75 0.12 0.05 0.04 0.02 0.04 0.01 0.01 13.82 
4 166 0.98 0.09 0.04 0.11 0.00 0.03 0.01 0.03 14.87 
5 143 0.70 0.13 0.05 0.06 0.00 0.02 0.01 0.02 13.92 
6 119 0.77 0.13 0.05 0.04 0.00 0.02 0.02 0.05 12.99 
7 90 0.98 0.16 0.01 0.08 0.00 0.03 0.03 0.05 13.50 
8 74 0.94 0.18 0.04 0.04 0.00 0.01 0.03 0.01 15.65 




5.6.4 The total annual direct costs of epilepsy per child for the incident 
group 
The total direct costs of epilepsy per child over the first 8 years of follow-up 
after the diagnosis of epilepsy for the incident group are illustrated in. The 
figure showed the mean costs per child of the actual recorded events in THIN 
data.  The mean cost per child was higher (£811(SD= £1,718); range £30-
16,305) in the first year of diagnosis compared to a mean of £458 (SD=£1,633); 
range £368-587) in consecutive follow-up years principally due to higher 
inpatient hospital care costs. The total hospital care costs comprised 75% of the 
total costs in the first year and ranged from 45% to 67% of the total cost per 
year, AED costs ranged from 21% to 47% and the costs of GP consultations 
from 4% to 10%. The highest contribution of hospital care costs was principally 
the cost of inpatient admissions which ranged from 34% to 61%. 
Figure 5-3 illustrates an example of the distribution of total costs of HRU for 
individual CYP in the first four years after epilepsy diagnosis. The distribution 
was right-skewed with a few CYP (4%-11%) consumed high levels of health 
resource and had a total cost of more than £2000 each year of follow-up period. 






Figure 5-2: Actual calculated total annual direct medical costs per child for 
newly diagnosed CYP with epilepsy (incident group) 
 
 
Figure 5-3: The distribution of total medical costs in the first four years after 
diagnosis 




Under the new practice recommendations for the diagnosis of epilepsy, the costs 
of HRU were re-estimated in first year of diagnosis after adding one outpatient 
visit to paediatric neurology. The new total direct costs of epilepsy per child 
over the first 8 years of follow-up after the diagnosis of epilepsy for the incident 
group are shown in Table 5-8. The mean cost per child was higher (£1,153 
(SD=£1,808); range £384-16,659) in the first year of diagnosis compared to a 
mean of £458 (SD=£1,633), range £368-587) in further follow-up years 
principally due to the costs of referrals to paediatric neurologists.  
Each year the largest contribution to the total health care cost was made by the 
costs of hospital care followed by the costs of AEDs. Figure 5-5 illustrates the 
contribution of the elements of the health resource to the total direct cost per 
child. The hospital care costs comprised 82% of the total costs in the first year 
and ranged from 45% to 67% in further years, AED costs ranged from 20% to 
47% and the costs of GP consultations ranged from 4% to 7%. The highest 
contribution of hospital care was principally the cost of inpatient admissions 
which ranged from 34% to 59%. 
During the first 8 years after diagnosis, the mean cost of all AEDs per child 
increased from £118 (SD=£267) in the first year to £208 (SD=£325) in the 
eighth year (Figure 5-4).The increase in the annual mean costs of AEDs was 
due to increased costs of new AEDs, whereas the costs of old AEDs slightly 
decreased. 
The recently published population estimates for UK by the ONS indicated that 
there were 11.6 million CYP younger than 16 years in mid-2010 accounting for 
18% of the total UK population 28. From this study, the estimated prevalence of 
epilepsy in CYP was 4.5/1000 population in 2004. If epilepsy has the same 
prevalence for the year 2010, there would be 51,040 CYP with epilepsy in the 
UK. The mean annual direct cost per child for prevalent cases of epilepsy was 
estimated at £458 (SD=£1,633). This would suggest that, from the perspective 
of the healthcare provider, the total direct cost of treating CYP with epilepsy 
was £23,019,040 in the year 2010.  




Table 5-8: The mean direct cost of epilepsy per child per annum for the incident group (n=798) 
Cost category  Year1 
No of CYP=798 
Year 2 
No of CYP=754 
Year 3 
No of CYP=653 
Year 4 
No of CYP=530 
No of 
events 












Mean cost (SD) 
range 
GP consultations 2041 81(77); 30-900 711 28 (46); 0-360 549 24 (43);0-330 408 22 (41); 0-330 
Hospital care  
 Outpatient 
  Paediatric neurology  











354 (0); 354-354 
45 (143);0-1515 
492 (1713); 0-15455 










25 (94); 0-808 
230 (1223);0-21637 










17 (76); 0-1212 
241 (1487); 0-24728 






















2 (16); 0-190 
16 (41);0-279 







3 (17); 0-186 







4 (21); 0-186 






0.4 (6); 0-95 
3 (18); 0-186 
7 (49); 0-815 
Blood chemistry tests  43 0.1 (0.3); 0-2 41 0.1 (0.3) 0-5 20 0.1 (0.2); 0-2 20 0.1 (0.2); 1-2 
Cost of AEDs 
Old AEDs 





94 (250); 0-6369 





108 (168); 0-2250 





110 (250); 0-4720 





107 (202); 0-2383 
70 (166); 0-1509 
Total cost of hospital care 
 per child 
 955 (1776); 0-16377  276 (1254); 0-22142  281 (1503); 0-24930  232 (1465); 0-25132 
Total cost of drugs per child  118 (267); 0-6369  157 (228); 0-2971  170 (297); 0-4720  177 (274); 0-2383 
Total direct cost per child  1153 (1808); 384-16659  461 (1281); 2-22154  475 (1548);2-24946  430 (1529); 3-25215 
Total cost per year   637,868  347,584  310,722  228,353 
All estimated costs were rounded to nearest whole UK£.      




Table 5-8: Continued  
Cost category  Year 5 
No of CYP=400 
Year 6 
No of CYP=319 
Year 7 
No of CYP=223 
Year 8 















Mean cost (SD) 
range 
GP appointments 292 21 (32); 0-180 200 18 (34); 0-240 138 17 (42); 0-480 137 21 (48); 0-480 









21 (73); 0-505 
349 (2848);0-40183 






13 (59); 0-606 
136 (838); 0-9273 






19 (69); 0-606 
166 (1085);0-12364 






16 (50); 0-303 
141 (727); 0-6182 
16 (79); 0-568 









0.5 (7); 0-95 
















4 (23); 0-186 







2 (12); 0-93 
5 (27); 0-163 
Blood chemistry tests  9 0.1(0.2); 0-1 8 0.1 (0.2);0-2 3 0.1(0.1); 0-1 4 0.1 (0.2); 1-2 
Cost of AEDs 
Old AEDs 





102 (175); 0-2020 

















92 (119); 0-724 
117(298); 0-2533 
Total cost of hospital care  
per child 
 393 (2874);0-43275  177(885); 0-9459  217(1115); 0-12364  184 (754); 0-6750 
Total cost of drugs per child  173 (253); 0-2187  174 (260); 0-2173  194 (269); 0-1959  208 (325); 0-2533 
Total direct cost per child -- 587(2914); (2-41192)  368 (949);1-9842  429 (1160);3-12487  413 (863); 1-7003 
Total cost per year  -- 259,227  113,495  104,485  73,801 
All estimated costs were rounded to nearest whole UK£.      





Figure 5-4: Total annual costs of old and new AEDs per child (incident group) 
 
 
Figure 5-5: Total annual direct costs per child for newly diagnosed CYP with 
epilepsy (incident group) after re-estimating the cost of the first year 
 





and adherence to AEDs. Compared to that of female children, the mean total 
costs per child were non-significantly higher in male children during the first 
four years of follow-up except for the first year (bootstrapped t-test, annual p 
values are shown in Table 5-9) 
The mean total direct costs per child were higher in younger age groups (<2 
years) of CYP and tended to be lower in older age groups (>12 years) during the 
first four years after diagnosis. The variation of the total direct costs was 
significantly different between age groups (ANOVA test, annual p values are 
shown in Table 5-9). The total direct costs did not significantly vary by 
Townsend deprivation quintiles (ANOVA test, annual p values are shown in 
Table 5-9). 
The association between the total direct costs and adherence to AEDs are shown 
in Table 5-9. The percentage of non-adherent CYP was approximately 50% in 
each year of the first four years of follow-up.  In the first year following 
diagnosis, the non-adherent group consumed more hospital care resource and 
had higher associated hospital care costs (£1072; SD=2033) than the adherent 
group (864; SD=1485). However, the mean total direct cost was not 
significantly different for non-adherent group (bootstrapped t-test p=0.56) 
principally because the adherent group consumed higher drug costs. The mean 
total direct costs remained non- significantly different during consecutive years 
of follow-up.





 First year (n=798) Second year (n=754) 
 No of 







Total costs  
(95% CI)a 








Total costs  
(95% CI) a 
Sex      p       p 








Female  354 (44) 748 (1194) 125 (353) 80 (79) 952  
(840-1124) 
 334 (44) 214 (857) 151 (189) 30 (48) 395  
(324-528) 
 
Age time-varying (years)             
< 2  192 (24) 1266 (2279) 136 (473) 102 (99) 1504 
(1209-1877) 
0.01c 102 (14)  823 (2683) 149 (229) 35 (51) 1007  
(619-1705) 
0.01c 
2-6 255 (32) 997 (1906) 92 (99) 79 (68) 1168  
(962-1457) 
248 (32) 298 (1060) 150 (230) 31 (55) 478  
(371-659) 
7-12 303 (38) 789 (1355) 125 (183) 69 (53) 983  
(846-1153) 
321 (43) 112 (599) 161 (236) 22 (36) 296  
(236-383) 
>12 48 (6) 525 (473) 146 (166) 76 (58) 747  
(634-920) 
 83  (11) 134 (580) 124 (145) 32 (44) 290  
(179-438) 
 
Townsend quintiles             
1 147 (18)  811 (1387) 119 (112) 85 (79) 1015  
(819-1291) 




2 123 (15) 1258 (2275) 101 (97) 76 (56) 1435  
(1062-1887) 
 113 (15)  410 (1456) 134 (117) 26 (46) 577  
(352-911) 
 
3 168 (21) 949 (1598) 150 (511) 69 (54) 1167  
(942-1447) 
 157 (21) 231(860) 156 (211) 31 (45) 419 
(303-619) 
 
4 170 (21)  612 (1849) 117 (219) 86 (83) 1170  
(920-1490) 
 159 (21) 268 (1086) 180 (291) 29 (47) 477 
(338-686) 
 
5 135 (17) 548 (1882) 106 (117) 86 (100) 1095  
(846-1485) 
 129 (17)  222 (876)  155 (271) 28 (50) 405  
(255-562) 
 
Missing  55 (7) 388 (1406) 91 (65) 80 (78) 913  
(625-1424) 
 53 (7) 467 (3038) 126 (140) 22 (37) 615  
(169-1869) 
 
Adherence groups (MPR)             









 Non-adherent (MPR<0.8) 411 (1) 1072 (2033) 88 (93) 86 (88) 1247  
(1069-1474) 
355 (47) 260 (1378) 99 (123) 26 (44) 388  
(288-636) 
Non-treated (MPR=0) 70 (9) 676 (1259) 0 48 (30) 724   22 (3) 738 (2129) 0 22 (30) 760   
a: bootstrapped bias corrected and accelerated confidence intervals       b: boot-strapped t-test p-value      c: boot-strapped one way ANOVA p-value      




Table 5-9: continued 
 Third year (n=653) Fourth year (n=530) 
 No of 

















Total costs (SD) 
(95% CI)a 
Sex      P       P 









 Female  290 (45) 225 (923) 165 (250) 25 (43) 415  
(324-567) 
238 (45) 215 (1296) 176 (297) 23 (44) 414  
(295-721) 
Age time-varying (years)             
< 2  0 0 0 0 0  
0.02c 
0 0 0 0 0  
0.05c 2-6 259 (40) 635 (1906) 202 (384) 25 (50) 743  
(508-1083) 
175 (33) 311 (1079) 229 (345) 28 (51) 697  
(428-1173) 
7-12 306 (47) 133 (688) 150 (217) 24 (38) 306  
(244-407) 
264 (50) 143 (812) 158 (220) 18 (33) 318 
(236-449) 
>12 88 (13) 96 (470) 150 (231) 24 (33) 270  
(170-373) 
91 (17) 77 (475) 131 (248) 25 (40) 233  
(144-382) 
Townsend deprivation score             








2 102 (15) 246 (1001) 109 (134) 24 (45) 397  
(233-645) 
82 (15) 82 (419) 167 (215) 25 (45) 275  
(195-415) 
3 133 (21) 200 (880) 182 (244) 19 (35) 411  
(256-585) 
113 (22) 297 (1576) 202 (327) 19 (33) 518  
(290-945) 
4 143 (22) 385 (1828) 194 (326) 30 (55) 608 
(394-1030) 
115 (22) 164 (1024) 216 (339) 27 (54) 407  
(265-688) 
5 111 (17) 316 (1173) 144 (190) 26 (38) 486  
(293-708) 
93 (18) 130 (594)  144 (202) 25 (39) 299 
(190-448) 
Missing  45 (7) 388 (1406) 157 (254) 17 (28) 808  
(203-2400) 
36 (7) 828 (4198) 186 (368) 16 (27) 1030  
(239-3070) 
Adherence groups (MPR)             









Non-adherent (MPR<0.8) 316 (48) 263 (1621) 104 (197) 21 (38) 387 
(260-691) 
254 (48) 255(1786) 86 (112) 20 (40) 362 
(218-755) 
Non-treated (MPR=0) 25 (4) 52 (66) 0 23 (20) 72   20 (4) 226 (815) 0 20 (22) 249   
a: bootstrapped bias corrected and accelerated confidence intervals       b: boot-strapped t-test p-value      c: boot-strapped one way ANOVA p-value      




5.6.5 The total annual direct costs of epilepsy per child for the prevalent 
group 
The total direct costs of epilepsy per child over the first 4 years of follow-up 
since the first recoding of epilepsy in THIN for the prevalent group are shown 
in Table 5-10. The mean direct cost per child slightly changed over the 4 years 
of follow-up and ranged from £405(SD 817) in the first year to £368 (SD=£772) 
in the fourth year.  
The mean costs of all AEDs slightly changed over the 4 years with the cost of 
old AEDs almost unchanged and remained of higher mean cost than that of new 
AEDs (Figure 5-6). Each year the largest contribution to the total health care 
cost was made by the costs of hospital care and AEDs. Figure 5-7 illustrates the 
contribution of the elements of resources to the total direct cost per child. The 
hospital care costs ranged from 42% to 58% of the total direct cost per year, 
AED costs ranged from 32% to 50% and the costs of GP consultations ranged 
from 6% to 15%.  




Table 5-10: The mean direct cost of epilepsy per child per annum for the prevalent group (n=269) 
Cost category  Year1 
No of CYP=269 
Year 2 
No of CYP=222 
Year 3 
No of CYP=192 
Year4 















Mean cost (SD) 
range 
GP consultations 596 63 (75); 0-540 223 30 (58); 0-450 141 22 (40); 0-270 157 29 (49); 0-330 
Hospital care episodes 











15 (60); 0-404 
150(765); 0-6182 

















6 (57); 0-708 
12 (50); 0-404 
145(727); 0-6182 








8 (35); 0-202 
130 (710); 0-6182 
12 (73); 0-568 









0.7 (8); 0-95 
7 (28); 0-186 






1 (11); 0-95 
1(11); 0-93 






2 (14); 0-95 
3(16); 0-93 






0.6 (7); 0-95 
3 (19); 0-186 
1 (13); 0-163 
Blood chemistry tests  5 0.1 (0.2); 1-2 2 0.1(0.1); 0-1 2 0.1(0.1); 0-1 4 0.1(0.1); 0-1 
Cost of AEDs 
Old AEDs 





97 (161); 0-1549 





110 (135); 0-862 





109 (151); 0-1225 





108 (129); 0-770 
76 (144); 0-744 
Total cost of hospital care  
per child 
 190 (772); 0-6182  296 (1249); 0-9374  176 (749); 0-6586  156 (723); 0-6275 
Total cost of AEDs per child  152 (247); 0-1762  182 (238); 0-2111  178 (225); 0-1858  184 (200); 0-1050 
Total cost per child -- 405 (817); 1-6207  508 (1281); 5-9625  376 (824); 5-6968  368 (772); 6- 6366 
Total cost per year  -- 113,035  110,661  70,107  58,705 
All estimated costs were rounded to nearest whole UK£.      









Figure 5-7: Total annual direct medical costs per child for CYP with 
established epilepsy (prevalent group) 
  




5.7 Discussion  
5.7.1 The of cost health resource utilisation by the CYP 
The direct cost of treating CYP with epilepsy was examined based on the 
recorded HRU in THIN primary care database. To examine whether there was 
any difference between the cost of epilepsy in newly diagnosed CYP and those 
with established epilepsy, the data were reported separately for the incident 
and prevalent groups of the study cohort. There was a wide variation within the 
overall direct cost of treating epilepsy between individual children based on the 
variety of investigations required, hospital care and drug treatment choices. For 
example, the right-skewed distribution of the total direct costs, in the first four 
years after epilepsy diagnosis, reflects that a few CYP consumed high levels of 
health resources that increased the mean annual costs of the whole cohort.  
The data also showed that CYP with newly diagnosed epilepsy consumed 
higher health care resources and consequently higher associated mean cost in 
the first year, compared to consecutive years of follow-up or that consumed by 
the prevalent group. Higher total cost of healthcare in the first year was 
expected EHFDXVHRILQYHVWLJDWLRQVDQGVSHFLDOLVWV¶FRnsultations. The variation 
in the costs of resource use between individual children may reflect the 
heterogenic nature of epilepsy in terms of clinical severity and response to 
treatment. As each year, some CYP may have had uncontrolled (drug-resistant) 
seizures which may lead to consumption of more hospital care services and/or 
higher drug costs. It was not possible to assess the cost by epilepsy subtypes as 
they are not well-recorded in THIN for the majority of the study cohort. The 
association between the cost and severity of seizures was reported by Jacoby et 
al. (1998) who conducted a large cross-sectional prevalence survey study in the 
UK on a total of 789 people with epilepsy and included 93 CYP <16 years 336. 
Data were obtained from GP records and from patient questionnaires to 
investigate the cost of HRU in the previous 12 months. The authors reported 
that patients with more frequent seizures consumed more than one-half of total 
combined costs of direct and indirect care for epilepsy. 




The present findings revealed that the highest contribution to the direct costs of 
epilepsy per year was that of hospital care where the cost of inpatient 
admissions ranged from 34% to 59%, followed by AED costs ranged (20%-
47%), GP consultations (4% -7%) and outpatient attendances (4-5%). The 
same pattern was obtained for CYP with established epilepsy (prevalent 
group). 
To date, few studies have been examined the cost of treating epilepsy in the 
UK. The differences in study design, data collection, definition of epilepsy, 
and including aggregated adults data in the cohort have made it difficult to 
compare the study findings.  For example, previous published data on the cost 
of epilepsy in the UK were performed using prospective longitudinal cohort 
study 67, survey design 336 and local data confined to certain geographical area 
337
. Despite these differences, the contribution of HRU to the mean direct cost 
of epilepsy was consistent with the previous studies of adult and children with 
epilepsy in the UK. Similar to this analysis, Cockerell et al. (1994) estimated 
higher cost in the first year of prospective follow-up of 602 patients (including 
25% under 15 years) from primary care settings 67. The estimated cost of 
hospital inpatient admissions in 1-year period that was 59% of the total 
medical costs followed by AEDs (20%), outpatient attendances (13%) and GP 
consultations (6%).  
Jacoby et al. (1998) estimated similar contribution of HRU to the total direct 
cost. The estimated cost of inpatient hospital admissions was 58%, followed by 
AEDs (23%), outpatient attendances (7%) and GP consultations (2%) in 12 
months period 336.  
The percentage of AEDs cost per year was higher in this study (ranged from 
£118 to £208) than estimated in previous stdies which may be attributed to the 
introduction of more expensive new AEDs especially in later follow-up years. 
Jacoby et al. (1998) reported a mean cost of £161 of AEDs per patient per year 
336
.  
The comparison of the direct costs of treating epilepsy to different countries is 
difficult because of monetary differences and the nature of health care systems. 
However,  a review of European studies to estimate the costs of treating 




epilepsy was conducted by Pugliatti et al. (2007) 65. The review included 
studies which had different study designs, age ranges and health care settings. 
Some of these studies have conducted on children 345 and others included 
children as a part of the cohort 346-348. The estimated costs of health resource 
use were converted to Euro and were inflated to the year 2004.  Of these 
studies, an Italian study reported higher rates of hospitalisations and 
investigations than the present study 345. The authors identified a total of 189 
Italian children and adolescents with epilepsy from secondary care settings 
who were followed prospectively for 12 months. The authors showed that the 
annual HRU such as investigations (mean EEG ranged 1.8-3.5) and hospital 
admissions were higher in newly diagnosed children with epilepsy and 
children with drug-resistant epilepsy. The annual cost per patient was 
HVWLPDWHGDW¼ZKLFKFRUUHVSRQGVWR. 
5.7.2 The costs of HRU and CYPǯ 
The total direct costs per child revealed higher but no significant difference 
between males and females. The possible principal reason is that there is no 
clinical epilepsy subtype difference that affects males and females and hence 
the same health resource was consumed. The direct costs per child were 
significantly different among age groups of CYP and tended to be lower in 
older age groups (6-12 and >12 years) which may be attributed to more 
frequent hospitalisations and visits to the emergency departments in young 
ages. This probably because the age of onset of some drug-resistant epilepsy 
subtypes (e.g. West syndrome and DrDYHW¶VV\QGURPHZKLFKPDQLIHVWPRUH
frequent seizures is at infancy and early childhood 16. Similar findings were 
reported by Morgan and Kerr (2004) who estimated the costs of hospital care 
using a local database of 3892 patients with epilepsy in Cardiff and the Vale of 
Glamorgan-UK 337. The authors estimated higher inpatient costs in children 
younger than 5 years than the other age groups. No statistics were presented.  
The association between the mean costs of treating epilepsy and adherence 
showed non-adherence was associated with higher hospital care utilisation in 
the first year which led to a higher value of the mean total cost per child. This 
was similar to an earlier study by Faught et al. (2009) who reported that non-




adherence to AEDs was associated with higher incidence of inpatient 
admissions, total inpatient days and emergency room visits and consequent 
higher costs in 33,658 adult populations with epilepsy 170.  Similar findings 
were reported by Davis et al. (2008) in a large population study which 
examined AED non-adherence in adult population in the USA. The authors 
reported that non-adherence was associated with higher inpatient and ED 
services and costs 156. Both studies analysed databases and adherence was 
measured using the method of MPR. However, the mean total costs did not 
significantly vary between adherent and non-adherent groups which reflect that 
higher drug costs consumed by the adherent group outweighed lower hospital 
care cost.  
From the second year after diagnosis, adherent and non-adherent groups 
consumed similar mean hospital care costs. It is difficult to draw an 
explanation as because some of hospital care may not have related to epilepsy 
in both groups; however, this may suggest that non-adherent group may have 
had less severe epilepsy subtypes or they achieved remission of seizures. 
5.7.3 The health resource utilisation recorded in THIN  
Although the distribution of direct cost in this analysis was similar to previous 
studies, the recorded HRU were slightly different. For example, CYP of the 
incident group had a mean of 2.6 GP consultations and 93% of CYP were 
treated by AEDs (mean=11.6 prescriptions) in the first year. These findings 
were similar to that reported by Jacoby et al. (1998) who reported that 41% of 
CYP had epilepsy-related consultations with GP (mean=2.9) and that 87% of 
CYP were treated by AEDs 336. 
However, the recorded hospital care services in THIN were lower than that 
reported in previous studies in the UK. This probably because of the 
completeness and accuracy of recording hospital events in THIN were not 
much high. Another cause was the different method of data collection and 
study design.  For instance, during the first year of diagnosis, 14% of CYP had 
outpatient attendances (mean=0.46), 11% admitted to hospital (mean 0.16), 4% 




had emergency visits, 15% had EEG, 7% had MRI and 2% had CT scans 
(mean=0.33 for all diagnostic imaging).  
Compared to the present findings, Cockerell et al. (1994) reported higher 
percentage of consumed hospital care 67. For the prospectively followed cohort 
of patients, 92% of patients had initial hospital assessment as inpatients or 
outpatients in the first year. Jacoby et al. (1998) reported higher percentage 
(86%) of children attended hospital as outpatients and 18% had epilepsy-
related inpatient hospital admissions 336. However, the bulk of data were 
FROOHFWHGXVLQJSDWLHQWV¶TXHVWLRQQDLUHVZKLFKFDQEHVXEMHFWHGWRUHFDOOELDV
Compared to the present findings, Morgan and Kerr (2004) reported higher 
utilisation of hospital services that were a mean of 0.6 outpatient attendances 
and 1.8 inpatient admissions in 1999 for 3892 patients with epilepsy 337. 
However, Morgan and Kerr collected their data from secondary care settings.  
Since the previous cost studies in the UK had different study designs to the 
present study, the HRU in present study were compared to some worldwide 
studies which used databases. Kurth et al. (2010) conducted a large 
retrospective cohort study in the USA by using insurance claim databases of 14 
million persons between 2005 and 2007 to investigate HRU in patients with 
active epilepsy 349. The authors identified 46,857 patient with active epilepsy 
included 8,671CYP under 18 years old. As compared to the present study, the 
authors reported a lower mean of epilepsy-related GP consultations (1.8 per 
year) and a lower mean of drug prescriptions for epilepsy (7.6 per year).  
However, the authors  reported higher utilisation of hospital care that was a 
mean of 10.1 outpatient attendances, 0.8 emergency room admissions and 24.8 
diagnostic tests and procedures per year of which 1.1 a year were related to 
epilepsy [15]. 
In a Canadian study, Jette et al. (2008) investigated the HRU over 1 year 
period in patients with epilepsy using three administrative databases from 
secondary care (inpatient, emergency and physician claim) 338. The authors 
identified 1431 prevalent cases with epilepsy with a mean age of 
37.3(SD=17.3) years. The authors reported the means of HRU per patient in 




the year 2001 that were 1.6 GP visits, 2.5 outpatient physician visits,  0.8 
neurology visits, 0.2  inpatients and 0.1 emergency room visits 338.  
5.8 Strength and limitations of the present analysis 
To the reseDUFKHU¶VNQRZOHGJHWKLVZDVthe first study in the UK that has 
focused on estimating the direct costs related to epilepsy in CYP. The study 
group was a representative sample to CYP with epilepsy in the general 
population of the UK so the findings of HRU and associated cost can be 
generalised. This study estimated the direct costs on an incident group initially 
and over time and not only in the first year like some studies where the costs 
have been reported higher in the first year than for subsequent years.  
A number of limitations have been encountered in this study. First due to the 
retrospective nature of data analysis, a number of assumptions have been made 
to estimate the cost of treating epilepsy. These assumptions were used to 
correct for lower recorGLQJRIQHXURORJLVWV¶DSSRLQWPHQWVDQGFDWHJRULVDWLRQRI
elective and non-elective hospital admissions. These assumptions included, for 
example, the cost of one paediatric neurology visit per child in the first year; 
however, it was considered reasonable based on recommendation made by 
NICE guideline 2004 and its update 2012 for better diagnosis of epilepsy in 
children. However, LWLVOLNHO\WKDWDFWXDOVSHFLDOLVWV¶YLVLWVZHUH
underestimated in subsequent years of diagnosis.  
The costs of hospital care were estimated from the average costs per episode 
from the DH reference cost data 2011 as it was not possible to distinguish 
between epilepsy-related and non-epilepsy related hospital care. The cost of 
hospital care including diagnostic imaging was based on the recorded data in 
THIN and it was not possible to ascertain using secondary care data. However, 
the hospital care comprised the highest contribution to the direct cost of 
epilepsy as reported in previous studies. 
Prospective data collection on the speciaOLVWV¶DSSRLQWPHQWVDQGKRVSLWDOFDUH
may be required for future analysis of the direct cost of treating epilepsy.  





The mean direct costs of treating epilepsy in CYP were higher in the first year 
of diagnosis than the following years due to diagnostic process. The cost of 
inpatient hospital care was the major contributor to the total direct costs of 
epilepsy followed by the costs of AEDs. The total direct costs did not 
significantly vary by sociodemographic characteristics of CYP.  No significant 
difference in the total direct costs was observed among higher adherent and 
less adherent groups due to higher costs of drugs themselves.  
 




6 Chapter 6: Conclusions and implications for practice 
and policy  
6.1 Summary of findings 
This thesis investigated the pattern of AED use to manage epilepsy in CYP, the 
long-term adherence to medication, the clinical outcomes of epilepsy and health 
resource utilisation with associated direct costs for treating epilepsy in primary 
care in the UK. 
The background from the literature review on epilepsy demonstrated that 
epilepsy is a heterogeneous set of serious neurological disorders that has a 
higher incidence in children than adults. About one-half of epilepsy syndromes 
have age of onset in CYP that have been shown to have different aetiologies and 
prognosis than adults. In addition, some AEDs are not approved for use in 
younger children less than 6 years. Epilepsy has serious adverse educational, 
developmental, psychosocial and vocational consequences in CYP. The 
negative impacts of epilepsy on physical, psychosocial functions and HRQOL 
of CYP were discussed. The literature review has shown that there is limited 
information about the patterns of prescribing AEDs and long-term adherence to 
AEDs, although poor medication adherence is suspected. Limited data are 
available about the clinical consequences of improper use of medications in 
CYP with epilepsy. Common methods of measuring medication adherence and 
possible causes of non-adherence to AEDs were described. The additional role 
related to parents/caregivers in medication adherence of CYP was also 
discussed. Considering the potential population impact of poor management of 
epilepsy in this age group, there was a clear rationale for exploring this further 
using population-level data.  
This thesis identified CYP who were born on or after 1st January 1988 and 
diagnosed with epilepsy before the age of 18 from THIN database, to allow 
investigation of the profiles of four main areas; prescribing of AEDs, 
medication adherence, clinical outcomes and associated costs in primary care. 
This study estimated annual incidence rates of epilepsy ranged from 42 to 




61/100,000 person-years and annual prevalence of 2-4.6/1000 CYP that were in 
concordance with previous population-based epidemiological studies in the UK 
and Europe and provided assurance that the study cohort was representative of 
CYP in the general population. The incidence of epilepsy was higher in the first 
year of life [83 /100,000 person-years (95% CI, 73-95)] and in children aged 
less than 5 years [54/100,000 person-years (95% CI, 51-59), p=0.05]. However, 
the prevalence showed increasing trend with increasing age. Relatively higher 
incidence of epilepsy in CYP living in areas of high socioeconomic deprivation 
(p<0.01) suggests that there is a potential link between living in areas of greater 
socioeconomic deprivation and development of epilepsy. However, it was not 
possible to determine what socioeconomic factors are related to the incidence of 
epilepsy. This may provide evidence to the lack of consensus in published 
research about the link between epilepsy and socioeconomic deprivation.  
The investigation of patterns of AED prescribing showed that old AEDs, such 
as sodium valproate and carbamazepine, were the first-line choices in the 
management of epilepsy in 75% of CYP and were ever prescribed as 
monotherapy for 45% of CYP in this study. These two old AEDs were more 
frequently prescribed to CYP compared with other old AEDs and new AEDs. 
There was, however, an increasing trend of prescribing new AEDs, particularly 
lamotrigine and topiramate over the study period. The data indicate that safety 
warnings about the serious and irreversible visual defects of vigabatrin 350-352 
influenced GP prescribing, which was reflected in the sharp decline in 
vigabatrin prescribing from 1997.  
Employing the method of MPR, the overall and the long-term annual adherence 
to the prescribed AEDs showed that from 51% to 66% of CYP were issued at 
least 80% of their medicines over the follow-up time of each individual. 
&KLOGUHQ¶VGHPRJUDSKLFVZLWKWKHH[FHSWLRQRIDJHGLGQRWVLJQLILFDQWO\DIIHFW
adherence to AEDs. The population mean annual adherence rate to AEDs was 
significantly higher (68%, p=0.03) in older children, aged 2-12 years, compared 
to that of infants under 2 years (65%). The fact that sociodemographic factors 
showed marginal association may reflect that primary care is working well to 
effectively monitor prescribing in all patients regardless of these factors.   




Medically-attended seizures in THIN were used to investigate the clinical 
prognosis of epilepsy in CYP. Perhaps it was surprising to find that higher 
measured adherence to AEDs was associated with lower seizure control. It 
follows that the association between adherence to AEDs and increased seizure 
frequency may be due to the severity of the condition and, thus, may reflect 
increased children and parental motivation to adhere to medication regimens. In 
other words, it appears that CYP who suffered from more seizures were more 
likely to adhere to their prescribed medicines. However, it was not possible to 
distinguish CYP with possibly poor adherence who required continuous drug 
treatment from CYP who were truly in remission of seizures and were taken off 
medications. 
Compared to young people, the calculated higher incidence of medically-
attended seizures in infants and children less than 6 years may indicate either 
different severity of epilepsy subtypes in infants and young children or lower 
reporting of seizure events in young people. This study showed that 
approximately one-half of CYP can move into long-term remission of seizures 
for 5 years or more.  
The mean direct medical costs of managing individual CYP with epilepsy were 
higher in the first year of diagnosis (mean £1,153, SD £1,808) than that in 
consecutive years (mean £458, SD £1,633) which reflect higher health care 
utilisation in the first year related to the diagnostic process. The estimated direct 
FRVWVGLGQRWVLJQLILFDQWO\YDU\E\&<3¶VVRFLRGHPRJUDSKLFFKDUDFWHULVWLFVZLWK
the exception of age, where the costs were higher in infants and young children 
(p=0.01) because of more frequent hospitalisations. This may reflect that the 
severity and higher reported frequency of seizures in infants led to higher 
utilisation of hospital services which resulted in higher associated costs.  
CYP who adhered to at least 80% of their prescribed medication showed lower 
hospital-related costs compared to CYP who adhered to less than 80%. 
However, the total direct costs were not significantly different among adherent 
and non-adherent groups (p>0.05) because the higher costs of drugs in the 
adherent group offset the higher costs of hospital care in the less adherent 
group.  




6.2 Implications for policy 
This thesis described the nature of AED prescribing in primary care and the 
profile of medication use in CYP with epilepsy. The choice of first-line drug 
treatment and the trend of prescribing AEDs for CYP may indicate that old 
AEDs are effective to manage childhood epilepsy syndromes.  Although the 
prescribing of AEDs is normally initialised by specialists and followed by GPs 
353
, the trend of prescribing AEDs suggests that GPs were aware of the 
recommendations of clinical trials and consensus of specialists and experts 
about the management of epilepsy.  
With observed increase in prevalence of epilepsy over time and regarding 
1,&(¶VUHFRPPHQGDtion in 2004 that all suspected cases of epilepsy in CYP 
should be seen by neurologists within two weeks of first seizure attack 1, the 
work load impact on neurologist services should be considered. In 2008, a 
survey conducted by Epilepsy Action in PCTs and acute trusts across the UK 
revealed that only 18% of patients with epilepsy had their first QHXURORJLVW¶V
appointment within two weeks 354. Therefore, a national plan to increase the 
number of paediatric neurologists should be considered in order to shorten 
average waiting times and improve paediatric neurology services.   
Although the calculated adherence in this study does not capture the actual 
consumption of medicines by CYP, it reflects fair prescribing of AEDs at the 
population level regardless of sex, age and socioeconomic status. However, 
achieving long-term good adherence levels to the prescribed medicines is 
challenging and medication review and monitoring of adherence by GPs may 
assist in saving health resource. The source data enabled the thesis to capture 
RQO\DVPDOOQXPEHURIIDFWRUVWKDWPD\LQIOXHQFH&<3¶VPHGLFDWLRQWDNLQJ
although many other factors have been suggested 176. The findings from this 
study showed that lower adherence was observed in infants and young children, 
then it is important to emphasise the role of parents and their responsibilities 
toward monitoring medication taking of their children. Self-management 
educational interventions have been suggested to be valuable for CYP with 
epilepsy and their families who feel stigmatised or excluded 355. These 





knowledge to understand the nature of epilepsy, treatment instructions and to 
reinforce the importance of adherence to medicines. Psychosocial support (e.g., 
improving self-efficacy) and sometimes therapeutic interventions for CYP and 
parents who suffer from behavioural problems such as anxiety and depression 
are also important for changing attitudes toward epilepsy and providing coping 
skills which may lead to improved seizure control. However, the long-term 
effects of such interventions are not known.  
This study demonstrated poor recording of clinical outcomes of epilepsy in 
THIN. The finding that medically±attended seizures, recorded during GP 
consultations, were associated with higher adherence may suggest that 
experience of seizures potentially motivated CYP and their parents to visit their 
physicians and monitor their treatment. Therefore, the Department of Health 
should motivate GPs to regularly monitor treatment and outcomes for all 
patients. The current policy of Quality and Outcomes Framework (QOF) for GP 
incentives to improve patient care in the UK does not include CYP under 18 
years in clinical indicators for epilepsy 356. This may affect management of 
epilepsy and quality of care delivered to CYP.   
Although limitations existed in identifying HRU, this is the first study to 
provide longitudinal estimates of the costs associated with treating epilepsy in 
CYP in the UK. This study highlighted the economic burden of epilepsy and 
provided new data to the scarcity of cost of illness studies in CYP with epilepsy. 
The study implies that the expenditure on newly diagnosed cases of epilepsy is 
high. However, the costs of treating epilepsy in subsequent years following 
diagnosis are much lower than the first year and vary slightly over the years. 
The cost of inpatient hospital care was the major contributor to the total direct 
costs of treating epilepsy which suggests that better seizure control via 
appropriate evidence-based prescribing and adherence to medication may 
reduce the costs of epilepsy. High adherence rates to prescribed medicines have 
been associated with lower HRU and associated costs in other chronic diseases 
such as asthma 357 and diabetes 358.  




Using data in THIN, the total direct cost of treating children younger than 16 
years was suggested to be £23,019,040 in the year 2010. The annual cost per 
child is (£458  SD 1,633) in this study is lower than that reported for children 
and adults with type 1 diabetes (£1,323 per patient) and type 2 diabetes (£1,080 
per patient) in the UK for the year 2007 using THIN 359. The NHS estimates for 
asthma have reported the overall direct costs of treating all people with asthma 
in the UK in 2004; however, it did not include cost per patient or separate data 
for children 360.  
6.3 Implications for practice  
The pattern of AED use in this study supports the current evidence from clinical 
trials which have recommended old AEDs for the first-line treatment of epilepsy 
provided that they are tolerated by CYP. This was indicated by the more 
frequent prescribing of old AEDs over the study period, particularly sodium 
valproate and carbamazepine. However, the straight rise in prescribing of new 
AEDs suggests that they were tried as add-on therapies and to a lesser extent as 
alternatives to old AEDs. The trend of combining AEDs showed that 
monotherapy is favoured and effective in managing epilepsy in the majority of 
CYP. 
There was a rapid increase in prescribing of lamotrigine which may suggest that 
this drug shows favoured efficacy and/or tolerability as an adjunctive to old 
AEDs. Its use as a monotherapy was not high in this study. Two other 
REVHUYDWLRQDOVWXGLHVFRQGXFWHGXVLQJFKLOGUHQDQGDGXOWV¶ primary care data in 
the UK including one in 2012 support the current findings 118, 289.  
Although GPs record data and attach notes on what they think is important for 
the management of their patients, GPs need to consider better recording of 
initial and ongoing individual-specific information such as diagnostic subtypes 
of epilepsy and dose instructions especially those recommended in secondary 
care settings. More complete recording of longitudinal data for monitoring and 
prognosis of epilepsy in individual children, such as seizure frequency and 
remission periods should also be considered in general practice. These data will 
also help policy makers as it will enable researchers to assess the association 




between the current plan of management and the clinical outcomes and 
prognosis of epilepsy in CYP.   
This thesis demonstrated that adherence to medications in CYP with epilepsy is 
suboptimal. However, being adherent or non-adherent to prescribed medication 
is not a phenotype, but rather a dynamic process that may deteriorate over time 
and potential remission of seizures must also be taken into consideration. In 
chronic diseases like epilepsy, the motivation toward medication is likely to 
decrease, particularly in asymptomatic periods, and then it is the role GPs and 
clinicians to assess and monitor symptoms, outcomes and medication regimens 
with CYP and their parents over time.  In the case of CYP who demonstrate low 
adherence to medication, physicians need to invite CYP and their parents for 
medication review to assess whether they have had seizures for which they did 
not seek medical care, and if so, invest time to talk about the necessity of long-
term therapy and address any medication-related factors that may cause low 
adherence. Practitioners need to be encouraged to discuss whether those CYP 
chose not to adhere to their medicines or they could be managed on lower doses 
or should be taken off medicines because their conditions are well-controlled.  
6.4 Implications for pharmacists 
Pharmacists represent the junction between prescribers and patients so play an 
important role in improving medication use processes (prescribing, dispensing 
and advice on administration) and thereby clinical outcomes 361. By virtue of 
their expertise, pharmacists may exhibit a key role by distributing knowledge 
about epilepsy and the proper use of AEDs through informal contacts with CYP 
and their parents during dispensing of medicines 362. There should be increased 
awareness among pharmacists that adherence to AEDs is an issue particularly in 
infants and young children under 5 years and that medication adherence was 
found to be negatively associated with long duration of treatment. Pharmacists 
may then contribute to improving medication use by checking that 
parents/caregivers understand prescription instructions and by counselling about 
the necessity of long-term and persistent use of AEDs for better outcomes.  




In this study, multiple AEDs (polytherapy) were prescribed to CYP who 
experienced an increased level of seizure attacks. Pharmacists have an important 
role to play in this group of CYP. Further advice and support on medication can 
be provided during community based medicine management services such as 
the UK community pharmacy Medicine Use Review service 363 through 
reviewing appropriateness of AED prescribing. Pharmacists should work in 
collaboration with GPs to assist in preventing AED-related problems, improving 
CYP safety and increasing adherence to drugs 364.  A previous study 
investigated the association between pharmacist-managed AED therapy and the 
rate of hospitalisation of Medicare patients identified from 950 hospitals in the 
US 365. The authors reported that death rates were 121% higher (OR=1.55, 95% 
CI 1.10±2.19, p=0.01) in hospitals without pharmacist managed AED therapy.   
Pharmacists may choose to identity and follow-up CYP who do not present 
themselves at the pharmacy to collect their prescribed medications. Pharmacists 
may specifically target these CYP and invite them for a medication review in 
order to check whether they have remission of seizures. Pharmacists can also 
check whether these CYP are withdrawn from their medication by prescribers.  
The cost of AEDs is the second largest cost contributing to the total medical 
costs of epilepsy after the cost of hospital care. Pharmacists can assist in saving 
HRU by identifying trend of prescribing of AEDs for groups of CYP with 
epilepsy and giving advices about the unnecessary use of medicines. 
Pharmacists can then report to prescribers their findings and recommending 
changes to AED prescribing and thus aid in lowering complexity of AED 
regimens and improving clinical outcomes of epilepsy.




6.5 Implications for future research 
The findings of this study contribute to the validation of using the routinely 
collected general practice THIN database to explore the incidence and 
prevalence of epilepsy in CYP and the prescribing patterns of AEDs at the 
population level in the UK. Prescription records within THIN are considered to 
reflect the real-life clinical practice of managing epilepsy in primary care. 
Although this study presented an estimate of the long-term medication 
adherence of CYP that was comparable with previous findings, the 
methodology for adherence depended on the frequency of issued prescriptions 
and not the actual consumption of medicines. The size of the effect of the 
examined factors within THIN on adherence of CYP was small. In fact, THIN 
data was not able to capture many reasons for non-adherence. Therefore, 
qualitative or other patient level research is needed to explain the origin of 
variation in adherence and to consider the possible effects of other factors on 
adherence such as child-SK\VLFLDQVFRPPXQLFDWLRQDQG&<3DQGSDUHQWV¶
beliefs about AED treatment.   
The estimated long-term seizure outcomes according to what was recorded in 
general practices demonstrated variable degree of seizure remission among 
CYP. Further research is needed to assess routine updates from physicians and 
parents on seizure frequency and severity and to also address the association 
between adherence and clinical outcomes of epilepsy.  
The study estimated the direct costs associated with health resource utilisation 
in primary care and what was recorded in general practices as referrals to 
secondary care. It provides baseline data for further economic evaluations on the 
burden of epilepsy in CYP. Since the care of CYP with epilepsy is a 
collaboration between primary and secondary care settings, further research is 
needed to estimate epilepsy-related health resource utilisation in secondary care 
for CYP. This will enable a more comprehensive view of the associated costs of 
treating epilepsy to be available to health policy makers. The methods for 
estimating adherence and costs used in this thesis could also be valuable in 
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Appendix 1: International Classification of Epilepsies and 
Epileptic Syndromes (1989)   
1. Localization-related (focal, local, partial) epilepsies and syndromes 
1.1. Idiopathic with age-related onset 
A. Benign childhood epilepsy with centrotemporal spikes 
B. Childhood epilepsy with occipital paroxysms 
 
1.2. Symptomatic 
A. Chronic progressive epilepsia partialis continua of childhood 
B. Syndromes characterized by seizures with specific modes of precipitation 
C. Temporal lobe epilepsies 
D. Frontal lobe epilepsies 
E. Parietal lobe epilepsies 




2. Generalized epilepsies and syndromes 
2.1. Idiopathic, with age-related onset (listed in order of age) 
A. Benign neonatal familial convulsions 
B. Benign neonatal convulsions 
C. Benign myoclonic epilepsy in infancy 
D. Childhood absence epilepsy (pyknolepsy) 
E. Juvenile absence epilepsy 
F. Juvenile myoclonic epilepsy (impulsive petit mal) 
G. Epilepsy with grand mal seizures on awakening 
H. Other generalized idiopathic epilepsies not defined above 
I. Epilepsies with seizures precipitated by specific modes of activation 
 
2.2. Idiopathic and/or symptomatic (listed in order of age) 
A. West syndrome (infantile spasms) 
B. Lennox-Gastaut syndrome 
C. Epilepsy with myoclonic-astatic seizures 
D. Epilepsy with myoclonic absences 
 
2.3. Symptomatic 
A. Nonspecific aetiology 
a. Early myoclonic encephalopathy 
b. Early infantile epileptic encephalopathy with suppression burst 
c. Other symptomatic generalized epilepsies not defined above 
B. Specific etiology 
a. Epileptic seizures may complicate many disease states 
 
3. Epilepsies and syndromes undetermined as to whether they are focal or 
generalized 
3.1. With both generalized and focal seizures 
A. Neonatal seizures 





C. Epilepsy with continuous spike waves during slow-wave sleep 
D. Acquired epileptic aphasia (Landau-Kleffner syndrome) 
E. Other undetermined epilepsies not defined above 
 
3.2. Without unequivocal generalized or focal features 
4. Special syndromes 
4.1. Situation-related seizures 
A. Febrile convulsions 
B. Isolated, apparently unprovoked epileptic events 
C. Seizures related to other identifiable situations such as stress, hormonal changes, 





Appendix 2: International Classification of Epileptic Seizures 
(1981) 
I. Focal seizures (previously known as partial or local seizures) 
   A. Simple focal seizures  
       1. With motor signs  
          a. Focal motor without march  
          b. Focal motor with march (Jacksonian)  
          c. Versive  
          d. Postural  
          e. Phonatory 
      2. With somatosensory or special-sensory symptoms  
         a. Somatosensory  
         b. Visual  
         c. Auditory  
         d. Olfactory  
         e. Gustatory  
         f. Vertiginous 
     3. With autonomic symptoms or signs 
     4. With psychic symptoms  
         a. Dysphasia  
         b. Dysmnesic  
         c. Cognitive 
         d. Affective  
         e. Illusions  
         f. Structured hallucinations 
  B. Complex focal seizures  
      1. Simple focal seizures at onset, followed by impairment of consciousness  
         a. With simple focal features  
         b. With automatisms 
      2. With impairment of consciousness at onset  
         a. With impairment of consciousness only  
         b. With automatisms 
  C. Focal seizures evolving to secondarily generalized seizures  
II. Generalized seizures  
    A. Absence seizures  
        1. Typical absence seizures  
           a. Impairment of consciousness only  
           b. With mild clonic components  
           c. With atonic components  
           d. With tonic components  
           f. With autonomic components 
       2. Atypical absence seizures 
   B. Myoclonic seizures  
   C. Clonic seizures  
   D. Tonic seizures  
   E. Tonic-clonic seizures  





Appendix 3: Epilepsies typical of childhood 7, 18  
 




Epilepsy in Infancy 
(BMEI 
Brief bursts of 
generalized myoclonic 
seizures 
6 months -2 
years 
Easily controlled by 
appropriate treatment. 
Sodium valproate is the 
drug of choice 
Dravet Syndrome 
(Severe Myoclonic 
Epilepsy in Infancy) 
Prolonged tonic-clonic 
seizures. Myoclonic jerks 
appear secondary 
first year of 
life 
Very resistant to AEDs. 
Sodium valproate  and 
the benzodiazepines  are 








4 -7 months Steroids and vigabatrin 












seizures and atypical 
absences with clonic and 
tonic components 
7 months - 
6 years. 
 
Sodium valproate is the 








Multiple include: brief 
tonic, atonic, myoclonic 
and atypical absence 
seizures. 









Epilepsy (Petit mal, 
Pyknolepsy) 
Very frequent typical 
absence seizures 
4 -10 years Sodium valproate  is the 
drug of first choice. 











1 - 12 years Combination of Sodium 
valproate and 






Appendix 3: Continued  
 






The absences are more 
severe than in pyknolepsy 
associated with frequent 
generalized tonic-clonic 
seizures 










Bilateral, single or 
repetitive arrhythmic, 
irregular myoclonic jerks 
Around 
puberty 
Clonazepam is effective 
in combination. 
Lamotrigine added to 
sodium valproate 
effective in resistant 
cases. 
 
Rolandic epilepsy Mixed simple partial 
(motor) and complex 
partial seizures. 
3 - 13 years It is usually resolves by 
age of 14 years. Drug of 







Mainly, motor focal 
seizures but are often 
associated with other 
seizure types. 
2 - 10 years AEDs are not effective. 
Hemispheric 
disconnection surgery is 







Appendix 4: Common side effects of antiepileptic drugs 
3, 78, 271
 
Drug Side effects 
Carbamazepine Headache, ataxia, transient leukopenia, thrombocytopaenia, 
agranulocytosis, hyponatraemia, rare aplastic anaemia and 
Hepatitis 
 
Ethosuximide Nausea, anorexia, headache; blood dyscrasias and gingival 
hypertrophy 
Gabapentin Side effects less common; diarrhoea, dry mouth, dyspepsia, not 
associated with end-organ toxicity 
Lamotrigine Rash in 1:1000 overall, about 1:50 in children, especially with 
rapid titration and with valproate; headache and hepatic 
dysfunction.  
 
Levetiracetam Few idiosyncratic side effects; Nausea, vomiting and dyspepsia 
Oxcarbazepine Side effects less frequent than with carbamazepine; 
hyponatraemia common; no auto-induction to liver microsomal 
enzymes.  
 
Phenobarbital Sedation, paradoxical hyperactivity in children, hepatitis, 
possible learning difficulties and mental retardation, depression, 
osteomalacia, rare but serious Stevens±Johnson syndrome 
 
Phenytoin Gum hyperplasia, hirsutism, dose-related nystagmus and 
cerebellar ataxia; peripheral neuropathy, folate deficiency; rare 
hypersensitivity hepatitis 
Primidone Less sedating than phenobarbital in some patients; macrocytic 
anaemia 
 
Sodium valproate  Rare but life-threatening idiosyncratic hepatitis and 
pancreatitis; tremors, weight gain, alopecia, thrombocytopenia, 
benign elevation of liver function tests common; transient her 
loss. 
Tiagabine Not associated with end-organ toxicity; may precipitate non-
convulsive status in patients with generalized epilepsy 
Topiramate Cognitive impairment common above 400 mg/d; rare kidney 
stones (1%); rare glaucoma and cognitive side effects.  
 
Vigabatrin  Drowsiness, fatigue, visual field defects and behavioural effects 
such as excitation and agitation.  
Zonisamide Kidney stones (1%); impaired sweating in children; rare rash 







Appendix 5: The 2004 NICE guidance for the choice of AEDs by 
seizure type 1 










































































































a: Hepatic enzyme-inducing AED. 
b: Should be used as a first choice under circumstances as outlined in the NICE 
technology appraisal of newer AEDs1  
c: Should rarely be initiated ± if a barbiturate is required, phenobarbital is preferred. 





Appendix 6: The 2004 NICE guidance  for the choice of AEDs by 
epilepsy syndrome 1 
Epilepsy 
syndrome 
First-line drugs Second-line 
drugs 
Other drugs that 
may be 
considered 







































































































































































































a: Hepatic enzyme-inducing AED. 
b: Should be used as a first choice under circumstances as outlined in the NICE 
technology appraisal of newer AEDs 1. 
c: Should rarely be initiated ± if a barbiturate is required, phenobarbital is 
preferred. 
d: Steroids: prednisolone or ACTH (adrenocorticotrophic hormone). 






Appendix 7: Search methods for identification of adherence 
studies for CYP (EMBASE, MEDLINE and PsycINFO)  
# Key word(s) Results 
1 compliance.mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, nm, tc, id] 
287094 
2 patient compliance.mp. [mp=ti, ab, sh, hw, tn, 
ot, dm, mf, nm, tc, id] 
134829 
3 medication compliance.mp. [mp=ti, ab, sh, 
hw, tn, ot, dm, mf, nm, tc, id] 
12039 
4 noncompliance.mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id] 
169956 
5 adherence.mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, nm, tc, id] 
70102 
6 drug adherence.mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id] 
674 
7 patient adherence.mp. [mp=ti, ab, sh, hw, tn, 
ot, dm, mf, nm, tc, id] 
4105 
8 nonadherence.mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id] 
6011 
9 medication adherence.mp. [mp=ti, ab, sh, hw, 
tn, ot, dm, mf, nm, tc, id] 
11855 
10 drug misuse.mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id]  
6052 
11 drug therapy.mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id] 
568100 
12 6 or 11 or 3 or 7 or 9 or 2 or 8 or 1 or 4 or 10 
or 5 
976460 
13 child$.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
4074746 
14 pediatric.mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, nm, tc, id, tw] 
368699 
15 girl$.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
100902 
16 boy$.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
104158 
17 young people.mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id, tw] 
44769 
18 youth$.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
108755 





dm, mf, nm, tc, id, tw] 
20 parent.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
332022 
21 parents.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
345960 
22 father.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
64694 
23 mother.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
249170 
24 family.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
1554267 
25 family therapy.mp[mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id, tw] 
39706 
26 caregivers.mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, nm, tc, id, tw] 
81096 
27 intervention.mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id, tw] 
794144 
28 improve.mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, nm, tc, id, tw] 
887712 
29 treatment outcomes.mp. [mp=ti, ab, sh, hw, 
tn, ot, dm, mf, nm, tc, id, tw] 
43599 
30 social support.mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id, tw] 
146769 
31 educational intervention.mp. [mp=ti, ab, sh, 
hw, tn, ot, dm, mf, nm, tc, id, tw] 
7807 
32 health beliefs.mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id, tw] 
5684 
33 health care profession$.mp. [mp=ti, ab, sh, 
hw, tn, ot, dm, mf, nm, tc, id, tw] 
33005 
34 medication routine.mp. [mp=ti, ab, sh, hw, tn, 
ot, dm, mf, nm, tc, id, tw] 
42 
35 self efficacy.mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id, tw] 
49486 
36 transition.mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, nm, tc, id, tw] 
363831 
37 drug cost.mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, nm, tc, id, tw] 
53051 
38 school.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
830214 
39 preschool.mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, nm, tc, id, tw] 
1214533 





dm, mf, nm, tc, id, tw] 
41 students.mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, nm, tc, id, tw] 
726963 
42 epilep$.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
287852 
43 seizure.mp. [mp=ti, ab, sh, hw, tn, ot, dm, mf, 
nm, tc, id, tw] 
169152 
44 convulsion.mp. [mp=ti, ab, sh, hw, tn, ot, dm, 
mf, nm, tc, id, tw] 
31408 
45 antiepilept$.mp. [mp=ti, ab, sh, hw, tn, ot, 
dm, mf, nm, tc, id, tw] 
40982 
46 18 or 19 or 16 or 13 or 17 or 15 or 14 5708978 
47 25 or 22 or 21 or 24 or 26 or 23 or 20 2208107 
48 35 or 27 or 33 or 32 or 28 or 34 or 37 or 30 or 
29 or 31 
1883590 
49 38 or 39 or 40 or 36 or 41 2765331 
50 42 or 45 or 43 or 44 405190 
51 46 and 12 and 48 and 47 5841 
54 50 and 51 133 
52 limit 51 to English language 117 






Appendix 8: Code list for diagnosis of epilepsy and epilepsy 
syndromes 
Medical code Medical description within the database 
1473.00 H/O: epilepsy 
1O30.00 Epilepsy confirmed 
2126000 Epilepsy resolved 
212J.00 Epilepsy resolved 
667..00 Epilepsy monitoring 
6671.00 Initial epilepsy assessment 
6672.00 Follow-up epilepsy assessment 
6674.00 Epilepsy associated problems 
6677.00 Epilepsy drug side effects 
6678.00 Epilepsy treatment changed 
6679.00 Epilepsy treatment started 
667A.00 Epilepsy treatment stopped 
667B.00 Nocturnal epilepsy 
667C.00 Epilepsy control good 
667D.00 Epilepsy control poor 
667G.00 Epilepsy restricts employment 
667H.00 Epilepsy prevents employment 
667J.00 Epilepsy impairs education 
667K.00 Epilepsy limits activities 
667L.00 Epilepsy does not limit activities 
667M.00 Epilepsy management plan given 
667N.00 Epilepsy severity 
667W.00 Emergency epilepsy treatment since last appointment 
667X.00 No epilepsy drug side effects 
667Z.00 Epilepsy monitoring NOS 
8BIF.00 Epilepsy medication review 
9Of3.00 Epilepsy monitoring verbal invite 
9Of4.00 Epilepsy monitoring telephone invite 
F132100 Progressive myoclonic epilepsy 
F132200 Myoclonic encephalopathy 
F25..00 Epilepsy 
F250.00 Generalised nonconvulsive epilepsy 
F250000 Petit mal (minor) epilepsy 
F250011 Epileptic absences 
F250100 Pykno-epilepsy 
F250200 Epileptic seizures - atonic 
F250300 Epileptic seizures - akinetic 
F250400 Juvenile absence epilepsy 
F250500 Lennox-Gastaut syndrome 
F250y00 Other specified generalised nonconvulsive epilepsy 





F251.00 Generalised convulsive epilepsy 
F251000 Grand mal (major) epilepsy 
F251011 Tonic-clonic epilepsy 
F251100 Neonatal myoclonic epilepsy 
F251111 Otohara syndrome 
F251200 Epileptic seizures - clonic 
F251300 Epileptic seizures - myoclonic 
F251400 Epileptic seizures - tonic 
F251500 Tonic-clonic epilepsy 
F251y00 Other specified generalised convulsive epilepsy 
F251z00 Generalised convulsive epilepsy NOS 
F254.00 Partial epilepsy with impairment of consciousness 
F254000 Temporal lobe epilepsy 
F254100 Psychomotor epilepsy 
F254200 Psychosensory epilepsy 
F254300 Limbic system epilepsy 
F254500 Complex partial epileptic seizure 
F254z00 Partial epilepsy with impairment of consciousness NOS 
F255.00 Partial epilepsy without impairment of consciousness 
F255000 Jacksonian, focal or motor epilepsy 
F255011 Focal epilepsy 
F255012 Motor epilepsy 
F255100 Sensory induced epilepsy 
F255200 Somatosensory epilepsy 
F255300 Visceral reflex epilepsy 
F255311 Partial epilepsy with autonomic symptoms 
F255400 Visual reflex epilepsy 
F255500 Unilateral epilepsy 
F255600 Simple partial epileptic seizure 
F255y00 Partial epilepsy without impairment of consciousness OS 
F255z00 Partial epilepsy without impairment of consciousness NOS 
F256.00 Infantile spasms 
F256.12 West syndrome 
F256100 Salaam attacks 
F256z00 Infantile spasms NOS 
F257.00 Kojevnikov's epilepsy 
F259.00 Early infant epileptic encephalopathy with suppression bursts 
F259.11 Ohtahara syndrome 
F25A.00 Juvenile myoclonic epilepsy 
F25B.00 Alcohol-induced epilepsy 
F25C.00 Drug-induced epilepsy 
F25D.00 Menstrual epilepsy 
F25E.00 Stress-induced epilepsy 
F25F.00 Photosensitive epilepsy 
F25y.00 Other forms of epilepsy 





F25y100 Gelastic epilepsy 
F25y200 Locl-rlt(foc)(part)idiop epilep&epilptic syn seiz locl onset 
F25y400 Benign Rolandic epilepsy 
F25y500 Panayiotopoulos syndrome 
F25yz00 Other forms of epilepsy NOS 
F25z.00 Epilepsy NOS 
F25z.11 Fit (in known epileptic) NOS 
Fyu5000 [X]Other generalized epilepsy and epileptic syndromes 
Fyu5100 [X]Other epilepsy 
SC20000 Traumatic epilepsy 
AHD code Description 
1009200000 Epilepsy check - Fit Details 
1009250000 Epilepsy check - DVLC Informed 







Appendix 9: Code list of licensed AEDs until 2004 
Multilex 
code BNF code Generic name 
93530998 04.08.01.00 CARBAMAZEPINE chewable tab 100mg 
93530997 04.08.01.00 CARBAMAZEPINE chewable tab 200mg 
96885998 04.08.01.00 CARBAMAZEPINE liq 100mg/5ml 
98360998 04.08.01.00 CARBAMAZEPINE liq 100mg/5ml 
88217998 04.08.01.00 CARBAMAZEPINE mr tab 200mg 
88217997 04.08.01.00 CARBAMAZEPINE mr tab 400mg 
84311998 04.07.03.00 CARBAMAZEPINE oral susp 500mg/5ml 
92734998 04.08.01.00 CARBAMAZEPINE supp 125mg 
92734997 04.08.01.00 CARBAMAZEPINE supp 250mg 
92837998 04.08.01.00 CARBAMAZEPINE tabs 100mg 
92837997 04.08.01.00 CARBAMAZEPINE tabs 200mg 
92837996 04.08.01.00 CARBAMAZEPINE tabs 400mg 
97158992 04.08.01.00 CLOBAZAM 1 MG SUS 
97159992 04.08.01.00 CLOBAZAM 2.5 MG CAP 
97161992 04.08.01.00 CLOBAZAM 5 MG CAP 
96160992 04.08.01.00 CLOBAZAM 5 MG TAB 
97160992 04.08.01.00 CLOBAZAM 7.5 MG CAP 
96648998 04.08.01.00 CLOBAZAM caps 10mg 
82714998 04.08.01.15 CLOBAZAM oral susp 25mg/5ml 
93529990 04.08.01.00 CLOBAZAM tabs 10mg 
96634996 04.08.02.00 CLONAZEPAM conc soln inj 1mg/1ml 
88422998 04.08.01.15 CLONAZEPAM oral drops 2.5mg/ml 
85559998 04.08.01.15 CLONAZEPAM oral soln 250micrograms/5ml 
88423996 04.08.01.00 CLONAZEPAM sf oral soln 2mg/5ml 
86604998 04.08.01.00 CLONAZEPAM sf soln 500micrograms/5ml 
88423997 04.08.01.00 CLONAZEPAM susp 500micrograms/5ml 
92356990 04.08.01.00 CLONAZEPAM tabs 2mg 
92357990 04.08.01.00 CLONAZEPAM tabs 500 micrograms 
97292992 04.08.02.00 DIAZEPAM RECTAL 2 MG/ML SOL 
97291992 04.08.02.00 DIAZEPAM RECTAL 4 MG SOL 
89501998 04.08.02.00 DIAZEPAM rectal tubes 10mg 
96407996 04.08.02.00 DIAZEPAM rectal tubes 2.5mg 
91354998 04.08.02.00 DIAZEPAM rectal tubes 20mg 
94665990 04.08.02.00 DIAZEPAM rectal tubes 5mg 
92901998 04.01.02.00 DIAZEPAM supp 10mg 
96408998 04.01.02.00 DIAZEPAM supp 5mg 
86109998 04.08.01.00 ETHOSUXIMIDE caps 250mg 
85954998 04.08.01.00 ETHOSUXIMIDE syrp 250mg/5ml 
89991998 04.08.01.00 FOSPHENYTOIN SODIUM conc soln inf 750mg/10ml 





92872990 04.08.01.00 GABAPENTIN caps 100mg 
92871990 04.08.01.00 GABAPENTIN caps 300mg 
92870990 04.08.01.00 GABAPENTIN caps 400mg 
93743990 04.08.01.03 GABAPENTIN oral soln 250mg/5ml 
90426998 04.08.01.00 GABAPENTIN tabs 600mg 
90426997 04.08.01.00 GABAPENTIN tabs 800mg 
85379998 04.08.01.05 LAMOTRIGINE (IPU) disp tab 200mg 
92700996 04.08.01.00 LAMOTRIGINE disp tab 100mg 
92700997 04.08.01.00 LAMOTRIGINE disp tab 25mg 
91465997 04.08.01.00 LAMOTRIGINE disp tab 2mg 
86019998 04.08.01.00 LAMOTRIGINE disp tab 50mg 
92700998 04.08.01.00 LAMOTRIGINE disp tab 5mg 
84903998 04.08.01.05 LAMOTRIGINE oral liq 
93491990 04.08.01.00 LAMOTRIGINE tabs 100mg 
91465998 04.08.01.00 LAMOTRIGINE tabs 200mg 
93493990 04.08.01.00 LAMOTRIGINE tabs 25mg 
93492990 04.08.01.00 LAMOTRIGINE tabs 50mg 
85968998 04.08.01.00 LEVETIRACETAM conc soln inf 500mg/5ml 
84953998 04.08.01.00 LEVETIRACETAM oral liq 
87195998 04.08.01.00 LEVETIRACETAM oral soln 100mg/ml 
89210996 04.08.01.00 LEVETIRACETAM tabs 1000mg 
89210998 04.08.01.00 LEVETIRACETAM tabs 250mg 
89210997 04.08.01.00 LEVETIRACETAM tabs 500mg 
87194998 04.08.01.00 LEVETIRACETAM tabs 750mg 
83946998 04.08.01.00 OXCARBAZEPINE oral liq 
91218998 04.08.01.00 OXCARBAZEPINE sf oral susp 60mg/ml 
91625998 04.08.01.00 OXCARBAZEPINE tabs 150mg 
91625997 04.08.01.00 OXCARBAZEPINE tabs 300mg 
89231998 04.08.01.00 OXCARBAZEPINE tabs 600mg 
97081998 04.08.02.00 PARALDEHYDE IM inj 
98091998 04.08.02.00 PARALDEHYDE IV inj 
98091997 04.08.02.00 PARALDEHYDE rectal soln 
93454998 04.08.01.00 PHENOBARBITAL SODIUM inj 15mg/1ml 
95553998 04.08.01.00 PHENOBARBITAL SODIUM inj 200mg/1ml 
93454997 04.08.01.00 PHENOBARBITAL SODIUM inj 30mg/1ml 
93454996 04.08.01.00 PHENOBARBITAL SODIUM inj 60mg/1ml 
97080998 04.08.01.00 PHENOBARBITAL SODIUM tabs 30mg 
97080997 04.08.01.00 PHENOBARBITAL SODIUM tabs 60mg 
98087998 04.08.01.00 PHENOBARBITAL elixir 15mg/5ml 
98087997 04.08.01.07 PHENOBARBITAL oral soln 50mg/5ml 
82052998 04.08.01.07 PHENOBARBITAL oral soln 75mg/5ml 
96866990 04.08.01.00 PHENOBARBITAL tabs 100mg 
97103990 04.08.01.00 PHENOBARBITAL tabs 15mg 





97203996 04.08.01.00 PHENOBARBITAL tabs 60mg 
93404992 04.08.01.00 PHENOBARBITONE 10 MG TAB 
94282992 04.08.01.00 PHENOBARBITONE 15 MG CAP 
95418992 04.08.01.00 PHENOBARBITONE 20 MG TAB 
94279992 04.08.01.00 PHENOBARBITONE 22.5 MG TAB 
94521992 04.08.01.00 PHENOBARBITONE 30 MG CAP 
94285992 04.08.01.00 PHENOBARBITONE 50 MG CAP 
95421992 04.08.01.00 PHENOBARBITONE 50 MG TAB 
94284992 04.08.01.00 PHENOBARBITONE 7.5 MG TAB 
94520992 04.08.01.00 PHENOBARBITONE 75 MG SUP 
94278992 04.08.01.00 PHENOBARBITONE S/R 100 MG CAP 
90904998 04.08.01.07 PHENYTOIN + PHENOBARBITAL caps 100mg + 50mg 
99694998 04.08.01.07 PHENYTOIN + PHENOBARBITAL caps 100mg + 50mg 
94288992 04.08.01.00 PHENYTOIN 150 MG SUS 
94525992 04.08.01.00 PHENYTOIN 25 MG SYR 
97897992 04.08.01.00 PHENYTOIN 30 MG TAB 
90780996 04.08.01.00 PHENYTOIN SODIUM caps 100mg 
90780998 04.08.01.00 PHENYTOIN SODIUM caps 25mg 
90776998 04.08.01.00 PHENYTOIN SODIUM caps 300mg 
90780997 04.08.01.00 PHENYTOIN SODIUM caps 50mg 
92701990 04.08.02.00 PHENYTOIN SODIUM inj 250mg/5ml 
92614990 04.08.01.00 PHENYTOIN SODIUM tabs 100mg 
97140990 04.08.01.00 PHENYTOIN SODIUM tabs 50mg 
97896992 04.08.01.00 PHENYTOIN SODIUM/ PHENOBARBITONE CAP 
95838992 04.08.01.00 PHENYTOIN SODIUM/ PHENOBARBITONE SODIUM TAB 
95532998 04.08.01.00 PHENYTOIN caps 100mg 
95533997 04.08.01.00 PHENYTOIN caps 25mg 
95532996 04.08.01.00 PHENYTOIN caps 300mg 
95533996 04.08.01.00 PHENYTOIN caps 50mg 
95533998 04.08.01.00 PHENYTOIN paed tab 50mg 
92812998 04.08.01.00 PHENYTOIN sf susp 90mg/5ml 
95532997 04.08.01.00 PHENYTOIN susp 30mg/5ml 
87398998 04.08.01.00 PREGABALIN caps 100mg 
87397998 04.08.01.00 PREGABALIN caps 150mg 
87396998 04.08.01.00 PREGABALIN caps 200mg 
84233998 04.08.01.00 PREGABALIN caps 225mg 
87401998 04.08.01.00 PREGABALIN caps 25mg 
87395998 04.08.01.00 PREGABALIN caps 300mg 
87400998 04.08.01.00 PREGABALIN caps 50mg 
87399998 04.08.01.00 PREGABALIN caps 75mg 
97949992 04.08.01.00 PRIMIDONE 200 MG TAB 
85534998 04.08.01.07 PRIMIDONE caps 
95403997 04.08.01.00 PRIMIDONE oral susp 250mg/5ml 





83790998 04.08.01.00 SODIUM VALPROATE + VALPROIC ACID MR granules 
1000mg 
83793998 04.08.01.00 SODIUM VALPROATE + VALPROIC ACID MR granules 250mg 
83792998 04.08.01.12 SODIUM VALPROATE + VALPROIC ACID MR granules 500mg 
83791998 04.08.01.00 SODIUM VALPROATE + VALPROIC ACID MR granules 750mg 
92917998 04.08.01.00 SODIUM VALPROATE + VALPROIC ACID mr tab 200mg 
92917997 04.08.01.00 SODIUM VALPROATE + VALPROIC ACID mr tab 300mg 
92917996 04.08.01.00 SODIUM VALPROATE + VALPROIC ACID mr tab 500mg 
82857998 04.08.01.00 SODIUM VALPROATE MR granules 1000mg 
81956998 04.08.01.00 SODIUM VALPROATE MR granules 100mg 
81955998 04.08.01.00 SODIUM VALPROATE MR granules 250mg 
83705998 04.08.01.00 SODIUM VALPROATE MR granules 500mg 
81957998 04.08.01.00 SODIUM VALPROATE MR granules 50mg 
81954998 04.08.01.00 SODIUM VALPROATE MR granules 750mg 
94409996 04.08.01.00 SODIUM VALPROATE crushable tab 100mg 
83480998 04.08.01.00 SODIUM VALPROATE ec tab 200mg 
83479998 04.08.01.00 SODIUM VALPROATE ec tab 500mg 
84088998 04.08.01.00 SODIUM VALPROATE inj 1000mg/10ml 
85029998 04.08.01.00 SODIUM VALPROATE inj 300mg/3ml 
84667998 04.08.01.00 SODIUM VALPROATE mr cap 150mg 
84666998 04.08.01.00 SODIUM VALPROATE mr cap 300mg 
83321998 04.08.01.00 SODIUM VALPROATE mr tab 200mg 
88177998 04.08.01.00 SODIUM VALPROATE mr tab 300mg 
88178998 04.08.01.00 SODIUM VALPROATE mr tab 500mg 
93148998 04.08.01.00 SODIUM VALPROATE pwdr/inj.soln 400mg 
92802996 04.08.01.00 SODIUM VALPROATE sf liq 200mg/5ml 
89408997 04.08.01.00 TIAGABINE tabs 10mg 
89408996 04.08.01.00 TIAGABINE tabs 15mg 
89408998 04.08.01.00 TIAGABINE tabs 5mg 
88868998 04.08.01.00 TOPIRAMATE caps 15mg 
88868997 04.08.01.00 TOPIRAMATE caps 25mg 
88396998 04.08.01.00 TOPIRAMATE caps 50mg 
91050997 04.08.01.00 TOPIRAMATE tabs 100mg 
91050996 04.08.01.00 TOPIRAMATE tabs 200mg 
91044998 04.08.01.00 TOPIRAMATE tabs 25mg 
91050998 04.08.01.00 TOPIRAMATE tabs 50mg 
94068998 04.08.01.00 VALPROIC ACID (AS SEMISODIUM SALT) ec tab 250mg 
94068997 04.08.01.00 VALPROIC ACID (AS SEMISODIUM SALT) ec tab 500mg 
93015998 04.08.01.00 VALPROIC ACID ec soft gelatin ca 150mg 
93015997 04.08.01.00 VALPROIC ACID ec soft gelatin ca 300mg 
93015996 04.08.01.00 VALPROIC ACID ec soft gelatin ca 500mg 
93770996 04.08.01.13 VIGABATRIN caps 125mg 
93769997 04.08.01.00 VIGABATRIN sf pwdr 500mg 






Appendix 10: The International Statistical Classification of 
Diseases and Related Health Problems-10th Revision-2007 
Chapter VI: Diseases of the nervous system (G00-G99)  





Excludes:  Landau-Kleffner syndrome ( F80.3 )  
seizure (convulsive) NOS ( R56.8 )  
status epilepticus ( G41.- )  
Todd's paralysis ( G83.8 )  
G40.0  
 
Localization-related (focal)(partial) idiopathic epilepsy and epileptic 
syndromes with seizures of localized onset  
  
Benign childhood epilepsy with centrotemporal EEG spikes  
Childhood epilepsy with occipital EEG paroxysms  
G40.1  
 
Localization-related (focal)(partial) symptomatic epilepsy and epileptic 
syndromes with simple partial seizures  
  
Attacks without alteration of consciousness  
Simple partial seizures developing into secondarily generalized seizures  
G40.2  
 
Localization-related (focal)(partial) symptomatic epilepsy and epileptic 
syndromes with complex partial seizures  
  
Attacks with alteration of consciousness, often with automatisms  
Complex partial seizures developing into secondarily generalized seizures  
G40.3  
 
Generalized idiopathic epilepsy and epileptic syndromes  
  
Benign:  
·  myoclonic epilepsy in infancy  
·  neonatal convulsions (familial)  
Childhood absence epilepsy [pyknolepsy]  
Epilepsy with grand mal seizures on awakening  
Juvenile:  
·  absence epilepsy  
·  myoclonic epilepsy [impulsive petit mal]  
Nonspecific epileptic seizures:  
·  atonic  
·  clonic  
·  myoclonic  
·  tonic  
·  tonic-clonic  
G40.4  
 
Other generalized epilepsy and epileptic syndromes  
  
Epilepsy with:  
·  myoclonic absences  
·  myoclonic-astatic seizures  
Infantile spasms  
Lennox-Gastaut syndrome  
Salaam attacks  
Symptomatic early myoclonic encephalopathy  
West's syndrome  
G40.5  
 
Special epileptic syndromes  
  





Epileptic seizures related to:  
·  alcohol  
·  drugs  
·  hormonal changes  
·  sleep deprivation  
·  stress  
G40.6  
 
Grand mal seizures, unspecified (with or without petit mal)  
G40.7  
 
Petit mal, unspecified, without grand mal seizures  
G40.8  
 
Other epilepsy  
  




Epilepsy, unspecified  
  
Epileptic:  
·  convulsions NOS  
·  fits NOS  
·  seizures NOS  
G41   Status epilepticus  
G41.0   Grand mal status epilepticus  
  
Tonic-clonic status epilepticus  
 
Excludes:  epilepsia partialis continua [Kozhevnikof] ( G40.5 )  
G41.1  Petit mal status epilepticus  
 
Epileptic absence status  
G41.2  Complex partial status epilepticus  
G41.8  Other status epilepticus  






Appendix 11: Code list of seizures and epilepsy symptoms  
Medical codes Description 
1B63.11 Fit - had one, symptom 
1B64.00 Had a convulsion 
1B64.11 Convulsion - symptom 
282..00 O/E - fit/convulsion 
282..11 O/E - a convulsion 
282..12 O/E - a fit 
282..13 O/E - a seizure 
2822.00 O/E - grand mal fit 
2823.00 O/E - petit mal fit 
2824.00 O/E - focal (Jacksonian) fit 
2824.11 O/E - Jacksonian fit 
2824.12 O/E - focal fit 
2825.00 O/E - psychomotor fit 
2828.00 Absence seizure 
282Z.00 O/E - fit/convulsion NOS 
6676.00 Last fit 
667Q.00 Had a fit 
667R.00 Had a fit 
667T.00 Daily seizures 
F132z12 Myoclonic seizure 
F250200 Epileptic seizures - atonic 
F250300 Epileptic seizures - akinetic 
F251200 Epileptic seizures - clonic 
F251300 Epileptic seizures - myoclonic 
F251400 Epileptic seizures - tonic 
F251600 Grand mal seizure 
F252.00 Petit mal status 
F253.00 Grand mal status 
F253.11 Status epilepticus 
F254500 Complex partial epileptic seizure 
F255600 Simple partial epileptic seizure 
F256.00 Infantile spasms 
F256z00 Infantile spasms NOS 
F25X.00 Status epilepticus, unspecified 
F25z.11 Fit (in known epileptic) NOS 
Q480.00 Convulsions in newborn 
Q480.11 Fits in newborn 
Q480.12 Seizures in newborn 
R003.00 [D]Convulsions 
R003100 [D]Convulsions, infantile 
R003200 [D]Fit 
R003400 [D]Nocturnal seizure 
R003y00 [D]Other specified convulsion 
R003z00 [D]Convulsion NOS 






Appendix 12: Diagnostic terms of epilepsy and epilepsy 
subtypes 
Read codes of the database Assigned epilepsy subtype 
Benign Rolandic epilepsy Benign Rolandic epilepsy  
Complex partial epileptic seizure Complex focal epilepsy 
Early infant epileptic encephalopathy  Early infant epileptic encephalopathy 
Epilepsy Epilepsy (unspecified)  
Epilepsy NOS Epilepsy (unspecified ) 
Epilepsy associated problems Epilepsy (unspecified ) 
Epilepsy check - Fit Details Epilepsy (unspecified ) 
Epilepsy confirmed Epilepsy (unspecified ) 
Epilepsy control good Epilepsy (unspecified ) 
Epilepsy control poor Epilepsy (unspecified ) 
Epilepsy drug side effects Epilepsy (unspecified ) 
Epilepsy medication review Epilepsy (unspecified ) 
Epilepsy monitoring Epilepsy (unspecified ) 
Epilepsy monitoring NOS Epilepsy (unspecified ) 
Epilepsy resolved Epilepsy (unspecified ) 
Epilepsy treatment changed Epilepsy (unspecified ) 
Epilepsy treatment started Epilepsy (unspecified ) 
Epileptic absences Generalised epilepsy -absence seizures 
Epileptic seizures - akinetic Generalised epilepsy -atonic seizures 
Epileptic seizures - atonic Generalised epilepsy -atonic seizures 
Epileptic seizures - clonic Generalised epilepsy -clonic seizures 
Epileptic seizures - myoclonic Generalised epilepsy -myclonic seizures 
Epileptic seizures - tonic Generalised epilepsy -tonic seizures 
Fit (in known epileptic) NOS Epilepsy (unspecified ) 
Focal epilepsy Focal epilepsy  
Follow-up epilepsy assessment Epilepsy (unspecified ) 
Generalised convulsive epilepsy Generalised epilepsy 
Generalised nonconvulsive epilepsy Generalised epilepsy -absence seizures 
Generalised nonconvulsive epilepsy NOS Epileptic absences 
Grand mal (major) epilepsy 
Generalised epilepsy-tonic-clonic 
seizures 
H/O: epilepsy Epilepsy (unspecified ) 
Infantile spasms West syndrome 
Infantile spasms NOS West syndrome 
Initial epilepsy assessment Epilepsy (unspecified )  
Jacksonian, focal or motor epilepsy Focal epilepsy 
Juvenile absence epilepsy Juvenile absence epilepsy 
Juvenile myoclonic epilepsy Juvenile myoclonic epilepsy 
Locl-rlt(foc)(part)idiop epilep&epilptic Focal epilepsy  
Myoclonic encephalopathy Myoclonic encephalopathy  
Neonatal myoclonic epilepsy Neonatal myoclonic epilepsy 





Other forms of epilepsy Epilepsy (unspecified ) 
Other forms of epilepsy NOS Epilepsy (unspecified )  
Otohara syndrome Early infant epileptic encephalopathy  
Partial epilepsy with impairment of 
consciousness  
Complex focal epilepsy 
Partial epilepsy without impairment of 
consciousness  
Focal epilepsy 
Petit mal (minor) epilepsy Generalised epilepsy -absence seizures 
Progressive myoclonic epilepsy Progressive myoclonic epilepsy  
Salaam attacks West syndrome  
Temporal lobe epilepsy Focal epilepsy 
Tonic-clonic epilepsy Generalised epilepsy-tonic-clonic 
seizures 
Traumatic epilepsy Epilepsy (unspecified )  












Eu41.00 [X]Other anxiety disorders  Anxiety disorder 
Eu41100 [X]Generalized anxiety disorder  Anxiety disorder 
Eu41111 [X]Anxiety neurosis  Anxiety disorder 
Eu41112 [X]Anxiety reaction  Anxiety disorder 
Eu41113 [X]Anxiety state  Anxiety disorder 
Eu41200 [X]Mixed anxiety and depressive disorder  Anxiety disorder 
Eu41211 [X]Mild anxiety depression  Anxiety disorder 
Eu41300 [X]Other mixed anxiety disorders  Anxiety disorder 
Eu41y00 [X]Other specified anxiety disorders  Anxiety disorder 
Eu41y11 [X]Anxiety hysteria  Anxiety disorder 
Eu41z00 [X]Anxiety disorder, unspecified  Anxiety disorder 
Eu41z11 [X]Anxiety NOS  Anxiety disorder 
Eu43012 [X]Acute reaction to stress  Anxiety disorder 
E200.00 Anxiety states  Anxiety disorders 
E200000 Anxiety state unspecified  Anxiety disorders 
E200100 Panic disorder  Anxiety disorders 
E200111 Panic attack  Anxiety disorders 
E200200 Generalised anxiety disorder  Anxiety disorders 
E200300 Anxiety with depression  Anxiety disorders 
E200400 Chronic anxiety  Anxiety disorders 
E200500 Recurrent anxiety  Anxiety disorders 
E200z00 Anxiety state NOS  Anxiety disorders 
Eu40.00 [X]Phobic anxiety disorders  Anxiety/phobic disorders 
Eu40000 [X]Agoraphobia  Anxiety/phobic disorders 
Eu40011 
[X]Agoraphobia without history of panic 
disorder  Anxiety/phobic disorders 
Eu40012 [X]Panic disorder with agoraphobia  Anxiety/phobic disorders 
Eu40100 [X]Social phobias  Anxiety/phobic disorders 
Eu40111 [X]Anthropophobia  Anxiety/phobic disorders 
Eu40112 [X]Social neurosis  Anxiety/phobic disorders 
Eu40200 [X]Specific (isolated) phobias  Anxiety/phobic disorders 
Eu40211 [X]Acrophobia  Anxiety/phobic disorders 
Eu40212 [X]Animal phobias  Anxiety/phobic disorders 
Eu40213 [X]Claustrophobia  Anxiety/phobic disorders 
Eu40214 [X]Simple phobia  Anxiety/phobic disorders 
Eu40300 [X]Needle phobia  Anxiety/phobic disorders 
Eu40y00 [X]Other phobic anxiety disorders  Anxiety/phobic disorders 
Eu40z00 [X]Phobic anxiety disorder, unspecified  Anxiety/phobic disorders 
Eu40z11 [X]Phobia NOS  Anxiety/phobic disorders 
Eu40z12 [X]Phobic state NOS  Anxiety/phobic disorders 





E202.11 Social phobic disorders  Anxiety/phobic disorders 
E202.12 Phobic anxiety  Anxiety/phobic disorders 
E202000 Phobia unspecified  Anxiety/phobic disorders 
E202100 Agoraphobia with panic attacks  Anxiety/phobic disorders 
E202200 Agoraphobia without mention of panic attc  Anxiety/phobic disorders 
E202300 Social phobia, fear of eating in public  Anxiety/phobic disorders 
E202400 Social phobia, fear of public speaking  Anxiety/phobic disorders 
E202500 Social phobia, fear of public washing  Anxiety/phobic disorders 
E28z.11 Examination fear  Anxiety/phobic disorders 
E28z.12 Flying phobia  Anxiety/phobic disorders 
E28z.13 Stage fright  Anxiety/phobic disorders 
Eu9..00 
[X]Behavioural/emotional disords onset 
childhood/adolescence 
Behavioural &emotional disorders of childhood onset 
Eu93000 [X]Separation anxiety disorder of childhood Behavioural &emotional disorders of childhood onset 
Eu93100 [X]Phobic anxiety disorder of childhood Behavioural &emotional disorders of childhood onset 
Eu93200 [X]Social anxiety disorder of childhood Behavioural &emotional disorders of childhood onset 
Eu93211 [X]Avoidant disorder childhood Behavioural &emotional disorders of childhood onset 
Eu93300 [X]Sibling rivalry disorder Behavioural &emotional disorders of childhood onset 
Eu93311 [X]Sibling jealousy Behavioural &emotional disorders of childhood onset 
Eu93y00 [X]Other childhood emotional disorders Behavioural &emotional disorders of childhood onset 
Eu93y11 [X]Childhood identity disorder Behavioural &emotional disorders of childhood onset 
Eu93y12 [X]Childhood overanxious disorder Behavioural &emotional disorders of childhood onset 
Eu93z00 
[X]Childhood emotional disorder, 
unspecified 
Behavioural &emotional disorders of childhood onset 
Eu94.00 
[X]Disorder social funct onset specific 
childhood/adolesc 
Behavioural &emotional disorders of childhood onset 
Eu94000 [X]Elective mutism Behavioural &emotional disorders of childhood onset 
Eu94011 [X]Selective mutism Behavioural &emotional disorders of childhood onset 
Eu94100 
[X]Reactive attachment disorder of 
childhood 
Behavioural &emotional disorders of childhood onset 
Eu94200 
[X]Disinhibited attachment disorder of 
childhood 
Behavioural &emotional disorders of childhood onset 
Eu94211 [X]Affectionless psychopathy Behavioural &emotional disorders of childhood onset 
Eu94212 [X]Institutional syndrome Behavioural &emotional disorders of childhood onset 
Eu94y00 
[X]Other childhood disorders of social 
functioning 
Behavioural &emotional disorders of childhood onset 
Eu94z00 
[X]Childhood disorder of social functioning, 
unspecified 
Behavioural &emotional disorders of childhood onset 
E270.00 Stammering or stuttering Behavioural &emotional disorders of childhood onset 
E270.11 Stammering Behavioural &emotional disorders of childhood onset 
E270.12 Stuttering Behavioural &emotional disorders of childhood onset 
E272.00 Tics Behavioural &emotional disorders of childhood onset 
E272000 Tic disorder unspecified Behavioural &emotional disorders of childhood onset 
E272100 Transient childhood tic Behavioural &emotional disorders of childhood onset 
E272200 Chronic motor tic disorder Behavioural &emotional disorders of childhood onset 
E272300 Gilles de la Tourette's disorder Behavioural &emotional disorders of childhood onset 
E272z00 Tic NOS 
Behavioural &emotional disorders of childhood onset 
E273.00 Stereotyped repetitive movements Behavioural &emotional disorders of childhood onset 





E273100 Head-banging Behavioural &emotional disorders of childhood onset 
E273200 Spasmus nutans - nodding spasm Behavioural &emotional disorders of childhood onset 
E273z00 Stereotyped repetitive movements NOS Behavioural &emotional disorders of childhood onset 
E27z000 Hair plucking Behavioural &emotional disorders of childhood onset 
E27z400 Nail-biting Behavioural &emotional disorders of childhood onset 
E27z500 Thumb-sucking Behavioural &emotional disorders of childhood onset 
E292000 Separation anxiety disorder Behavioural &emotional disorders of childhood onset 
E292100 Adolescent emancipation disorder Behavioural &emotional disorders of childhood onset 
E292300 Specific academic or work inhibition Behavioural &emotional disorders of childhood onset 
E292311 Specific academic or work inhibition Behavioural &emotional disorders of childhood onset 
E292312 Specific work inhibition Behavioural &emotional disorders of childhood onset 
Eu5..00 
[X]Behav synd assoc with physiolgcl disturb 
+ physical fctrs 
Behavioural syndromes associated with physiological 
disturbances 
Eu50.00 [X]Eating disorders 
Behavioural syndromes associated with physiological 
disturbances 
Eu50000 [X]Anorexia nervosa 
Behavioural syndromes associated with physiological 
disturbances 
Eu50100 [X]Atypical anorexia nervosa 
Behavioural syndromes associated with physiological 
disturbances 
Eu50200 [X]Bulimia nervosa 
Behavioural syndromes associated with physiological 
disturbances 
Eu50211 [X]Bulimia NOS 
Behavioural syndromes associated with physiological 
disturbances 
Eu50212 [X]Hyperorexia nervosa 
Behavioural syndromes associated with physiological 
disturbances 
Eu50300 [X]Atypical bulimia nervosa 
Behavioural syndromes associated with physiological 
disturbances 
Eu50400 
[X]Overeating associated with other 
psychological disturbncs 
Behavioural syndromes associated with physiological 
disturbances 
Eu50411 [X]Psychogenic overeating 
Behavioural syndromes associated with physiological 
disturbances 
Eu50500 
[X]Vomiting associated with other 
psychological disturbances 
Behavioural syndromes associated with physiological 
disturbances 
Eu50511 [X]Psychogenic vomiting 
Behavioural syndromes associated with physiological 
disturbances 
Eu50y00 [X]Other eating disorders 
Behavioural syndromes associated with physiological 
disturbances 
Eu50y12 [X]Psychogenic loss of appetite 
Behavioural syndromes associated with physiological 
disturbances 
Eu50z00 [X]Eating disorder, unspecified 
Behavioural syndromes associated with physiological 
disturbances 
Eu52z00 
[X]Unspec sex dysfunction not caused by 
organic disordr/dis 
Behavioural syndromes associated with physiological 
disturbances 
Eu53.00 
[X]Mental and behav disorders assoc with 
the puerperium NEC 
Behavioural syndromes associated with physiological 
disturbances 
Eu53000 
[X]Mild mental/behav disorder assoc with 
the puerperium NEC 
Behavioural syndromes associated with physiological 
disturbances 
Eu53011 [X]Postnatal depression NOS 
Behavioural syndromes associated with physiological 
disturbances 
Eu53012 [X]Postpartum depression NOS 
Behavioural syndromes associated with physiological 
disturbances 
Eu53100 
[X]Severe mental and behav disorder assoc 
wth puerperium NEC 
Behavioural syndromes associated with physiological 
disturbances 
Eu53111 [X]Puerperal psychosis NOS 
Behavioural syndromes associated with physiological 
disturbances 
Eu53y00 
[X]Oth mental and behav disorders assoc 
with puerperium NEC 
Behavioural syndromes associated with physiological 
disturbances 







[X]Psychological/behav factor assoc with 
disorder or dis EC 
Behavioural syndromes associated with physiological 
disturbances 
Eu5z.00 
[X]Unsp behav synd assoc with physiol 
disturb physical facts 
Behavioural syndromes associated with physiological 
disturbances 
Eu5z.11 
[X]Psychogenic physiological dysfunction 
NOS 
Behavioural syndromes associated with physiological 
disturbances 
E27..00 Psychogenic syndromes NEC 
Behavioural syndromes associated with physiological 
disturbances 
E271.00 Anorexia nervosa 
Behavioural syndromes associated with physiological 
disturbances 
E275.00 
Other and unspecified non-organic eating 
disorders 
Behavioural syndromes associated with physiological 
disturbances 
E275000 Unspecified non-organic eating disorder 
Behavioural syndromes associated with physiological 
disturbances 
E275100 Bulimia (non-organic overeating) 
Behavioural syndromes associated with physiological 
disturbances 
E275111 Compulsive eating disorder 
Behavioural syndromes associated with physiological 
disturbances 
E275200 Pica 
Behavioural syndromes associated with physiological 
disturbances 
E275300 Psychogenic rumination 
Behavioural syndromes associated with physiological 
disturbances 
E275400 Psychogenic vomiting NOS 
Behavioural syndromes associated with physiological 
disturbances 
E275500 Non-organic infant feeding disturbance 
Behavioural syndromes associated with physiological 
disturbances 
E275600 Non-organic loss of appetite 
Behavioural syndromes associated with physiological 
disturbances 
E275700 Psychogenic polydipsia 
Behavioural syndromes associated with physiological 
disturbances 
E275711 Compulsive water drinking 
Behavioural syndromes associated with physiological 
disturbances 
E275800 Specific food craving 
Behavioural syndromes associated with physiological 
disturbances 
E275y00 
Other specified non-organic eating 
disorder 
Behavioural syndromes associated with physiological 
disturbances 
E275z00 Non-organic eating disorder NOS 
Behavioural syndromes associated with physiological 
disturbances 
E27z300 Masturbation 
Behavioural syndromes associated with physiological 
disturbances 
E27zz00 Psychogenic syndromes NOS 
Behavioural syndromes associated with physiological 
disturbances 
E204.11 Postnatal depression 
Behavioural syndromes associated with physiological 
disturbances  
E114.00 Bipolar affective disorder, currently manic Bipolar affective disorder 
E114.11 Manic-depressive - now manic Bipolar affective disorder 
E114000 
Bipolar affective disorder, currently manic, 
unspecified Bipolar affective disorder 
E114100 
Bipolar affective disorder, currently manic, 
mild Bipolar affective disorder 
E114200 
Bipolar affective disorder, currently manic, 
moderate Bipolar affective disorder 
E114300 
Bipolar affect disord, currently manic, 
severe, no psychosis Bipolar affective disorder 
E114400 
Bipolar affect disord, currently 
manic,severe with psychosis Bipolar affective disorder 
E114500 
Bipolar affect disord,currently manic, 
part/unspec remission Bipolar affective disorder 
E114600 
Bipolar affective disorder, currently manic, 






Bipolar affective disorder, currently manic, 
NOS Bipolar affective disorder 
E115.00 
Bipolar affective disorder, currently 
depressed Bipolar affective disorder 
E115.11 Manic-depressive - now depressed Bipolar affective disorder 
E115000 
Bipolar affective disorder, currently 
depressed, unspecified Bipolar affective disorder 
E115100 
Bipolar affective disorder, currently 
depressed, mild Bipolar affective disorder 
E115200 
Bipolar affective disorder, currently 
depressed, moderate Bipolar affective disorder 
E115300 
Bipolar affect disord, now depressed, 
severe, no psychosis Bipolar affective disorder 
E115400 
Bipolar affect disord, now depressed, 
severe with psychosis Bipolar affective disorder 
E115500 
Bipolar affect disord, now depressed, 
part/unspec remission Bipolar affective disorder 
E115600 
Bipolar affective disorder, now depressed, 
in full remission Bipolar affective disorder 
E115z00 
Bipolar affective disorder, currently 
depressed, NOS Bipolar affective disorder 
E116.00 Mixed bipolar affective disorder Bipolar affective disorder 
E116000 
Mixed bipolar affective disorder, 
unspecified Bipolar affective disorder 
E116100 Mixed bipolar affective disorder, mild Bipolar affective disorder 
E116200 Mixed bipolar affective disorder, moderate Bipolar affective disorder 
E116300 
Mixed bipolar affective disorder, severe, 
without psychosis Bipolar affective disorder 
E116400 
Mixed bipolar affective disorder, severe, 
with psychosis Bipolar affective disorder 
E116500 
Mixed bipolar affective disorder, 
partial/unspec remission Bipolar affective disorder 
E116600 
Mixed bipolar affective disorder, in full 
remission Bipolar affective disorder 
E116z00 Mixed bipolar affective disorder, NOS Bipolar affective disorder 
E117.00 Unspecified bipolar affective disorder Bipolar affective disorder 
E117000 
Unspecified bipolar affective disorder, 
unspecified Bipolar affective disorder 
E117100 Unspecified bipolar affective disorder, mild Bipolar affective disorder 
E117200 
Unspecified bipolar affective disorder, 
moderate Bipolar affective disorder 
E117300 
Unspecified bipolar affective disorder, 
severe, no psychosis Bipolar affective disorder 
E117400 
Unspecified bipolar affective 
disorder,severe with psychosis Bipolar affective disorder 
E117500 
Unspecified bipolar affect disord, 
partial/unspec remission Bipolar affective disorder 
E117600 
Unspecified bipolar affective disorder, in 
full remission Bipolar affective disorder 
E117z00 Unspecified bipolar affective disorder, NOS Bipolar affective disorder 
E118.00 Seasonal affective disorder Bipolar affective disorder 
E11y.00 
Other and unspecified manic-depressive 
psychoses Bipolar affective disorder 
E11y000 Unspecified manic-depressive psychoses Bipolar affective disorder 
E11y300 Other mixed manic-depressive psychoses Bipolar affective disorder 
E11yz00 
Other and unspecified manic-depressive 
psychoses NOS Bipolar affective disorder 





Eu31.11 [X]Manic-depressive illness Bipolar affective disorder 
Eu31.12 [X]Manic-depressive psychosis Bipolar affective disorder 
Eu31.13 [X]Manic-depressive reaction Bipolar affective disorder 
Eu31000 
[X]Bipolar affective disorder, current 
episode hypomanic Bipolar affective disorder 
Eu31100 
[X]Bipolar affect disorder cur epi manic 
wout psychotic symp Bipolar affective disorder 
Eu31200 
[X]Bipolar affect disorder cur epi manic 
with psychotic symp Bipolar affective disorder 
Eu31300 
[X]Bipolar affect disorder cur epi mild or 
moderate depressn Bipolar affective disorder 
Eu31400 
[X]Bipol aff disord, curr epis sev depress, 
no psychot symp Bipolar affective disorder 
Eu31500 
[X]Bipolar affect dis cur epi severe depres 
with psyc symp Bipolar affective disorder 
Eu31600 
[X]Bipolar affective disorder, current 
episode mixed Bipolar affective disorder 
Eu31700 
[X]Bipolar affective disorder, currently in 
remission Bipolar affective disorder 
Eu31y00 [X]Other bipolar affective disorders Bipolar affective disorder 
Eu31y11 [X]Bipolar II disorder Bipolar affective disorder 
Eu31y12 [X]Recurrent manic episodes Bipolar affective disorder 
Eu31z00 [X]Bipolar affective disorder, unspecified Bipolar affective disorder 
E2C..00 Disturbance of conduct NEC Conduct disorder 
E2C..11 Behaviour disorder Conduct disorder 
E2C0.00 Aggressive unsocial conduct disorder Conduct disorder 
E2C0000 Aggressive outburst Conduct disorder 
E2C0100 Anger reaction Conduct disorder 
E2C0z00 Aggressive unsocial conduct disorder NOS Conduct disorder 
E2C1.00 Nonaggressive unsocial conduct disorder Conduct disorder 
E2C1000 Unsocial childhood truancy Conduct disorder 
E2C1011 School refusal Conduct disorder 
E2C1100 Solitary stealing Conduct disorder 
E2C1z00 
Nonaggressive unsocial conduct disorder 
NOS Conduct disorder 
E2C2.00 Socialised conduct disorder Conduct disorder 
E2C2000 Socialised childhood truancy Conduct disorder 
E2C2300 Group delinquency Conduct disorder 
E2C2z00 Socialised conduct disorder NOS Conduct disorder 
E2C3.00 Impulse control disorder NEC Conduct disorder 
E2C3000 Impulse control disorder, unspecified Conduct disorder 
E2Cy.00 Other conduct disturbances Conduct disorder 
E2Cyz00 Other conduct disturbances NOS Conduct disorder 
E2Cz.00 Unspecified disturbance of conduct Conduct disorder 
E2Cz000 Juvenile delinquency unspecified Conduct disorder 
E2Czz00 Disturbance of conduct NOS Conduct disorder 
Eu91.00 [X]Conduct disorders Conduct disorder 
Eu91000 
[X]Conduct disorder confined to the family 
context Conduct disorder 
Eu91100 [X]Unsocialized conduct disorder Conduct disorder 
Eu91111 
[X]Conduct disorder, solitary aggressive 





Eu91112 [X]Unsocialised aggressive disorder Conduct disorder 
Eu91200 [X]Socialized conduct disorder Conduct disorder 
Eu91211 [X]Conduct disorder, group type Conduct disorder 
Eu91212 [X]Group delinquency Conduct disorder 
Eu91213 
[X]Offences in the context of gang 
membership Conduct disorder 
Eu91214 [X]Stealing in company of others Conduct disorder 
Eu91215 [X]Truancy from school Conduct disorder 
Eu91300 [X]Oppositional defiant disorder Conduct disorder 
Eu91y00 [X]Other conduct disorders Conduct disorder 
Eu91z00 [X]Conduct disorder, unspecified Conduct disorder 
Eu91z11 [X]Childhood behavioural disorder NOS Conduct disorder 
Eu91z12 [X]Childhood conduct disorder NOS Conduct disorder 
E2C1200 Tantrums Conduct disorder  
Eu44.00 [X]Dissociative [conversion] disorders Dissociative [conversion] disorders 
Eu44.11 [X]Conversion hysteria Dissociative [conversion] disorders 
Eu44.12 [X]Conversion reaction Dissociative [conversion] disorders 
Eu44.13 [X]Hysteria Dissociative [conversion] disorders 
Eu44.14 [X]Hysterical psychosis Dissociative [conversion] disorders 
Eu44000 [X]Dissociative amnesia Dissociative [conversion] disorders 
Eu44100 [X]Dissociative fugue Dissociative [conversion] disorders 
Eu44200 [X]Dissociative stupor Dissociative [conversion] disorders 
Eu44300 [X]Trance and possession disorders Dissociative [conversion] disorders 
Eu44400 [X]Dissociative motor disorders Dissociative [conversion] disorders 
Eu44411 [X]Psychogenic aphonia Dissociative [conversion] disorders 
Eu44412 [X]Psychogenic dysphonia Dissociative [conversion] disorders 
Eu44500 [X]Dissociative convulsions Dissociative [conversion] disorders 
Eu44511 [X]Pseudoseizures Dissociative [conversion] disorders 
Eu44600 
[X]Dissociative anaesthesia and sensory 
loss 
Dissociative [conversion] disorders 
Eu44611 [X]Psychogenic deafness Dissociative [conversion] disorders 
Eu44700 
[X]Mixed dissociative [conversion] 
disorders 
Dissociative [conversion] disorders 
Eu44y00 
[X]Other dissociative [conversion] 
disorders 
Dissociative [conversion] disorders 
Eu44y11 [X]Ganser's syndrome Dissociative [conversion] disorders 
Eu44y12 [X]Multiple personality Dissociative [conversion] disorders 
Eu44y13 [X]Psychogenic confusion Dissociative [conversion] disorders 
Eu44y14 [X]Psychogenic twilight state Dissociative [conversion] disorders 
Eu44z00 
[X]Dissociative [conversion] disorder, 
unspecified 
Dissociative [conversion] disorders 
E201.00 Hysteria Dissociative [conversion] disorders 
E201000 Hysteria unspecified Dissociative [conversion] disorders 
E201100 Hysterical blindness Dissociative [conversion] disorders 
E201200 Hysterical deafness Dissociative [conversion] disorders 
E201300 Hysterical tremor Dissociative [conversion] disorders 
E201400 Hysterical paralysis Dissociative [conversion] disorders 
E201500 Hysterical seizures Dissociative [conversion] disorders 





E201600 Other conversion disorder Dissociative [conversion] disorders 
E201611 Astasia - abasia, hysterical Dissociative [conversion] disorders 
E201700 Hysterical amnesia Dissociative [conversion] disorders 
E201800 Hysterical fugue Dissociative [conversion] disorders 
E201900 Multiple personality Dissociative [conversion] disorders 
E201A00 Dissociative reaction unspecified Dissociative [conversion] disorders 
E201C00 Phantom pregnancy Dissociative [conversion] disorders 
E201z00 Hysteria NOS Dissociative [conversion] disorders 
E201z11 Aphonia - hysterical Dissociative [conversion] disorders 
E201z12 Ataxia - hysterical Dissociative [conversion] disorders 
E201z13 Ganser's syndrome - hysterical Dissociative [conversion] disorders 
1474.00 H/O: migraine Migraine 
1967.00 Abdominal migraine - symptom Migraine 
8B6N.00 Migraine prophylaxis Migraine 
F26..00 Migraine Migraine 
F260.00 Classical migraine Migraine 
F261.00 Common migraine Migraine 
F261000 Atypical migraine Migraine 
F261100 Sick headache Migraine 
F261z00 Common migraine NOS Migraine 
F262.00 Migraine variants Migraine 
F262200 Abdominal migraine Migraine 
F262300 Basilar migraine Migraine 
F262400 Ophthalmic migraine Migraine 
F262500 Periodic migrainous neuralgia Migraine 
F262z00 Migraine variant NOS Migraine 
F26y.00 Other forms of migraine Migraine 
F26y000 Hemiplegic migraine Migraine 
F26y100 Ophthalmoplegic migraine Migraine 
F26y111 Moebius' ophthalmoplegic migraine Migraine 
F26y200 Status migrainosus Migraine 
F26y300 Complicated migraine Migraine 
F26yz00 Other forms of migraine NOS Migraine 
F26z.00 Migraine NOS Migraine 
Fyu5300 [X]Other migraine Migraine 
K584.11 Migraine - menstrual Migraine 
R090D00 [D]Abdominal migraine Migraine 
E2C4.00 Mixed disturbance of conduct and emotion Mixed disorders of conduct and emotions 
E2C4z00 
Mixed disturbance of conduct and emotion 
NOS Mixed disorders of conduct and emotions 
Eu92.00 
[X]Mixed disorders of conduct and 
emotions Mixed disorders of conduct and emotions 
Eu92.11 [X]Emotional behavioural problems Mixed disorders of conduct and emotions 
Eu92000 [X]Depressive conduct disorder Mixed disorders of conduct and emotions 
Eu92y00 
[X]Other mixed disorders of conduct and 
emotions Mixed disorders of conduct and emotions 
Eu92y11 
[X]Conduct disorder associated with 






[X]Conduct disorder associated with 
neurotic disorder Mixed disorders of conduct and emotions 
Eu93.00 
[X]Emotional disorders with onset specific 
to childhood Mixed disorders of conduct and emotions 
1475.00 H/O: trigeminal neuralgia Neuropathic pain 
A531.11 Post-herpetic neuralgia Neuropathic pain 
A531200 Postherpetic trigeminal neuralgia Neuropathic pain 
A531500 Postzoster neuralgia Neuropathic pain 
A531511 Postherpetic neuralgia Neuropathic pain 
C327413 Anderson-Fabry disease Neuropathic pain 
F262100 Horton's (histamine) neuralgia Neuropathic pain 
F300.00 Post-herpetic trigeminal neuralgia Neuropathic pain 
F301.00 Other specified trigeminal neuralgia Neuropathic pain 
F321.00 Glossopharyngeal neuralgia Neuropathic pain 
F356100 Morton's neuralgia Neuropathic pain 
F36..00 
Hereditary and idiopathic peripheral 
neuropathy 
Neuropathic pain 
F360.00 Hereditary peripheral neuropathy Neuropathic pain 
F362.00 Hereditary sensory neuropathy Neuropathic pain 
F367.00 Peripheral neuropathy Neuropathic pain 
F372.12 Diabetic neuropathy Neuropathic pain 
F372000 Acute painful diabetic neuropathy Neuropathic pain 
F372100 Chronic painful diabetic neuropathy Neuropathic pain 
F372200 Asymptomatic diabetic neuropathy Neuropathic pain 
M271100 Neuropathic diabetic ulcer - foot Neuropathic pain 
N11y200 Neuropathic spondylopathy Neuropathic pain 
N242.00 
Neuralgia, neuritis and radiculitis 
unspecified 
Neuropathic pain 
N242000 Neuralgia unspecified Neuropathic pain 
N242100 Neuritis unspecified Neuropathic pain 
N242300 Neuropathic pain Neuropathic pain 
N242z00 Neuralgia, neuritis or radiculitis NOS Neuropathic pain 
Eu45.00 [X]Somatoform disorders Neurotic, stress - related and somoform disorders 
Eu45000 [X]Somatization disorder Neurotic, stress - related and somoform disorders 
Eu45011 [X]Multiple psychosomatic disorder Neurotic, stress - related and somoform disorders 
Eu45012 [X]Briquet's syndrome Neurotic, stress - related and somoform disorders 
Eu45013 [X]Briquet's disorder Neurotic, stress - related and somoform disorders 




Neurotic, stress - related and somoform disorders 
Eu45200 [X]Hypochondriacal disorder Neurotic, stress - related and somoform disorders 
Eu45211 [X]Body dysmorphic disorder Neurotic, stress - related and somoform disorders 
Eu45212 [X]Dysmorphophobia nondelusional Neurotic, stress - related and somoform disorders 
Eu45213 [X]Hypochondriacal neurosis Neurotic, stress - related and somoform disorders 
Eu45214 [X]Hypochondriasis Neurotic, stress - related and somoform disorders 
Eu45215 [X]Nosophobia Neurotic, stress - related and somoform disorders 
Eu45300 [X]Somatoform autonomic dysfunction Neurotic, stress - related and somoform disorders 
Eu45311 [X]Cardiac neurosis Neurotic, stress - related and somoform disorders 





Eu45313 [X]Gastric neurosis Neurotic, stress - related and somoform disorders 
Eu45314 [X]Neurocirculatory asthenia Neurotic, stress - related and somoform disorders 
Eu45y12 [X]Globus hystericus Neurotic, stress - related and somoform disorders 
Eu45y13 [X]Psychogenic pruritis Neurotic, stress - related and somoform disorders 
Eu45y14 [X]Psychogenic torticollis Neurotic, stress - related and somoform disorders 
Eu45y15 [X]Teeth-grinding Neurotic, stress - related and somoform disorders 
Eu45z00 [X]Somatoform disorder, unspecified Neurotic, stress - related and somoform disorders 
Eu45z11 [X]Psychosomatic disorder NOS Neurotic, stress - related and somoform disorders 
Eu46.00 [X]Other neurotic disorders Neurotic, stress - related and somoform disorders 
Eu46000 [X]Neurasthenia Neurotic, stress - related and somoform disorders 
Eu46011 [X]Fatigue syndrome Neurotic, stress - related and somoform disorders 
Eu46100 
[X]Depersonalization - derealization 
syndrome 
Neurotic, stress - related and somoform disorders 
Eu46y00 [X]Other specified neurotic disorders Neurotic, stress - related and somoform disorders 
Eu46y11 [X]Briquet's disorder Neurotic, stress - related and somoform disorders 
Eu46y12 [X]Dhat syndrome Neurotic, stress - related and somoform disorders 
Eu46y13 
[X]Occupational neurosis, including writer's 
cramp 
Neurotic, stress - related and somoform disorders 
Eu46y14 [X]Psychasthenia Neurotic, stress - related and somoform disorders 
Eu46y15 [X]Psychasthenia neurosis Neurotic, stress - related and somoform disorders 
Eu46y16 [X]Psychogenic syncope Neurotic, stress - related and somoform disorders 
Eu46z00 [X]Neurotic disorder, unspecified Neurotic, stress - related and somoform disorders 
Eu46z11 [X]Neurosis NOS Neurotic, stress - related and somoform disorders 
E204.00 Neurotic depression reactive type Neurotic, stress - related and somoform disorders 
E205.00 Neurasthenia - nervous debility Neurotic, stress - related and somoform disorders 
E205.11 Nervous exhaustion Neurotic, stress - related and somoform disorders 
E205.12 Tired all the time Neurotic, stress - related and somoform disorders 
E206.00 Depersonalisation syndrome Neurotic, stress - related and somoform disorders 
E207.00 Hypochondriasis Neurotic, stress - related and somoform disorders 
E20y.00 Other neurotic disorders Neurotic, stress - related and somoform disorders 
E20y000 Somatization disorder Neurotic, stress - related and somoform disorders 
E20y011 Briquet's disorder Neurotic, stress - related and somoform disorders 
E20y100 Writer's cramp neurosis Neurotic, stress - related and somoform disorders 
E20y200 Other occupational neurosis Neurotic, stress - related and somoform disorders 
E20y300 Psychasthenic neurosis Neurotic, stress - related and somoform disorders 
E20yz00 Other neurotic disorder NOS Neurotic, stress - related and somoform disorders 
E20z.00 Neurotic disorder NOS Neurotic, stress - related and somoform disorders 
E20z.11 Nervous breakdown Neurotic, stress - related and somoform disorders 
E2...00 
Neurotic, personality and other 
nonpsychotic disorders 
Neurotic, stress - related and somoform disorders 
E20..00 Neurotic disorders Neurotic, stress - related and somoform disorders 
E201612 Globus hystericus Neurotic, stress - related and somoform disorders 
Eu4..00 
[X]Neurotic, stress - related and somoform 
disorders 
Neurotic, stress - related and somoform disorders 
Eu43.00 
[X]Reaction to severe stress, and 
adjustment disorders 
Neurotic, stress - related and somoform disorders 
Eu43000 [X]Acute stress reaction Neurotic, stress - related and somoform disorders 
Eu43011 [X]Acute crisis reaction Neurotic, stress - related and somoform disorders 





Eu43013 [X]Combat fatigue Neurotic, stress - related and somoform disorders 
Eu43014 [X]Crisis state Neurotic, stress - related and somoform disorders 
Eu43015 [X]Psychic shock Neurotic, stress - related and somoform disorders 
Eu43100 [X]Post - traumatic stress disorder Neurotic, stress - related and somoform disorders 
Eu43111 [X]Traumatic neurosis Neurotic, stress - related and somoform disorders 
Eu43200 [X]Adjustment disorders Neurotic, stress - related and somoform disorders 
Eu43211 [X]Culture shock Neurotic, stress - related and somoform disorders 
Eu43212 [X]Grief reaction Neurotic, stress - related and somoform disorders 
Eu43213 [X]Hospitalism in children Neurotic, stress - related and somoform disorders 
Eu43y00 [X]Other reactions to severe stress Neurotic, stress - related and somoform disorders 
Eu43z00 [X]Reaction to severe stress, unspecified Neurotic, stress - related and somoform disorders 
13H4.12 Marital stress Neurotic, stress - related and somoform disorders 
13HT100 Stress at home Neurotic, stress - related and somoform disorders 
13HT111 Domestic stress Neurotic, stress - related and somoform disorders 
13JM.13 Stress at work Neurotic, stress - related and somoform disorders 
1B1L.00 Stress related problem Neurotic, stress - related and somoform disorders 
7P0H400 Stress echocardiography Neurotic, stress - related and somoform disorders 
9ON..00 Stress monitoring admin. Neurotic, stress - related and somoform disorders 
9ON..11 Stress clinic administration Neurotic, stress - related and somoform disorders 
9ON3.00 Stress monitoring default Neurotic, stress - related and somoform disorders 
9ON7.00 Stress monitoring verbal inv. Neurotic, stress - related and somoform disorders 
E28..00 Acute reaction to stress Neurotic, stress - related and somoform disorders 
E28..11 Combat fatigue Neurotic, stress - related and somoform disorders 
E280.00 
Acute panic state due to acute stress 
reaction Neurotic, stress - related and somoform disorders 
E281.00 
Acute fugue state due to acute stress 
reaction Neurotic, stress - related and somoform disorders 
E282.00 
Acute stupor state due to acute stress 
reaction Neurotic, stress - related and somoform disorders 
E283.00 Other acute stress reactions Neurotic, stress - related and somoform disorders 
E283000 Acute situational disturbance Neurotic, stress - related and somoform disorders 
E283100 Acute posttrauma stress state Neurotic, stress - related and somoform disorders 
E283z00 Other acute stress reaction NOS Neurotic, stress - related and somoform disorders 
E284.00 
Stress reaction causing mixed disturbance 
of emotion/conduct 
Neurotic, stress - related and somoform disorders 
E28z.00 Acute stress reaction NOS Neurotic, stress - related and somoform disorders 
E29..00 Adjustment reaction Neurotic, stress - related and somoform disorders 
E290.00 Brief depressive reaction Neurotic, stress - related and somoform disorders 
E290000 Grief reaction Neurotic, stress - related and somoform disorders 
E290011 Bereavement reaction Neurotic, stress - related and somoform disorders 
E290z00 Brief depressive reaction NOS Neurotic, stress - related and somoform disorders 
E291.00 Prolonged depressive reaction Neurotic, stress - related and somoform disorders 
E292.00 
Adjustment reaction, predominant 
disturbance other emotions 
Neurotic, stress - related and somoform disorders 
E292400 Adjustment reaction with anxious mood Neurotic, stress - related and somoform disorders 
E292500 Culture shock Neurotic, stress - related and somoform disorders 
E292y00 
Adjustment reaction with mixed 
disturbance of emotion 
Neurotic, stress - related and somoform disorders 
E292z00 
Adjustment reaction with disturbance of 
other emotion NOS 






Adjustment reaction with predominant 
disturbance of conduct 
Neurotic, stress - related and somoform disorders 
E293000 Adjustment reaction with aggression Neurotic, stress - related and somoform disorders 
E293100 
Adjustment reaction with antisocial 
behaviour 
Neurotic, stress - related and somoform disorders 
E293200 Adjustment reaction with destructiveness Neurotic, stress - related and somoform disorders 
E293z00 
Adjustment reaction with predominant 
disturbance conduct NOS 
Neurotic, stress - related and somoform disorders 
E294.00 
Adjustment reaction with disturbance 
emotion and conduct 
Neurotic, stress - related and somoform disorders 
E29y.00 Other adjustment reactions Neurotic, stress - related and somoform disorders 
E29y000 Concentration camp syndrome Neurotic, stress - related and somoform disorders 
E29y100 Other post-traumatic stress disorder Neurotic, stress - related and somoform disorders 
E29y200 
Adjustment reaction with physical 
symptoms 
Neurotic, stress - related and somoform disorders 
E29y300 
Elective mutism due to an adjustment 
reaction 
Neurotic, stress - related and somoform disorders 
E29y400 Adjustment reaction due to hospitalisation Neurotic, stress - related and somoform disorders 
E29y500 Other adjustment reaction with withdrawal Neurotic, stress - related and somoform disorders 
E29yz00 Other adjustment reactions NOS Neurotic, stress - related and somoform disorders 
E29z.00 Adjustment reaction NOS Neurotic, stress - related and somoform disorders 
Eu41000 
[X]Panic disorder [episodic paroxysmal 
anxiety] 
Neurotic, stress - related and somoform disorders 
Eu41011 [X]Panic attack Neurotic, stress - related and somoform disorders 
Eu41012 [X]Panic state Neurotic, stress - related and somoform disorders 
Eu41012 [X]Acute reaction to stress Neurotic, stress - related and somoform disorders 
Eu43y00 [X]Other reactions to severe stress Neurotic, stress - related and somoform disorders 
F25E.00 Stress-induced epilepsy Neurotic, stress - related and somoform disorders 
Eu51.00 [X]Nonorganic sleep disorders Nonorganic sleep disorders 
Eu51000 [X]Nonorganic insomnia Nonorganic sleep disorders 
Eu51100 [X]Nonorganic hypersomnia Nonorganic sleep disorders 
Eu51200 
[X]Nonorganic disorder of the sleep-wake 
schedule 
Nonorganic sleep disorders 
Eu51211 
[X]Psychogenic inversion of circadian 
rhythm 
Nonorganic sleep disorders 
Eu51212 
[X]Psychogenic inversion of nyctohemeral 
rhythm 
Nonorganic sleep disorders 
Eu51213 [X]Psychogenic inversion of sleep rhythm Nonorganic sleep disorders 
Eu51300 [X]Sleepwalking Nonorganic sleep disorders 
Eu51400 [X]Sleep terrors Nonorganic sleep disorders 
Eu51500 [X]Nightmares Nonorganic sleep disorders 
Eu51511 [X]Dream anxiety disorder Nonorganic sleep disorders 
Eu51y00 [X]Other nonorganic sleep disorders Nonorganic sleep disorders 
Eu51z00 [X]Nonorganic sleep disorder, unspecified Nonorganic sleep disorders 
Eu51z11 [X]Emotional sleep disorder NOS Nonorganic sleep disorders 
1B1B.00 Cannot sleep - insomnia Nonorganic sleep disorders 
1B1B.11 C/O - insomnia Nonorganic sleep disorders 
1B1B000 Initial insomnia Nonorganic sleep disorders 
1B1B100 Middle insomnia Nonorganic sleep disorders 
1B1B200 Late insomnia Nonorganic sleep disorders 





E274.11 Hypersomnia of non-organic origin Nonorganic sleep disorders  
E274.12 Insomnia due to nonorganic sleep disorder Nonorganic sleep disorders  
E274000 Unspecified non-organic sleep disorder Nonorganic sleep disorders  
E274100 Transient insomnia Nonorganic sleep disorders  
E274111 Insomnia NOS Nonorganic sleep disorders  
E274200 Persistent insomnia Nonorganic sleep disorders  
E274300 Transient hypersomnia Nonorganic sleep disorders  
E274311 Hypersomnia NOS Nonorganic sleep disorders  
E274400 Persistent hypersomnia Nonorganic sleep disorders  
E274500 Jet lag syndrome Nonorganic sleep disorders  
E274600 Shifting sleep-work schedule Nonorganic sleep disorders  
E274700 Somnambulism - sleep walking Nonorganic sleep disorders  
E274800 Night terrors Nonorganic sleep disorders  
E274900 Nightmares Nonorganic sleep disorders  
E274A00 Sleep drunkenness Nonorganic sleep disorders  
E274B00 
Repeated rapid eye movement sleep 
interruptions Nonorganic sleep disorders  
E274C00 Other sleep stage or arousal dysfunction Nonorganic sleep disorders  
E274D00 Repetitive intrusions of sleep Nonorganic sleep disorders  
E274D11 Restless sleep Nonorganic sleep disorders  
E274E00 "Short-sleeper" Nonorganic sleep disorders  
E274F00 Inversion of sleep rhythm Nonorganic sleep disorders  
E274y00 Other non-organic sleep disorder Nonorganic sleep disorders  
E274y11 Dreams Nonorganic sleep disorders  
E274z00 Non-organic sleep disorder NOS Nonorganic sleep disorders 
Eu42.00 [X]Obsessive - compulsive disorder Obsessive-compulsive disorder  
Eu42.11 [X]Anankastic neurosis Obsessive-compulsive disorder  
Eu42.12 [X]Obsessive-compulsive neurosis Obsessive-compulsive disorder  
Eu42000 
[X]Predominantly obsessional thoughts or 
ruminations Obsessive-compulsive disorder  
Eu42100 
[X]Predominantly compulsive acts 
[obsessional rituals] Obsessive-compulsive disorder  
Eu42200 [X]Mixed obsessional thoughts and acts Obsessive-compulsive disorder  
Eu42y00 [X]Other obsessive-compulsive disorders Obsessive-compulsive disorder  
Eu42z00 
[X]Obsessive-compulsive disorder, 
unspecified Obsessive-compulsive disorder  
Eu3y.00 [X]Other mood affective disorders Other mood affective disorders 
Eu3y000 [X]Other single mood affective disorders Other mood affective disorders 
Eu3y011 [X]Mixed affective episode Other mood affective disorders 
Eu3y100 
[X]Other recurrent mood affective 
disorders Other mood affective disorders 
Eu3y111 [X]Recurrent brief depressive episodes Other mood affective disorders 
Eu3yy00 
[X]Other specified mood affective 
disorders Other mood affective disorders 
Eu3z.00 [X]Unspecified mood affective disorder Other mood affective disorders 
Eu34.00 [X]Persistent mood affective disorders Other mood affective disorders 
Eu3..00 [X]Mood - affective disorders Other mood affective disorders 
E11zz00 Other affective psychosis NOS Other mood affective disorders  






Psychosis, schizophrenia + bipolar affective 
disord resolved Psychoses 
212X.00 Psychosis resolved Psychoses 
E02..00 Drug psychoses Psychoses 
E02y.00 Other drug psychoses Psychoses 
E03..00 Transient organic psychoses Psychoses 
E03y.00 Other transient organic psychoses Psychoses 
E03y300 Unspecified puerperal psychosis Psychoses 
E04..00 Other chronic organic psychoses Psychoses 
E040.11 Korsakoff's non-alcoholic psychosis Psychoses 
E04y.00 Other specified chronic organic psychoses Psychoses 
E0y..00 Other specified organic psychoses Psychoses 
E1...00 Non-organic psychoses Psychoses 
E11..00 Affective psychoses Psychoses 
E11..11 Bipolar psychoses Psychoses 
E11..12 Depressive psychoses Psychoses 
E11..13 Manic psychoses Psychoses 
E110.11 Hypomanic psychoses Psychoses 
E110400 
Single manic episode, severe, with 
psychosis Psychoses 
E111400 
Recurrent manic episodes, severe, with 
psychosis Psychoses 
E112400 
Single major depressive episode, severe, 
with psychosis Psychoses 
E113400 
Recurrent major depressive episodes, 
severe, with psychosis Psychoses 
E11z.00 Other and unspecified affective psychoses Psychoses 
E11z000 Unspecified affective psychoses NOS Psychosis 
E12..00 Paranoid states Psychoses 
E120.00 Simple paranoid state Psychoses 
E121.00 Chronic paranoid psychosis Psychoses 
E121.11 Sander's disease Psychoses 
E123.00 Shared paranoid disorder Psychoses 
E123.11 Folie a deux Psychoses 
E12y.00 Other paranoid states Psychoses 
E12y000 Paranoia querulans Psychoses 
E12yz00 Other paranoid states NOS Psychoses 
E12z.00 Paranoid psychosis NOS Psychoses 
E13..00 Other nonorganic psychoses Psychoses 
E13..11 Reactive psychoses Psychoses 
E130.00 Reactive depressive psychosis Psychoses 
E131.00 Acute hysterical psychosis Psychoses 
E132.00 Reactive confusion Psychoses 
E133.00 Acute paranoid reaction Psychoses 
E133.11 Bouffee delirante Psychoses 
E134.00 Psychogenic paranoid psychosis Psychoses 
E13y.00 Other reactive psychoses Psychoses 
E13y000 Psychogenic stupor Psychoses 





E13yz00 Other reactive psychoses NOS Psychoses 
E13z.00 Nonorganic psychosis NOS Psychoses 
E13z.11 Psychotic episode NOS Psychoses 
E14..00 Psychoses with origin in childhood Psychoses 
E141.00 Disintegrative psychosis Psychoses 
E141000 Active disintegrative psychoses Psychoses 
E141100 Residual disintegrative psychoses Psychoses 
E14y.00 Other childhood psychoses Psychoses 
E14y000 Atypical childhood psychoses Psychoses 
E14y100 Borderline psychosis of childhood Psychoses 
E14yz00 Other childhood psychoses NOS Psychoses 
E14z.00 Child psychosis NOS Psychoses 
E14z.11 Childhood schizophrenia NOS Psychoses 
E1y..00 Other specified non-organic psychoses Psychoses 
Eu04.13 [X]Acute / subacute infective psychosis Psychoses 
Eu05y11 [X]Epileptic psychosis NOS Psychoses 
Eu0z.11 [X]Organic psychosis NOS Psychoses 
Eu0z.12 [X]Symptomatic psychosis NOS Psychoses 
Eu22.00 [X]Persistent delusional disorders Psychoses 
Eu22000 [X]Delusional disorder Psychoses 
Eu22011 [X]Paranoid psychosis Psychoses 
Eu22012 [X]Paranoid state Psychoses 
Eu22013 [X]Paraphrenia - late Psychoses 
Eu22014 [X]Sensitiver Beziehungswahn Psychoses 
Eu22015 [X]Paranoia Psychoses 
Eu22100 [X]Delusional misidentification syndrome Psychoses 
Eu22111 [X]Capgras syndrome Psychoses 
Eu22200 [X]Cotard syndrome Psychoses 
Eu22y00 [X]Other persistent delusional disorders Psychoses 
Eu22y11 [X]Delusional dysmorphophobia Psychoses 
Eu22y12 [X]Involutional paranoid state Psychoses 
Eu22y13 [X]Paranoia querulans Psychoses 
Eu22z00 
[X]Persistent delusional disorder, 
unspecified Psychoses 
Eu23.00 [X]Acute and transient psychotic disorders Psychoses 
Eu23000 
[X]Acute polymorphic psychot disord 
without symp of schizoph Psychoses 
Eu23011 [X]Bouffee delirante Psychoses 
Eu23012 [X]Cycloid psychosis Psychoses 
Eu23100 
[X]Acute polymorphic psychot disord with 
symp of schizophren Psychoses 
Eu23111 
[X]Bouffee delirante with symptoms of 
schizophrenia Psychoses 
Eu23112 
[X]Cycloid psychosis with symptoms of 
schizophrenia Psychoses 
Eu23200 
[X]Acute schizophrenia-like psychotic 
disorder Psychoses 
Eu23211 [X]Brief schizophreniform disorder Psychoses 





Eu23213 [X]Oneirophrenia Psychoses 
Eu23214 [X]Schizophrenic reaction Psychoses 
Eu23300 
[X]Other acute predominantly delusional 
psychotic disorders Psychoses 
Eu23312 [X]Psychogenic paranoid psychosis Psychoses 
Eu23y00 
[X]Other acute and transient psychotic 
disorders Psychoses 
Eu23z00 
[X]Acute and transient psychotic disorder, 
unspecified Psychoses 
Eu23z11 [X]Brief reactive psychosis NOS Psychoses 
Eu23z12 [X]Reactive psychosis Psychoses 
Eu24.00 [X]Induced delusional disorder Psychoses 
Eu24.11 [X]Folie a deux Psychoses 
Eu24.12 [X]Induced paranoid disorder Psychoses 
Eu24.13 [X]Induced psychotic disorder Psychoses 
Eu25.00 [X]Schizoaffective disorders Psychoses 
Eu25000 [X]Schizoaffective disorder, manic type Psychoses 
Eu25011 [X]Schizoaffective psychosis, manic type Psychoses 
Eu25012 [X]Schizophreniform psychosis, manic type Psychoses 
Eu25100 [X]Schizoaffective disorder, depressive type Psychoses 
Eu25111 
[X]Schizoaffective psychosis, depressive 
type Psychoses 
Eu25112 
[X]Schizophreniform psychosis, depressive 
type Psychoses 
Eu25200 [X]Schizoaffective disorder, mixed type Psychoses 
Eu25211 [X]Cyclic schizophrenia Psychoses 
Eu25212 
[X]Mixed schizophrenic and affective 
psychosis Psychoses 
Eu25y00 [X]Other schizoaffective disorders Psychoses 
Eu25z00 [X]Schizoaffective disorder, unspecified Psychoses 
Eu25z11 [X]Schizoaffective psychosis NOS Psychoses 
Eu2y.00 [X]Other nonorganic psychotic disorders Psychoses 
Eu2y.11 [X]Chronic hallucinatory psychosis Psychoses 
Eu2z.00 [X]Unspecified nonorganic psychosis Psychoses 
Eu2z.11 [X]Psychosis NOS Psychoses 
Eu32312 
[X]Single episode of psychogenic 
depressive psychosis Psychoses 
Eu32314 
[X]Single episode of reactive depressive 
psychosis Psychoses 
Eu33314 
[X]Recurr severe episodes/psychogenic 
depressive psychosis Psychoses 
Eu33316 
[X]Recurrent severe episodes/reactive 
depressive psychosis Psychoses 
Eu3z.11 [X]Affective psychosis NOS Psychoses 
Eu44.14 [X]Hysterical psychosis Psychoses 
Eu84013 [X]Infantile psychosis Psychoses 
Eu84111 [X]Atypical childhood psychosis Psychoses 
Eu84312 [X]Disintegrative psychosis Psychoses 
Eu84314 [X]Symbiotic psychosis Psychoses 
R20..00 [D]Senility, without mention of psychosis Psychoses 
ZV11111 










14B4.00 H/O: asthma Asthma 
1O2..00 Asthma confirmed Asthma 
663..11 Asthma monitoring Asthma 
663e.00 Asthma restricts exercise Asthma 
663e000 Asthma sometimes restricts exercise Asthma 
663e100 Asthma severely restricts exercise Asthma 
663f.00 Asthma never restricts exercise Asthma 
663h.00 Asthma - currently dormant Asthma 
663j.00 Asthma - currently active Asthma 
663N.00 Asthma disturbing sleep Asthma 
663n.00 Asthma treatment compliance satisfactory Asthma 
663N000 Asthma causing night waking Asthma 
663N100 Asthma disturbs sleep weekly Asthma 
663N200 Asthma disturbs sleep frequently Asthma 
663O.00 Asthma not disturbing sleep Asthma 
663O000 Asthma never disturbs sleep Asthma 
663P.00 Asthma limiting activities Asthma 
663p.00 Asthma treatment compliance unsatisfactory Asthma 
663q.00 Asthma daytime symptoms Asthma 
663Q.00 Asthma not limiting activities Asthma 
663r.00 Asthma causes night symptoms 1 to 2 times per month Asthma 
663s.00 Asthma never causes daytime symptoms Asthma 
663t.00 




Asthma causes daytime symptoms 1 to 2 times per 
week 
Asthma 
663U.00 Asthma management plan given Asthma 
663v.00 Asthma causes daytime symptoms most days Asthma 
663V.00 Asthma severity Asthma 
663V000 Occasional asthma Asthma 
663V100 Mild asthma Asthma 
663V200 Moderate asthma Asthma 
663V300 Severe asthma Asthma 
663w.00 Asthma limits walking up hills or stairs Asthma 
663x.00 Asthma limits walking on the flat Asthma 
663y.00 Number of asthma exacerbations in past year Asthma 
66Y5.00 Change in asthma management plan Asthma 
66Y9.00 Step up change in asthma management plan Asthma 
66YA.00 Step down change in asthma management plan Asthma 
66YC.00 Absent from work or school due to asthma Asthma 
66YE.00 Asthma monitoring due Asthma 
66YK.00 Asthma follow-up Asthma 





66YQ.00 Asthma monitoring by nurse Asthma 
66YR.00 Asthma monitoring by doctor Asthma 
8793.00 Asthma control step 0 Asthma 
8794.00 Asthma control step 1 Asthma 
8795.00 Asthma control step 2 Asthma 
8796.00 Asthma control step 3 Asthma 
8797.00 Asthma control step 4 Asthma 
8798.00 Asthma control step 5 Asthma 
8B3j.00 Asthma medication review Asthma 
8CR0.00 Asthma clinical management plan Asthma 
9OJ..00 Asthma monitoring admin. Asthma 
9OJ..11 Asthma clinic administration Asthma 
9OJ1.00 Attends asthma monitoring Asthma 
9OJ4.00 Asthma monitor 1st letter Asthma 
9OJ5.00 Asthma monitor 2nd letter Asthma 
9OJ6.00 Asthma monitor 3rd letter Asthma 
9OJ7.00 Asthma monitor verbal invite Asthma 
9OJ8.00 Asthma monitor phone invite Asthma 
9OJA.00 Asthma monitoring check done Asthma 
9OJA.11 Asthma monitored Asthma 
9OJZ.00 Asthma monitoring admin.NOS Asthma 
H33..00 Asthma Asthma 
H33..11 Bronchial asthma Asthma 
H330.00 Extrinsic (atopic) asthma Asthma 
H330.11 Allergic asthma Asthma 
H330.12 Childhood asthma Asthma 
H330.13 Hay fever with asthma Asthma 
H330.14 Pollen asthma Asthma 
H330000 Extrinsic asthma without status asthmaticus Asthma 
H330011 Hay fever with asthma Asthma 
H330100 Extrinsic asthma with status asthmaticus Asthma 
H330111 Extrinsic asthma with asthma attack Asthma 
H330z00 Extrinsic asthma NOS Asthma 
H331.00 Intrinsic asthma Asthma 
H331.11 Late onset asthma Asthma 
H331000 Intrinsic asthma without status asthmaticus Asthma 
H331100 Intrinsic asthma with status asthmaticus Asthma 
H331111 Intrinsic asthma with asthma attack Asthma 
H331z00 Intrinsic asthma NOS Asthma 
H332.00 Mixed asthma Asthma 
H334.00 Brittle asthma Asthma 
H33z.00 Asthma unspecified Asthma 
H33z011 Severe asthma attack Asthma 
H33z100 Asthma attack Asthma 
H33z111 Asthma attack NOS Asthma 





H33zz00 Asthma NOS Asthma 
H33zz11 Exercise induced asthma Asthma 
H33zz12 Allergic asthma NEC Asthma 
H35y600 Sequoiosis (red-cedar asthma) Asthma 
H35y700 Wood asthma Asthma 
H47y000 Detergent asthma Asthma 
TJF7.00 Adverse reaction to antiasthmatics Asthma 
TJF7300 Adverse reaction to theophylline (asthma) Asthma 
TJF7z00 Adverse reaction to antiasthmatic NOS Asthma 
U60F600 
[X]Antiasthmats caus adverse effects in therapeut use, 
NEC 
Asthma 
U60F611 [X] Adverse reaction to antiasthmatics Asthma 
U60F615 [X] Adverse reaction to theophylline - asthma Asthma 
U60F61A [X] Adverse reaction to antiasthmatic NOS Asthma 
14A..00 H/O: cardiovascular disease Cardiovascular diseases 
66f..00 Cardiovascular disease monitoring Cardiovascular diseases 
G....00 Circulatory system diseases Cardiovascular diseases 
G....11 Cardiovascular system diseases Cardiovascular diseases 
G....12 Cardiac diseases Cardiovascular diseases 
G....13 Heart diseases Cardiovascular diseases 
G0...00 Acute rheumatic fever Cardiovascular diseases 
G00..00 Rheumatic fever without heart involvement Cardiovascular diseases 
G01..00 Rheumatic fever with heart involvement Cardiovascular diseases 
G010.00 Acute rheumatic pericarditis Cardiovascular diseases 
G011.00 Acute rheumatic endocarditis Cardiovascular diseases 
G012.00 Acute rheumatic myocarditis Cardiovascular diseases 
G01y.00 Other acute rheumatic heart disease Cardiovascular diseases 
G01y000 Acute rheumatic pancarditis Cardiovascular diseases 
G01yz00 Other acute rheumatic heart disease NOS Cardiovascular diseases 
G01z.00 Acute rheumatic heart disease NOS Cardiovascular diseases 
G02..00 Rheumatic chorea Cardiovascular diseases 
G02..11 Sydenham's chorea Cardiovascular diseases 
G020.00 Rheumatic chorea with heart involvement Cardiovascular diseases 
G021.00 
Rheumatic chorea without mention of heart 
involvement 
Cardiovascular diseases 
G02z.00 Rheumatic chorea NOS Cardiovascular diseases 
G0y..00 Other specified acute rheumatic fever Cardiovascular diseases 
G0z..00 Acute rheumatic fever NOS Cardiovascular diseases 
G1...00 Chronic rheumatic heart disease Cardiovascular diseases 
G10..00 Chronic rheumatic pericarditis Cardiovascular diseases 
G100.00 Adherent rheumatic pericardium Cardiovascular diseases 
G101.00 Chronic rheumatic mediastinopericarditis Cardiovascular diseases 
G102.00 Chronic rheumatic myopericarditis Cardiovascular diseases 
G10z.00 Chronic rheumatic pericarditis NOS Cardiovascular diseases 
G11..00 Mitral valve diseases Cardiovascular diseases 
G11..11 Rheumatic mitral valve disease Cardiovascular diseases 





G110.11 Rheumatic mitral stenosis Cardiovascular diseases 
G111.00 Rheumatic mitral insufficiency Cardiovascular diseases 
G111.11 Mitral incompetence - rheumatic Cardiovascular diseases 
G111.12 Mitral regurgitation - rheumatic Cardiovascular diseases 
G112.00 Mitral stenosis with insufficiency Cardiovascular diseases 
G112.12 Mitral stenosis with incompetence Cardiovascular diseases 
G112.13 Mitral stenosis with regurgitation Cardiovascular diseases 
G113.00 Nonrheumatic mitral valve stenosis Cardiovascular diseases 
G114.00 Ruptured mitral valve cusp Cardiovascular diseases 
G11z.00 Mitral valve disease NOS Cardiovascular diseases 
G12..00 Rheumatic aortic valve disease Cardiovascular diseases 
G120.00 Rheumatic aortic stenosis Cardiovascular diseases 
G121.00 Rheumatic aortic insufficiency Cardiovascular diseases 
G121.11 Aortic incompetence - rheumatic Cardiovascular diseases 
G121.12 Aortic regurgitation - rheumatic Cardiovascular diseases 
G122.00 Rheumatic aortic stenosis with insufficiency Cardiovascular diseases 
G12z.00 Rheumatic aortic valve disease NOS Cardiovascular diseases 
G13..00 Diseases of mitral and aortic valves Cardiovascular diseases 
G130.00 Mitral and aortic stenosis Cardiovascular diseases 
G131.00 Mitral stenosis and aortic insufficiency Cardiovascular diseases 
G131.13 Mitral stenosis and aortic incompetence Cardiovascular diseases 
G131.14 Mitral stenosis and aortic regurgitation Cardiovascular diseases 
G132.00 Mitral insufficiency and aortic stenosis Cardiovascular diseases 
G132.12 Mitral incompetence and aortic stenosis Cardiovascular diseases 
G132.13 Mitral regurgitation and aortic stenosis Cardiovascular diseases 
G133.00 Mitral and aortic incompetence Cardiovascular diseases 
G133.11 Mitral and aortic insufficiency Cardiovascular diseases 
G133.12 Mitral and aortic regurgitation Cardiovascular diseases 
G13y.00 Multiple mitral and aortic valve involvement Cardiovascular diseases 
G13z.00 Mitral and aortic valve disease NOS Cardiovascular diseases 
G14..00 Other chronic rheumatic endocardial disease Cardiovascular diseases 
G140.00 Tricuspid valve disease NEC Cardiovascular diseases 
G140000 Rheumatic tricuspid stenosis Cardiovascular diseases 
G140100 Rheumatic tricuspid insufficiency Cardiovascular diseases 
G140111 Tricuspid regurgitation - rheumatic Cardiovascular diseases 
G140112 Tricuspid incompetence - rheumatic Cardiovascular diseases 
G140200 Rheumatic tricuspid stenosis and insufficiency Cardiovascular diseases 
G14021X Rheumatic tricuspid stenosis and regurgitation Cardiovascular diseases 
G14021Y Rheumatic tricuspid stenosis and incompetence Cardiovascular diseases 
G140300 Tricuspid stenosis, cause unspecified Cardiovascular diseases 
G140400 Tricuspid insufficiency, cause unspecified Cardiovascular diseases 
G140412 Tricuspid incompetence, cause unspecified Cardiovascular diseases 
G140413 Tricuspid regurgitation, cause unspecified Cardiovascular diseases 
G140500 Tricuspid stenosis and insufficiency, cause unspecified Cardiovascular diseases 





G140514 Tricuspid stenosis and regurgitation, cause unspecified Cardiovascular diseases 
G140z00 Rheumatic tricuspid valve disease NOS Cardiovascular diseases 
G141.00 Rheumatic pulmonary valve disease Cardiovascular diseases 
G141000 Rheumatic pulmonary stenosis Cardiovascular diseases 
G141100 Rheumatic pulmonary insufficiency Cardiovascular diseases 
G141200 Rheumatic pulmonary stenosis and insufficiency Cardiovascular diseases 
G141z00 Rheumatic pulmonary valve disease NOS Cardiovascular diseases 
G14z.00 Rheumatic endocarditis NOS Cardiovascular diseases 
G14z.11 Rheumatic valvulitis, chronic NOS Cardiovascular diseases 
G1y..00 Other specified chronic rheumatic heart disease Cardiovascular diseases 
G1y0.00 Rheumatic myocarditis Cardiovascular diseases 
G1yz.00 Other and unspecified rheumatic heart disease Cardiovascular diseases 
G1yz000 Rheumatic heart disease unspecified Cardiovascular diseases 
G1yz100 Rheumatic left ventricular failure Cardiovascular diseases 
G1yzz00 Other rheumatic heart disease NOS Cardiovascular diseases 
G1z..00 Chronic rheumatic heart disease NOS Cardiovascular diseases 
G3...00 Ischaemic heart disease Cardiovascular diseases 
G3...11 Arteriosclerotic heart disease Cardiovascular diseases 
G3...12 Atherosclerotic heart disease Cardiovascular diseases 
G3...13 IHD - Ischaemic heart disease Cardiovascular diseases 
G30..00 Acute myocardial infarction Cardiovascular diseases 
G30..11 Attack - heart Cardiovascular diseases 
G30..12 Coronary thrombosis Cardiovascular diseases 
G30..13 Cardiac rupture following myocardial infarction (MI) Cardiovascular diseases 
G30..14 Heart attack Cardiovascular diseases 
G30..15 MI - acute myocardial infarction Cardiovascular diseases 
G30..16 Thrombosis - coronary Cardiovascular diseases 
G30..17 Silent myocardial infarction Cardiovascular diseases 
G300.00 Acute anterolateral infarction Cardiovascular diseases 
G301.00 Other specified anterior myocardial infarction Cardiovascular diseases 
G301000 Acute anteroapical infarction Cardiovascular diseases 
G301100 Acute anteroseptal infarction Cardiovascular diseases 
G301z00 Anterior myocardial infarction NOS Cardiovascular diseases 
G302.00 Acute inferolateral infarction Cardiovascular diseases 
G303.00 Acute inferoposterior infarction Cardiovascular diseases 
G304.00 Posterior myocardial infarction NOS Cardiovascular diseases 
G305.00 Lateral myocardial infarction NOS Cardiovascular diseases 
G306.00 True posterior myocardial infarction Cardiovascular diseases 
G307.00 Acute subendocardial infarction Cardiovascular diseases 
G307000 Acute non-Q wave infarction Cardiovascular diseases 
G307100 Acute non-ST segment elevation myocardial infarction Cardiovascular diseases 
G308.00 Inferior myocardial infarction NOS Cardiovascular diseases 
G309.00 Acute Q-wave infarct Cardiovascular diseases 
G30A.00 Mural thrombosis Cardiovascular diseases 
G30B.00 Acute posterolateral myocardial infarction Cardiovascular diseases 





G30X000 Acute ST segment elevation myocardial infarction Cardiovascular diseases 
G30y.00 Other acute myocardial infarction Cardiovascular diseases 
G30y000 Acute atrial infarction Cardiovascular diseases 
G30y100 Acute papillary muscle infarction Cardiovascular diseases 
G30y200 Acute septal infarction Cardiovascular diseases 
G30yz00 Other acute myocardial infarction NOS Cardiovascular diseases 
G30z.00 Acute myocardial infarction NOS Cardiovascular diseases 
G31..00 Other acute and subacute ischaemic heart disease Cardiovascular diseases 
G310.00 Postmyocardial infarction syndrome Cardiovascular diseases 
G310.11 Dressler's syndrome Cardiovascular diseases 
G311.00 Preinfarction syndrome Cardiovascular diseases 
G311.11 Crescendo angina Cardiovascular diseases 
G311.12 Impending infarction Cardiovascular diseases 
G311.13 Unstable angina Cardiovascular diseases 
G311.14 Angina at rest Cardiovascular diseases 
G311000 Myocardial infarction aborted Cardiovascular diseases 
G311011 MI - myocardial infarction aborted Cardiovascular diseases 
G311100 Unstable angina Cardiovascular diseases 
G311200 Angina at rest Cardiovascular diseases 
G311300 Refractory angina Cardiovascular diseases 
G311400 Worsening angina Cardiovascular diseases 
G311500 Acute coronary syndrome Cardiovascular diseases 
G311z00 Preinfarction syndrome NOS Cardiovascular diseases 
G312.00 
Coronary thrombosis not resulting in myocardial 
infarction 
Cardiovascular diseases 
G31y.00 Other acute and subacute ischaemic heart disease Cardiovascular diseases 
G31y000 Acute coronary insufficiency Cardiovascular diseases 
G31y100 Microinfarction of heart Cardiovascular diseases 
G31y200 Subendocardial ischaemia Cardiovascular diseases 
G31y300 Transient myocardial ischaemia Cardiovascular diseases 
G31yz00 Other acute and subacute ischaemic heart disease NOS Cardiovascular diseases 
G32..00 Old myocardial infarction Cardiovascular diseases 
G32..11 Healed myocardial infarction Cardiovascular diseases 
G32..12 Personal history of myocardial infarction Cardiovascular diseases 
G33..00 Angina pectoris Cardiovascular diseases 
G330.00 Angina decubitus Cardiovascular diseases 
G330000 Nocturnal angina Cardiovascular diseases 
G330z00 Angina decubitus NOS Cardiovascular diseases 
G331.00 Prinzmetal's angina Cardiovascular diseases 
G331.11 Variant angina pectoris Cardiovascular diseases 
G332.00 Coronary artery spasm Cardiovascular diseases 
G33z.00 Angina pectoris NOS Cardiovascular diseases 
G33z000 Status anginosus Cardiovascular diseases 
G33z100 Stenocardia Cardiovascular diseases 
G33z200 Syncope anginosa Cardiovascular diseases 
G33z300 Angina on effort Cardiovascular diseases 





G33z500 Post infarct angina Cardiovascular diseases 
G33z600 New onset angina Cardiovascular diseases 
G33z700 Stable angina Cardiovascular diseases 
G33zz00 Angina pectoris NOS Cardiovascular diseases 
G34..00 Other chronic ischaemic heart disease Cardiovascular diseases 
G340.00 Coronary atherosclerosis Cardiovascular diseases 
G340.11 Triple vessel disease of the heart Cardiovascular diseases 
G340.12 Coronary artery disease Cardiovascular diseases 
G340000 Single coronary vessel disease Cardiovascular diseases 
G340100 Double coronary vessel disease Cardiovascular diseases 
G341.00 Aneurysm of heart Cardiovascular diseases 
G341.11 Cardiac aneurysm Cardiovascular diseases 
G341000 Ventricular cardiac aneurysm Cardiovascular diseases 
G341100 Other cardiac wall aneurysm Cardiovascular diseases 
G341111 Mural cardiac aneurysm Cardiovascular diseases 
G341200 Aneurysm of coronary vessels Cardiovascular diseases 
G341300 Acquired atrioventricular fistula of heart Cardiovascular diseases 
G341z00 Aneurysm of heart NOS Cardiovascular diseases 
G342.00 Atherosclerotic cardiovascular disease Cardiovascular diseases 
G343.00 Ischaemic cardiomyopathy Cardiovascular diseases 
G344.00 Silent myocardial ischaemia Cardiovascular diseases 
G34y.00 Other specified chronic ischaemic heart disease Cardiovascular diseases 
G34y000 Chronic coronary insufficiency Cardiovascular diseases 
G34y100 Chronic myocardial ischaemia Cardiovascular diseases 
G34yz00 Other specified chronic ischaemic heart disease NOS Cardiovascular diseases 
G34z.00 Other chronic ischaemic heart disease NOS Cardiovascular diseases 
G34z000 Asymptomatic coronary heart disease Cardiovascular diseases 
G35..00 Subsequent myocardial infarction Cardiovascular diseases 
G350.00 Subsequent myocardial infarction of anterior wall Cardiovascular diseases 
G351.00 Subsequent myocardial infarction of inferior wall Cardiovascular diseases 
G353.00 Subsequent myocardial infarction of other sites Cardiovascular diseases 
G35X.00 Subsequent myocardial infarction of unspecified site Cardiovascular diseases 
G36..00 




























Thrombosis atrium,auric append&vent/curr comp foll 
acute MI 
Cardiovascular diseases 
G37..00 Cardiac syndrome X Cardiovascular diseases 


















Postoperative transmural myocardial infarction unspec 
site 
Cardiovascular diseases 
G384.00 Postoperative subendocardial myocardial infarction Cardiovascular diseases 
G38z.00 Postoperative myocardial infarction, unspecified Cardiovascular diseases 
G3y..00 Other specified ischaemic heart disease Cardiovascular diseases 
G3z..00 Ischaemic heart disease NOS Cardiovascular diseases 
G54..00 Other diseases of endocardium Cardiovascular diseases 
G54..11 Heart valve disorders - non rheumatic Cardiovascular diseases 
G540.00 Mitral valve incompetence Cardiovascular diseases 
G540.12 Mitral valve insufficiency Cardiovascular diseases 
G540.14 Mitral valve regurgitation Cardiovascular diseases 
G540.15 Mitral valve prolapse Cardiovascular diseases 
G540.16 Mitral regurgitation Cardiovascular diseases 
G540000 Mitral incompetence, non-rheumatic Cardiovascular diseases 
G540100 Mitral incompetence, cause unspecified Cardiovascular diseases 
G540200 Mitral valve prolapse Cardiovascular diseases 
G540300 Mitral valve leaf prolapse Cardiovascular diseases 
G540z00 Mitral valve disorders NOS Cardiovascular diseases 
G541.00 Aortic valve disorders Cardiovascular diseases 
G541000 Aortic incompetence, non-rheumatic Cardiovascular diseases 
G541011 Aortic insufficiency, non-rheumatic Cardiovascular diseases 
G541012 Aortic regurgitation, non-rheumatic Cardiovascular diseases 
G541100 Aortic stenosis, non-rheumatic Cardiovascular diseases 
G541200 Aortic incompetence alone, cause unspecified Cardiovascular diseases 
G541211 Aortic insufficiency alone, cause unspecified Cardiovascular diseases 
G541212 Aortic regurgitation alone, cause unspecified Cardiovascular diseases 
G541300 Aortic stenosis alone, cause unspecified Cardiovascular diseases 
G541400 Aortic valve stenosis with insufficiency Cardiovascular diseases 
G541500 Aortic stenosis Cardiovascular diseases 
G541600 Aortic valve sclerosis Cardiovascular diseases 
G541700 Aortic valve calcification Cardiovascular diseases 
G541z00 Aortic valve disorders NOS Cardiovascular diseases 
G542.00 Tricuspid valve disorders, non-rheumatic Cardiovascular diseases 
G542000 Tricuspid incompetence, non-rheumatic Cardiovascular diseases 
G542011 Tricuspid insufficiency, non-rheumatic Cardiovascular diseases 
G542012 Tricuspid regurgitation, non-rheumatic Cardiovascular diseases 
G542100 Tricuspid stenosis, non-rheumatic Cardiovascular diseases 
G542200 
Nonrheumatic tricuspid valve stenosis with 
insufficiency 
Cardiovascular diseases 
G542X00 Nonrheumatic tricuspid valve disorder, unspecified Cardiovascular diseases 
G542z00 Tricuspid valve disorders NOS Cardiovascular diseases 
G543.00 Pulmonary valve disorders Cardiovascular diseases 





G543011 Pulmonary insufficiency, non-rheumatic Cardiovascular diseases 
G543012 Pulmonary regurgitation, non-rheumatic Cardiovascular diseases 
G543100 Pulmonary stenosis, non-rheumatic Cardiovascular diseases 
G543200 Pulmonary incompetence, cause unspecified Cardiovascular diseases 
G543213 Pulmonary insufficiency, cause unspecified Cardiovascular diseases 
G543215 Pulmonary regurgitation, cause unspecified Cardiovascular diseases 
G543300 Pulmonary stenosis, cause unspecified Cardiovascular diseases 
G543311 Pulmonary stenosis, cause unspecified Cardiovascular diseases 
G543400 Pulmonary valve stenosis with insufficiency Cardiovascular diseases 
G543z00 Pulmonary valve disorders NOS Cardiovascular diseases 
G544.00 Multiple valve diseases Cardiovascular diseases 
G544000 Disorders of both aortic and tricuspid valves Cardiovascular diseases 
G544100 Disorders of both mitral and tricuspid valves Cardiovascular diseases 
G544200 
Combined disorders of mitral, aortic and tricuspid 
valves 
Cardiovascular diseases 
G544X00 Multiple valve disease, unspecified Cardiovascular diseases 
G54z.00 Endocarditis, valve unspecified Cardiovascular diseases 
G54z000 Incompetence of unspecified heart valve Cardiovascular diseases 
G54z013 Regurgitation of unspecified heart valve Cardiovascular diseases 
G54z014 Insufficiency of unspecified heart valve Cardiovascular diseases 
G54z100 Stenosis of unspecified heart valve Cardiovascular diseases 
G54z200 Chronic cardiac valvulitis NOS Cardiovascular diseases 
G54z300 Endocarditis, valve unspecified, OS Cardiovascular diseases 
G54z400 Endocarditis in disease EC Cardiovascular diseases 
G54z500 Valvular heart disease Cardiovascular diseases 
G54zz00 Endocarditis, valve unspecified, NOS Cardiovascular diseases 
G58..00 Heart failure Cardiovascular diseases 
G58..11 Cardiac failure Cardiovascular diseases 
G580.00 Congestive heart failure Cardiovascular diseases 
G580.11 Congestive cardiac failure Cardiovascular diseases 
G580.12 Right heart failure Cardiovascular diseases 
G580.13 Right ventricular failure Cardiovascular diseases 
G580.14 Biventricular failure Cardiovascular diseases 
G580000 Acute congestive heart failure Cardiovascular diseases 
G580100 Chronic congestive heart failure Cardiovascular diseases 
G580200 Decompensated cardiac failure Cardiovascular diseases 
G580300 Compensated cardiac failure Cardiovascular diseases 
G580400 Congestive heart failure due to valvular disease Cardiovascular diseases 
G581.00 Left ventricular failure Cardiovascular diseases 
G581.11 Asthma - cardiac Cardiovascular diseases 
G581.12 Pulmonary oedema - acute Cardiovascular diseases 
G581.13 Impaired left ventricular function Cardiovascular diseases 
G581000 Acute left ventricular failure Cardiovascular diseases 
G582.00 Acute heart failure Cardiovascular diseases 
G58z.00 Heart failure NOS Cardiovascular diseases 





G58z.12 Cardiac failure NOS Cardiovascular diseases 
G5y..00 Other specified heart disease Cardiovascular diseases 
G5y0.00 Myocarditis NOS Cardiovascular diseases 
G5y1.00 Myocardial degeneration Cardiovascular diseases 
G5y2.00 Cardiovascular arteriosclerosis unspecified Cardiovascular diseases 
G5yX.00 Cardiovascular disease, unspecified Cardiovascular diseases 
G5yy500 Hyperkinetic heart disease Cardiovascular diseases 
G5yy600 Atrial thrombosis Cardiovascular diseases 
G5yy700 Left ventricular thrombosis Cardiovascular diseases 
G5yy800 Right ventricular thrombosis Cardiovascular diseases 
G5yy900 Left ventricular systolic dysfunction Cardiovascular diseases 
G5yyA00 Left ventricular diastolic dysfunction Cardiovascular diseases 
G5yyz00 Other ill-defined heart disease NOS Cardiovascular diseases 
G5yz.00 Other heart disease NOS Cardiovascular diseases 
G5z..00 Heart disease NOS Cardiovascular diseases 
Gyu5g00 [X]Cardiovascular disease, unspecified Cardiovascular diseases 
Eu81100 [X]Specific spelling disorder Cognitive dsiorder 
Eu81111 
[X]Specific spelling retardation without reading 
disorder 
Cognitive dsiorder 
Eu81200 [X]Specific disorder of arithmetical skills Cognitive dsiorder 
Eu81211 [X]Developmental acalculia Cognitive dsiorder 
Eu81212 [X]Developmental arithmetical disorder Cognitive dsiorder 
Eu81213 [X]Developmental Gerstmann's syndrome Cognitive dsiorder 
Eu81300 [X]Mixed disorder of scholastic skills Cognitive dsiorder 
Eu81y00 [X]Other developmental disorders of scholastic skills Cognitive dsiorder 
Eu81y11 [X]Developmental expressive writing disorder Cognitive dsiorder 
Eu81z00 
[X]Developmental disorder of scholastic skills, 
unspecified 
Cognitive dsiorder 
Eu81z11 [X]Learning disability NOS Cognitive dsiorder 
Eu81z12 [X]Learning disorder NOS Cognitive dsiorder 
Eu81z13 [X]Learn acquisition disab NOS Cognitive dsiorder 
Eu05700 [X]Mild cognitive disorder Cognitive dsiorder 
28E..00 Cognitive decline Cognitive dsiorder 
7L1a.00 Cognitive behavioural therapy Cognitive dsiorder 
7L1a000 Cognitive behavioural therapy by unidisciplinary team Cognitive dsiorder 
7L1a100 
Cognitive behavioural therapy by multidisciplinary 
team 
Cognitive dsiorder 
7L1az00 Cognitive behavioural therapy NOS Cognitive dsiorder 
8G13.00 Cognitive-behaviour therapy Cognitive dsiorder 
8G14.00 Cognitive analytic therapy Cognitive dsiorder 
3AE1.00 GDS level 2 - very mild cognitive decline Cognitive dsiorder 
3AE2.00 GDS level 3 - mild cognitive decline Cognitive dsiorder 
3AE3.00 GDS level 4 - moderate cognitive decline Cognitive dsiorder 
3AE4.00 GDS level 5 - moderately severe cognitive decline Cognitive dsiorder 
3AE5.00 GDS level 6 - severe cognitive decline Cognitive dsiorder 
3AE6.00 GDS level 7 - very severe cognitive decline Cognitive dsiorder 





8G11.00 Psychotherapy - cognitive Cognitive dsiorder 
8G15.00 Computerised cognitive behavioural therapy Cognitive dsiorder 
Z46..00 Cognitively-based interventions to modify behaviour Cognitive dsiorder 
Z52..00 Cognitive and behavioural therapy Cognitive dsiorder 
Z521.00 Cognitive - behaviour therapy Cognitive dsiorder 
Z521.11 CBT - Cognitive - behaviour therapy Cognitive dsiorder 
Z521.12 Cognitive-behavioural therapy approach Cognitive dsiorder 
Z521.13 Cognitive-behaviour therapy Cognitive dsiorder 
Z521100 Generic cognitive behavioural therapy Cognitive dsiorder 
Z522.00 Behavioural psychotherapy Cognitive dsiorder 
Z522.11 Behaviour therapy Cognitive dsiorder 
Z522.13 Cognitive therapy approach Cognitive dsiorder 
Z522.14 Cognitive approach Cognitive dsiorder 
Z523.00 Cognitive therapy Cognitive dsiorder 
Z523.11 Cognitive therapy approach Cognitive dsiorder 
Z523.12 Cognitive approach Cognitive dsiorder 
Z523100 Beck's cognitive therapy Cognitive dsiorder 
Z523300 Cognitive restructuring Cognitive dsiorder 
Z582100 Cognitive analytic therapy Cognitive dsiorder 
Z73..00 Cognitive intervention strategies Cognitive dsiorder 
Z7A1.00 Cognitive skills training Cognitive dsiorder 
Z7A2100 Strategy training for cognitive skills Cognitive dsiorder 
Z7C..00 Cognitive function observations Cognitive dsiorder 
ZD15.00 Cognitive neuropsychological language therapy Cognitive dsiorder 
ZD38200 Cognitive behavioural language therapy Cognitive dsiorder 
1B1A.00 Memory loss - amnesia Cognitive dsiorder 
1B1a.00 Poor auditory sequential memory Cognitive dsiorder 
1B1A.11 Amnesia symptom Cognitive dsiorder 
1B1A.12 Memory loss symptom Cognitive dsiorder 
1B1A.13 Memory disturbance Cognitive dsiorder 
Z7CE.00 Memory observations Cognitive dsiorder 
Z7CE.11 Observations relating to memory Cognitive dsiorder 
Z7CE.12 Observations relating to retention of information Cognitive dsiorder 
Z7CE111 Average memory Cognitive dsiorder 
Z7CE300 Recovery of memory Cognitive dsiorder 
Z7CE400 Memory disturbance (& amnesia (& symptom)) Cognitive dsiorder 
Z7CE411 Amnesia symptom Cognitive dsiorder 
Z7CE412 Memory loss symptom Cognitive dsiorder 
Z7CE413 Memory loss - amnesia Cognitive dsiorder 
Z7CE414 Memory disturbance Cognitive dsiorder 
Z7CE415 Loss of memory Cognitive dsiorder 
Z7CE500 Forgetful Cognitive dsiorder 
Z7CE600 Amnesia Cognitive dsiorder 
Z7CE611 Memory loss Cognitive dsiorder 
Z7CE612 Memory gone Cognitive dsiorder 





Z7CE614 Memory loss - amnesia Cognitive dsiorder 
Z7CE615 Loss of memory Cognitive dsiorder 
Z7CE616 LOM - Loss of memory Cognitive dsiorder 
Z7CE800 Anterograde amnesia Cognitive dsiorder 
Z7CE811 Antegrade amnesia Cognitive dsiorder 
Z7CE900 Retrograde amnesia Cognitive dsiorder 
Z7CE911 RA - Retrograde amnesia Cognitive dsiorder 
Z7CEA00 Impairment of registration Cognitive dsiorder 
Z7CEA11 Impairment of working memory Cognitive dsiorder 
Z7CEA12 Impairment of immediate recall Cognitive dsiorder 
Z7CEA13 Impairment of primary memory Cognitive dsiorder 
Z7CEB00 Amnesia for remote events Cognitive dsiorder 
Z7CEB11 Loss of memory for remote events Cognitive dsiorder 
Z7CEB12 Poor memory for remote events Cognitive dsiorder 
Z7CEC00 Amnesia for recent events Cognitive dsiorder 
Z7CEC11 Loss of memory for recent events Cognitive dsiorder 
Z7CEC12 No memory for recent events Cognitive dsiorder 
Z7CED00 Amnesia for day to day facts Cognitive dsiorder 
Z7CEE00 Amnesia for important personal information Cognitive dsiorder 
Z7CEG00 Transient memory loss Cognitive dsiorder 
Z7CEH00 Memory impairment Cognitive dsiorder 
Z7CEH11 Memory dysfunction Cognitive dsiorder 
Z7CEH12 Memory deficit Cognitive dsiorder 
Z7CEH13 Bad memory Cognitive dsiorder 
Z7CEH14 Memory problem Cognitive dsiorder 
Z7CEH15 Poor memory Cognitive dsiorder 
Z7CEI00 Mixes past with present Cognitive dsiorder 
Z7CEJ00 Memory lapses Cognitive dsiorder 
Z7CEK00 Minor memory lapses Cognitive dsiorder 
Z7CEL00 Mild memory disturbance Cognitive dsiorder 
Z7CEM00 Distortion of memory Cognitive dsiorder 
Z7CEN00 Confabulation Cognitive dsiorder 
Z7CEN11 Invents experiences to compensate for loss of memory Cognitive dsiorder 
Z7CEO00 Momentary confabulation Cognitive dsiorder 
Z7CEP00 Fantastical confabulation Cognitive dsiorder 
1B1W.00 Transient epileptic amnesia Cognitive dsiorder 
E201700 Hysterical amnesia Cognitive dsiorder 
G655.00 Transient global amnesia Cognitive dsiorder 
R00z500 [D]Anterograde amnesia Cognitive dsiorder 
Ryu5000 [X]Other amnesia Cognitive dsiorder 
C370.00 Cystic fibrosis Cystic fibrosis 
C370.11 Fibrocystic disease Cystic fibrosis 
C370.12 Mucoviscidosis Cystic fibrosis 





C370100 Cystic fibrosis with meconium ileus Cystic fibrosis 
C370111 Meconium ileus in cystic fibrosis Cystic fibrosis 
C370200 Cystic fibrosis with pulmonary manifestations Cystic fibrosis 
C370300 Cystic fibrosis with intestinal manifestations Cystic fibrosis 
C370y00 Cystic fibrosis with other manifestations Cystic fibrosis 
C370y11 Cystic fibrosis with combined manifestations Cystic fibrosis 
C370z00 Cystic fibrosis NOS Cystic fibrosis 
1465.00 H/O: depression Depression  
212S.00 Depression resolved Depression  
32E4.00 ECG: S-T depression Depression  
8CAa.00 Patient given advice about management of depression Depression  
8HHq.00 Referral for guided self-help for depression Depression  
9H90.00 Depression annual review Depression  
9H91.00 Depression medication review Depression  
9kQ..11 On full dose long term treatment for depression Depression  
9Ov..00 Depression monitoring administration Depression  
9Ov0.00 Depression monitoring first letter Depression  
9Ov1.00 Depression monitoring second letter Depression  
9Ov2.00 Depression monitoring third letter Depression  
9Ov3.00 Depression monitoring verbal invite Depression  
9Ov4.00 Depression monitoring telephone invite Depression  
E112.00 Single major depressive episode Depression  
E112.11 Agitated depression Depression  
E112.12 Endogenous depression first episode Depression  
E112.13 Endogenous depression first episode Depression  
E112.14 Endogenous depression Depression  
E112000 Single major depressive episode, unspecified Depression  
E112100 Single major depressive episode, mild Depression  
E112200 Single major depressive episode, moderate Depression  
E112300 
Single major depressive episode, severe, without 
psychosis 
Depression  
E112400 Single major depressive episode, severe, with psychosis Depression  
E112500 
Single major depressive episode, partial or unspec 
remission 
Depression  
E112600 Single major depressive episode, in full remission Depression  
E112z00 Single major depressive episode NOS Depression  
E113.00 Recurrent major depressive episode Depression  
E113.11 Endogenous depression - recurrent Depression  
E113000 Recurrent major depressive episodes, unspecified Depression  
E113100 Recurrent major depressive episodes, mild Depression  
E113200 Recurrent major depressive episodes, moderate Depression  
E113300 








Recurrent major depressive episodes,partial/unspec 
remission 
Depression  





E113700 Recurrent depression Depression  
E113z00 Recurrent major depressive episode NOS Depression  
E11z200 Masked depression Depression  
E130.11 Psychotic reactive depression Depression  
E135.00 Agitated depression Depression  
E2B1.00 Chronic depression Depression  
Eu32.00 [X]Depressive episode Depression  
Eu32.11 [X]Single episode of depressive reaction Depression  
Eu32.12 [X]Single episode of psychogenic depression Depression  
Eu32.13 [X]Single episode of reactive depression Depression  
Eu32000 [X]Mild depressive episode Depression  
Eu32100 [X]Moderate depressive episode Depression  
Eu32200 












[X]Single episode vital depression w'out psychotic 
symptoms 
Depression  
Eu32300 [X]Severe depressive episode with psychotic symptoms Depression  
Eu32311 
[X]Single episode of major depression and psychotic 
symptoms 
Depression  
Eu32312 [X]Single episode of psychogenic depressive psychosis Depression  
Eu32313 [X]Single episode of psychotic depression Depression  
Eu32314 [X]Single episode of reactive depressive psychosis Depression  
Eu32400 [X]Mild depression Depression  
Eu32y00 [X]Other depressive episodes Depression  
Eu32y11 [X]Atypical depression Depression  
Eu32y12 [X]Single episode of masked depression NOS Depression  
Eu32z00 [X]Depressive episode, unspecified Depression  
Eu32z11 [X]Depression NOS Depression  
Eu32z12 [X]Depressive disorder NOS Depression  
Eu32z13 [X]Prolonged single episode of reactive depression Depression  
Eu32z14 [X] Reactive depression NOS Depression  
Eu33.00 [X]Recurrent depressive disorder Depression  
Eu33.11 [X]Recurrent episodes of depressive reaction Depression  
Eu33.12 [X]Recurrent episodes of psychogenic depression Depression  
Eu33.13 [X]Recurrent episodes of reactive depression Depression  
Eu33.14 [X]Seasonal depressive disorder Depression  
Eu33000 [X]Recurrent depressive disorder, current episode mild Depression  
Eu33100 




























[X]Recurrent depress disorder cur epi severe with psyc 
symp 
Depression  
Eu33311 [X]Endogenous depression with psychotic symptoms Depression  
Eu33312 








[X]Recurr severe episodes/psychogenic depressive 
psychosis 
Depression  
Eu33315 [X]Recurrent severe episodes of psychotic depression Depression  
Eu33316 
[X]Recurrent severe episodes/reactive depressive 
psychosis 
Depression  
Eu33400 [X]Recurrent depressive disorder, currently in remission Depression  
Eu33y00 [X]Other recurrent depressive disorders Depression  
Eu33z00 [X]Recurrent depressive disorder, unspecified Depression  
Eu33z11 [X]Monopolar depression NOS Depression  
E2B..00 Depressive disorder NEC Depression  
Eu8..00 [X]Disorders of psychological development 
Developmental disorders of speech 
and language  
Eu80.00 
[X]Specific developmental disorders of speech and 
language 
Developmental disorders of speech 
and language  
Eu80000 [X]Specific speech articulation disorder 
Developmental disorders of speech 
and language  
Eu80011 [X]Developmental phonological disorder 
Developmental disorders of speech 
and language  
Eu80012 [X]Developmental speech articulation disorder 
Developmental disorders of speech 
and language  
Eu80013 [X]Dyslalia 
Developmental disorders of speech 
and language  
Eu80014 [X]Functional speech articulation disorder 
Developmental disorders of speech 
and language  
Eu80015 [X]Lalling 
Developmental disorders of speech 
and language  
Eu80100 [X]Expressive language disorder 
Developmental disorders of speech 
and language  
Eu80111 [X]Developmental dysphasia, expressive type 
Developmental disorders of speech 
and language  
Eu80112 [X]Developmental aphasia, expressive type 
Developmental disorders of speech 
and language  
Eu80200 [X]Receptive language disorder 
Developmental disorders of speech 
and language  
Eu80211 [X]Congenital auditory imperception 
Developmental disorders of speech 
and language  
Eu80212 [X]Developmental dysphasia, receptive type 
Developmental disorders of speech 
and language  
Eu80213 [X]Developmental Wernicke's aphasia 
Developmental disorders of speech 
and language  
Eu80214 [X]Word deafness 
Developmental disorders of speech 
and language  
Eu80215 [X]Developmental aphasia, receptive type 
Developmental disorders of speech 
and language  
Eu80300 [X]Acquired aphasia with epilepsy [Landau - Kleffner] 
Developmental disorders of speech 
and language  
Eu80400 [X]Cocktail party syndrome 
Developmental disorders of speech 
and language  
Eu80500 [X]Semantic-pragmatic disorder 
Developmental disorders of speech 






[X]Other developmental disorders of speech and 
language 
Developmental disorders of speech 
and language  
Eu80y11 [X]Lisping 
Developmental disorders of speech 
and language  
Eu80z00 
[X]Developmental disorder of speech and language 
unspecified 
Developmental disorders of speech 
and language  
Eu80z11 [X]Language development disorder NOS 
Developmental disorders of speech 
and language  
Eu81.00 [X]Specific developmental disorders of scholastic skills 
Developmental disorders of speech 
and language  
Eu81000 [X]Specific reading disorder 
Developmental disorders of speech 
and language  
Eu81011 [X]Backward reading 
Developmental disorders of speech 
and language  
Eu81012 [X]Developmental dyslexia 
Developmental disorders of speech 
and language  
Eu81013 [X]Specific reading retardation 
Developmental disorders of speech 
and language  
1434.00 H/O: diabetes mellitus Diabetes mellitus 
42c..00 HbA1 - diabetic control Diabetes mellitus 
42W..00 Hb. A1C - diabetic control Diabetes mellitus 
42WZ.00 Hb. A1C - diabetic control NOS Diabetes mellitus 
66A..00 Diabetic monitoring Diabetes mellitus 
66A4.00 Diabetic on oral treatment Diabetes mellitus 
66A5.00 Diabetic on insulin Diabetes mellitus 
66A8.00 Has seen dietician - diabetes Diabetes mellitus 
66A9.00 Understands diet - diabetes Diabetes mellitus 
66Aa.00 Diabetic diet - poor compliance Diabetes mellitus 
66AA.11 Injection sites - diabetic Diabetes mellitus 
66AG.00 Diabetic drug side effects Diabetes mellitus 
66AH.00 Diabetic treatment changed Diabetes mellitus 
66AI.00 Diabetic - good control Diabetes mellitus 
66Ai.00 Diabetic 6 month review Diabetes mellitus 
66AJ.00 Diabetic - poor control Diabetes mellitus 
66AJ.11 Unstable diabetes Diabetes mellitus 
66AJ100 Brittle diabetes Diabetes mellitus 
66AJz00 Diabetic - poor control NOS Diabetes mellitus 
66AK.00 Diabetic - cooperative patient Diabetes mellitus 
66Ak.00 Diabetic monitoring - lower risk albumin excretion Diabetes mellitus 
66Al.00 Diabetic monitoring - higher risk albumin excretion Diabetes mellitus 
66AL.00 Diabetic-uncooperative patient Diabetes mellitus 
66AM.00 Diabetic - follow-up default Diabetes mellitus 
66AN.00 Date diabetic treatment start Diabetes mellitus 
66An.00 Diabetes type 1 review Diabetes mellitus 
66AO.00 Date diabetic treatment stopp. Diabetes mellitus 
66Ao.00 Diabetes type 2 review Diabetes mellitus 
66AP.00 Diabetes: practice programme Diabetes mellitus 
66AQ.00 Diabetes: shared care programme Diabetes mellitus 
66AU.00 Diabetes care by hospital only Diabetes mellitus 





66AW.00 Diabetic foot risk assessment Diabetes mellitus 
66AY.00 Diabetic diet - good compliance Diabetes mellitus 
66AZ.00 Diabetic monitoring NOS Diabetes mellitus 
8A12.00 Diabetic crisis monitoring Diabetes mellitus 
8B3l.00 Diabetes medication review Diabetes mellitus 
8BL2.00 Patient on maximal tolerated therapy for diabetes Diabetes mellitus 
8CA4100 Pt advised re diabetic diet Diabetes mellitus 
8CS0.00 Diabetes care plan agreed Diabetes mellitus 
8H2J.00 Admit diabetic emergency Diabetes mellitus 
8H3O.00 Non-urgent diabetic admission Diabetes mellitus 
8HBG.00 Diabetic retinopathy 12 month review Diabetes mellitus 
8HBH.00 Diabetic retinopathy 6 month review Diabetes mellitus 
9NN8.00 Under care of diabetologist Diabetes mellitus 
9NN9.00 Under care of diabetes specialist nurse Diabetes mellitus 
9OL..00 Diabetes monitoring admin. Diabetes mellitus 
9OL..11 Diabetes clinic administration Diabetes mellitus 
9OL1.00 Attends diabetes monitoring Diabetes mellitus 
9OL3.00 Diabetes monitoring default Diabetes mellitus 
9OL4.00 Diabetes monitoring 1st letter Diabetes mellitus 
9OL5.00 Diabetes monitoring 2nd letter Diabetes mellitus 
9OL6.00 Diabetes monitoring 3rd letter Diabetes mellitus 
9OL7.00 Diabetes monitor.verbal invite Diabetes mellitus 
9OL8.00 Diabetes monitor.phone invite Diabetes mellitus 
9OLA.00 Diabetes monitor. check done Diabetes mellitus 
9OLA.11 Diabetes monitored Diabetes mellitus 
9OLD.00 
Diabetic patient unsuitable for digital retinal 
photography 
Diabetes mellitus 
9OLZ.00 Diabetes monitoring admin.NOS Diabetes mellitus 
C10..00 Diabetes mellitus Diabetes mellitus 
C100.00 Diabetes mellitus with no mention of complication Diabetes mellitus 
C100000 
Diabetes mellitus, juvenile type, no mention of 
complication 
Diabetes mellitus 
C100011 Insulin dependent diabetes mellitus Diabetes mellitus 
C100111 Maturity onset diabetes Diabetes mellitus 
C100112 Non-insulin dependent diabetes mellitus Diabetes mellitus 
C100z00 Diabetes mellitus NOS with no mention of complication Diabetes mellitus 
C101.00 Diabetes mellitus with ketoacidosis Diabetes mellitus 
C101000 Diabetes mellitus, juvenile type, with ketoacidosis Diabetes mellitus 
C101y00 Other specified diabetes mellitus with ketoacidosis Diabetes mellitus 
C101z00 Diabetes mellitus NOS with ketoacidosis Diabetes mellitus 
C102.00 Diabetes mellitus with hyperosmolar coma Diabetes mellitus 
C102000 
Diabetes mellitus, juvenile type, with hyperosmolar 
coma 
Diabetes mellitus 
C102z00 Diabetes mellitus NOS with hyperosmolar coma Diabetes mellitus 
C103.00 Diabetes mellitus with ketoacidotic coma Diabetes mellitus 





C103y00 Other specified diabetes mellitus with coma Diabetes mellitus 
C103z00 Diabetes mellitus NOS with ketoacidotic coma Diabetes mellitus 
C104.00 Diabetes mellitus with renal manifestation Diabetes mellitus 
C104.11 Diabetic nephropathy Diabetes mellitus 
C104000 




Other specified diabetes mellitus with renal 
complications 
Diabetes mellitus 
C104z00 Diabetes mellitis with nephropathy NOS Diabetes mellitus 
C105.00 Diabetes mellitus with ophthalmic manifestation Diabetes mellitus 
C105000 




Other specified diabetes mellitus with ophthalmic 
complicatn 
Diabetes mellitus 
C105z00 Diabetes mellitus NOS with ophthalmic manifestation Diabetes mellitus 
C106.00 Diabetes mellitus with neurological manifestation Diabetes mellitus 
C106.11 Diabetic amyotrophy Diabetes mellitus 
C106.12 Diabetes mellitus with neuropathy Diabetes mellitus 
C106.13 Diabetes mellitus with polyneuropathy Diabetes mellitus 
C106000 




Other specified diabetes mellitus with neurological 
comps 
Diabetes mellitus 
C106z00 Diabetes mellitus NOS with neurological manifestation Diabetes mellitus 
C107.00 Diabetes mellitus with peripheral circulatory disorder Diabetes mellitus 
C107.11 Diabetes mellitus with gangrene Diabetes mellitus 
C107.12 Diabetes with gangrene Diabetes mellitus 
C107000 








Diabetes mellitus NOS with peripheral circulatory 
disorder 
Diabetes mellitus 
C108.00 Insulin dependent diabetes mellitus Diabetes mellitus 
C108.11 IDDM-Insulin dependent diabetes mellitus Diabetes mellitus 
C108.12 Type 1 diabetes mellitus Diabetes mellitus 
C108.13 Type I diabetes mellitus Diabetes mellitus 
C108000 
Insulin-dependent diabetes mellitus with renal 
complications 
Diabetes mellitus 
C108011 Type I diabetes mellitus with renal complications Diabetes mellitus 
C108012 Type 1 diabetes mellitus with renal complications Diabetes mellitus 
C108100 
Insulin-dependent diabetes mellitus with ophthalmic 
comps 
Diabetes mellitus 
C108111 Type I diabetes mellitus with ophthalmic complications Diabetes mellitus 
C108112 Type 1 diabetes mellitus with ophthalmic complications Diabetes mellitus 
C108200 



















C108311 Type I diabetes mellitus with multiple complications Diabetes mellitus 
C108312 Type 1 diabetes mellitus with multiple complications Diabetes mellitus 
C108400 Unstable insulin dependent diabetes mellitus Diabetes mellitus 
C108411 Unstable type I diabetes mellitus Diabetes mellitus 
C108412 Unstable type 1 diabetes mellitus Diabetes mellitus 
C108500 Insulin dependent diabetes mellitus with ulcer Diabetes mellitus 
C108511 Type I diabetes mellitus with ulcer Diabetes mellitus 
C108512 Type 1 diabetes mellitus with ulcer Diabetes mellitus 
C108600 Insulin dependent diabetes mellitus with gangrene Diabetes mellitus 
C108611 Type I diabetes mellitus with gangrene Diabetes mellitus 
C108612 Type 1 diabetes mellitus with gangrene Diabetes mellitus 
C108700 Insulin dependent diabetes mellitus with retinopathy Diabetes mellitus 
C108711 Type I diabetes mellitus with retinopathy Diabetes mellitus 
C108712 Type 1 diabetes mellitus with retinopathy Diabetes mellitus 
C108800 Insulin dependent diabetes mellitus - poor control Diabetes mellitus 
C108811 Type I diabetes mellitus - poor control Diabetes mellitus 
C108812 Type 1 diabetes mellitus - poor control Diabetes mellitus 
C108900 Insulin dependent diabetes maturity onset Diabetes mellitus 
C108911 Type I diabetes mellitus maturity onset Diabetes mellitus 
C108912 Type 1 diabetes mellitus maturity onset Diabetes mellitus 
C108A00 Insulin-dependent diabetes without complication Diabetes mellitus 
C108A11 Type I diabetes mellitus without complication Diabetes mellitus 
C108A12 Type 1 diabetes mellitus without complication Diabetes mellitus 
C108B00 
Insulin dependent diabetes mellitus with 
mononeuropathy 
Diabetes mellitus 
C108B11 Type I diabetes mellitus with mononeuropathy Diabetes mellitus 
C108B12 Type 1 diabetes mellitus with mononeuropathy Diabetes mellitus 
C108C00 
Insulin dependent diabetes mellitus with 
polyneuropathy 
Diabetes mellitus 
C108C11 Type I diabetes mellitus with polyneuropathy Diabetes mellitus 
C108C12 Type 1 diabetes mellitus with polyneuropathy Diabetes mellitus 
C108D00 Insulin dependent diabetes mellitus with nephropathy Diabetes mellitus 
C108D11 Type I diabetes mellitus with nephropathy Diabetes mellitus 
C108D12 Type 1 diabetes mellitus with nephropathy Diabetes mellitus 
C108E00 
Insulin dependent diabetes mellitus with 
hypoglycaemic coma 
Diabetes mellitus 
C108E11 Type I diabetes mellitus with hypoglycaemic coma Diabetes mellitus 
C108E12 Type 1 diabetes mellitus with hypoglycaemic coma Diabetes mellitus 
C108F00 
Insulin dependent diabetes mellitus with diabetic 
cataract 
Diabetes mellitus 
C108F11 Type I diabetes mellitus with diabetic cataract Diabetes mellitus 
C108F12 Type 1 diabetes mellitus with diabetic cataract Diabetes mellitus 
C108G11 Type I diabetes mellitus with peripheral angiopathy Diabetes mellitus 
C108G12 Type 1 diabetes mellitus with peripheral angiopathy Diabetes mellitus 
C108H00 Insulin dependent diabetes mellitus with arthropathy Diabetes mellitus 
C108H11 Type I diabetes mellitus with arthropathy Diabetes mellitus 





C108J11 Type I diabetes mellitus with neuropathic arthropathy Diabetes mellitus 
C108J12 Type 1 diabetes mellitus with neuropathic arthropathy Diabetes mellitus 
C108y00 Other specified diabetes mellitus with multiple comps Diabetes mellitus 
C108z00 
Unspecified diabetes mellitus with multiple 
complications 
Diabetes mellitus 
C109.00 Non-insulin dependent diabetes mellitus Diabetes mellitus 
C109.11 NIDDM - Non-insulin dependent diabetes mellitus Diabetes mellitus 
C109.12 Type 2 diabetes mellitus Diabetes mellitus 
C109.13 Type II diabetes mellitus Diabetes mellitus 
C109000 
Non-insulin-dependent diabetes mellitus with renal 
comps 
Diabetes mellitus 
C109011 Type II diabetes mellitus with renal complications Diabetes mellitus 
C109012 Type 2 diabetes mellitus with renal complications Diabetes mellitus 
C109100 
Non-insulin-dependent diabetes mellitus with 
ophthalm comps 
Diabetes mellitus 
C109111 Type II diabetes mellitus with ophthalmic complications Diabetes mellitus 
C109112 Type 2 diabetes mellitus with ophthalmic complications Diabetes mellitus 
C109200 












Non-insulin-dependent diabetes mellitus with multiple 
comps 
Diabetes mellitus 
C109311 Type II diabetes mellitus with multiple complications Diabetes mellitus 
C109312 Type 2 diabetes mellitus with multiple complications Diabetes mellitus 
C109400 Non-insulin dependent diabetes mellitus with ulcer Diabetes mellitus 
C109411 Type II diabetes mellitus with ulcer Diabetes mellitus 
C109412 Type 2 diabetes mellitus with ulcer Diabetes mellitus 
C109500 Non-insulin dependent diabetes mellitus with gangrene Diabetes mellitus 
C109511 Type II diabetes mellitus with gangrene Diabetes mellitus 
C109512 Type 2 diabetes mellitus with gangrene Diabetes mellitus 
C109600 
Non-insulin-dependent diabetes mellitus with 
retinopathy 
Diabetes mellitus 
C109611 Type II diabetes mellitus with retinopathy Diabetes mellitus 
C109612 Type 2 diabetes mellitus with retinopathy Diabetes mellitus 
C109700 Non-insulin dependent diabetes mellitus - poor control Diabetes mellitus 
C109711 Type II diabetes mellitus - poor control Diabetes mellitus 
C109712 Type 2 diabetes mellitus - poor control Diabetes mellitus 
C109900 
Non-insulin-dependent diabetes mellitus without 
complication 
Diabetes mellitus 
C109911 Type II diabetes mellitus without complication Diabetes mellitus 
C109912 Type 2 diabetes mellitus without complication Diabetes mellitus 
C109A00 
Non-insulin dependent diabetes mellitus with 
mononeuropathy 
Diabetes mellitus 
C109A11 Type II diabetes mellitus with mononeuropathy Diabetes mellitus 
C109A12 Type 2 diabetes mellitus with mononeuropathy Diabetes mellitus 
C109B00 
Non-insulin dependent diabetes mellitus with 
polyneuropathy 
Diabetes mellitus 
C109B11 Type II diabetes mellitus with polyneuropathy Diabetes mellitus 






Non-insulin dependent diabetes mellitus with 
nephropathy 
Diabetes mellitus 
C109C11 Type II diabetes mellitus with nephropathy Diabetes mellitus 
C109C12 Type 2 diabetes mellitus with nephropathy Diabetes mellitus 
C109D00 
Non-insulin dependent diabetes mellitus with 
hypoglyca coma 
Diabetes mellitus 
C109D11 Type II diabetes mellitus with hypoglycaemic coma Diabetes mellitus 
C109D12 Type 2 diabetes mellitus with hypoglycaemic coma Diabetes mellitus 
C109E00 
Non-insulin depend diabetes mellitus with diabetic 
cataract 
Diabetes mellitus 
C109E11 Type II diabetes mellitus with diabetic cataract Diabetes mellitus 
C109E12 Type 2 diabetes mellitus with diabetic cataract Diabetes mellitus 
C109F11 Type II diabetes mellitus with peripheral angiopathy Diabetes mellitus 
C109F12 Type 2 diabetes mellitus with peripheral angiopathy Diabetes mellitus 
C109G00 
Non-insulin dependent diabetes mellitus with 
arthropathy 
Diabetes mellitus 
C109G11 Type II diabetes mellitus with arthropathy Diabetes mellitus 
C109G12 Type 2 diabetes mellitus with arthropathy Diabetes mellitus 
C109H11 Type II diabetes mellitus with neuropathic arthropathy Diabetes mellitus 
C109H12 Type 2 diabetes mellitus with neuropathic arthropathy Diabetes mellitus 
C109J00 Insulin treated Type 2 diabetes mellitus Diabetes mellitus 
C109J11 Insulin treated non-insulin dependent diabetes mellitus Diabetes mellitus 
C109J12 Insulin treated Type II diabetes mellitus Diabetes mellitus 
C109K00 
Hyperosmolar non-ketotic state in type 2 diabetes 
mellitus 
Diabetes mellitus 
C10A.00 Malnutrition-related diabetes mellitus Diabetes mellitus 
C10A000 Malnutrition-related diabetes mellitus with coma Diabetes mellitus 
C10A100 




























Malnutrit-related diabetes mellitus with unspec 
complics 
Diabetes mellitus 
C10AX00 Malnutrit-relat diabetes mellitus with other spec comps Diabetes mellitus 
C10B.00 Diabetes mellitus induced by steroids Diabetes mellitus 
C10B000 Steroid induced diabetes mellitus without complication Diabetes mellitus 
C10C.00 Diabetes mellitus autosomal dominant Diabetes mellitus 
C10C.11 Maturity onset diabetes in youth Diabetes mellitus 
C10C.12 Maturity onset diabetes in youth type 1 Diabetes mellitus 
C10D.00 Diabetes mellitus autosomal dominant type 2 Diabetes mellitus 
C10D.11 Maturity onset diabetes in youth type 2 Diabetes mellitus 
C10E.00 Type 1 diabetes mellitus Diabetes mellitus 





C10E.12 Insulin dependent diabetes mellitus Diabetes mellitus 
C10E000 Type 1 diabetes mellitus with renal complications Diabetes mellitus 
C10E011 Type I diabetes mellitus with renal complications Diabetes mellitus 
C10E012 
Insulin-dependent diabetes mellitus with renal 
complications 
Diabetes mellitus 
C10E100 Type 1 diabetes mellitus with ophthalmic complications Diabetes mellitus 
C10E111 Type I diabetes mellitus with ophthalmic complications Diabetes mellitus 
C10E112 












Insulin-dependent diabetes mellitus with neurological 
comps 
Diabetes mellitus 
C10E300 Type 1 diabetes mellitus with multiple complications Diabetes mellitus 
C10E311 Type I diabetes mellitus with multiple complications Diabetes mellitus 
C10E312 
Insulin dependent diabetes mellitus with multiple 
complicat 
Diabetes mellitus 
C10E400 Unstable type 1 diabetes mellitus Diabetes mellitus 
C10E411 Unstable type I diabetes mellitus Diabetes mellitus 
C10E412 Unstable insulin dependent diabetes mellitus Diabetes mellitus 
C10E500 Type 1 diabetes mellitus with ulcer Diabetes mellitus 
C10E511 Type I diabetes mellitus with ulcer Diabetes mellitus 
C10E512 Insulin dependent diabetes mellitus with ulcer Diabetes mellitus 
C10E600 Type 1 diabetes mellitus with gangrene Diabetes mellitus 
C10E611 Type I diabetes mellitus with gangrene Diabetes mellitus 
C10E612 Insulin dependent diabetes mellitus with gangrene Diabetes mellitus 
C10E700 Type 1 diabetes mellitus with retinopathy Diabetes mellitus 
C10E711 Type I diabetes mellitus with retinopathy Diabetes mellitus 
C10E712 Insulin dependent diabetes mellitus with retinopathy Diabetes mellitus 
C10E800 Type 1 diabetes mellitus - poor control Diabetes mellitus 
C10E811 Type I diabetes mellitus - poor control Diabetes mellitus 
C10E812 Insulin dependent diabetes mellitus - poor control Diabetes mellitus 
C10E900 Type 1 diabetes mellitus maturity onset Diabetes mellitus 
C10E911 Type I diabetes mellitus maturity onset Diabetes mellitus 
C10E912 Insulin dependent diabetes maturity onset Diabetes mellitus 
C10EA00 Type 1 diabetes mellitus without complication Diabetes mellitus 
C10EA11 Type I diabetes mellitus without complication Diabetes mellitus 
C10EA12 Insulin-dependent diabetes without complication Diabetes mellitus 
C10EB00 Type 1 diabetes mellitus with mononeuropathy Diabetes mellitus 
C10EB11 Type I diabetes mellitus with mononeuropathy Diabetes mellitus 
C10EB12 
Insulin dependent diabetes mellitus with 
mononeuropathy 
Diabetes mellitus 
C10EC00 Type 1 diabetes mellitus with polyneuropathy Diabetes mellitus 
C10EC11 Type I diabetes mellitus with polyneuropathy Diabetes mellitus 
C10EC12 
Insulin dependent diabetes mellitus with 
polyneuropathy 
Diabetes mellitus 
C10ED00 Type 1 diabetes mellitus with nephropathy Diabetes mellitus 





C10ED12 Insulin dependent diabetes mellitus with nephropathy Diabetes mellitus 
C10EE00 Type 1 diabetes mellitus with hypoglycaemic coma Diabetes mellitus 
C10EE11 Type I diabetes mellitus with hypoglycaemic coma Diabetes mellitus 
C10EE12 
Insulin dependent diabetes mellitus with 
hypoglycaemic coma 
Diabetes mellitus 
C10EF00 Type 1 diabetes mellitus with diabetic cataract Diabetes mellitus 
C10EF11 Type I diabetes mellitus with diabetic cataract Diabetes mellitus 
C10EF12 
Insulin dependent diabetes mellitus with diabetic 
cataract 
Diabetes mellitus 
C10EG00 Type 1 diabetes mellitus with peripheral angiopathy Diabetes mellitus 
C10EG11 Type I diabetes mellitus with peripheral angiopathy Diabetes mellitus 
C10EH00 Type 1 diabetes mellitus with arthropathy Diabetes mellitus 
C10EH11 Type I diabetes mellitus with arthropathy Diabetes mellitus 
C10EH12 Insulin dependent diabetes mellitus with arthropathy Diabetes mellitus 
C10EJ00 Type 1 diabetes mellitus with neuropathic arthropathy Diabetes mellitus 
C10EJ11 Type I diabetes mellitus with neuropathic arthropathy Diabetes mellitus 
C10EK00 Type 1 diabetes mellitus with persistent proteinuria Diabetes mellitus 
C10EK11 Type I diabetes mellitus with persistent proteinuria Diabetes mellitus 
C10EL00 




Type I diabetes mellitus with persistent 
microalbuminuria 
Diabetes mellitus 
C10EM00 Type 1 diabetes mellitus with ketoacidosis Diabetes mellitus 
C10EM11 Type I diabetes mellitus with ketoacidosis Diabetes mellitus 
C10EN00 Type 1 diabetes mellitus with ketoacidotic coma Diabetes mellitus 
C10EN11 Type I diabetes mellitus with ketoacidotic coma Diabetes mellitus 
C10EP00 Type 1 diabetes mellitus with exudative maculopathy Diabetes mellitus 
C10EP11 Type I diabetes mellitus with exudative maculopathy Diabetes mellitus 
C10EQ00 Type 1 diabetes mellitus with gastroparesis Diabetes mellitus 
C10F.00 Type 2 diabetes mellitus Diabetes mellitus 
C10F.11 Type II diabetes mellitus Diabetes mellitus 
C10F000 Type 2 diabetes mellitus with renal complications Diabetes mellitus 
C10F011 Type II diabetes mellitus with renal complications Diabetes mellitus 
C10F100 Type 2 diabetes mellitus with ophthalmic complications Diabetes mellitus 
C10F111 Type II diabetes mellitus with ophthalmic complications Diabetes mellitus 
C10F200 




Type II diabetes mellitus with neurological 
complications 
Diabetes mellitus 
C10F300 Type 2 diabetes mellitus with multiple complications Diabetes mellitus 
C10F311 Type II diabetes mellitus with multiple complications Diabetes mellitus 
C10F400 Type 2 diabetes mellitus with ulcer Diabetes mellitus 
C10F411 Type II diabetes mellitus with ulcer Diabetes mellitus 
C10F500 Type 2 diabetes mellitus with gangrene Diabetes mellitus 
C10F511 Type II diabetes mellitus with gangrene Diabetes mellitus 
C10F600 Type 2 diabetes mellitus with retinopathy Diabetes mellitus 
C10F611 Type II diabetes mellitus with retinopathy Diabetes mellitus 
C10F700 Type 2 diabetes mellitus - poor control Diabetes mellitus 





C10F900 Type 2 diabetes mellitus without complication Diabetes mellitus 
C10F911 Type II diabetes mellitus without complication Diabetes mellitus 
C10FA00 Type 2 diabetes mellitus with mononeuropathy Diabetes mellitus 
C10FA11 Type II diabetes mellitus with mononeuropathy Diabetes mellitus 
C10FB00 Type 2 diabetes mellitus with polyneuropathy Diabetes mellitus 
C10FB11 Type II diabetes mellitus with polyneuropathy Diabetes mellitus 
C10FC00 Type 2 diabetes mellitus with nephropathy Diabetes mellitus 
C10FC11 Type II diabetes mellitus with nephropathy Diabetes mellitus 
C10FD00 Type 2 diabetes mellitus with hypoglycaemic coma Diabetes mellitus 
C10FD11 Type II diabetes mellitus with hypoglycaemic coma Diabetes mellitus 
C10FE00 Type 2 diabetes mellitus with diabetic cataract Diabetes mellitus 
C10FE11 Type II diabetes mellitus with diabetic cataract Diabetes mellitus 
C10FF00 Type 2 diabetes mellitus with peripheral angiopathy Diabetes mellitus 
C10FF11 Type II diabetes mellitus with peripheral angiopathy Diabetes mellitus 
C10FG00 Type 2 diabetes mellitus with arthropathy Diabetes mellitus 
C10FG11 Type II diabetes mellitus with arthropathy Diabetes mellitus 
C10FH00 Type 2 diabetes mellitus with neuropathic arthropathy Diabetes mellitus 
C10FH11 Type II diabetes mellitus with neuropathic arthropathy Diabetes mellitus 
C10FJ00 Insulin treated Type 2 diabetes mellitus Diabetes mellitus 
C10FJ11 Insulin treated Type II diabetes mellitus Diabetes mellitus 
C10FK00 
Hyperosmolar non-ketotic state in type 2 diabetes 
mellitus 
Diabetes mellitus 
C10FL00 Type 2 diabetes mellitus with persistent proteinuria Diabetes mellitus 
C10FL11 Type II diabetes mellitus with persistent proteinuria Diabetes mellitus 
C10FM00 




Type II diabetes mellitus with persistent 
microalbuminuria 
Diabetes mellitus 
C10FN00 Type 2 diabetes mellitus with ketoacidosis Diabetes mellitus 
C10FN11 Type II diabetes mellitus with ketoacidosis Diabetes mellitus 
C10FP00 Type 2 diabetes mellitus with ketoacidotic coma Diabetes mellitus 
C10FP11 Type II diabetes mellitus with ketoacidotic coma Diabetes mellitus 
C10FQ00 Type 2 diabetes mellitus with exudative maculopathy Diabetes mellitus 
C10FQ11 Type II diabetes mellitus with exudative maculopathy Diabetes mellitus 
C10FR00 Type 2 diabetes mellitus with gastroparesis Diabetes mellitus 
C10FS00 Maternally inherited diabetes mellitus Diabetes mellitus 
C10G.00 Secondary pancreatic diabetes mellitus Diabetes mellitus 
C10G000 
Secondary pancreatic diabetes mellitus without 
complication 
Diabetes mellitus 
C10H.00 Diabetes mellitus induced by non-steroid drugs Diabetes mellitus 
C10M.00 Lipoatrophic diabetes mellitus Diabetes mellitus 
C10M000 Lipoatrophic diabetes mellitus without complication Diabetes mellitus 
C10N.00 Secondary diabetes mellitus Diabetes mellitus 
C10N000 Secondary diabetes mellitus without complication Diabetes mellitus 
C10N100 Cystic fibrosis related diabetes mellitus Diabetes mellitus 
C10y.00 Diabetes mellitus with other specified manifestation Diabetes mellitus 
C10y000 
Diabetes mellitus, juvenile, + other specified 
manifestation 
Diabetes mellitus 







Diabetes mellitus NOS with other specified 
manifestation 
Diabetes mellitus 
C10z.00 Diabetes mellitus with unspecified complication Diabetes mellitus 
C10z000 




Other specified diabetes mellitus with unspecified 
comps 
Diabetes mellitus 
C10zz00 Diabetes mellitus NOS with unspecified complication Diabetes mellitus 
C11y000 Steroid induced diabetes Diabetes mellitus 
Cyu2.00 [X]Diabetes mellitus Diabetes mellitus 
Cyu2000 [X]Other specified diabetes mellitus Diabetes mellitus 
Cyu2100 








[X]Unspecified diabetes mellitus with renal 
complications 
Diabetes mellitus 
F171100 Autonomic neuropathy due to diabetes Diabetes mellitus 
F345000 Diabetic mononeuritis multiplex Diabetes mellitus 
F35z000 Diabetic mononeuritis NOS Diabetes mellitus 
F372.00 Polyneuropathy in diabetes Diabetes mellitus 
F372.11 Diabetic polyneuropathy Diabetes mellitus 
F372.12 Diabetic neuropathy Diabetes mellitus 
F372000 Acute painful diabetic neuropathy Diabetes mellitus 
F372100 Chronic painful diabetic neuropathy Diabetes mellitus 
F372200 Asymptomatic diabetic neuropathy Diabetes mellitus 
F381300 Myasthenic syndrome due to diabetic amyotrophy Diabetes mellitus 
F381311 Diabetic amyotrophy Diabetes mellitus 
F3y0.00 Diabetic mononeuropathy Diabetes mellitus 
F420.00 Diabetic retinopathy Diabetes mellitus 
F420000 Background diabetic retinopathy Diabetes mellitus 
F420100 Proliferative diabetic retinopathy Diabetes mellitus 
F420200 Preproliferative diabetic retinopathy Diabetes mellitus 
F420300 Advanced diabetic maculopathy Diabetes mellitus 
F420400 Diabetic maculopathy Diabetes mellitus 
F420500 Advanced diabetic retinal disease Diabetes mellitus 
F420600 Non proliferative diabetic retinopathy Diabetes mellitus 
F420700 High risk proliferative diabetic retinopathy Diabetes mellitus 
F420800 High risk non proliferative diabetic retinopathy Diabetes mellitus 
F420z00 Diabetic retinopathy NOS Diabetes mellitus 
F440700 Diabetic iritis Diabetes mellitus 
F464000 Diabetic cataract Diabetes mellitus 
G73y000 Diabetic peripheral angiopathy Diabetes mellitus 
K01x100 Nephrotic syndrome in diabetes mellitus Diabetes mellitus 
Kyu0300 [X]Glomerular disorders in diabetes mellitus Diabetes mellitus 
M037200 Cellulitis in diabetic foot Diabetes mellitus 
M271000 Ischaemic ulcer diabetic foot Diabetes mellitus 





M271200 Mixed diabetic ulcer - foot Diabetes mellitus 
N030000 Diabetic cheiroarthropathy Diabetes mellitus 
N030011 Diabetic cheiropathy Diabetes mellitus 
N030100 Diabetic Charcot arthropathy Diabetes mellitus 
R054200 [D]Gangrene of toe in diabetic Diabetes mellitus 
R054300 [D]Widespread diabetic foot gangrene Diabetes mellitus 
TJ23.00 Adverse reaction to insulins and antidiabetic agents Diabetes mellitus 
TJ23z00 
Adverse reaction to insulins and antidiabetic agents 
NOS 
Diabetes mellitus 
U602311 [X] Adverse reaction to insulins and antidiabetic agents Diabetes mellitus 
U60231E 
[X] Adverse reaction to insulins and antidiabetic agents 
NOS 
Diabetes mellitus 
ZC2C800 Dietary advice for diabetes mellitus Diabetes mellitus 
ZC2C900 Dietary advice for type I diabetes Diabetes mellitus 
ZC2C911 Diet advice for insulin-dependent diabetes Diabetes mellitus 
ZC2CA00 Dietary advice for type II diabetes Diabetes mellitus 
ZC2CA11 Dietary advice non-insulin-dependent diabetes Diabetes mellitus 
43C3.11 HIV positive HIV  
A788.00 Acquired immune deficiency syndrome HIV  
A788.11 Human immunodeficiency virus infection HIV  
A788000 Acute human immunodeficiency virus infection HIV  
A788100 Asymptomatic human immunodeficiency virus infection HIV  
A788200 












Human immunodeficiency virus with secondary 
infection 
HIV  
A788600 Human immunodeficiency virus with secondary cancers HIV  
A788U00 
HIV disease result/haematological+immunologic 
abnorms,NEC 
HIV  
A788V00 HIV disease resulting in multiple diseases CE HIV  
A788W00 












Acquired human immunodeficiency virus infection 
syndrome NOS 
HIV  
A789.00 Human immunodef virus resulting in other disease HIV  
A789000 HIV disease resulting in mycobacterial infection HIV  
A789100 HIV disease resulting in cytomegaloviral disease HIV  
A789200 HIV disease resulting in candidiasis HIV  
A789300 
HIV disease resulting in Pneumocystis carinii 
pneumonia 
HIV  
A789400 HIV disease resulting in multiple infections HIV  
A789500 HIV disease resulting in Kaposi's sarcoma HIV  
A789600 HIV disease resulting in Burkitt's lymphoma HIV  





A789800 HIV disease resulting in multiple malignant neoplasms HIV  
A789900 
HIV disease resulting in lymphoid interstitial 
pneumonitis 
HIV  
A789A00 HIV disease resulting in wasting syndrome HIV  
A789X00 
HIV dis reslt/oth mal neopl/lymph,h'matopoetc+reltd 
tissu 
HIV  
AyuC.00 [X]Human immunodeficiency virus disease HIV  
AyuC000 [X]HIV disease resulting in other bacterial infections HIV  
AyuC100 [X]HIV disease resulting in other viral infections HIV  
AyuC200 [X]HIV disease resulting in other mycoses HIV  
AyuC300 [X]HIV disease resulting in multiple infections HIV  
AyuC400 












[X]HIV dis reslt/oth mal 
neopl/lymph,h'matopoetc+reltd tissu 
HIV  
AyuC800 [X]HIV disease resulting in other malignant neoplasms HIV  
AyuC900 
[X]HIV disease resulting in unspecified malignant 
neoplasm 
HIV  
AyuCA00 [X]HIV disease resulting in multiple diseases CE HIV  
AyuCB00 
[X]HIV disease result/haematological+immunologic 
abnorms,NEC 
HIV  
AyuCC00 [X]HIV disease resulting in other specified conditions HIV  
AyuCD00 
[X]Unspecified human immunodeficiency virus [HIV] 
disease 
HIV  
Eu02400 [X]Dementia in human immunodef virus [HIV] disease HIV  
R109.00 
[D]Laboratory evidence of human immunodefiency 
virus [HIV] 
HIV  
E2E..00 Childhood hyperkinetic syndrome Hyperkinetic disorder 
E2E..11 Overactive child syndrome Hyperkinetic disorder 
E2E0.00 Child attention deficit disorder Hyperkinetic disorder 
E2E0000 Attention deficit without hyperactivity Hyperkinetic disorder 
E2E0100 Attention deficit with hyperactivity Hyperkinetic disorder 
E2E0z00 Child attention deficit disorder NOS Hyperkinetic disorder 
E2E1.00 Hyperkinesis with developmental delay Hyperkinetic disorder 
E2E2.00 Hyperkinetic conduct disorder Hyperkinetic disorder 
E2Ey.00 Other hyperkinetic manifestation Hyperkinetic disorder 
E2Ez.00 Hyperkinetic syndrome NOS Hyperkinetic disorder 
ZS9..00 Disorders of attention and motor control Hyperkinetic disorder 
ZS91.00 Attention deficit disorder Hyperkinetic disorder 
ZS91.11 ADD - Attention deficit disorder Hyperkinetic disorder 
ZS91.12 [X]Attention deficit disorder Hyperkinetic disorder 
ZS92.00 Persistent developmental avoidance Hyperkinetic disorder 
ZS92.11 PDA - Persistent developmental avoidance Hyperkinetic disorder 
ZS93.00 Deficits in attention motor control and perception Hyperkinetic disorder 
ZS93.11 
DAMP - Deficits in attention motor control and 
perception 
Hyperkinetic disorder 
ZS94.00 Minimal brain dysfunction Hyperkinetic disorder 





ZS94.12 Soft neurological signs Hyperkinetic disorder 
Eu90100 [X]Hyperkinetic conduct disorder Hyperkinetic disorder 
Eu90111 
[X]Hyperkinetic disorder associated with conduct 
disorder 
Hyperkinetic disorder 
E3...00 Mental retardation Mental retardation 
E30..00 Mild mental retardation, IQ in range 50-70 Mental retardation 
E30..11 Educationally subnormal Mental retardation 
E30..12 Feeble-minded Mental retardation 
E30..13 Moron Mental retardation 
E31..00 Other specified mental retardation Mental retardation 
E310.00 Moderate mental retardation, IQ in range 35-49 Mental retardation 
E310.11 Imbecile Mental retardation 
E311.00 Severe mental retardation, IQ in range 20-34 Mental retardation 
E312.00 Profound mental retardation with IQ less than 20 Mental retardation 
E312.11 Idiocy Mental retardation 
E31z.00 Other specified mental retardation NOS Mental retardation 
E3y..00 Other specified mental retardation Mental retardation 
E3z..00 Mental retardation NOS Mental retardation 
Eu7..00 [X]Mental retardation Mental retardation 
Eu70.00 [X]Mild mental retardation Mental retardation 
Eu70.11 [X]Feeble-mindedness Mental retardation 
Eu70.12 [X]Mild mental subnormality Mental retardation 
Eu70000 












[X]Mild mental retardation without mention 
impairment behav 
Mental retardation 
Eu71.00 [X]Moderate mental retardation Mental retardation 
Eu71.11 [X]Moderate mental subnormality Mental retardation 
Eu71000 




[X]Mod mental retard sig impairment behav req 
attent/treatmt 
Mental retardation 
Eu71y00 [X]Mod retard oth behav impair Mental retardation 
Eu71z00 
[X]Mod mental retardation without mention 
impairment behav 
Mental retardation 
Eu72.00 [X]Severe mental retardation Mental retardation 
Eu72.11 [X]Severe mental subnormality Mental retardation 
Eu72000 












[X]Sev mental retardation without mention impairment 
behav 
Mental retardation 
Eu73.00 [X]Profound mental retardation Mental retardation 
Eu73.11 [X]Profound mental subnormality Mental retardation 
Eu73000 
















[X]Prfnd mental retardation without mention 
impairment behav 
Mental retardation 
Eu7y.00 [X]Other mental retardation Mental retardation 
Eu7y000 












[X]Other mental retardation without mention 
impairment behav 
Mental retardation 
Eu7z.00 [X]Unspecified mental retardation Mental retardation 
Eu7z.11 [X]Mental deficiency NOS Mental retardation 
Eu7z.12 [X]Mental subnormality NOS Mental retardation 
Eu7z000 












[X]Unsp mental retardation without mention 
impairment behav 
Mental retardation 
8893.00 Renal perfusion Renal disorder 
1A52.00 Renal colic Renal disorder 
1A52.11 Renal colic, symptom Renal disorder 
1A53.00 Lumbar ache - renal Renal disorder 
44J5.00 Renal profile Renal disorder 
7B0..11 Renal operations Renal disorder 
7L1A000 Renal dialysis Renal disorder 
8L5..00 Renal/urological operation planned Renal disorder 
8L50.00 Renal transplant planned Renal disorder 
A954.11 Renal syphilis Renal disorder 
B4A..11 Renal malignant neoplasm Renal disorder 
B7D..11 Renal benign neoplasms Renal disorder 
B91z111 Renal neoplasm of uncertain behaviour Renal disorder 
C341111 Renal stone - uric acid Renal disorder 
C354711 Renal calcinosis Renal disorder 
D410400 Renal polycythaemia Renal disorder 
F421200 Renal retinopathy Renal disorder 
G701.00 Renal artery atherosclerosis Renal disorder 
K034.00 Renal cortical necrosis unspecified Renal disorder 
K035.00 Renal medullary necrosis unspecified Renal disorder 
K04..00 Acute renal failure Renal disorder 
K040.00 Acute renal tubular necrosis Renal disorder 
K041.00 Acute renal cortical necrosis Renal disorder 
K042.00 Acute renal medullary necrosis Renal disorder 
K042.11 Necrotising renal papillitis Renal disorder 





K04z.00 Acute renal failure NOS Renal disorder 
K05..00 Chronic renal failure Renal disorder 
K05..11 Chronic uraemia Renal disorder 
K05..12 End stage renal failure Renal disorder 
K050.00 End stage renal failure Renal disorder 
K06..00 Renal failure unspecified Renal disorder 
K06..11 Uraemia NOS Renal disorder 
K060.00 Renal impairment Renal disorder 
K060.11 Impaired renal function Renal disorder 
K07..00 Renal sclerosis unspecified Renal disorder 
K070.00 Atrophy of kidney Renal disorder 
K071.00 Renal fibrosis Renal disorder 
K072.00 Glomerulosclerosis Renal disorder 
K07z.00 Renal sclerosis NOS Renal disorder 
K08..00 Impaired renal function disorder Renal disorder 
K080.00 Renal osteodystrophy Renal disorder 
K080000 Phosphate-losing tubular disorders Renal disorder 
K080100 Renal dwarfism Renal disorder 
K080200 Renal infantilism Renal disorder 
K080300 Renal rickets Renal disorder 
K080z00 Renal osteodystrophy NOS Renal disorder 
K081.00 Nephrogenic diabetes insipidus Renal disorder 
K08y.00 Other impaired renal function disorder Renal disorder 
K08y000 Hypokalaemic nephropathy Renal disorder 
K08y100 Secondary hyperparathyroidism Renal disorder 
K08y200 Lightwood - Albright syndrome Renal disorder 
K08y211 Albright's renal tubular acidosis Renal disorder 
K08y300 Renal function impairment with growth failure Renal disorder 
K08y400 Renal tubular acidosis Renal disorder 
K08y412 Renal tubular acidaemia Renal disorder 
K08y500 Acute interstitial nephritis Renal disorder 
K08yz00 Other impaired renal function disorder NOS Renal disorder 
K08yz11 Renal acidaemia Renal disorder 
K08yz12 Renotubular acidaemia Renal disorder 
K08z.00 Impaired renal function disorder NOS Renal disorder 
K0B..00 Renal tubulo-interstitial disorders in diseases EC Renal disorder 
K0B1.00 Renal tubulo-interstitial disorder/ neoplastic diseases Renal disorder 
K0B3.00 Renal tubulo-interstitial disorders in metabolic diseases Renal disorder 
K0B4000 Renal tubulo-interstitial disorder in SLE Renal disorder 
K0B5.00 Renal tubulo-interstitial disordrs in transplant rejectn Renal disorder 
K10..00 Infections of kidney Renal disorder 
K10..11 Renal infections Renal disorder 
K100.00 Chronic pyelonephritis Renal disorder 
K100000 Chronic pyelonephritis without medullary necrosis Renal disorder 
K100100 Chronic pyelonephritis with medullary necrosis Renal disorder 





K100300 Chronic pyonephrosis Renal disorder 
K100400 
Nonobstructive reflux-associated chronic 
pyelonephritis Renal disorder 
K100500 Chronic obstructive pyelonephritis Renal disorder 
K100600 Calculous pyelonephritis Renal disorder 
K100z00 Chronic pyelonephritis NOS Renal disorder 
K101.00 Acute pyelonephritis Renal disorder 
K101000 Acute pyelonephritis without medullary necrosis Renal disorder 
K101100 Acute pyelonephritis with medullary necrosis Renal disorder 
K101200 Acute pyelitis Renal disorder 
K101300 Acute pyonephrosis Renal disorder 
K101z00 Acute pyelonephritis NOS Renal disorder 
K102.00 Renal and perinephric abscess Renal disorder 
K102000 Renal abscess Renal disorder 
K102100 Perinephric abscess Renal disorder 
K102200 Renal carbuncle Renal disorder 
K102z00 Renal and perinephric abscess NOS Renal disorder 
K103.00 Pyeloureteritis cystica Renal disorder 
K103.11 Ureteritis cystica Renal disorder 
K103.12 Infestation of renal pelvis with ureter Renal disorder 
K104.00 Xanthogranulomatous pyelonephritis Renal disorder 
K10y.00 Pyelonephritis and pyonephrosis unspecified Renal disorder 
K10y000 Pyelonephritis unspecified Renal disorder 
K10y100 Pyelitis unspecified Renal disorder 
K10y200 Pyonephrosis unspecified Renal disorder 
K10y300 Pyelonephritis in diseases EC Renal disorder 
K10y400 Pyelitis in diseases EC Renal disorder 
K10yz00 Unspecified pyelonephritis NOS Renal disorder 
K10z.00 Infection of kidney NOS Renal disorder 
K120.12 Renal calculus Renal disorder 
K120.13 Renal stone Renal disorder 
K120z00 Renal calculus NOS Renal disorder 
K138.11 Renal vascular disorders Renal disorder 
K138000 Renal artery embolism Renal disorder 
K138011 Renal artery embolus Renal disorder 
K138100 Renal artery haemorrhage Renal disorder 
K138200 Renal artery thrombosis Renal disorder 
K138z00 Renal vascular disorders NOS Renal disorder 
K138z11 Renal infarction Renal disorder 
L093.00 Renal failure following abortive pregnancy Renal disorder 
L093200 Renal shutdown following abortive pregnancy Renal disorder 
L093300 Renal tubular necrosis following abortive pregnancy Renal disorder 
L093z00 Renal failure NOS following abortive pregnancy Renal disorder 
L121.00 
Renal hypertension in 
pregnancy/childbirth/puerperium Renal disorder 
L121000 
Renal hypertension in pregnancy/childbirth/puerp 
unspecified Renal disorder 







Renal hypertension in preg/childb/puerp -deliv with 
p/n comp Renal disorder 
L121300 
Renal hypertension in preg/childbirth/puerp - not 
delivered Renal disorder 
L121400 
Renal hypertension in preg/childb/puerp + p/n 
complication Renal disorder 
L121z00 
Renal hypertension in 
pregnancy/childbirth/puerperium NOS Renal disorder 
P769000 Renal artery stenosis Renal disorder 
PD0..00 Renal agenesis and dysgenesis Renal disorder 
PD00.00 Renal agenesis, unspecified Renal disorder 
PD00z00 Renal agenesis, unspecified NOS Renal disorder 
PD0z.00 Renal agenesis or dysgenesis NOS Renal disorder 
PD2..00 Renal pelvis and ureter obstructive defects Renal disorder 
PD30.12 Renal duplication NEC Renal disorder 
Q20yz13 Renal injury due to birth trauma Renal disorder 
S760111 
Renal haematoma without mention of open wound 
into cavity Renal disorder 
S761111 Renal haematoma with open wound into cavity Renal disorder 
SB24.00 Renal blood vessel injury Renal disorder 
SB24000 Renal blood vessel injury, unspecified Renal disorder 
SB24100 Renal artery injury Renal disorder 
SB24200 Renal vein injury Renal disorder 
SB24z00 Renal blood vessel injury NOS Renal disorder 
SK05.00 Renal failure following crush syndrome Renal disorder 
SK05.11 Renal failure after crushing Renal disorder 
SP15400 Renal failure as a complication of care Renal disorder 
TB00111 Renal transplant with complication, without blame Renal disorder 
TB11.11 Renal dialysis with complication, without blame Renal disorder 
14G1.00 H/O: rheumatoid arthritis Rheumatoid arthritis 
F371200 Polyneuropathy in rheumatoid arthritis Rheumatoid arthritis 
F396400 Myopathy due to rheumatoid arthritis Rheumatoid arthritis 
N04..00 
Rheumatoid arthritis and other inflammatory 
polyarthropathy 
Rheumatoid arthritis 
N040200 Rheumatoid arthritis of shoulder Rheumatoid arthritis 
N040300 Rheumatoid arthritis of sternoclavicular joint Rheumatoid arthritis 
N040400 Rheumatoid arthritis of acromioclavicular joint Rheumatoid arthritis 
N040500 Rheumatoid arthritis of elbow Rheumatoid arthritis 
N040600 Rheumatoid arthritis of distal radio-ulnar joint Rheumatoid arthritis 
N040700 Rheumatoid arthritis of wrist Rheumatoid arthritis 
N040800 Rheumatoid arthritis of MCP joint Rheumatoid arthritis 
N040900 Rheumatoid arthritis of PIP joint of finger Rheumatoid arthritis 
N040A00 Rheumatoid arthritis of DIP joint of finger Rheumatoid arthritis 
N040B00 Rheumatoid arthritis of hip Rheumatoid arthritis 
N040C00 Rheumatoid arthritis of sacro-iliac joint Rheumatoid arthritis 
N040D00 Rheumatoid arthritis of knee Rheumatoid arthritis 
N040E00 Rheumatoid arthritis of tibio-fibular joint Rheumatoid arthritis 





N040G00 Rheumatoid arthritis of subtalar joint Rheumatoid arthritis 
N040H00 Rheumatoid arthritis of talonavicular joint Rheumatoid arthritis 
N040J00 Rheumatoid arthritis of other tarsal joint Rheumatoid arthritis 
N040K00 Rheumatoid arthritis of 1st MTP joint Rheumatoid arthritis 
N040L00 Rheumatoid arthritis of lesser MTP joint Rheumatoid arthritis 
N040M00 Rheumatoid arthritis of IP joint of toe Rheumatoid arthritis 
N040N00 Rheumatoid vasculitis Rheumatoid arthritis 
N040Q00 Rheumatoid bursitis Rheumatoid arthritis 
N040R00 Rheumatoid nodule Rheumatoid arthritis 
N040S00 Rheumatoid arthritis - multiple joint Rheumatoid arthritis 
N040T00 Flare of rheumatoid arthritis Rheumatoid arthritis 
N041.00 Felty's syndrome Rheumatoid arthritis 
N042.00 
Other rheumatoid arthropathy + visceral/systemic 
involvement 
Rheumatoid arthritis 
N042000 Rheumatic carditis Rheumatoid arthritis 
N042100 Rheumatoid lung disease Rheumatoid arthritis 
N042200 Rheumatoid nodule Rheumatoid arthritis 
N042z00 
Rheumatoid arthropathy + visceral/systemic 
involvement NOS 
Rheumatoid arthritis 
N043.00 Juvenile rheumatoid arthritis - Still's disease Rheumatoid arthritis 
N043000 Juvenile rheumatoid arthropathy unspecified Rheumatoid arthritis 
N043100 Acute polyarticular juvenile rheumatoid arthritis Rheumatoid arthritis 
N043200 Pauciarticular juvenile rheumatoid arthritis Rheumatoid arthritis 
N043300 Monarticular juvenile rheumatoid arthritis Rheumatoid arthritis 
N043z00 Juvenile rheumatoid arthritis NOS Rheumatoid arthritis 
N044.00 Chronic post-rheumatic arthropathy Rheumatoid arthritis 
N044.11 Jaccoud's syndrome Rheumatoid arthritis 
N044.12 Nodular fibrositis of chronic rheumatic disease Rheumatoid arthritis 
N045.00 Other juvenile arthritis Rheumatoid arthritis 
N045000 Juvenile ankylosing spondylitis Rheumatoid arthritis 
N045100 Juvenile seronegative polyarthritis Rheumatoid arthritis 
N045200 Juvenile arthritis in psoriasis Rheumatoid arthritis 
N045300 Juvenile arthritis in Crohn's disease Rheumatoid arthritis 
N045400 Juvenile arthritis in ulcerative colitis Rheumatoid arthritis 
N045500 Juvenile rheumatoid arthritis Rheumatoid arthritis 
N045600 Pauciarticular onset juvenile chronic arthritis Rheumatoid arthritis 
N047.00 Seropositive errosive rheumatoid arthritis Rheumatoid arthritis 
N04X.00 Seropositive rheumatoid arthritis, unspecified Rheumatoid arthritis 
N04y.00 Other specified inflammatory polyarthropathy Rheumatoid arthritis 
N04y011 Caplan's syndrome Rheumatoid arthritis 
N04y012 Fibrosing alveolitis associated with rheumatoid arthritis Rheumatoid arthritis 
N04yz00 Other specified inflammatory polyarthropathy NOS Rheumatoid arthritis 
N04z.00 Inflammatory polyarthropathy NOS Rheumatoid arthritis 
Nyu1100 [X]Other seropositive rheumatoid arthritis Rheumatoid arthritis 
Nyu1200 [X]Other specified rheumatoid arthritis Rheumatoid arthritis 
1464.00 H/O: schizophrenia Schizophrenia 





E10..00 Schizophrenic disorders Schizophrenia 
E100.00 Simple schizophrenia Schizophrenia 
E100.11 Schizophrenia simplex Schizophrenia 
E100000 Unspecified schizophrenia Schizophrenia 
E100100 Subchronic schizophrenia Schizophrenia 
E100200 Chronic schizophrenic Schizophrenia 
E100300 Acute exacerbation of subchronic schizophrenia Schizophrenia 
E100400 Acute exacerbation of chronic schizophrenia Schizophrenia 
E100500 Schizophrenia in remission Schizophrenia 
E101.00 Hebephrenic schizophrenia Schizophrenia 
E101000 Unspecified hebephrenic schizophrenia Schizophrenia 
E101100 Subchronic hebephrenic schizophrenia Schizophrenia 
E101200 Chronic hebephrenic schizophrenia Schizophrenia 
E101300 




Acute exacerbation of chronic hebephrenic 
schizophrenia 
Schizophrenia 
E101500 Hebephrenic schizophrenia in remission Schizophrenia 
E101z00 Hebephrenic schizophrenia NOS Schizophrenia 
E102.00 Catatonic schizophrenia Schizophrenia 
E102000 Unspecified catatonic schizophrenia Schizophrenia 
E102100 Subchronic catatonic schizophrenia Schizophrenia 
E102200 Chronic catatonic schizophrenia Schizophrenia 
E102300 
Acute exacerbation of subchronic catatonic 
schizophrenia 
Schizophrenia 
E102400 Acute exacerbation of chronic catatonic schizophrenia Schizophrenia 
E102500 Catatonic schizophrenia in remission Schizophrenia 
E102z00 Catatonic schizophrenia NOS Schizophrenia 
E103.00 Paranoid schizophrenia Schizophrenia 
E103000 Unspecified paranoid schizophrenia Schizophrenia 
E103100 Subchronic paranoid schizophrenia Schizophrenia 
E103200 Chronic paranoid schizophrenia Schizophrenia 
E103300 
Acute exacerbation of subchronic paranoid 
schizophrenia 
Schizophrenia 
E103400 Acute exacerbation of chronic paranoid schizophrenia Schizophrenia 
E103500 Paranoid schizophrenia in remission Schizophrenia 
E103z00 Paranoid schizophrenia NOS Schizophrenia 
E104.00 Acute schizophrenic episode Schizophrenia 
E106.00 Residual schizophrenia Schizophrenia 
E106.11 Restzustand - schizophrenia Schizophrenia 
E10y.00 Other schizophrenia Schizophrenia 
E10y.11 Cenesthopathic schizophrenia Schizophrenia 
E10y000 Atypical schizophrenia Schizophrenia 
E10y100 Coenesthopathic schizophrenia Schizophrenia 
E10yz00 Other schizophrenia NOS Schizophrenia 
E10z.00 Schizophrenia NOS Schizophrenia 
Eu20.00 [X]Schizophrenia Schizophrenia 





Eu20011 [X]Paraphrenic schizophrenia Schizophrenia 
Eu20100 [X]Hebephrenic schizophrenia Schizophrenia 
Eu20111 [X]Disorganised schizophrenia Schizophrenia 
Eu20200 [X]Catatonic schizophrenia Schizophrenia 
Eu20211 [X]Catatonic stupor Schizophrenia 
Eu20212 [X]Schizophrenic catalepsy Schizophrenia 
Eu20213 [X]Schizophrenic catatonia Schizophrenia 
Eu20214 [X]Schizophrenic flexibilatis cerea Schizophrenia 
Eu20300 [X]Undifferentiated schizophrenia Schizophrenia 
Eu20311 [X]Atypical schizophrenia Schizophrenia 
Eu20400 [X]Post-schizophrenic depression Schizophrenia 
Eu20500 [X]Residual schizophrenia Schizophrenia 
Eu20511 [X]Chronic undifferentiated schizophrenia Schizophrenia 
Eu20512 [X]Restzustand schizophrenic Schizophrenia 
Eu20600 [X]Simple schizophrenia Schizophrenia 
Eu20y00 [X]Other schizophrenia Schizophrenia 
Eu20y11 [X]Cenesthopathic schizophrenia Schizophrenia 
Eu20y12 [X]Schizophreniform disord NOS Schizophrenia 
Eu20y13 [X]Schizophrenifrm psychos NOS Schizophrenia 
Eu20z00 [X]Schizophrenia, unspecified Schizophrenia 
ZV11000 [V]Personal history of schizophrenia Schizophrenia 






Appendix 15: The generalized linear model (GLM) - an 
overview277 
The standard linear regression model (e.g. OLS) relies on several assumptions, 
among which are the following: 
1. Each observation of the response variable is characterized by the normal or 
Gaussian distribution; 
yia1ȝiı2i). 
2. Homoscedasticity, the distributions for all observations have a common 
YDULDQFHı2i  ı2 for all i. 
3. There is a direct or "identical" relationship between the linear predictor 
(linear combination of covariate values and associated parameters) and the 
expected values of the model; xiȕ ȝi 
Common characteristics of many outcome variables (y) in health economics 
and biostatistics are heteroscedasticity, heavy skewness in the right tail, and 
kurtotic distributions in which the OLS is inefficient 276.  The regression of 
logarithmic transformation of y using the OLS is a way to overcome the 
problems of heteroscedasticity and severe skewness. However, the 
transformation of heavy skewed data is most often not sufficient to normalise 
the data. When the log-scale residuals showed evidence of heteroscedasticity, 
estimates based on OLS can produce a biased assessment of the impact of 
covariates on expected values of y on raw scale. In such case, an alternative 
approach is one of the GLM models 275. 
The purpose of GLMs is to specify the relationship between the observed 
response variable and some number of covariates. By restructuring the 
relationship between the linear predictor and the fit, relationships that initially 
seem to be nonlinear can be linearised.  The traditional linear model is not 
appropriate when data are not normally distributed or if the response variable 
has a limited outcome set. 
The models placed under the GLM framework had been fitted using a 







link function. The GLMs specify a relationship between the mean of the 
random variable y and a function of the linear combination of the predictors. 
The outcome dependent variable y is assumed to be generated from a particular 
distribution function in the exponential family which include a large range of 
probability distributions. In fact, the exponential family admits a model 
specification that allows modelling continuous, discrete, proportional, count 
and binary outcomes. Among continuous distributions is the Gaussian, log-
normal, inverse-Gaussian, exponential, gamma, Weibull, etc. Among discrete 
distributions is the Bernoulli, binomial, Poisson, geometric, negative binomial, 
etc. 
The estimation algorithm allowed researchers to more easily estimate many 
models previously considered to be non-linear by constructing them into 
GLMs. 
Model components 
The GLMs consist of some elements which can be listed as follow: 
1. A random component for the response, y, which has a distribution following 
the exponential family. 
2. A linear systematic component, relating the linear predictor, Ș ;ȕto the 
LQGHSHQGHQWH[SODQDWRU\YDULDEOHV;DQGWKHSDUDPHWHUVȕ 
3. A known monotonic, one-to-one, differentiable link function g(-) relating the 
linear predictor to the fitted values. Since the function is one-to-one, there is 
an inverse IXQFWLRQUHODWLQJWKHPHDQH[SHFWHGUHVSRQVH(\ ȝWRWKHOLQHDU
predictor. 
4. The variance may change with the covariates only as a function of the mean. 
5. There is one IRLS (Iteratively Reweighted Least Squares) algorithm that 
suffices to fit all members of the class. 
 
Assumptions of GLMs 
7KHOLQNIXQFWLRQUHODWHVWKHPHDQȝ (\WRWKHOLQHDUSUHGLFWRU;ȕDQGWKH
variance function relates the variance as a function of the mean V(y)= 
Dĳ9ȝZKHUHDĳLVWKHVFDOHSDUDPHWHU 









4. The link function is correctly specified. 
5. Explanatory variables are of the correct form. 
6. There is no undue influence of the individual observations on the fit. 
 
The distribution function is derived from the exponential family and has the 
form: 
f(y) = exp [ ɅିሺɅሻሺɔሻ  F\ĳ@ 
WKHUHșLVWKHFDQRQLFDOQDWXUDOSDUDPHWHUWKDWGHWHUPLQHVWKHORFDWLRQRI
GLVWULEXWLRQDQGĳis the scale parameter required to produce standard errors 
following a distribution in the exponential family of distributions. 
The joint probability density fuQFWLRQPD\EHH[SUHVVHGDVDIXQFWLRQRIșDQG
ĳDQGLVFDOOHGWKHOLNHOLKRRGL. Given the product in the likelihood, it is more 
convenient to work with the log likelihood. The estimates with GLMs aim to 




Goodness of fit 
The fit of the GLM model to the data is measured as twice the difference 
between the log likelihoods of the model of interest, and a saturated model. 
Since this difference is a measure of the deviation of the model of interest from 
DSHUIHFWO\ILWWLQJPRGHOWKHPHDVXUHLVFDOOHGWKH³GHYLDQFH´7KHGHYLDQFHLV
quantified as twice the negative log likelihood. 
deviance= -ORJƐ 
The main goal in modelling is to find the simplest model (fewest parameters) 
that has the smallest deviance (reproduces the data).  The values of the 
parameters that minimize the deviance are the same as the values of the 





Two other criteria can be used to compare competing models which are 
Akaike¶V,QIRUPDWLRQ&ULWHULRQ$,&DQG%D\HVLDQ,QIRUPDWLRQ&riterion 
(BIC). A comparison may be made to non-nested models or models calculated 
across different samples.  The AIC is such that the lower the value, the better 
fitting the model. Moreover, a difference of greater than two indicates a 
marked preference for the model with the smaller criterion measure. Like the 
AIC statistic, the better fitting the model is the one having the smaller BIC 
value. The BIC is often negative, thus, the model having the most negative 
value is preferred. 
 
 
GLM- the gamma family 
The gamma model is used for data situations in which the response can take 
only values greater than or equal to 0. The GLM gamma family is used 
primarily with continuous-response data and can be also used with count data. 
Ideally, the gamma model is best used with positive responses having a 
constant coefficient of variation. However, the model is robust to wide 
deviations from the latter criterion. In fact, because the shape of the two-
parameter gamma distribution is flexible and can be parameterized to fit many 
response shapes, it may be preferable over the Gaussian model for many 
strictly positive response data situations. 
As with other GLM families, there are many commonly used link functions to 
provide the relationship between the linear predictor and the mean of the 
distribution function. The choice between different links of the same model 
family may sometimes be hard. Choosing the model having the least value for 
the deviance may be preferable. 
The log-linked gamma represents the log-rate of the response. The log-gamma 
model, like its reciprocal counterpart, is used with data in which the response 
is greater than 0. Log-gamma technique is used now to model data which were 
generally modelled using Gaussian regression with a log-transformed 
response. Although the results are usually similar between the two methods, 
the log-gamma, which requires no external transformation, is easier to interpret 






Appendix 16: Generalized estimating equations (GEE) for 
longitudinal data analysis 
A major challenge comes in analysing longitudinal data is the correlation of 
observations within subjects, in which data are clustered within related 
subjects (subgroups). Failure to incorporate correlation of responses can lead 
to incorrect estimation of regression model parameters, particularly when such 
correlations are large 366. The regressiRQHVWLPDWHVȕVDUHOHVVHIILFLHQWWKDW
is, they are more widely scattered around the true population value than they 
would be if the within subject correlation were incorporated in the analysis 366. 
Unlike the Gaussian data, the traditional maximum likelihood approaches 
cannot be used for non-Gaussian data as the integral does not have a closed 
form. To overcome these problems, Liang and Zeger introduced the 
Generalized Estimating Equation (GEE) to produce more efficient and 
unbiased regression estimates for use in analyzing longitudinal or repeated 
measures research designs with non-normal response variables 283. The GEE 
models are an extension of generalized linear models, which facilitate 
regression analyses on dependent variables that are not normally distributed 
367
. The GEE models are consistent and can handle a variety of correlated data 
even if the correlation structure is misspecified 284. 
The GEE tests hypotheses regarding the influence of factors on binary and 
other exponentially (e.g., Poisson, Gamma, negative binomial) distributed 
response variables collected within subjects across time. 
The GEE method is based on multivariate quasi likelihood theory and it can 
handle the complexities of longitudinal data which takes into account the 
correlation arising due to a longitudinal study design, resulting in increased 
efficiency of standard error estimates 366. 
Inference about the mean of the outcome as a function of a set of covariates is 
the main focus of the GEE 276.  It specifies the marginal expectations and the 
marginal covariance matrix of the responses for longitudinal or clustered data 
as a function of  the covariates 282. The marginal effect is the population 





other words, for every one-unit increase in a covariate across the population, 
GEE tells the user how much the average response would change 285 
This method avoids the use of multivariate distribution by assuming a 
functional form for marginal distribution at each time, making it useful for 
non-Gaussian outcomes. The advantage of using the GEE method is that the 
solutions are consistent, i.eWKHHVWLPDWHRIȕDUHQHDUO\HIILFLHQWDQG 






Appendix 17: Read codes list for outpatient attendances 
including paediatric neurology 
Medical code Description 
64QZ.00 Child specific referral NOS 
6613.00 Next hospital appointment 
8H4..00 Referral to physician 
8H42.00 Referral to paediatrician 
8H42.11 Paediatric referral 
8H46.00 Neurological referral 
8H49.00 Psychiatric referral 
8H4f.00 Referral to learning disabilities psychiatrist 
8H4h.00 Referral to neurologist 
8H4M.00 Referral to community paediatrician 
8H4O.00 Referral to paediatric neurologist 
8H4P.00 Referral to child psychiatrist 
8H4Y.00 Referral to neurology special interest general practitioner 
8H4Z.00 Referral to physician NOS 
8H55.00 Neurosurgical referral 
8H65.00 Refer to hospital registrar 
8H7a.00 Refer to hospital 
8H7b.00 Refer to day hospital 
8Hh..00 Self-referral 
8Hi..00 Earlier referral for specialist review 
8HJ3.00 Psychiatric self-referral 
8HJ5.00 Paediatric self-referral 
8HJE.00 Neurology self-referral 
8HkS.00 Referral to clinical neurophysiology service 




9b9O.00 Paediatric neurology 
9bA..00 Psychiatry 
9bA2.00 Child and adolescent psychiatry 
ZL18P00 Under care of neurologist 
ZL19.00 Under care of paediatrician 
ZL19300 Under care of paediatric neurologist 
ZL1B.00 Under care of psychiatrist 
ZL1B100 Under care of child and adolescent psychiatrist 
ZL1GK00 Under care of neurosurgeon 
ZL57.00 Referral to paediatrician 
ZL57100 Referral to community paediatrician 





ZL59300 Referral to neuropathologist 
ZL5A.00 Referral to physician 
ZL5A900 Referral to clinical neurophysiologist 
ZL5AO00 Referral to neurologist 
ZL5B.00 Referral to psychiatrist 
ZL5B100 Referral to child and adolescent psychiatrist 
ZL5B111 Referral to child psychiatrist 
ZL5GL00 Referral to neurosurgeon 
ZL87.00 Referral to speech and language therapist 
ZL87.11 Refer to speech therapist 
ZL87100 Referral to community-based speech and language therapist 
ZL87111 Referral to community speech and language therapist 
ZL97.00 Seen by paediatrician 
ZL97300 Seen by paediatric neurologist 
ZL9AP00 Seen by neurologist 
ZL9D.00 Seen by psychiatrist 
ZL9GJ00 Seen by neurosurgeon 
ZLD2V00 Discharge by paediatric neurologist 
ZLD3900 Discharge by clinical neurophysiologist 
ZLD3P00 Discharge by neurologist 




















Appendix 18: Code list of inpatient and emergency hospital care 
Medical code Description 
6611.00 Last hospital in-patient 
9116.11 Emergency treatment registration 
9144.00 Patient in hospital 
9451.00 Death notification from hospital 
9495.00 Patient died in hospital 
13F8.00 Hospital patient 
13F8.11 Hospital inpatient 
13F8100 Long stay hospital inpatient 
13F8200 Previous multiple hospital admissions 
13FS.00 Long stay hospital inpatient 
667W.00 Emergency epilepsy treatment since last appointment 
8B1..00 Emergency treatment 
8B11.00 Emergency dressing 
8B1Z.00 Emergency treatment NOS 
8CO..00 Inpatient care 
8H1..00 Admit to intensive care unit 
8H1..11 Admit to I.T.U. 
8H13.00 Admit to neurological ITU 
8H16.00 Admission to special care baby unit 
8H1Z.00 Admit to intensive CU. NOS 
8H2..00 Emergency hospital admission 
8H21.00 Admit medical emergency unsp. 
8H22.00 Admit surgical emergency unsp. 
8H23.00 Admit psychiatric emergency 
8H23000 Emergency psychiatric admission MHA 
8H25.00 Admit paediatric emergency 
8H2A.00 Admit trauma emergency 
8H2E.00 Admit neurology emergency 
8H2N.00 Admit neurosurgical emergency 
8H2Z.00 Admit hospital emergency NOS 
8H3..00 Non-urgent hospital admission 
8H31.00 Non-urgent hospital admission unspecified 
8H36.00 Non-urgent medical admission 
8H38.00 Non-urgent psychiatric admission 
8H3J.00 Non-urgent neurology admission 
8H3S.00 Non-urgent neurosurgical admission 
8H3Z.00 Other hospital admission NOS 
8Ha..00 Voluntary admission 
8Hb..00 Involuntary admission 
8HC..00 Refer to hospital casualty 





8Hd..00 Admission to hospital 
8Hd0.00 Admission to community hospital 
8HE..00 Discharged from hospital 
8HE7.00 Discharged from hospital within 6 hours of delivery 
8HE8.00 Discharged from accident and emergency 
8HF..12 Transferred from hospital 
8HG..00 Died in hospital 
8HG..11 Death in hospital 
8HJJ.00 Self-referral to accident and emergency department 
8HM6.00 Listed for Neurology admission 
8HTF.00 Referral to emergency clinic 
945..00 Hospital death discharge notification 
945Z.00 Hospital death discharge NOS 
949B.00 Patient died in community hospital 
94D..00 Hospital notified of death 
9b00.00 A&E report 
9b09.00 Day case report 
9b0A.00 Discharge report 
9b0B.00 Discharge summary report 
9b0C.00 Emergency consultation note 
9b0K.00 Hospital admission note 
9b0L.00 Hospital inpatient report 
9b0l.00 Surgery consultation note 
9b8D.00 Accident & emergency 
9Ee0F00 Admission history and physical report 
9N58.00 Emergency appointment 
9N62.00 Referred by hospital doctor 
9NM4.00 Attending day hospital 
9NNQ.00 Under care of hospital psychiatric team 
9R6..00 Hospital reference number: 
9U4..00 Formal complaint about hospital care 
9U5..00 Formal complaint about hospital care RE: self 
9U6..00 Formal complaint about hospital care RE: relative 
Eu43213 [X]Hospitalism in children 
Z177800 Inpatient care 
ZIF3.00 Ensuring patient's carer prepared for hospital discharge 
ZL11.00 Under care of accident and emergency doctor 
ZL11.11 Under care of A & E doctor 
ZL11.12 Under care of casualty doctor 
ZL16.00 Under care of intensive care specialist 
ZL16.11 Under care of ITU specialist 
ZL51.00 Referral to accident and emergency doctor 
ZL51.12 Referral to A & E doctor 





ZL56.00 Referral to intensive care specialist 
ZL56.11 Referral to ITU specialist 
ZL56200 Referral to paediatric intensive care specialist 
ZL56211 Referral to paediatric ITU specialist 
ZL87200 Referral to hospital-based speech and language therapist 
ZL87211 Referral to hospital speech and language therapist 
ZL91.00 Seen by accident and emergency doctor 
ZL91.11 Seen by A & E doctor 
ZL91.12 Seen by casualty doctor 
ZLD2100 Discharge by accident and emergency doctor 
ZLD2111 Discharge by casualty doctor 
ZLD2112 Discharge by A & E doctor 
ZLD2a00 Discharge by psychiatrist 
ZLD2b00 Discharge by child and adolescent psychiatrist 
ZLD2R00 Discharge by paediatrician 
ZLDP.00 Discharge by speech and language therapist 
ZLDP200 Discharge by hospital-based speech and language therapist 
ZLDP211 Discharge by hospital speech and language therapist 
ZLEL100 Discharge from hospital speech and language therapy service 
ZLEL200 Discharge from hospital speech and language therapy service 
ZLF1100 Discharge from hospice day hospital 
ZLF2.00 Discharge from hospital 
ZLF2100 Discharge from day hospital 
ZLF2200 Discharge from psychiatry day hospital 
ZLF3.00 Discharge from ward 
ZLF3100 Discharge from day ward 
ZLG6.00 Discharge to hospital 
ZLG6100 Discharge to long stay hospital 
ZLG6200 Discharge to community hospital 
ZLG6300 Discharge to GP hospital 
ZLG6400 Discharge to tertiary referral hospital 
ZLG6411 Discharge to tertiary referral centre 
ZLG6500 Discharge to tertiary referring hospital 
ZLG8.00 Discharge to ward 










Appendix 19: Code list of diagnostic imaging and laboratory 
investigations for epilepsy 
Medical code  Description (diagnostic imaging) 
3113000 EEG normal 
3114000 EEG abnormal 
3119.00 Electroencephalogram 
31C..00 EEG observations 
563..00 Tomography 
5631.00 Tomography requested 
5632.00 Tomography normal 
5633.00 Tomography abnormal 
5634.00 Tomography - head/neck 
563Z.00 Tomography - NOS 
567..00 Computerised axial tomography 
567..11 CAT scan 
567..12 Computer axial scan 
567..13 Computerised tomography scan 
5671.00 CAT scan requested 
5672.00 CAT scan normal 
5673.00 CAT scan abnormal 
5675.00 CAT scan - brain 
567B.00 CAT scan - whole body 
567C.00 CAT scan brain - abnormal 
567Z.00 CAT scan - NOS 
569..00 Nuclear magnetic resonance 
569..11 NMR Scan 
569..12 Magnetic resonance imaging 
5691.00 Nuclear magn.reson.requested 
5692.00 Nuclear magnreson normal 
5692.11 MRI scan normal 
5693.00 Nuclear magn.reson. abnormal 
5693.11 MRI scan abnormal 
5694.00 Magnetic resonance imaging of brain abnormal 
569F.00 Magnetic resonance imaging of brain normal 
569K.00 Magnetic resonance imaging of head 
569K.11 MRI of head 
569K000 Magnetic resonance imaging of brain 
569Z.00 Nuclear magnetic resonance NOS 
7065000 Electroencephalography 
7065600 Video EEG 
7065611 EEG video telemetry 





7P00000 Computed tomography of whole body 
7P00100 Magnetic resonance imaging of whole body 
7P00z00 Diagnostic imaging of whole body NOS 
7P02000 Computed tomography of head 
7P02100 Magnetic resonance imaging of head 
7P02200 Functional magnetic resonance imaging of head 
7P0J000 Magnetic resonance imaging NEC 
7P10000 Electroencephalograph telemetry 
8HQ3.11 Refer for MRI 
8HR5.00 Refer for EEG 
R140100 [D]Echoencephalogram abnormal 
R140200 [D]Electroencephalogram (EEG) abnormal 
7P0M100 Positron emission tomography with computed 
tomography 
 
Medical code  Description (laboratory investigations) 
44W2.00 Serum phenobarbitone level 
44W3.00 Serum phenytoin level 
44W3.11 Phenytoin: blood level 
44W4.00 Serum sodium valproate level 
44W4.11 Epilim: blood level 
44W4.12 Sodium valproate: blood level 
44W5.00 Serum carbamazepine level 
44W5.11 Carbamazepine: blood level 
44W6.00 Serum ethosuximide level 
44W7.00 Serum primidone level 
44Wf.00 Serum vigabatrin level 
44Wg.00 Serum lamotrigine level 
44Wn.00 Serum gabapentin level 
44Ws.00 Plasma carbamazepine level 
44Wt.00 Serum diazepam level 
44u5.00 Serum clonazepam level 
44uC.00 Serum topiramate level 
44uF.00 Serum clobazam level 
44vA.00 Serum levetiracetam level 
8HP..00 Referral for laboratory tests 
8HP1.00 Referral for haematology test 
8HPZ.00 Referral for lab test NOS 
44vA.00 Serum levetiracetam level 
9bC3.00     Haematology (specialty) 
9bC7.00     Neuropathology 
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